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1
 On November 14, 2014, Advanced Cell Technology (ACT) changed its corporate name to “Ocata Therapeutics, Inc.”.   
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[xxii] 
 
SHI Statutory Health Insurance  
shRNA Short Hairpin RNA  
SMD Stargardt Macular Dystrophy  
SNU Seoul National University  
SSN Servizio Sanitario Nazionale (National Health Service) 
S&T Science and Technology 
TC Tetraploid Complementation 
TE Trophectoderm  
TEU Treaty on European Union  
TFEU Treaty on the Functioning of the European Union  
TRIPS Agreement on Trade-Related Aspects of Intellectual Property Rights 
TSI Tarjata Sanitaria Individual
3
 
TSM Test Teaching-Suggestion-Motivation Test 
UDHR Universal Declaration of Human Rights 
UKIPO United Kingdom Intellectual Property Office  
UKT Unique Key Themes 
UKW Unique Key Words 
UMC Uppsala Monitoring Centre  
UN United Nations 
UNESCO United Nations Educational, Scientific and Cultural Organization 
UP Unitary Patent 
UPC Unified Patent Court  
UPOV International Union for the Protection of New Varieties of Plants  
USPTO U.S. Patent and Trademark Office 
WARF Wisconsin Alumni Research Foundation 
WHO World Health Organization 
WIPO World Intellectual Property Organization 
WMA World Medical Association  
WTO World Trade Organization  
 
 
 
 
 
 
 
 
 
                                                 
3
 Health card from the Department of Social Security, Spain. 
[xxiii] 
 
Case List 
 
Case Page 
Consumer Watchdog v. Wisconsin Alumni Research Foundation, Case 13-
1377, Fed. Cir. 2014 
82, 92, 103 
Coombs v. North Dorset NHS PCT (2013) EWCA Civ 471, (2013) MHLO 
35 
68 
Costa and Pavan v. Italy, Application no. 54270/10, European Court of 
Human Rights (Second Section) 28 Aug. 2012 
17 
Diamond v. Chakrabarty 447 U. S. 306 (1980) 70 
Graham v. John Deere Co., 383 U.S. 1 (1966) 81 
Grogan v. Bexley NHS Care Trust & Ors (2006) [2006] EWHC 44 (Admin) 68 
International Stem Cell Corporation v. Comptroller General of Patents, 
Designs and Trade Marks, Case C‑364/13, Judgment of the Court (Grand 
Chamber) 18 Dec. 2014 
1, 73, 107 
KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007) 82 
Moore v. Regents of the University of California, 51 Cal. 3d 120, 271 Cal. 
Rptr. 146, 793 P.2d 479, cert. denied 499 U.S. 936 (1991) 
56 
National Federation of Independent Business, et al. v. Sebelius, Secretary of 
Health and Human Services, et al. 567 U.S. ___ (2012), 132 S.Ct 2566 
1, 68, 142 
Litowitz v. Litowitz, 48 P.3d 261 (Wash. 2002) 17 
Oliver Brüstle v. Greenpeace e.V, C-34/10, Judgment of the Court (Grand 
Chamber) 18 Oct. 2011 
1, 2, 16, 17, 
45, 46, 75, 80, 
107, 143 
Pharmaceutical Manufacturers’ Association and 41 Others v. President of 
South 
Africa and 9 Others, High Court of South Africa (Transvaal Provincial 
Division), Case No. 4183/98 (2001) 
61 
R. v. North and East Devon HA Ex p. Coughlan (1999) [2001] Q.B, 213; 
[2000] 2 W.L.R. 622 CA (Civ Div) 
 
Roche Products, Inc. v. Bolar Pharmaceutical Co., Inc., 733 F.2d 858 (Fed. 96 
[xxiv] 
 
Cir. 1984) 
Sherley v. Sebelius, No. 11-5241, Slip op. at 8 (D.C. Cir. August 24, 2012) 2, 104 
Voda v. Cordis Corp., No. 05-1238 (Fed. Cir. Feb. 1, 2007) 112 
 
 
1 
 
CHAPTER 1 
INTRODUCTION, PROBLEM SPACE, RESEARCH QUESTIONS, RESEARCH AIMS,  
METHODOLOGY AND OUTLINE OF THE THESIS 
 
1.1 INTRODUCTION 
 
The monograph is a research work of interdisciplinary nature. It has special implications for the IP 
protection of human Stem Cell based Inventions/Innovations (hereinafter referred to as hSCI). 
Human Stem Cell Research (hereinafter referred to as hSCR) and patent/IP protection of hSCI have 
been examined from the legal, ethical and scientific perspectives. The laws and policies of Germany, 
Italy, Lithuania, Spain and the United Kingdom in Europe and California, Massachusetts, New 
Jersey, South Dakota and Texas from amongst the States in the USA are revisited for the writing of 
the monograph. The “hSCR policy” and “provisions on exclusion from patent” are different in 
different jurisdictions. Stem cell research policies are different (from restrictive to liberal) among 
Germany, Italy, Lithuania, Spain and United Kingdom. Significant differences can be observed in 
hSCR policy within the USA. Although the Federal policy is liberal, there are differences in the State 
level. Liberal policy can be observed in the California, Massachusetts and New Jersey but 
restrictive/conservative policies are prevalent in Texas and South Dakota. The reason for selection of 
those countries is that they follow “different stem cell research policies” and also have “different 
provisions on exclusion from patentable inventions.”  
 
This work comes after several groundbreaking events have taken place in the related fields. To name 
few: 
• The Unitary Patent Package is taking off in Europe; 
• In National Federation of Independent Business, et al. v. Sebelius, Secretary of 
Health and Human Services, et al. (2012),
1
 the Affordable Care Act 2010 survived in 
most part in the United States Supreme Court; 
• Two very relevant cases on the subject were decided differently in two continents, 
i.e., Brüstle (2011)
2
 and Sherley (2012);
3
 
• Three years after the case of Oliver Brüstle v.Greenpeace e.V. (2011),4 the CJEU 
took more liberal approach towards the human stem cell patents in the case of 
International Stem Cell Corporation v. Comptroller General of Patents, Designs and 
Trade Marks(2014);
5
 
• The first iPSC human trial in Japan took place, etc. 
 
Therefore, an interdisciplinary study examining “the techniques of hSCR, ethical and legal 
intricacies involved and the patent protection of hSCI” is a very timely exercise.  
 
The thesis aims to explore “the adequacy of the patent system for the hSCI at present”, along with 
the ethical and bioethical issues involved in the context. Therefore, it attempts to answer what is the 
                                                 
1
 567 U.S. ___ (2012), 132 S.Ct 2566. 
2
 Oliver Brüstle v. Greenpeace e. V., C-34/10, Judgment of the Court (Grand Chamber) 18 Oct. 2011, also available at 
http://curia.europa.eu/juris/liste.jsf?language=en&num=C-34/10 (last visited July 25, 2014). 
3
 No. 11-5241, Slip op. at 8 (D.C. Cir. August 24, 2012). 
4
 Brüstle, supra note 2. 
5
 Case C‑364/13, 18 Dec. 2014, also available at 
http://curia.europa.eu/juris/document/document.jsf;jsessionid=9ea7d0f130de9c4121923b8f43769c42c1706a04f989.e34K
axiLc3eQc40LaxqMbN4ObheSe0?text=&docid=160936&pageIndex=0&doclang=EN&mode=lst&dir=&occ=first&part
=1&cid=88991#Footnote*(last visited Dec. 22, 2014). 
2 
 
best possible way to offer intellectual property right (IPR) to those inventions/innovations that would 
create environment for wider accessibility to the therapy in one hand and allow adequate incentive 
for innovation on the other hand. In order to find answer to the above queries an empirical research 
was also carried out. The primary investigation was conducted through a partly completely-
structured, partly open-ended online (email) questionnaire in which experts on bioethics, life science 
and intellectual property law were interrogated. The study took place between 6
th 
September 2013 
and 29
th 
January 2014. A total number of 31 respondents participated in the primary investigation.
6
  
 
1.2 IDENTIFYING THE MAJOR PROBLEMS  
Human Stem Cell Research (hSCR) is an area where significant differences exist (regarding the 
purview of research and the patent protection) among the countries due to prevailing political, 
economic, social and cultural conditions. Despite Europe’s recent Unitary Patent package, the fast 
growth of biomedical research and inventions/innovations from evolutionary developmental biology 
(Evo-Devo) is becoming hard for the patent law to cope up with. The widening of the purview of 
patent law for inventions/innovations in those fields of science that uses human biological material 
obscures the boundary of the patentability criteria. Countries perceive the spirit of bioethics 
differently for the hSCR. So far, the patent had been the mostly exercised IP protection tool for the 
inventions from the biomedical research and Evo-Devo using human biological material. One 
important kind of hSCR is the human embryonic stem cell (hESC) research. Inventions 
encompassing the destruction of human embryo have been excluded from patent protection in 
Europe by the decision of the Court of Justice of the European Union (hereinafter referred to as 
CJEU) in Brüstle’s case.7 On the contrary, the funding of the National Institute of Health (NIH) is 
again made available in the US after the U.S. Court of Appeal for the District of Columbia concluded 
in favor of removal of the injunction on funding for stem cell research in the case of Sherley v. 
Sebelius.
8
 Patent is available in the US for hESC based inventions that employ supernumerary 
embryos, i.e., the embryos that are no longer required for the fertility purpose, in other words, the 
IVF redundant embryos. Germany, Italy, Lithuania, Spain and United Kingdom- all have different 
stem cell research policies (ranging from restrictive to liberal).   
 
Safety of human subject and patient is a major concern for all emerging stem cell based 
inventions/innovations. Ethical issues being understood from different perspectives, can be invoked 
in almost all of the stem cell researches. At present, there is not much uniformity in the ideology and 
practice of patent protection in the field of hSCI. Uncertainty of patent protection and patenting hSCI 
both have many repercussions. The irreconcilable differences about ethical interpretation regarding 
the legitimacy of stem cell research and means of protection of the inventions among countries is the 
driving force for my research to explore a functional recommendation. The 
recommendations/proposals I am making after the analysis of the empirical study, is expected to 
maintain a balance among the three important aspects, i.e., 
 offering incentive to invention/innovation,  
 allowing the access to therapies at an affordable expenses and 
 mitigating the ethical debate to a significant extent. 
 
The existing patent system is multilayered in Europe. Extremely strong IP protection of inventions 
that are meant for health care may have been detrimental to “access to therapy.” Without proper IP 
                                                 
6
 The respondents are coming from 16 countries representing most of the continents, i.e., Africa, Americas, Asia and 
Europe. 
7
 Brüstle, supra note 2. 
8
 No. 11-5241, Slip op. (D.C. Cir. August 24, 2012). 
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protection there may be dearth in research and innovation. A balanced approach is missing in the 
current patent system that protects inventions having implications for health care. Moreover, fast 
changes and breakthrough developments in the protocol of hSCR call for the revisiting of the IP 
protection framework and ethical boundaries, thereby, posing legal challenges.  
 
1.3 THE RESEARCH QUESTIONS OF THE MONOGRAPH 
 
The research questions of the monograph are the following: 
 
I. What is the best way to offer IP protection to “human Stem Cell based 
Inventions/Innovations” (hSCI) / “Inventions/Innovations that use Biological Materials of 
Human Origin” (IBMHO) that would ensure incentive for invention/innovation and allow 
wider access to therapies? 
II. What are the legal/ethical/bioethical issues in human Stem cell Research (hSCR) and what 
needs to be addressed for “ethical” hSCR? 
III. What does an empirical investigation and a qualitative analysis reveal from a survey 
conducted amongst the experts in order to answer the research question nos. I and II? 
 
 
1.4 RESEARCH AIMS AND OBJECTIVES 
The objectives are: 
I. To explore the ethical9 issues involved in the hSCR;  
 
II. To revisit “the legal framework of hSCR” and “IP protection regime built by patent for the 
hSCI”, while observing the prevailing circumstances and divergence in the select country 
context; 
 
 
III. To find how the experts as respondents view the “ethical and legal issues in hSCR” and 
“patent/IP protection of hSCI” through an empirical investigation; 
 
IV. To make limited recommendations on modernizing intellectual property protection for the 
hSCI/IBMHO; and 
 
 
V. To make recommendations for addressing the ethical issues and for fostering access to the 
therapy.  
 
The aim is to achieve and find a balance among the three main aspects, i.e., innovation, ethics and 
access to therapy. In order to achieve those aims and objectives, both theoretical and empirical 
investigations were conducted. 
 
                                                 
9
 “Ethics” is a general term reflective of the societal/collective perception towards an action. “Morality” is the 
individualistic embodiment of a virtue; differs between individuals. 
The terms “ethics” and “morality” have not been redefined in this monograph. They shall be deemed to have retained 
their conventional and literal “meaning and differences”. 
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1.5 METHODOLOGY 
The Monograph is comprised of both theoretical and empirical parts. 
The monograph encompasses the following topics and exercises: 
• Stem cell research; 
• Examination of ethics and bioethics; 
• Health care policy; 
• Access to therapy; 
• Patent framework; 
• Qualitative Content Analysis of the Survey data. 
 
1.5.1 THE THEORETICAL DISCUSSION 
The laws and policies on human stem cell research and patent protection of Germany, Italy, 
Lithuania, Spain and the United Kingdom in Europe and California, Massachusetts, New Jersey, 
South Dakota and Texas from amongst the States in the USA are revisited for the theoretical 
discussion of the monograph.  
For the theoritical discusion, the scientific developments already taken place in the field of human 
stem cell research were examined and the ethical issues involved in those select techniques were 
detailed. The legal frameworks of stem cell research and the patent protection in those countries were 
revisited by way of a comparative study. Among other issues, the comparative discussion highlighted 
the legal, ethical and bioethical issues in hSCR, access to the therapy and IP/patent protection of 
hSCI. 
The relevant cases, international conventions, treaties, community legislation in Europe and the 
Federal laws in the USA in the study context are painstakingly examined. Patent database and 
clinical trial database were well-investigated. Patents (US patents/EP) granted/filed for the recent and 
select human stem cell based inventions were examined. 
1.5.2 THE EMPIRICAL RESEARCH 
The primary investigation (empirical research) began in the 1
st
week of September 2013 by sending 
email to the experts and the questionnaire in attachment as Microsoft word document. This process 
of sending questionnaire and receiving answers continued until last week of January 2014. 
Therefore, the survey can be said to be conducted in a time frame between September 2013 and 
January 2014. The convenience sampling approach was adopted for collection of the responses. The 
answers received were voluntary submission of the respondents to my inbox of the email account 
aaajamil@yahoo.com. 
As the experts/respondents participating in the study come from several different continents, email 
correspondence was the most effective means of communication. The emails are preserved and in 
some cases, the respondents have clarified the queries, if there were any ambiguity.  
The respondents were free to choose from the suggested options in the questionnaire, change and 
alter the suggested answers, write a new answer or make any comment. The design of the 
questionnaire allowed the respondents to be creative and ensured their best self-representation. 
Therefore, a semi-structured/mixed-type questionnaire was the appropriate instrument for this study 
and the Qualitative analysis was conducted on the comments made by the respondents.  
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1.5.2.1 METHODOLOGY OF THE EMPIRICAL RESEARCH  
The primary investigation was conducted through a partly completely-structured, partly open-ended 
questionnaire in which experts on bioethics, life science and intellectual property law were inquired 
to give their responses. 
Key information about the study is as follows: 
i. Total participant 31; Total country 16.10 
ii. Participating respondents are from diverse backgrounds.  
iii. Highest number of the respondents belonging to a single country is Lithuania. Several 
respondents are from Italy and the USA. Two respondents are from Egypt and rest of the 
respondents individually represents his/her country.  
 
 Table 1.1 Country of the Respondents 
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 The continents are Africa, America, Asia and Europe. 
Country Frequency Percent Cumulative % 
Bangladesh 1 3.23 3.23 
Botswana 1 3.23 6.45 
Chile 1 3.23 9.68 
India 1 3.23 12.9 
Denmark 1 3.23 16.13 
Egypt 2 6.45 22.58 
Kyrgyzstan 1 3.23 25.81 
Malaysia 1 3.23 29.03 
Italy 5 16.13 45.16 
Japan 1 3.23 48.39 
Lithuania 8 25.81 74.19 
Spain 1 3.23 77.42 
Suriname 1 3.23 80.65 
UAE 1 3.23 83.87 
USA 4 12.9 96.77 
Mexico 1 3.23 100 
Total 31 100  
6 
 
1.5.2.2 THE RESPONDENTS AT A GLANCE 
The diverse professional backgrounds of the participating respondents and the country they represent 
are summarized in table 1.2 and 1.1, respectively. 
 
 
Table 1.2 Profession of the Respondents 
 
 
 
1.5.2.3 PURPOSE AND GOALS OF THE EMPIRICAL RESEARCH 
As the questionnaire was exploring the adequacy of the patent system and ethical issues in hSCR, the 
findings from the data analysis of the empirical investigation are likely to strengthen the conclusions 
the monograph. Hence, the goal is to increase the credibility and weight of the monograph. 
 
 
1.5.2.4 QUALITATIVE DATA ANALYSIS  
Qualitative Content Analysis (QCA) was conduceted on the comments/opinion of the respondents. 
The QCA is restricted to the independent comments made by the respondents. Since some of the 
Profession Frequency Percent Cumulative % 
Academic (any field) 2 6.45 6.45 
Ethicist/Bioethicist 2 6.45 12.9 
Lawyer 5 16.13 29.03 
Patent Examiner 2 6.45 35.48 
Patient Advocate 2 6.45 41.94 
Physician 1 3.23 45.16 
Researcher (any field) 2 6.45 51.61 
Academic & Lawyer 3 9.68 61.29 
Academic & Researcher 3 9.68 70.97 
Academic, Bioethicist & Physician 1 3.23 74.19 
Academic, Bioethicist & Lawyer 1 3.23 77.42 
Academic, Lawyer & Patient 1 3.23 80.65 
Bioethicist & Lawyer 1 3.23 83.87 
Bioethicist & Researcher 1 3.23 87.1 
Lawyer & Scientist 1 3.23 90.32 
Patent Examiner & Researcher 1 3.23 93.55 
Scientist & Researcher (any field) 2 6.45 100 
Total 31 100  
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respondents made “comments/other opinions”, the qualitative data analysis performed here reflects 
the views and perceptions of those individuals. 
 
1.5.2.4.1. DIVERSITY OF QUALITATIVE DATA ANALYSIS APPROACHES: APPLYING 
CONCEPTS OF THE CONVENTIONAL CONTENT ANALYSIS 
In the realm of qualitative data analysis, there is a great diversity of approaches used for analyzing 
text data. Methodologies like ethnography, grounded theory, phenomenology, historical research, 
qualitative content analysis, etc. have been extensively used in a broad range of studies. However, 
the choice of analysis techniques and designs are guided mainly by the research questions in mind, 
type of data available and the amount of data transformation required to answer these questions. 
Accordingly, Qualitative Content Analysis (QCA) was deemed to be the most suitable method for 
analyzing the qualitative data derived from the present study. Hsieh and Shanon in their article 
defined QCA “as a research method for the subjective interpretation of the content of text data 
through the systematic classification process of coding and identifying themes or patterns” (2005, 
1278). Among the three basic approaches to QCA, qualitative data analysis in this study reflects the 
conventional approach. In the conventional approach, researchers do not depend on existing theories 
for coding or categorizing the data. Rather coding and subsequent “themes” emerge from the data 
itself.  New insights emerge from each respondent’s unique perspectives. The study findings may be 
subsequently interpreted and compared with relevant published findings and prevalent theories. They 
can potentially contribute to expanding the existing body of knowledge and suggest future research 
(Hsieh and Shanon 2005,1279). 
According to Richards and Morse (2007, 160):“A theme runs right through data and is not 
necessarily confined to a specific segment of text. However, once a theme is identified, you are more 
likely to see segments of text that are pertinent to it.” The goal for formulating themes is, therefore, 
to identify the underlying subtleties of each response and this process requires considerable amount 
of data transformation. The extent of data transformation is dependent upon the amount and quality 
of data available. This study is based on a semi-structured or mixed type questionnaire and the 
amount of data available for qualitative analysis is rather limited. This is because in the open options 
the respondents were free to give “comment/other opinion” and only those individuals who gave 
such voluntary responses were included in the qualitative content analysis. Therefore, those who 
chose from the structured suggested options only, were not included in the qualitative analysis. An 
opinion of Dr. Mary Ellen Young
11
was sought on qualitative data analysis of the questionnaire and 
responses for this study. Based on her suggestion, the following methodology of conventional 
content analysis was performed (Figure 1.2). The extent of data transformation performed and the 
emergent key themes qualify this content analysis as a “Thematic survey” as depicted in 
Sandelowski and Barroso (Figure 1, Sandelowski and Barroso 2003, 908). The figure from 
Sandelowski and Barroso shows the continuum of data transformation where “No finding” and 
“Topical survey” findings on the left hand side represent data that are the least transformed and do 
not constitute research and qualitative research, respectively and “Interpretive explanation” on the 
farthest right represents the most evolved form of findings with the highest level of data 
transformation by the researchers (Sandelowski and Barroso 2003, 908). 
                                                 
11
 Clinical Professor, Department of Behavioral Science and Community Health, College of Public Health and Health 
Professions, University of Florida, Florida, USA. 
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Fig. 1.1 “Typology of Qualitative Findings” (Figure 1, Sandelowski and Barroso 2003, 908) 
Major steps comprising the QCA is depicted in figure 1.2. Details of the following methodology can 
be found in appendix V, VA and VB. Appendix VA and VB comprise of step one (1) performed 
separately by two different analysts.
12
 Appendix V is the compilation of key words and major key 
themes (step 2-4) from both the analysts. Interpretation of the major key themes for each question 
and the overall summary is presented in chapters 5 and 6 of the monograph. 
                                                 
12
 Two analysts having different backgrounds are expected to have unique perspectives and yield a better quality of 
analysis. Analyst of appendix VA is Arif Jamil (Ph.D. Research Fellow (2012-2015) in Bioethics and Biolaw, Erasmus 
Mundus Joint International Doctoral Degree in Law, Science and Technology (LAST-JD); LL.M. in IP) and analyst of 
appendix VB is Tania S. Bonny (Ph.D. Research Fellow (2013 – Onward), Dept. of Environmental & Global Health, 
University of Florida, USA; Lecturer, Dept. of Microbiology, University of Dhaka, Bangladesh). Observations from both 
the analysts (developed in two separate appendices) were used to formulate “Common Key Themes (both analyst)” and 
“Unique Key Themes (one analyst)” which resulted in formulating the “Major Key Themes” and helped develop its 
interpretation. 
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Fig. 1.2 Sequence of actions in the Qualitative Content Analysis (QCA) 
 
 
 
 
Step 1 
Extracting “Key words” followed by identifying “Key themes” 
from each response (performed separately by both the 
analysts) 
Step 2 
For each response, the key words and the corresponding key 
themes identified by the two analysts are compared and 
compiled. These can be divided into: 
Unique Key Words (Extracted by 
one analyst only) 
↓ 
Unique Key Themes identified 
Common Key Words (Extracted 
by both the analysts) 
↓ 
Common Key Themes identified 
Step 3 
Interpretation of the major key 
themes 
Step 4 
Step 1-3 repeated with responses from 
all thirteen questions 
Step 5 
Overall Summary 
10 
 
1.6 OUTLINE OF THE THESIS 
The Monograph consists of seven (7) chapters. They have hereinafter stated contents. 
 
Ch. 1: INTRODUCTION: 
 
This chapter deals with the problem space, research questions, research aims, methodology and 
outline of the thesis. 
 
Ch. 2: DISCUSSION OF RELEVANT CONCEPTS: 
 
Chapter 2 attempts to provide a clarification of certain term/concept in the research context. The 
definition of “human embryo”, and an explanation of the expressions “human stem cell based 
invention/innovation” is provided.  
 
Ch. 3: HUMAN STEM CELL RESEARCH AND INVENTION: ANALYSIS OF ETHICAL AND 
LEGAL ISSUES: 
 
The most advanced techniques of derivation of human stem cells have been examined from the 
clinical and ethical perspectives in this chapter. They include:  
• Human Embryonic Stem Cells (hESC) from the Inner Cell Mass (ICM) of the Blastocyst; 
• Nuclear Transfer Embryonic Stem Cells (NT-ESC)/Somatic Cell Nuclear Transfer (SCNT); 
• Induced Pluripotent Stem Cells (iPSC); 
• Embryonic Stem Cells (ESC) from the blastomere cell of the pre-implantation stage embryo; 
and 
• Human Parthenogenetic Stem Cells (hpSC). 
 
Legal purview of hSCR, ethical and bioethical issues, access to the therapy, etc. were the important 
topics for the discussion in this chapter.  
 
 
Ch. 4: ANALYSIS OF IPR ISSUES: 
 
This chapter examined the patentability of hSCI and the “exclusions” from patenting. It talked about 
the divergence in the patent frameworks and the implications of divergence. Patent related concerns 
like regulatory data exclusivity, compulsory license, slim differences among the inventions, future 
legal complications, etc. were discussed in this chapter.  
 
 
Ch. 5: QUALITATIVE DATA ANALYSIS: 
 
This chapter is dedicated to qualitative data analysis (Qualitative Content Analysis (QCA)). 
Interpretation of the major key themes derived from the responses to all 13 questions is provided in 
this chapter.  
 
Ch. 6: SUMMARY:  
 
This chapter presents the summary of ethical and legal analysis and the summary on IPR issues. 
The contents of the overall summary of the QCA can be found in this chapter.  
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Ch. 7: CONCLUSION AND FURTHER RESEARCH: 
 
This chapter briefly presents the conclusions and future research. 
 
The integral explanatory parts are the following appendices: 
• Appendix I: Legal Framework; 
• Appendix II: Questionnaire; 
• Appendix III: Respondents; 
• Appendix IV: Questions’ Designs; 
• Appendix V: Qualitative Analysis (Qualitative Content Analysis (QCA)) 
• Appendix VA: Analyst AJ; 
• Appendix VB: Analyst Tania. 
The additional contents are:  
• Abbreviations; 
• Acknowledgment;  
• Case List; and 
• Index. 
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CHAPTER 2 
DISCUSSION OF RELEVANT CONCEPTS 
2.1 CLARIFICATION OF THE KEY CONCEPTS IN THE RESEARCH CONTEXT 
This chapter attempts to provide a definition of “human embryo”, and an explanation for the 
expressions “human stem cell based invention/innovation”. 
 
Many of the techniques of derivation of human stem cells examined from the clinical and ethical 
perspectives in this thesis use embryo and cloned embryo. Those techniques are:  
•  hESCs from the ICM of the Blastocyst; 
• ESC from the blastomere cell of the pre-implantation stage embryo; and 
• NT-ESC/SCNT. 
Certain use and destruction of the human embryo causes most of the ethical controversies in “hSCR 
and patenting of the hSCI,” thereby, requiring sharp explanation of the term.  
 
hSCR can result in both invention and innovation. Therefore, why the acronym hSCI shall mean the 
expressions “Human Stem Cell based Invention/Innovation” is explained here.  
 
There could be clarification of many other scientific terms in this chapter, but throughout the 
monograph, footnotes clarified the concepts as and when deemed necessary. Some well-established 
concepts in the field of IP do not require any new explanation. An explanation on “human embryo” 
and “hSCI” was necessary to incorporate, as different authors may explain those concepts 
differently.  Presenting them in a separate chapter allows to keep the other chapters less burdened. 
2.1.1 HUMAN EMBRYO 
What is human embryo? My intention here is to find a legal definition compatible to scientific 
explanations of the embryo. In fact, different legal texts use different connotations. What is deemed 
unacceptable from the ethical perspective would depend on how we have perceived the term “human 
embryo.” 
Clinical/Biological Definition of Human Embryo: 
Clinical gestational week is calculated approximately 2 weeks earlier than the actual event of 
fertilization.
1
 Embryonic period comprises of Carnegie stages 1-23 which span through week 1-8 
following fertilization (UNSW Embryology: Human Development Timeline 2015; UNSW 
Embryology: Timeline human development 2015; Tania S. Bonny, in Dropbox with the researcher, 
                                                 
1
 William A. Engle (“Lead author”) explained “Gestational age (completed weeks)” as “time elapsed between the first 
day of the last menstrual period and the day of delivery. If pregnancy was achieved using assisted reproductive 
technology, gestational age is calculated by adding 2 weeks to the conceptional age.” (2004, 1363; italics in original).  
 
It is not possible to determine the exact time/moment of the “fertilization event” in case of natural pregnancy, but it is 
possible in case of IVF. The procedures they use to inseminate eggs allow recording the time of fertilization. They just 
add 2 weeks more to this date to estimate expected delivery date. But in both cases, a 2-week Gestational Age (GA) is 
considered to calculate estimated delivery time. 
For natural pregnancy: If doctors know the 1
st
 day of LMP (Last Menstrual Period), they can estimate the approximate 
fertilization time, but not exactly. GA start from the first day of period (“first day of the last menstrual period” (Engle 
2004, 1363)). From this date (first day of period) the unknown time of fertilization is approximately within 2 weeks 
(following ovulation, the time of effective conception is actually quite narrow).  
For IVF: Fertilization time can be recorded. Then the embryo is implanted (“Transfer of the embryos” (The Johns 
Hopkins Fertility Center: In Vitro Fertilization (IVF) 2015)). GA is calculated by adding two more weeks to fertilization 
date. Then they estimate the probable delivery date. 
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April 18, 2015). So, clinically embryonic period ends at the 10
th
 week of gestation (UNSW 
Embryology: Human Development Timeline 2015; UNSW Embryology: Timeline human 
development 2015; Tania S. Bonny, in Dropbox with the researcher, April 18, 2015). Fetal period 
begins from Carnegie stage 24 at week 9 (clinical gestational week 11) (UNSW Embryology: 
Human Development Timeline 2015; UNSW Embryology: Timeline human development 2015; 
Tania S. Bonny, in Dropbox with the researcher, April 18, 2015). 
 
 
Fig. 2.1 “Human Development Timeline” (Illustration from UNSW Embryology: Human 
Development Timeline 2015) 
The Discussion Paper of Australian Government National Health and Medical Research Council 
(NHMRC) drew the following (Figs. 2.2--2.9) “key events of the naturally occurring mammalian 
developmental processes” (Figure 1, Australian Government 2006, 7--8):  
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Fig. 2.3 “During fertilization” (Figure 1, Australian Government 2006, 7--8) 
 
 
Fig. 2.4 “Fertilisation complete” (Figure 1, Australian Government 2006, 7--8) 
 
Fig. 2.2 “Before fertilization” (Figure 1, Australian Government 2006, 7--8) 
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Fig. 2.5 “Zygote” (Figure 1, Australian Government 2006, 7--8) 
 
Fig. 2.6 “Cleavage stages” (Figure 1, Australian Government 2006, 7--8) 
 
Fig. 2.7 “Blastocyst” (Figure 1, Australian Government 2006, 7--8) 
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Fig. 2.8 “Bilaminar embryonic disk” (Figure 1, Australian Government 2006, 7--8) 
 
 
Fig. 2.9 “Embryo proper” (Figure 1, Australian Government 2006, 7--8) 
When and at which stage (from what point following fertilization) we start calling the entity an 
“embryo”? Egle Radzeviciene, 2  a Lawyer and Scientist (Molecular Biology) said: “[The] term 
“embryo” lacks definition. It is unclear from which stage of development fertilized egg is deemed to 
be an embryo.” (In email with the researcher, November 4, 2013). 
Perception of Courts:  
The judgment of Brüstle Case
3
 has defined embryos or identified potential embryos even before the 
initiation of fertilization. Paragraph 53(1) of the Judgment of the Court (Grand Chamber) described 
the features and conditions that it considered as embryo: “any human ovum after fertilisation, any 
non-fertilised human ovum into which the cell nucleus from a mature human cell has been 
transplanted, and any non-fertilised human ovum whose division and further development have been 
stimulated by parthenogenesis constitute a „human embryo‟”. 4  In the International Stem Cell 
Corporation v. Comptroller General of Patents, Designs and Trade Marks the CJEU held: “Article 
6(2)(c) of Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the 
legal protection of biotechnological inventions must be interpreted as meaning that an unfertilised 
human ovum whose division and further development have been stimulated by parthenogenesis does 
not constitute a „human embryo‟, within the meaning of that provision, if, in the light of current 
scientific knowledge, it does not, in itself, have the inherent capacity of developing into a human 
                                                 
2
 Director, Intellectual Property, Thermo Fisher Scientific, Vilnius, Lithuania.  
3
 Oliver Brüstle v. Greenpeace e.V., C-34/10, Judgment of the Court (Grand Chamber) 18 Oct. 2011, also available at 
http://curia.europa.eu/juris/liste.jsf?language=en&num=C-34/10 (last visited Aug. 07, 2014). 
4
 Id. 
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being, this being a matter for the national court to determine.”5 Therefore, the combined reading of 
the Brüstle Case (2011) and International Stem Cell Corporation case (2014) leads to the conclusion 
that for the purpose of European patent, the parthenogenetically activated eggs will not be considered 
as human embryo if they lack the possibility/potential of developing into a human. The European 
Court of Human Rights
 
in the case of Costa and Pavan v. Italy
6
 used the term “embryo” for the 
organisms at the pre implantation stage of embryonic development.
7
  
In Litowitz v. Litowitz,
8
 the Washington Supreme Court in a dispute regarding the determination of 
fate of frozen or cryopreserved embryo originally created for fertility purpose referred the post 
fertilization cells/entity as “pre-embryo”.9  While referring the term pre-embryo, Smith J in that 
case
10
 noted the following explanation by Donna A. Katz (about the term pre-embryo): “The term 
"preembryo" denotes that stage in human development immediately after fertilization occurs.” (Katz 
1998, 628n42).
11
 Smith J also referred the explanation by Clifford Grobstein that says, it “comes into 
existence with the first cell division and lasts until the appearance of a single primitive streak, which 
is the first sign of organ differentiation. This [primitive streak] occurs at about fourteen days of 
development.” (Katz, 1998, 628n42).12 
In the Legal Texts of the Countries: 
It seems that some of the Spanish legal texts use the term “pre-embryo” for the developing organism 
until the expiry of 14 days after the fertilization.
13
 The “pre-embryos” are essentially those that are 
termed as “embryo” by the IVF clinics.14 However, UK allows fertilized cells to develop in vitro 
until the expiry of 14 days.
15
 Section 1(2)(1) of the Human Fertilisation and Embryology Act 2008 
interprets and gives meaning of embryo as “embryo means a live human embryo” and it includes “an 
egg that is in the process of fertilisation or is undergoing any other process capable of resulting in an 
embryo.”16 So, the texts of Spain and UK refer the same/similar organism as “pre-embryo” and 
“embryo.”  
Embryo, according to Section 8(1) of the German Embryo Protection Act, “means the human egg 
cell, fertilised and capable of developing, from the time of fusion of the nuclei, and further, each 
                                                 
5
 Case C ‑ 364/13, Judgment of the Court (Grand Chamber) 18 Dec. 2014, paragraph 39, also available at 
http://curia.europa.eu/juris/document/document.jsf;jsessionid=9ea7d0f130de9c4121923b8f43769c42c1706a04f989.e34K
axiLc3eQc40LaxqMbN4ObheSe0?text=&docid=160936&pageIndex=0&doclang=EN&mode=lst&dir=&occ=first&part
=1&cid=88991#Footnote* (last visited Dec. 22, 2014). 
6
 Application no. 54270/10, European Court of Human Rights (Second Section) 28 Aug. 2012, also available at 
http://hudoc.echr.coe.int/sites/eng/pages/search.aspx?i=001-112993 (last visited April 14, 2015). 
7
 They can be 2-5 days old. 
8
 48 P.3d 261 (Wash. 2002). 
9
 Id. 
10
 Litowitz v. Litowitz, supra note 8. 
11
 Id. 
12
 Id. 
13
 Ley 14/2006, de 26 de mayo, sobre técnicas de reproducción humana asistida [Law 14/2006, of 26 May, on Assisted 
Human Reproduction Techniques] (B.O.E. 2006, 9292), art. 15 (Spain), available at 
http://www.boe.es/boe/dias/2006/05/27/pdfs/A19947-19956.pdf (last visited Feb. 13, 2015); Ley 14/2007, de 3 de julio, 
de Investigación biomedical [Law 14/2007, of 3 July, on Biomedical Research] (B.O.E. 2007, 12945), art. 32, 33 (Spain), 
available at http://www.boe.es/boe/dias/2007/07/04/pdfs/A28826-28848.pdf (last visited Feb. 24, 2015); 
14
 Only difference is that the IVF clinics would be inclined to use them within 5/6 days of cell differentiation process 
after fertilization, for reproductive purposes. 
15
Human Fertilisation and Embryology Act, (1990) secs. 3(3)(a); 3(4) (U.K.), available at 
http://www.legislation.gov.uk/ukpga/1990/37/section/3 (last visited April 14, 2015). 
16
 Human Fertilisation and Embryology Act, (2008) secs. 1(2)(1)(a); 1(2)(1)(b)   (U.K.), available at 
http://www.legislation.gov.uk/ukpga/2008/22/section/3 (last visited April 14, 2015). 
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totipotent cell removed from an embryo that is assumed to be able to divide and to develop into an 
individual under the appropriate conditions for that.” 17 This definition includes as embryo: 
(a) human eggs from the moment of fertilization; and 
(b) each totipotent cells derived from that developing/growing organism. 
Cells remain totipotent until 4-8 cell stage of the embryonic development; this assessment varies in 
different cited sources. Then further cell division occurs and each cell no longer remains totipotent. 
Lithuanian definition of human embryo specifies the length of the developmental phase; and it is 
human embryo until the end of 8
th
 week from the formation of the zygote.
18
 In the 9
th
 week, 
Lithuanian law calls the organism “fetus,” and until birth it is called so. 19  According to the 
Lithuanian definitions, there are two defining name of the human organism in the developmental 
phase, i.e., embryo and fetus. The “embryo” starts from the formation of the “zygote” and the “fetus” 
ends at birth.
20
  
The embryo is defined in Section 2, Chapter 27 of the Acts of 2005 on “Enhancing Regenerative 
Medicine” for the State of Massachusetts, as “an organism of the species homo-sapiens whether 
formed by fertilization, somatic cell nuclear transfer, parthenogenesis or other means.”21 However, 
hESC research is allowed in that State.
22
 According to the Codified Law on Public Health and Safety 
of South Dakota, “human embryo, means a living organism of the species Homo sapiens at the 
earliest stages of development (including the single-celled stage) that is not located in a woman's 
body.”23 It means zygote formed in vitro is an embryo for the purpose of this definition. In South 
Dakota, non-therapeutic research encompassing destruction of embryo is prohibited.
24
  
Other Different Sources: 
Is the single cell “zygote” (right after the fertilization) or after the implantation of the blastocyst, the 
growing organism would be called embryo? Advanced Fertility Center of Chicago, an IVF clinic, for 
all IVF purposes uses the term “embryo” for the 2 and 3 days old fertilized cells and to refer to 5 
days‟ old blastocyst uses the term “embryo” as well (Advanced Fertility Center of Chicago 2013).  
 
In the chronological stages of the embryonic development, different terminologies are used to 
indicate different stages of the developing embryo, e.g., morula, blastula, blastocyst, gastrula. In 
medical science, all the developing components has been clearly identified and we have merged and 
divided them as and when necessary for the interpretational purposes. The brain formation 
commences in 3-5
th
 week of development (The Danish Council of Ethics 2004, 19) or 5
th
 week of 
gestational age (NIH MedlinePlus Fetal Development 2013). More studies are needed to know the 
                                                 
17
 Gesetz zum Schutz von Embryonen [The Embryo Protection Act], Dec. 13, 1990, Federal Law Gazette (Part I, No. 69, 
Dec. 19, 1990, Bonn,) at 2746, sec. 8(1) (Ger.), available at http://www.hinxtongroup.org/docs/Germany2.html (last 
visited Feb. 13, 2015). 
18
 Law on Ethics of Biomedical Research, Lietuvos Respublikos Seimas [The Seimas of the Republic of Lithuania], 11 
May 2000 [As amended upto 15 Nov. 2007 – No X-1325], VIII-1679, art. 2(4) (Lith.). 
19
 Id. art. 2(14).  
20
 Id. art. 2(4), 2(14). 
21
 2005 Mass. Act § 2. 
22
 According to Section 3(a) of the Act of 2005, “[r]esearch and clinical applications involving the derivation and use of 
human embryonic stem cells, including somatic cell nuclear transfer, human adult stem cells from any source, umbilical 
cord cells, parthenotes and placental cells shall be permitted.” 2005 Mass. Act § 3(a). 
23
 S.D. CODIFIED LAWS § 34-14-20 (2013), available at http://law.justia.com/codes/south-dakota/2013/title-34/chapter-
14/section-34-14-20/ (last visited April 15, 2015). 
24
 Id. § 34-14-16. 
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level of consciousness in the successive stages of fetal development. There are many definitions of 
the human embryo and it is hard to take one and say that, that one is perfect. Biology has prescribed 
certain stages of embryonic and fetal development but the legislations defined the human embryo 
quite differently from each other‟s.  
Tania S. Bonny
25
 commented on the diversity of prevalent legal definitions of “human embryo”:26 
1. Legal definition may or may not always conform to the current 
biological definitions. Sometimes they are simply not well updated as 
new knowledge is gathered. Some older legal definitions reflect older 
clinical/scientific definitions. Lithuanian law seems to be pretty recent 
compared to others and they have taken into consideration of the 
current medical definitions.  
2. Legal definitions also take into account of other perspectives; apart 
from the biological/clinical context. The definition often reflects the 
prevailing thoughts and philosophy, culture, prejudice in a particular 
country or State. 
3. In the absence of clinical expert comments, it is very unlikely that a 
layperson (or from different background) would be able to fully 
understand the clinical definitions. So, there is ample opportunity of 
coming up with different (legal) interpretations of the same 
definition/term for practical purposes. (In Dropbox with the researcher, 
April 17, 2015) 
Therefore, the difference between the embryo and fetus is straightforward, i.e., “less than 8 weeks is 
embryo” and “more than 8 weeks is fetus” (weeks after fertilization). The debatable question is that, 
from which point after fertilization we should name the developing entity an “embryo.” There are 
two school of thoughts: 
a) Representing broad definition: embryo = from fertilization up to 8 weeks (Australian Government 
2006, 3); and 
b) Representing restricted definition: embryo = from 14-16 days post fertilization (from gastrulation 
stage) up to 8 weeks (Australian Government 2006, 4). Scientists from this school of thought refer to 
this first 14-16 days after fertilization as “embryogenic phase” (Australian Government 2006, 4). In 
this phase primitive streak is formed which separates the structure that forms the embryo from the 
extraembryonic tissues. Once they are separated after 14-16 days, the embryogenic (embryo 
generating) phase is complete and embryo development period starts (Australian Government 2006, 
3--4). They like to call the entity during this 14-16 days (commencing from the fertilization) a 
“conceptus/pro-embryo/pre-embryo”, and NOT an embryo (Australian Government 2006, 4). 
Usually the broad definition is widely accepted and taught in clinical embryology and accordingly 
we have the UNSW Carnegie stages (Figure 2.1: “Human Development Timeline” (Illustration from 
UNSW Embryology: Human Development Timeline 2015)), i.e., Stage 1-23 = embryo and stage 24- 
onward= fetus. 
                                                 
25
 Ph.D. Research Fellow (2013 – Onward), Dept. of Environmental & Global Health, University of Florida, USA; 
Lecturer, Dept. of Microbiology, University of Dhaka. 
26
 I requested for an opinion on chapter 2.1 “CLARIFICATION OF THE KEY CONCEPTS IN THE RESEARCH 
CONTEXT”. 
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Clearly, we can see that there is no consensus on when we should call an entity after fertilization an 
“embryo.” This lack of consensus leaves room for different interpretations of embryo in the legal 
texts. Furthermore, how the legal definitions are formulated in accordance with the current 
knowledge and how different other perspectives (other than purely biological standpoint) are taken 
into consideration, make them (definitions/interpretations) even more diverse.
27
 The diversity of 
interpretation is evident from the various sources stated above, i.e., litigations, Country/State laws, 
etc. This diversity of views/opinions/interpretations on embryo‟s definition also has 
implication/connection in patenting the hESC based inventions.  
 
2.1.2 HUMAN STEM CELL BASED INVENTION/INNOVATION 
In this monograph, wherever the acronym hSCI appears it shall mean the expressions “Human Stem 
Cell based Invention/Innovation.” The terms “invention” and “innovation”, despite synonymous 
have some differences. The primary intention of the “patent” is to offer IP protection for an 
invention. A contribution has to be able to differentiate itself from the mere “discovery,” in order to 
apply for a patent. Some inventions neither completely represent the term “invention” nor 
“discovery,” but they may make significant contribution to solve a technical problem. It is better to 
address those contributions as “innovation.” Both the “invention” and “innovation” are different 
from mere “discovery.” MacQueen et al. ([2008] 2010, 512) described: “While discoveries and 
inventions both contribute new knowledge to the sum total of human understanding, an invention 
does so through the application of that knowledge, for example, by making something available that 
was previously beyond our reach.”  
The “invention” solves the existing technical problems and hence it is novel and non-obvious for the 
purpose of patenting. But the “innovation” might not be very novel and could be just an up-gradation 
in the existing state of the art and hence, might be questionable from the perspectives of fulfilling the 
“non-obviousness” requirement of patenting. Life science embodies situations for both the 
“invention and innovation.” I asked Tania S. Bonny 28  for an opinion on how invention and 
innovation occur in the process of hSCR. In her opinion: 
If you discover the genes encoding the specific transcription factors 
within the cell contributing to the character of pluripotency, this can be 
termed as an “innovation.” The knowledge so acquired does not 
necessarily solve a problem but have long term impacts in the future 
research. You may develop a mechanism by which you are able to 
switch on these pluripotency associated genes in somatic cells (non-
stem somatic cells do have these genes but they are switched off 
normally) and convert them to stem cells or behave like stem cells. 
One product derived using this approach is the induced pluripotent 
stem cells (iPSC). So, the iPSC can be termed as “an invention.” It can 
be potentially used to treat diseases. Here both innovation and 
invention are based on stem cells or their properties. (Tania S. Bonny; 
In email with the researcher, May 30, 2014) 
 
It is also necessary that the patented inventions show an “industrial application.” Since the hSCI is a 
developing field of knowledge, many patented “claims” at this phase do not show any direct and 
                                                 
27
 In recent years, many developments took place in the reprogramming techniques, e.g., reprogramming by defined 
factors (Lewitzky and Yamanaka 2007, 467--473; Takahashi et al. 2007, 1--12). 
28
 Supra note 25. 
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straightforward industrial application. Some of them will take long time to materialize the industrial 
application, although they were granted patents.
29
 They can rather be termed as the “innovation,” 
than “invention.” If a technology has promising future application and is useful for subsequent 
downstream research, the term “innovation” is well suited for such discovery in life science. Some 
patents may have claims having the future applications and they can be also based on previous 
inventions. The inventions protected by some patents are not readily available as any therapeutic 
tool; rather they have future applications and contributions in improving the state of the art.
 
 
In the “Description” part of the U.S. Patent No. 8,759,098, issued on June 24, 2014 for the “[m]ethod 
for cloning pluripotent stem cells”, assigned to Boston Biomedical Research Institute, Inc. 30 
mentioned as “Background of Invention”: “IPSCs derived from differentiated somatic cells of 
patients are potentially a powerful tool for biomedical research and may provide a source of cells for 
replacement therapies.”31  
The “Summary of the Invention” of the same patent (U.S. Patent No.  8,759,098, issued on June 24, 
2014) provides the information about the discovery of this invention and its connections and reliance 
with other preceding inventions : 
Embodiments of the present invention are based on the discovery that 
adult stem cells expanded in culture by the method of suppression of 
asymmetric cell kinetics ("SACK;" e.g. See U.S. Pat. Nos. 7,645,610; 
7,824,912, and 7,655,465) can be reprogrammed to undifferentiated 
(less differentiated) cells by culture in a cell growth media used for 
culturing embryonic stem cells (ESCs) in the absence of exogenous 
genes or proteins of the master transcription factors used for the 
production of iPSCs, i.e., Klf4, Oct3/4, c-Myc, Nanog, Lin 28, and Sox 
2. In addition, embodiments of the invention are based on the 
discovery that addition of xanthine (Xn; the agent originally used to 
expand the adult stem cells by suppression of asymmetric cell kinetics) 
to culturemedia developed for the culture of pluripotent cells increased 
the efficiency and speed of production of iPSCs.
 32
 [Italics added] 
The abovementioned patent will have implications for the subsequent researches and the invention 
itself is about improvisation of previous knowledge in the field. The background of the invention 
(U.S. Patent No.  8,759,098, issued on June 24, 2014) states that, “[t]he average success rate of 
producing iPSCs by the virus-mediate method is roughly one in 10,000 cells and takes about four 
weeks from start to finish.”33 The summary of this invention (U.S. Patent No. 8,759,098, issued on 
June 24, 2014) claims that, “[a]fter 2 weeks of culture in pluripotent stem cell culture medium, Xn-
responsive expanded tissue stem cells become reprogrammed without any additional treatment with 
an efficiency comparable to methods that employ gene or protein transfer.”34 So, this patent (U.S. 
Patent No. 8,759,098)
35
 claims to make iPSC in about “two” weeks instead of “four.” Moreover, it 
does not suggest direct industrial application of the patent and it relied heavily on the preceding 
                                                 
29
 By the time they will reach market, a substantial part of the “term of protection” may be lapsed.  
30
 The inventor is James L. Sherley. 
31
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,759,098.PN.&OS=PN/8,759,098&RS=PN/8,759,098 (last visited July 27, 2015). 
32
 Id. 
33
 Id.  
34
 Id.  
35
 Issued on June 24, 2014. Id. 
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inventions. Such process patents based on “methods” may be better suited if they are called 
“innovation.” These patented processes may contribute in overall iPSC production methodology but 
they are not substantial enough to be called “invention,” if the requirements of the patentability are 
understood strictly. But once they are patented, they automatically become “invention,” as the patent 
protects inventions only.  
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CHAPTER 3 
HUMAN STEM CELL RESEARCH AND INVENTION: ANALYSIS OF ETHICAL AND 
LEGAL ISSUES 
 
3.1 HUMAN STEM CELL RESEARCH: VARIOUS TYPES AND THEIR ETHICAL AND 
LEGAL ISSUES 
The Health and Safety Code of California defined and described human Stem Cell (hereinafter 
referred to as hSC) as, ―nonspecialized cells that have the capacity to divide in culture and to 
differentiate into more mature cells with specialized functions.‖1 This sub-chapter (3.1) of the 
monograph discusses various scientific, ethical and legal issues concerning the human Stem Cell 
Research (hereinafter referred to as hSCR). The following types of hSCR and the techniques of the 
derivation of hSC have been examined from the clinical, ethical and legal perspectives in this 
chapter:  
 Adult Stem Cell; 
 hESC (Human Embryonic Stem Cell) from ICM of the Blastocyst; 
 NT-ESC/SCNT (Somatic Cell Nuclear Transfer); 
 iPSC (Induced Pluripotent Stem Cell); 
 ESC (Embryonic Stem Cell) from the Blastomere Cell  (Extracted by embryo biopsy); 
 hpSC ((Human Parthenogenetic Stem Cell) By parthenogenetic activation of eggs); 
 
Following classification of the hSC researches is made for the purpose of the discussion: 
A. Human multipotent stem cells, i.e., the adult stem cells, somatic cells; and 
B. Human pluripotent stem cells, i.e., human Embryonic Stem Cell (hereinafter referred to as 
hESC) and induced Pluripotent Stem Cell (hereinafter referred to as iPSC), etc. 
 
This classification of human cells is done from the perspectives of the cell potency. Although the 
hESC and iPSC are grouped as pluripotent for the purpose of the discussion, they have notable 
differences and resemblances which are discussed throughout this sub-chapter. 
 
 
 
 
 
 
                                                 
1
 CAL. HEALTH & SAFETY CODE § 125292.10 (x) (West 2012). 
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The following figure published by Shoukhrat Mitalipov and Don Wolf (2009) shows the cell potency 
and how the reprogramming techniques create the cells with differing degree of potency at the 
different stages of the development of human organism. 
 
 
 
 
 
 
 
 
 
 
 
3.1.1 ADULT STEM CELLS AND SOMATIC CELLS 
Stem cells and its various derivation techniques can be better understood from the description of 
their methods, rather than from any confined definition. The California Institute for Regenerative 
Medicine described the features of the adult stem cells as following: ―These [adult stem cells] are 
specialized cells found in tissues of adults, children and fetuses. They are thought to exist in most of 
the body‘s tissues such as the blood, brain, liver, intestine or skin.‖ (California Institute for 
Regenerative Medicine: Stem Cell Definitions 2014). Adult stem cells are also the most constrained 
one in terms of cell potency, differentiation and application if compared with ESCs. They can repair 
the tissues of their own kind, i.e., the kind from which they were extracted (NIH Stem Cell 
Information 2013). This is why they are called ―tissue-specific stem cells‖ (California Institute for 
Regenerative Medicine 2013); and they are not capable to form any other kind of tissues of the body. 
Therefore, the adult stem cells are the undifferentiated cells that have the potential to give rise to 
other somatic (body) cells (which are fully differentiated cells) and new stem cells so that they can 
continue to replenish and repair the tissue from where they originated. The somatic or body cell
2
 has 
been a good ingredient for producing pluripotent stem cells by direct reprogramming through 
transcription factors (iPSC) or through Somatic Cell Nuclear Transfer. Research on adult stem cells 
attract the least debates for their source and process of extraction. However, adult stem cell has some 
potential and application, of course, e.g., in oncology treatments (Sipp 2011, 275--286).  
                                                 
2
 Germ cells i.e., sperm and egg cells are not somatic cells (NIH Stem Cell Information 2013). Adult human body has the 
following two basic types of cells in terms of the chromosome copy they carry: 
a) Somatic cells of all types: Each of these cells carry double copy of each chromosome (DNA are present in thread-like 
structures called the chromosomes). So, every gene is present in ―double copy‖; and  
b) Germ cell: Egg and sperm are the only germ cells in the body. These cells carry single copy of each gene. So, when a 
zygote is formed, it receives a single copy of the same chromosome from both the egg and sperm. Then the zygote 
becomes double chromosome copy again. Moreover, this amalgamation of chromosome from two different sources is the 
reason why a baby acquires some features of the mother and some from the father.  
The Somatic or body cells are of two types: 
1. Fully differentiated somatic cells; and 
2. Undifferentiated adult stem cells. 
Fig. 3.1 ―Development and reprogramming.‖ (Figure 1, Mitalipov and Wolf 2009, 12) 
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3.1.2 HUMAN PLURIPOTENT STEM CELLS  
The pluripotent stem cells have the capacity to differentiate into almost all cell types of the body. 
The pluripotent stem cells can be generated from embryonic and non-embryonic sources. This 
classification of stem cell as human Pluripotent Stem Cell (hereinafter referred to as hPSC), is a 
classification from the perspective of cell potency, not from the source of extraction. As of its own, 
hPSC is not a specific type of stem cell. It is rather a classification or identification of those cells that 
possess the particular level of differentiation capacity called ―pluripotency‖. 
 
3.1.2.1 EMBRYONIC STEM CELLS 
The ESCs were first derived by the team of James A. Thomson (Thomson et al. 1998). They were 
derived from the totipotent cells at the early stage of embryonic development and showed ―high 
levels of telomerase activity‖ which is associated to rejuvenation of cell lines (Thomson et al. 1998, 
1145). The study reported immense capacity of differentiation of the embryonic stem cell but 
reported teratoma formation in the mice (Thomson et al. 1998, 1146--1147).  
The hESCs can be derived both from the totipotent and pluripotent sources.
3
 The totipotent cells are 
derived at the earliest stage of the embryonic development, i.e., until the 8-cell stage (Intellepro IP 
management: Stem Cells 2014).
4
 But there is higher degree of legal constraint and ethical objections 
in derivation of totipotent cells, as these cells are capable of producing the live birth.
5
  
                                                 
3
 The possible derivation of the stem cells from the totipotent or pluripotent sources  directs  to two different stages of 
human (mammalian in general) development: 
First, the egg fertilized by sperm becomes one cell zygote. Zygote is totipotent and remains so until it divides up to at 
least 4-cell stage called ―blastomeres‖ (Mitalipov and Wolf 2009, 2); and 
Second, further cell division occurs and cells become more mature structure called ―blastocysts.‖ Blastocysts has two 
components namely the ―inner cell mass (ICM)‖ and ―trophectoderm (TE).‖ The pluripotent stem cells can be obtained 
from the ICM of the blastocyst and the totipotent stem cells can be derived from until at least the 4-cell stage (Mitalipov 
and Wolf 2009, 2). 
4
 4-8 cell stage, varies in different cited sources. 
5
 Shoukhrat Mitalipov and Don Wolf while explaining ―totipotency‖ narrated that: ―each totipotent cell is a self-
contained entity that can give rise to the whole organism. This is said to be true for the zygote and for early embryonic 
blastomeres up to at least the 4-cell stage embryo‖ (2009, 2). 
They are called ―totipotent‖ because they can give rise to a total organism. As totipotent cells can give rise to complete 
blastocysts (which is comprised of the Inner Cell Mass (ICM) and trophectoderm (TE)), they are capable of live birth. In 
contrast, stem cells derived from ICM are pluripotent because the blastocyst is destroyed when the stem cells are derived 
from the ICM. The ICM devoid of trophectoderm (TE) is incapable of live birth. Because the TE makes the placenta 
which is integral to the fetal development. 
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Generally, human embryonic pluripotent stem cells are collected from until about the fifth day of the 
embryonic development after the fertilization (California Institute for Regenerative Medicine: Stem 
Cell Definitions 2014). This commonly practiced  derivation of ESCs results in the destruction of the 
embryo/pre-embryo
6
 from which the cells are extracted.  
 
 
 
 
Fig. 3.3 ―Developmental stages and chronological time of normal early human development up to 
blastocyst stage. […]. These embryos cleave to morulae on Day 4 and to blastocysts on Day 5.‖ 
(Figure 1, Zhang et al. 2006, 2670) 
                                                 
6
 The embryonic entities from which the pluripotent cells are derived, are termed as ―embryo‖ or ―pre-embryo.‖ Since 
there is no conclusive scientific definition of embryo, the terminology depends on the legal text of the individual State. 
Fig. 3.2 Human Blastocyst on Day 5 (Figure 4, Zhang et al. 2009, 5; Illustration from UNSW 
Embryology: Blastocyst Development 2014) 
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3.1.2.2 REPROGRAMMING BY SOMATIC CELL NUCLEAR TRANSFER AND THE 
DIRECT INTRODUCTION OF TRANSCRIPTION FACTORS 
The iPSC is a pluripotent stem cell generated from the non-embryonic sources. Yu et al. (2007) and 
Takahashi et al. (2007) reported about the reprogramming of somatic cell into pluripotent stem cell 
that resemble the embryonic (human) stem cells. Yu et al. (2007)
7
 used OCT4, SOX2, NANOG and 
LIN28 genes and Takahashi et al. (2007)
8
 used Oct3/4, Sox2, c-Myc and Klf4 genes as the 
―transcription factor‖ for the reprogramming of the adult human cells into the state of pluripotency. 
The variation in reprogramming and the diverse approaches of producing the pluripotent stem cells 
by scientists can be observed from the recent publications.  
Before the direct reprogramming of the somatic cells to iPSC was invented by Takahashi and 
Yamanaka (2006), the most typical technique for therapeutic cloning existed is the SCNT procedure. 
The SCNT technique involves fusion of the adult somatic cell nucleus with the enucleated egg of the 
donor. John B. Gurdon employed the SCNT procedure to produce viable ―frog‖ in 1962 (Gurdon 
1962; Nobelprize.org.: Sir John B. Gurdon – Facts 2015), which is also the earliest successful 
example of cloning. Shoukhrat Mitalipov and his team claimed to have successfully cloned human 
embryos by employing an optimized SCNT protocol adapted to human (Tachibana et al. 2013).
 
It  is 
a modified SCNT protocol which is uniquely suited to produce ESC from human somatic (dermal 
fibroblast) cells and egg (oocyte) donated by healthy volunteers (Tachibana et al. 2013). The 
previous SCNT protocols involved amphibians (frog) and non-human primate model and had not 
been successful in human experimentation. Tachibana et al. (2013, 1228) claimed that, ―the 
derivation of human nuclear transfer-embryonic  stem cells (NT-ESCs) has not been achieved 
despite numerous attempts during the past decade.‖ This team came up with a modified SCNT 
protocol exclusively for human and produced good quantity of ICM. Masahito Tachibana et al. 
(2013, 1231) reported : ―[I]ncorporation of caffeine [a protein phosphatase inhibitor] during 
enucleation and fusion allowed improved blastocyst development and ESC line derivation.‖  
                                                 
7
 The team is known by the name of James A. Thomson. 
8
 The team is known for Shinya Yamanaka.  
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Fig. 3.4 ―SCNT Blastocyst Development Is Affected by Premature Cytoplast Activation [….]. (F) 
NT-ESC colony with typical morphology derived from a caffeine-treated SCNT human blastocyst.‖ 
(Figure 2, Tachibana et al. 2013, 1230) 
 
The SCNT technique was also applied to produce the sheep ―Dolly‖ in 1996 (Wilmut et al. 1997). 
By using the SCNT procedure, the sheep ―Dolly‖ was the first mammal to have been cloned from the 
adult somatic cell (Wilmut et al. 1997). But in that case, the embryo was brought to full term. On the 
other hand, Mitalipov team‘s goal was to produce mature blastocysts with abundant ICM so that the 
ESC can be derived. This procedure is also describable as ―human cloning‖ but the embryo was not 
brought to term; rather the hESCs were derived from the blastocyst stage by halting the development 
of the embryos grown in vitro. 
Both the SCNT and iPSC are used to generate cells that resemble and act like ESC, i.e., exhibiting 
the property of pluripotency, but the approaches are different. For the SCNT, through nuclear 
reprogramming, the nucleus of a somatic cell is inserted into an enucleated egg
9
 and allowed to 
propagate (Tachibana et al. 2013; Li et al. 2009; French et al. 2008). The resulting clone may 
develop into an embryo. Jianyuan Li et al. (2009, 43) published the ―[d]evelopment of […] human 
embryo derived from SCNT‖.  
                                                 
9
 Egg without its own nucleus. 
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Fig. 3.5 ―Development of a human embryo derived from SCNT. […]. (C) Four-cell stage. (D) 
Eightcell stage. (E) Morula. (F) Blastocyst.‖ (Figure 2, Li et al. 2009, 43) 
 
The SCNT technique can be applied in two ways: 
 a) Reproductive cloning, i.e., the embryo is implanted into a uterus and brought to term. The 
reproductive cloning (of human) is largely prohibited for ethical reasons.  
  b) Therapeutic cloning through the destruction of the embryo to derive the ESCs for research and 
therapeutic purposes. 
The following diagram of Paul Knoepfler ((2013); Knoepfler Lab Stem Cell Blog 2014) depicts the 
therapeutic and reproductive cloning: 
 
Fig. 3.6 Human SCNT Cloning Options (Illustration from Knoepfler 2013, 299--300; Knoepfler Lab 
Stem Cell Blog 2014) 
The SCNT has three major concerns (ethical and clinical): 
(i) it requires healthy eggs;10  
(ii) the efficiency is low; 
                                                 
10
  Tachibana et al. (2013, 1235) reported: ―[T]he oocyte quality is ultimately linked to the genetic constitution of 
individual egg donors.‖ 
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(iii) it causes destruction of the embryo to derive the ESCs used for research and therapy. 
The iPSC technology emerged in 2006.
11
 These cells were generated through direct nuclear 
reprogramming of somatic cells by introducing the transcription factors (Takahashi and Yamanaka 
2006). This technology does not involve any egg and embryo production and their subsequent 
destruction. Instead, the technique of generating iPSC employs only somatic or adult stem cell and a 
direct reprogramming of that somatic cell is performed to achieve an ESC-like cell. Therefore, the 
iPSC technology has no concern around egg donation and embryo destruction but it has concerns 
over the efficiency of production and safety in application. However, safety in application is a 
concern for all therapeutic applications stemming from all the emerging stem cell technologies. 
Christine L. Mummery and Bernard A. J. Roelen (2013) made a comparative discussion of the iPSC 
generation reported by Takahashi and Yamanaka (2006) and SCNT procedure by Tachibana et al. 
(2013). The differences between the two reprogramming are stated in the words of Mummery and 
Roelen as follows: 
In iPS cells, mitochondria (organelles that are the main source of 
cellular energy), as well as all other organelles, originate from the 
donor cell. In SCNT-ES cells, the mitochondria are derived from the 
oocyte and not from the donor of the nucleus. Apart from the nucleus, 
mitochondria are the only organelles that contain DNA, which encodes 
around ten genes. This means that SCNT-ES cells might activate the 
immune system of an individual who is ostensibly being treated with 
their ‗own‘ SCNT-ES cells and cause them to be rejected. [….] Direct 
reprogramming of human iPS cells takes several weeks, whereas 
SCNT-ES cells are reprogrammed within a few hours by the natural 
factors present in the oocyte, and could in principle give rise to new 
offspring. (Mummery and Roelen 2013, 174--75) 
  
However, in addition to the above discussion Mummery and Roelen (2013) drew an eloquent 
comparative diagram of the both reprogramming techniques.  
 
Fig. 3.7 Diagram of SCNT (NT-ESC) of Tachibana et al. (2013) (―a‖), and iPSC of Takahashi and 
Yamanaka (2006) (―b‖) (Figure 1, Mummery and Roelen 2013, 174) 
 
                                                 
11
 The first invention of its kind involved the reprogramming of the mouse somatic cells.  
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However, could the cloning of embryo by the team of Mitalipov (Tachibana et al. 2013) raise the 
concern of live birth of human? How different the technique is from the reproductive cloning? The 
scientist taking part in the study negated the chance of live birth by claiming that they tried this on 
monkeys and it did not produce live birth (Cyranoski 2013, 296). However, it appears that Mitalipov 
team destroyed the mature blastocysts and collected ICM from them. It is pertinent to mention that 
two things are required to produce a live birth: 
1. An intact and viable blastocyst which has both ICM and TE (Trophectoderm);
12
  
2. A living female uterus where this blastocyst will be implanted.
13
  
What they did is the completion of the first step of cloning (which is common protocol/step for both 
reproductive and therapeutic cloning) but they did not proceed towards placing the cloned embryo in 
the uterine environment (which is the further step towards the reproductive cloning); instead they 
destroyed the blastocyst and derived ESCs. The Mitalipov team followed the procedure towards the 
goal of the therapeutic cloning and did not proceed further towards the goal of reproductive cloning, 
after cloning the embryos.  
One of the core ethical objections against ESC research is that the destroyed embryo had a potential 
to become life. The deliberate destruction or certain use of embryos for commercial purposes, is the 
ethical concern, for certain school of moral philosophy. Do the iPSC and SCNT raise same or similar 
concern? The SCNT involves production of embryo to derive the ESCs. If the developing embryos 
(cloned embryos) were implanted in the optimal environment (conventionally within a uterus),
14
 
those embryos might have the potential to live birth. But the legal framework in order to approve or 
reject such research must make an objective evaluation of scientific integrity, ethics and potential 
application of those embryos. Customized therapy targeting specific patient may require the donation 
of egg and adult somatic cells from that patient. In this case an embryo will be made using SCNT 
destined to ―destruction,‖ solely because it was made with an intention to prepare the stem cell 
therapy. 
Takahashi et al. (2007) reported the success of direct reprogramming of somatic cell into iPSC 
(human) by transcription factors. Wernig et al. (2007) published that, ―iPS cells can establish all 
lineages of the embryo and thus have a similar developmental potential as ES cells.‖15 Several 
researches found birth of mice from ―several iPS cell lines‖ by ―tetraploid complementation‖ 
possible (Zhao et al. 2009; Kang et al. 2009). Therefore, the claim by Wernig et al. (2007) stating 
                                                 
12
 Without the TE and the external cell layer, the placenta can not be produced. 
13
 The placenta connects maternal circulation to the embryo. An embryo cannot develop if it is not placed in uterine 
environment and so it has to remain connected to the mother through the placenta during the entire period of fetal 
development until the birth. 
14
 There are legal restrictions regarding the development of an embryo outside of human body. For example, section 
3(3)(a) of the Human Fertilisation and Embryology Act, 1990 of UK prohibits ―keeping or using an embryo after the 
appearance of the primitive streak‖ and that limit is clarified as until the 14th day from the fertilization in section 3(4) of 
the same Act. Human Fertilisation and Embryology Act 1990, available at 
http://www.legislation.gov.uk/ukpga/1990/37/section/3 (last visited Feb. 05, 2015). It means that even in UK, which 
offers the most pragmatic legal framework in embryo related research, the human embryo cannot be developed outside of 
human uterus after the 14
th
 day of fertilization. The normal practice of post IVF (In Vitro Fertilization) embryo 
implantation serves the reproductive purpose only. For research and experiment, no human uterus is used and the legal 
restrictions do not seem to be flexible enough to by-pass. For example section 3(2)(a) of the Human Fertilisation and 
Embryology Act 1990 of the UK states that ―[n]o person shall place in a woman a live embryo other than a human 
embryo.‖ Human Fertilisation and Embryology Act 1990, available at 
http://www.legislation.gov.uk/ukpga/1990/37/section/3 (last visited Feb. 05, 2015). For the reproductive purpose, the 
IVF (In Vitro Fertilization) embryos are not prepared through nuclear reprogramming. They are fertilized in-vitro by 
fusing the egg and sperm cell and implanted into the uterus (NYU Fertility Center: About the In Vitro Fertilization (IVF) 
Process 2014). 
15
 That experiment was performed in mouse. 
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that ―somatic cells can be reprogrammed to a pluripotent state that is similar, if not identical, to that 
of normal ES cells‖, is quite acceptable. These studies indicate that human iPSC has a potential to 
contribute to a live birth, only if the tetraploid complementation assay is followed. It is important to 
mention that tetraploid complementation assay is used to test the pluripotency and developmental 
potential of the iPSCs; it is not an essential or integral procedure for the therapeutic application of 
the iPSC. For the therapeutic application, what will be needed is that the iPSC is reprogrammed 
efficiently and properly so that its achieved pluripotency can contribute to the desired therapeutic 
purpose. In case of iPSC, a somatic cell is directly reprogrammed to ESC-like cell and it does not 
involve embryo formation in order to go for therapeutic application. Therefore, the iPSC (that would 
be used for the therapy) itself does not have the direct ―potential to life.‖16 
 
Therefore, if the potentiality of live birth, i.e., the ―potential to life‖ is an ethically unacceptable 
situation for ESCs research, it may concern SCNT/NT-ESC more directly. In the process of the stem 
cell derivation, the difference between hESC (the one derived from the ICM of the Blastocyst) and 
NT-ESC (SCNT) is that: 
 the hESC (from ICM of the Blastocyst) would destroy an embryo (from the germ cell) that 
had a potential to life; and 
 the NT-ESC (SCNT) would destroy a ―cloned embryo‖ (from the somatic cell) the potential 
of which is presumed, not decisively established yet. 
 
If compared between the iPSC and embryo cloning by SCNT (NT-ESC), the iPSC may be more 
acceptable than SCNT on ethical ground, because the embryo production using healthy egg is an 
indispensable step for SCNT.  Requirement of healthy eggs and their supply for the lab would just 
not be limited to donation, if this technique becomes popular. David Cyranoski (2013, 296) reported: 
―Egg donors for the [Mitalipov‘s] experiment received US$3,000-7,000 in compensation.‖ 
 
The diverse choices of the respondents can be observed from their opinion on ―human embryo 
destruction‖ in response to the question no. 3.17 Following are the Major Key Themes derived from 
responses to question no. 3:
18
  
 
 Unethical in general; 
 Acceptable to employ embryo in limited circumstances; 
 Balance of rights; 
 Contribution of the research to the society and the individual; 
 Support for only the use embryos in research that are redundant for clinical purposes (e.g., 
IVF); 
 The creation of in-vitro embryo exclusively for research purposes considered unethical; 
 Proportion and reality; 
                                                 
16
 Some authors argue that having potential does not mean anything by itself, until it is realized into reality (Devolder 
2009, 1285). 
17
 Question No. 3 says: ―How do you see the act of destruction of human embryo for the purpose of research and 
invention/innovation‖. 
18
 Some of the words/phrases used/mentioned within quotation in the major key themes and their interpretations are the 
exact words/phrases used by the respondents. Appendix V: Qualitative Analysis (Qualitative Content Analysis (QCA)). 
 
The questionnaire mentioned that, ―the identity of the participants shall be kept anonymous, unless required to prove the 
authenticity of the study.‖ Appendix II: Questionnaire. 
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 The ―term ‗embryo‘ lacks definition‖; 
 The word ―destruction‖ has a negative connotation; 
 Embryo at early stage is a ―biological material of human origin‖ and a different component 
from the human being or human body; 
 Alternative sources are available; 
 Cord blood cells can provide the same types of stem cells; 
 Good scientific rationale, informed consent from embryo donors and careful monitoring are 
critical. 
 
The Interpretation of the Major Key Themes derived from responses to question no. 3 can be found in 
Ch. 5.  
 
3.1.2.3 STEM CELLS DERIVED FROM THE PRE-IMPLANTATION STAGE EMBRYO’S 
BLASTOMERE CELL, HUMAN PARTHENOGENETIC STEM CELLS, ETC. 
 
Irina Klimanskaya et al. (2006, 481) reported the derivation of embryonic stem cell ―from single 
blastomeres.‖  
 
Fig. 3.8 ―Derivation of hES cells from single blastomeres. a, Biopsy of a single blastomere.‖ (Figure 
1, Klimanskaya et al. 2006, 482) 
The United States Patent Number 7,893,315, issued on February 22, 2011 was assigned to Advanced 
Cell Technology, Inc. of Marlborough, Massachusetts, USA
19
 for the methods of derivation of 
human embryonic stem cells from 8-cell stage embryo through blastomere cell removal without 
causing destruction of the embryo‘s normal developments (Advanced Cell technology: Research 
&Development 2014).
20
 Another patent
21
 recently granted to the same group of inventors and 
                                                 
19
 Advanced Cell Technology has changed its corporate name to ―Ocata Therapeutics, Inc.‖ on November 14, 2014 
(Ocata Therapeutics, Inc.: Advanced Cell Technology Changes Name to Ocata Therapeutics 2014). 
20
 The inventors are Young Gie Chung, Robert Lanza and Irina V. Klimanskaya. 
21
 U.S. Patent Number 8,742,200 (issued June 3, 2014). 
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assignee
22
 for the ―[d]erivation of embryonic stem cells and embryo-derived cells‖ mentioned in the 
―summary of the invention‖ the following features of the inventions:    
The ES cells produced from the blastomere may be pluripotent or by 
some definitions totipotent.[….]. The embryo may be from the 2-cell 
stage to the 16 cell stage. In one embodiment, the embryo is from the 4 
cell stage to the 10 cell stage. In another embodiment the embryo is a 
6-8 cell stage embryo. In yet another embodiment, the embryo is an 8-
10 cell stage embryo. (U.S. Patent Number 8,742,200; issued June 3, 
2014) 
Since some of the derived cells are totipotent by some definitions, the derived totipotent cells may 
have the ―potential to life‖ (if provided with a conducive environment), given the fact that only 
pluripotent cells cannot culminate into live birth for lacking the ability to form the extraembryonic 
tissue. Another ethical concern for this method is that the process may undermine the safety of the 
biopsied embryo, if it is implanted after the extraction of the blastomere cell. Stem cell can be 
propagated from the blastomere cell taken out from a pre-implantation embryo (in conjunction with 
IVF; similar to PGD) and it is claimed in the ―[d]escription of the invention‖ that the remaining part 
of the developing embryo can be successfully implanted into the uterus.
23
 The ―summary of the 
invention‖ of the United States Patent No. 8,742,200, issued on June 3, 2014 states: 
―In another aspect, the invention provides a method of generating 
autologous stem cells concomitantly to performing genetic diagnosis. 
A blastomere is removed from an embryo, as is typically done during 
pre-implantation genetic diagnosis (PGD). The blastomere is cultured 
and permitted to divide at least once. After division, one progeny cell 
is used for genetic diagnosis, and the other progeny cell is further 
cultured (using any of the methods described herein) to produce an ES 
cell or ES cell line.‖24  
The description of the invention of United States Patent No. 8,742,200, issued on June 3, 2014 states 
that, ―[i]n one embodiment the invention provides methods for biopsy of a blastocyst which will 
produce embryonic stem cells, and the remainder of the blastocyst is implanted and results in a 
pregnancy and later in a live birth.‖25 Is it scientifically established that, that an implanted embryo 
brought to term
26
  did not have any developmental abnormality that might affect the quality of life of 
                                                 
22
 The assignee is the Advanced Cell Technology, Inc. (Marlborough, MA) and the inventors are Young Gie Chung,  
Robert Lanza and  Irina V. Klimanskaya. 
23
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at  
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,742,200.PN.&OS=PN/8,742,200&RS=PN/8,742,200 (last visited June 23, 2015). 
24
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at  
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,742,200.PN.&OS=PN/8,742,200&RS=PN/8,742,200 (last visited Mar.17, 2015). 
25
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at  
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,742,200.PN.&OS=PN/8,742,200&RS=PN/8,742,200 (last visited Nov. 27, 2014). 
26
 No published report of successful ―implantation‖ and ―live birth‖ was found corresponding (related to) to this 
assay/method; only the possibility (as a method) is claimed/stated. The ―summary of the invention‖ of the United States 
Patent No. 8,742,200, issued on June 3, 2014 states: ―The biopsied embryo may be implanted or cryopreserved.‖ United 
States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at  
http://patft.uspto.gov/netacgi/nph-
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the resulting child/human? What are the short or long-term consequences in the human born from a 
biopsied embryo? Embryo biopsy is usually conducted for the PGD. In the case of PGD, the same 
thing is done but with a different objective. For PGD a single blastomere cell is taken out and tests 
are conducted to find out any genetic abnormality that may be harmful for the optimum ―embryo 
development.‖ There is still concern and question as to how safe and effective PGD is to ensure that 
a healthy baby with normal genetic makeup would be born?  
Richard Sherbahn MD
27
 wrote: ―[M]ore studies on PGD for aneuploidy screening are needed. […]. 
Studies are needed for both day 3 biopsies with fresh embryo transfers and day 5-6 biopsies with 
frozen embryo transfers with evaluation of all 23 chromosomes‖ (Advanced Fertility Center of 
Chicago: PGS and IVF - Preimplantation Genetic Screening Using Day 3 Embryo Biopsy 2015). 
Those parents who have real concerns that some genetic abnormalities might be transferred to the 
offspring unless something is done to prevent it, mostly request that PGD procedure.
28
 This ―stem 
cell derivation process‖ is not employed under the belief that the embryo itself might have some 
diseases that need to be prevented or addressed. Moreover, early stage (2-16 cell)
29
 embryos are 
used/biopsied for this technique.
30
 The objective of this method seems to derive ES cell without 
destroying the developmental potential of the embryo.
31
 The US patent No. 8,742,200, issued on June 
3, 2014 stated as ―Methods of Conducting Research‖:  
―As detailed above, embryonic stem cell research has been partially 
hindered by political and ethical opposition to the destruction of 
embryos. The present invention not only provides an alternative 
method for efficiently generating cells and cell lines, including ES 
cells and cell lines, the present invention also provides a method that 
does not require that new embryos be destroyed as part of the process 
of ES cell derivation. Remaining embryos can be cryopreserved and 
perpetually preserved or reserved for additional, future research use.
32
 
                                                                                                                                                                    
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,742,200.PN.&OS=PN/8,742,200&RS=PN/8,742,200 (last visited June 25, 2015). 
Chung et al. (2008, 113) successfully grew the biopsied embryos to the blastocyst stage and froze them down. It was 
NOT proven/claimed that these cryopreserved blastocysts were later implanted and resulted in successful birth without 
any developmental defect/abnormality in the embryo/resulting child.   
27
 Program Director of the Advanced Fertility Center of Chicago.  
28
 However, there are some reports of PGD increasing the rate of successful IVF (Gianaroli et al. 1997, 1128; Sher et al. 
2009, 1886). 
29
 U.S. Patent Number 8,742,200, issued on June 3, 2014 states in the ―summary of the invention‖: ―The embryo may be 
from the 2-cell stage to the 16 cell stage.‖ United States Patent and Trademark Office, USPTO Patent Full-Text and 
Image Database, available at  http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,742,200.PN.&OS=PN/8,742,200&RS=PN/8,742,200 (last visited June 26, 2015). 
30
 Chung et al. (2008, 115) reported: ―An experiment was carried out with blastomeres removed from two frozen 
cleavage-stage embryos that were thawed and cultured in blastocyst medium for 2 hr prior to biopsy.‖ 
31
 The ―abstract‖ of the United States Patent No. 8,742,200, issued on June 3, 2014 states: ―This present invention 
provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring 
destruction of the embryo.‖ United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, 
available at  http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,742,200.PN.&OS=PN/8,742,200&RS=PN/8,742,200 (last visited June 18, 2015). 
32
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at  
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,742,200.PN.&OS=PN/8,742,200&RS=PN/8,742,200 (last visited June 19, 2015). 
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How does ―cryopreservation‖ works as substitute of the ―destruction‖ of the embryo to console the 
ethical controversies around the latter? The US patent No. 8,742,200, issued on June 3, 2014 stated 
in the ―Therapeutic Uses of ES and ED Cells‖ (as the description of the invention): 
In one embodiment the methods of the invention are used to remove a 
blastomere preceding implantation of a human embryo after which the 
blastomere would be cultured as described above in order to derive and 
store human ES cells for therapeutic uses using cell therapy should the 
child resulting from the human embryo require, for example, disease 
therapy, tissue repair, transplantation, treatment of a cellular 
debilitation, or treatment of cellular dysfunctions in the future.
33
 
[italics added] 
How do we know in advance that the resulting child/human might need ES cells in future? Ethical 
concern may persist, if an embryo is biopsied, stem cells derived and later implanted. However, 
Klimanskaya et al. (2006, 484; nn. omitted) mentioned: ―Numerous reports suggest that neither the 
survival rate nor the subsequent development and chances of implantation differ between intact 
human embryos […] and those following blastomere biopsy for PGD. However, until remaining 
doubts about safety are resolved, we do not recommend this procedure be applied outside the context 
of PGD.‖  
In 2001, Jose B. Cibelli et al. reported parthenogenetic
34
 activation of human eggs and demonstrated 
a ―protocol for parthenogenetic activation of human eggs, embryonic cleavage, and the formation of 
a blastocoele cavity‖ (Cibelli et al. 2001, 29). Brevini and Gandolfi published that parthenotes35 
created by parthenogenesis may be alternative source of the pluripotent stem cells (2008, 20--30). 
They claimed that the parthenotes created do not develop to the full term (Brevini and Gandolfi, 
2008, 21).  
The United States Patent Application No. 20140234968, published on August 21, 2014 claimed to 
have optimized both the pn-hPSC
36
 and NT-hPSC
37
 procedures.
38
 They claimed to have achieved the 
following: 
1. pn-hPSC through parthenogenesis: They found these stem cell lines to be immunocompatible to 
a broad category of patient population (i.e., being able to match to a wide range of patients with 
differing HLA histocompatibility);
39
 and 
                                                 
33
 Id. 
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 Brevini and Gandolfi (2008, 21) described: ―Parthenogenesis is the process by which a single egg can develop without 
the presence of the male counterpart and is a form of reproduction common to a variety of organisms such as fish, […], 
lizards and snakes[…].‖ 
Parthenogenetic development does not naturally occur in the reproductive process of the mammalian species and 
therefore, human organism‘s development in this process is not a naturally occurring phenomenon.  
35
 In both the papers (Brevini and Gandolfi 2008; Cibelli et al. 2001) the end product is the same. Brevini and Gandolfi 
(2008) used the term ―parthenotes‖ in their review paper, while Cibelli et al. (2001) named it ―autologous embryo‖.  
However, their strategy of parthenogenetic egg activation is slightly different. 
36
 Parthenote Derived Human Pluripotent Stem Cells. 
37
 Nuclear Transfer Human Pluripotent Stem Cell. 
38
 United States Patent Application 20140234968, published on August 21, 2014 having Young Gie Chung and Dong 
Ryul Lee as the inventors and Sung Kwang Medical Foundation, Seoul, Korea as the applicant and assignee. United 
States Patent and Trademark Office, Patent Application Full-Text and Image Database, available at   
 http://appft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s
1=%2220140234968%22.PGNR.&OS=DN/20140234968&RS=DN/20140234968 (last visited Nov. 14, 2014). 
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2. NT-hPSC through SCNT: This stem cell line is derived from enucleated eggs where patient 
somatic cell nucleus has been introduced. So, this type of stem cells are histocompatible to the 
patient in question and may facilitate autologous transplantation with reduced risk of immune 
rejection. However, this type of stem cell is individual patient-specific and not for a group of 
patients.
40
 
But the fact that egg procurement is integral part of the hpSC research, it requires some ethical issues 
to be addressed. Women shall be either encouraged to donate the eggs for such researches or egg 
procurement may open up new commercial avenues. Egg donation is not always harmless for the 
health of the women. The artificial ovulation may cause some harmful repercussions. There can be 
short and long-term effects of the procedure of the egg donation. Despite of the ethical dilemma 
associated to the procurement of good quality eggs, for research or for medically assisted 
reproduction, egg donation for ―monetary consideration‖ remains in practice. However, United 
States Patent No. 8,420,393, issued on April 16, 2013 for the ―[g]eneration of an autologous stem 
cell library from human oocytes parthenogenetically activated by high or low oxygen tension‖, 
having Elena S. Revazova,  Marina V. Pryzhkova, Leonid N. Kuzmichev and Jeffrey D. Janus as the 
inventors was assigned to the International Stem Cell Corporation (ISCO), California.
41
 It seems that 
for the purpose hSCR, procurement of eggs may become part of the trade. For some critics, the end 
may not justify the means.  
3.1.2.4 ARE THEY SUBSTITUTE OF EACH OTHER OR DIFFERENT FROM EACH 
OTHER? 
The hESC and iPSC have substantial differences. Although they can be merged into same genre of 
pluripotency, they are not same thing from the perspective of means of extraction and safety of 
application. However, the hESC is believed to hold more potential than the iPSC,
42
 whereas 
autologous iPSCs are believed to be more likely to overcome immune rejection.
43
 The human 
embryonic pluripotent stem cells are typically derived from the ICM of the Blastocyst and it is 
claimed that the derived cells do not possess the capacity to develop into human (Intellepro IP 
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 United States Patent No. 8,420,393, issued on April 16, 2013. United States Patent and Trademark Office, USPTO 
Patent Full-Text and Image Database, available at http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,420,393.PN.&OS=PN/8,420,393&RS=PN/8,420,393  (last visited Nov. 10, 2014). 
42
 The hESC is naturally both pluripotent and totipotent. For the purpose of hESC research, the most conventional 
derivation involves the extraction of the pluripotent cells. The iPSC is induced or reprogrammed to be pluripotent. If we 
consider efficiency in differentiation potential, clearly hESC have upper hand because it is naturally programmed to do 
so and it may be safer too. The current scientific endeavors related to iPSC basically want to ensure two things: 
1. iPSC should have similar differentiation potential and genetic stability as hESC; and 
2. When used as therapy, these cells should exhibit satisfactory level of efficacy but not elicit any undesirable immune 
reactions in the recipient (be it syngeneic or allogeneic iPSC). The autologous iPSC is preferred more than heterologous 
or allogeneic, as it minimizes many complications (e.g., lack of histocompatibility; the patient derived iPSC should be 
histocompatible when introduced into the body).  
The goal of iPSC is only to produce iPSC, which can be as comparable as possible to the ESC derived from ICM, in 
terms of differentiation potential and genetic stability. 
43
 Each type of pluripotent stem cell have its own kind of promises and its unique limitation from the scientific 
perspective and have different degree of constraint and concern from the conventional ethical perspective. 
The patient specific iPSC should theoretically overcome the problem of immune rejection. But it is found in recent 
studies that some syngeneic tissue derived (syngeneic meaning ―from the same host‖) iPSC did cause immunogenicity in 
the host (Cao et al. 2014, 1--3). Jiani Cao et al. (2014, 1) commented: ―The question whether iPSC derivatives are 
immnogeneic [immunogenic] or not is straightforward; however, the answer to this question is very complicated due to 
the developmental randomness of iPSC and the nondeterminacy of the abnormal expression of the minor antigens.‖ The 
authors concluded that this issue should be taken into serious consideration when implementing iPSC in clinical therapy 
(Cao et al. 2014). 
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management: Stem Cells 2014). The cells ―derived from fertilized oocytes, and cells of embryo up to 
about the 8 cell stage‖ are totipotent cells and it is claimed that totipotent cells have the capacity to 
develop as human (Intellepro IP management: Stem Cells 2014). But the extraction process may 
destroy the developmental potential of the embryo itself, from which the cells are extracted, 
depending on the extraction technique.
44
 The ―single-cell biopsy technique‖ invented and patented 
by the Advanced Cell Technology (Ocata Therapeutics, Inc.) claimed that their extraction of cells 
from the ―human blastomeres‖ does not harm the developmental potential of the embryo itself and 
the derived cells are ESC-like cells (ACT‘s Blastomere Technology 2014). The iPSCs are also at 
present believed to be reprogrammed as pluripotent.
45
 The year 2013 experienced another trial of 
SCNT technique that cloned human embryo from somatic cell (Tachibana et al. 2013). Are they 
substitute of each other or different from each other?  
However, if differences are to be drawn, some differences do persist among them, if viewed from the 
source of extraction, safety and efficacy in application. The production cost, e.g., donors sourced or 
IVF redundant, compensation for donation and the reprogramming costs etc. may also account for 
the differences. All of these three approaches have the following major concerns: 
 For the hESC (derived from the ICM of the Blastocyst), the major concern and challenge 
would be ethical consideration regarding embryo destruction, availability of good quality 
IVF redundant embryos, the immune compatibility and unknown health effects of the 
recipients.
 46
 
 For the embryo cloning through SCNT and hpSC, if the techniques become popular, they 
may trigger commercial transaction of human eggs under the plea of egg donation. The 
SCNT process requires a steady supply of healthy eggs (often stored as cryopreserved 
specimen).
47
  
 ES Cells from the blastomere cell of the pre-implantation stage embryo derives tiotipotent 
cells (in some instances). The major concern in extraction of blastomere cell from the pre-
implantation stage embryo is that this procedure may compromise the safety of the ―biopsied 
embryo‖ / ―the resulting child‖, if it is implanted and may cause unnecessary hindrance in the 
normal development of the fetus. If PGD is not necessary and this procedure is conducted on 
the ―to be implanted embryo‖, serious ethical controversies shall arise. 48 
 For the iPSC by direct reprogramming through transcription factors, further intense studies 
would be required to understand the reprogramming efficiency, cell behavior and genetic 
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 This destruction of the embryo invokes the ―exclusion‖ from the patentability on ethical grounds in many jurisdictions. 
45
 The pluripotency and the developmental potential of the iPSC had been tested in different animal model systems, 
except on human.  
46
 As the IVF redundant human embryo can be used for research, many countries legitimately do that. But for the 
effective therapeutic application, healthy eggs, sperms and embryo might be necessary. UK has liberal approach that 
allows donation of egg, sperm and embryo (HFEA: Donating for Research 2014).     
47
 Embryo cloning by SCNT is an invention of 2013 (Tachibana et al. 2013) and no study on efficacy in human for 
therapeutic purposes are done yet (at the time of this writing). No published reports are available/found on phase I or II 
clinical trial yet (at the time of this writing). 
48
 At present, one of the clinical trials (of ESC derived by blastomere cell extraction) are recruiting patients and research 
participants in USA ―to evaluate the effect of subretinal injection of human embryonic stem cell derived retinal pigment 
epithelium cells‖ (ClinicalTrials.gov: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE) Cells  in Patients 
With Stargardt's Macular Dystrophy 2014). 
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stability during and after the reprogramming event, vis-à-vis the immune compatibility and 
long-term health effect of the recipient.
 49
  
 
While the embryo cloning by SCNT directly surfaces concerns over egg donation and women‘s 
health, hESC research (by destruction of the embryo) is already prohibited in many countries. Since 
they are not exactly the same thing, for several reasons, there may be a boost in one type of research 
technique compared to others. Christoph Bock et al. (2011, 439) published that, ―substantial 
variation has been reported among pluripotent cell lines, which could affect their utility and clinical 
safety.‖ 
Since many researches are now focusing on iPSCs, could that reduce the necessity of hESC 
research?  Scott et al. was of the opinion that, ―[i]t is clear that iPSCs are not eclipsing hESCs but 
have instead emerged as a complimentary technology‖ (2011, 825). Since a lot of restrictions exist 
on hESC research, several other techniques of pluripotent stem cell researches are on the rise. 
Numerous research organizations and many literatures insist and advocate that all forms of stem cell 
research should continue (American Society of Hematology 2013; International Society for Stem 
Cell Research 2013; Sipp 2011, 275--286) in order to know more about their safety in application, 
cell behavior in differentiation process, future therapeutic application and further researches beyond. 
The iPSC should invoke the least objection on ethical grounds; because it is the only technique that 
is believed to be capable of generating pluripotent stem cells without the use and destruction of the 
human eggs and embryo. The concern from the bioethical perspectives in general, shall continue to 
exist for all the emerging techniques of stem cell researches to ensure the human subject protection 
in biomedical experimentation and the long-term safety of these research outcomes when 
implemented as therapy. 
3.1.2.5 CLINICAL, ETHICAL AND LEGAL CONCERNS OVER THE iPSC 
There are certain clinical, ethical and legal concerns that need to be satisfactorily addressed before 
the iPSC can be considered as ready for the therapeutic purposes: 
A. Safety: This is to make sure that ―the iPSC derived cells for transplantation‖ (Requena et al. 
2014, 4) are safe to human use and will not induce tumorigenicity and elicit any undesirable 
immune reaction in the patient‘s body. This is particularly important from the ―long-term 
malignancy risk‖ and the ―immune rejection‖ point of view.  
B. Efficacy: There is need to prove that iPSC lines generated from different somatic cells are: 
(a) fully reprogrammed, because the partially reprogrammed iPSCs have shown limited 
differentiation capacity in some respect (Zhao 2014, 76);  
(b) have minimal or no chance of genetic reversion (to previous somatic cell type from where 
they have been reprogrammed); and 
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 First human trial (clinical study/trial on human) of fully reprogrammed iPSC by direct transcription factors 
began/launched/initiated for age related blindness in August 2013 in Japan (Stem Cells Portal: World‘s First Induced 
Pluripotent Stem Cells Clinical Study on Humans Launches in Japan, 2014).  
 
The manufacturing costs can be a concern (Kamao et al. 2014, 215). It is going to be expensive, as there is additional cost 
of the reprogramming of the somatic cell into the pluripotent state like the Embryonic Stem Cells (ESC). Some 
alternative methods of producing ESC-like cells also show low frequency (Rao 2009, 618--19).  
 
The experiments already done to observe the pluripotency and developmental potential of the iPSC are conducted on 
mouse (Zhao et al. 2010) and non-human primates (Kamao et al. 2014, 205--18). 
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(c) they behave and function like normal ES cells, i.e., show the  pluripotency and 
differentiate to any cell type intended.   
Requena et al. (2014, 4) warned that, ―[f]urther research is warranted to determine the true long term 
threat of cancer of iPSC derived cells for transplantation[…].‖ 
C. The “potential to life” issue: 
The iPSC, if used as therapy in future, is likely to bypass certain clinical, ethical and legal concerns. 
The iPSC generated from the donor somatic cells with matched Human Leukocyte Antigen (HLA) 
type or the patient‘s own somatic cell would most likely minimize or eliminate the possibility of 
immune rejection when these cells are used for the treatment purpose. The regenerative potential of 
human iPSC still needs extensive research and scrutiny (Bock et al. 2011, 439) but definitely holds 
great promise as future therapy. 
The generation of iPSC will not require fertilized egg. Nevertheless, they will be fully reprogrammed 
to retain ESC-like pluripotency. In addition, their use will not raise the concern that says that the 
―developmental potential‖ of human organism is destroyed, as it is said for the ―human embryos.‖ 
The ethical debate around the hESC research (derivation from ICM) is that it destroys the 
―developmental potential‖ of life as those embryos could grow as human, had they not been 
destroyed in the research process. They had a ―potential to life,‖ if they were implanted into a human 
uterus. Some advocates find the hESC research as against the core ideas of human dignity. The iPSC 
is able to circumvent the ―developmental potential‖ of life debate triggered in case of ―embryo 
destruction.‖50 But if they (fully reprogrammed iPSC) are injected into the ―tetraploid blastocyst‖ 
and implanted into the ―mouse uterus‖51 (Zhao et al. 2010, 963--71), they show a ―potential to life‖ 
in a different manner, which might not trigger an ethical objection (if the manner of the therapeutic 
application is taken into consideration). The human embryo will not achieve its full potential unless 
it is ―implanted‖ / ―placed into a uterine environment‖ and created the circumstances for the gradual 
development. But it has the inherent ingredients to be called an organism with the developmental 
potential to become life. Although the techniques of tetraploid complementation is viewed as a 
means to confirm the pluripotency of the iPSCs, by employing this assay and by adding the 
additional step of implantation into the uterus of the recipient mouse, the iPSC satisfies the  
proposition of ―potential to life.‖ 
Human embryo as a human organism of earliest stage has the inherent characteristics of  
―developmental potential‖, bearing the prima facie ―potential to life‖. If it were implanted and 
allowed to develop inside the human uterus (instead of destroying for the research), it could achieve 
its ―potential to life‖ gradually and result to live birth. Therefore, human embryo have both 
―developmental potential‖ and ―potential to life.‖ 
The iPSC (reprogrammed through direct transcription factors) is the somatic cell fully reprogrammed 
to satisfy the pluripotent character as that of the hESC. As it is not a human organism of earliest 
stage, it does not have the inherent ―developmental potential‖. To test the developmental potential, 
the Tetraploid Complementation (TC) assay would inject the iPSC into the tetrapolid blastocyst. The 
iPSC itself can not be implanted into the uterus. Only the tetrapolid blastocyst can be implanted into 
the uterus. If the tetraploid blastocyst is implanted into the human uterus, the iPSC is likely to 
achieve a ―potential to life‖ gradually and result to live birth (apparently; should there were an 
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 The iPSC is not in itself any organism with inherent capacity to give rise to life. The iPSC is the reprogrammed 
somatic cells. So their use cannot be considered as the ―destruction of life,‖ in a straightforward sense. 
51
 Mouse serves as a mammalian (animal) model system. 
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experiment). Therefore, the iPSC is lacking the ―developmental potential‖, but showing a ―potential 
to life‖ if the TC is employed. 
It is necessary to mention that the tetraploid complementation essay of the fully reprogrammed iPSC 
has not been tested over human,
52
 as a wide ban exists on such experimentation and the 
―differentiation capacity‖ of the iPSC is ―still limited‖ (Zhao 2014, 76). It is important to keep in 
mind that tetraploid complementation is an ―assay‖ to test the pluripotency or efficacy of the iPSCs 
generated. This assay involves a mice based basic mammalian system. The outcome of this assay to 
confirm pluripotency is ―potential to live birth,‖ provided that the iPSCs are sufficient enough to give 
rise to a full term progeny as expected from normal ES cells (Zhao et al. 2010, 963--71). However, 
this type of assay based on human system to prove the pluripotency of human iPSC not only raises 
ethical concern, it has some peculiarities as well. For tetraploid complementation assay, some special 
genes are introduced in the iPSC lines in order to make the cells fluorescent or different colored from 
normal embryo. As a result of the color difference, the anatomical parts of the embryo that originated 
exclusively from the iPSC lines can be easily identified and the pluripotency potential of the cell 
lines can be established. If we try to replicate the same assay in the case of human, it requires 
implantation of the tetraploid blastocyst into a human uterus to experiment the developmental 
potential. This essentially means bringing the human embryo to full term and end up making a 
human baby or an organ with fluorescent color glowing. Therefore, this assay cannot go beyond the 
―mouse system‖ due to ethical reasons.  
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 So their pluripotency on human is not known. 
Fig. 3.9 ―Pluripotency of induced pluripotent stem cells established by using Oct4, Klf4, and low 
Sox2 (OK+LS-iPSCs). […]. (D) Contribution of OK+LS- iPSCs derivatives in mouse E15.5 or 
E16.5 chimeric embryos. The iPSC derivatives were visualized as blue cells by using X-gal 
staining. […].‖ (Figure 4, Yamaguchi et al. 2011, 182) 
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However, scientists are employing alternative assays to see the developmental potential and 
pluripotency of the iPSCs (Martí et al. 2013, 223--53; Bock et al. 2011, 439--52). The argumentation 
on iPSC’s potential to life can be viewed as unnecessary, if the focus can be restrained on procedure 
that is required for the application only. This tetraploid complementation assay is one of the methods 
used to test the pluripotency and the developmental potential of the iPSC; it is not any essential step 
to the therapeutic application. For the therapeutic application, the iPSC-derived cells require the 
perfect reprogramming only. 
3.1.2.6 HUMAN EMBRYO FOR THE STEM CELL RESEARCH: ETHICAL AND LEGAL 
DILEMMA  
The variations of judgment on ethical grounds are often created by circumstances, background, 
societal expectation, etc. What is morally wrong in a given context is a difficult question. If the 
embryo destruction or its particular use is an unethical act or not, that would largely depend on 
perceptions towards the embryo itself. If someone considers the human embryo as a ―life‖ capable of 
perceiving humanly attributes and attaches the status of ―human being‖ to an embryo, then the 
destruction of that embryo could be equated as killing of life according to that person. However, the 
death of a  human is marked by ascribing the status of ―deceased‖ and the expulsion of a fetus is 
termed as ―abortion.‖ The destruction of early embryo is neither of them. Therefore, ―destruction‖ is 
the mostly used expression for the obliteration of the embryo/pre-embryo for the purpose of 
scientific experimentation. However, most of the legal texts do not emphasize around the process of 
―destruction‖ of embryo, rather they are more focused on the ―use‖ and ―commercialization‖ of that 
embryo.
53
  Noticeable differences exist in the legal and policy framework of the countries around the 
embryo‘s use or destruction for the hSCR. The league of people who identifies destruction of embryo 
as killing of life, presents some arguments and the mostly used one is the ―empathy‖ for the 
embryo.
54
 Whether embryo is biologically equivalent to even an unborn human, or at the early stage 
of embryogenesis, it is a human biological material, that has to be understood both through and from 
the scientific and philosophical interpretations. Where scientific explanations have possibility to 
reduce the   multiplicity of opinion, philosophical or ideological convictions can never be unanimous 
on this issue.  
 ―When does life begin‖ is a common and the most valuable question, answer of which can solve the 
debate around the status of the embryo. Some strikingly significant events take place during the 
embryonic development, e.g., fusion of sperm and egg forming the zygote, blastocyst formation, 
implantation of the blastocyst, formation of the primitive streak, development of early organs, and 
formation of fetus. The most crucial and intriguing questions may involve at which stage we can say 
that human life has begun and when the emerging entity would be neurophysically capable of 
sensing its own existence. Himma (2003, 89-109) rejected the right as ―person‖ of the developing 
embryo in the first ―10 weeks of gestational age‖ and his reason was that their brain functionality 
comes into demonstration at or after that period. Condic (2011) while stressing that life of human 
being commences from the fertilization, i.e., forming the zygote, did not find enough rationale for 
the other arguments like ―viability‖, ―brain maturity‖ that ascribe human status at certain point of 
embryonic and fetal development. Antoine Suarez (2011, 190) thought that in order to answer when 
life begins, ―one has to take the body exhibiting human architecture and spontaneous movement‖ 
into consideration. According to him, ―capability [italics in the original] for spontaneous 
movements‖ at the early stage of development is ―the sign for rational ensoulment of a human 
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 For example, Article 6 (2)(c) of the Biotech Directive, 1998 states that, invention will be unpatentable if there is ―uses 
of human embryos for industrial or commercial purposes‖. Directive 98/44/EC of the European Parliament and of the 
Council of 6 July 1998 on the Legal Protection of Biotechnological Inventions, 1998 O.J. (L 213), 0013 – 0021, 18. 
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 Deontologists or moral absolutists may find destruction of embryo or its particular use for scientific experimentation in 
general disturbing.  
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body‖ (Suarez 2011, 190). Therefore, in the complex surroundings of differing contrasting opinion, 
it is hard to suggest an exact moment ―when life begins‖ or at which stage we can call the growing 
organism human body and award the status of a human.  
Do we need an existing rational human entity to ascribe the status of the ―human‖? Beyleveld and 
Brownsword (2001, 115) identified two properties of human, i.e., ―consciousness‖ and ―physical 
embodiment‖. Ernest Becker (1973, 69) wrote while interpreting Kierkegaard‘s view on human 
entity, that human is aware of its ―own death and decay‖. Fertilized human cells while passing 
through its early embryonic developmental stages (prior to formation of primitive streak), in vitro or 
in vivo, would not be able to sense its obliteration. The beginning of the ―brain functionality‖ or the 
formation of the brain is also a remarkable stage of embryonic and fetal development. There may be 
connection with the ―brain formation‖ and the determination of the status of the growing organism. 
We need a legal consensus on the terminologies used in the early stages of the embryonic and fetal 
development.  
Major Key Themes derived from responses to question no. 2
55
 shows the perception of the 
respondents about human embryo, human body and human life:
56
  
 The embryo has no rights; 
 Embryo at its earliest stage is a mass of undifferentiated cells; 
 Presence of ―soul‖ is vital to be considered as human body and human life; 
 Embryo has no soul; 
 Absence of preciseness, conclusiveness and consensus on the definition of embryo; 
 Embryo, human body and human life are integral parts of each other and collectively form a 
human being; 
 Assigning gender to embryo; 
 Non-existence of a universality of perceptions; 
 ―Special respect‖ for embryo. 
The Interpretation of the Major Key Themes derived from responses to question no. 2 can be found in 
Ch. 5. 
Major Key Themes derived from responses to question no. 1
57
 shows the opinion of the respondents 
about human stem cell research:
58
  
 Against destruction/use of human embryo, other methods are ok; 
 Destruction of embryo is ―killing‖; 
 Prejudiced about hSCR; 
 hSCR is like any other type of scientific research; 
 Promising area for therapy; 
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 Question No. 2 was: ―How do you perceive the terms ‗embryo‘, ‗human body‘ and ‗human life‘?‖. 
56
 Supra note 18. 
57
 Question No. 1 asked: ―Do you bear any negative impression / any prejudice about human stem cell research‖. 
58
 Supra note 18. 
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 Somatic/adult stem cell research is acceptable; 
 hSCR invokes differing opinions; 
 hESC research is politically and ethically controversial. 
The respondents expressed different opinions about the use and destruction of human embryo for the 
hSCR. The Interpretation of the Major Key Themes derived from responses to question no. 1 can be 
found in Ch. 5.  
The experts/respondents were asked (question no. 9): ―Which application of human embryo can be 
permitted according to your opinion‖. The Major Key Themes derived from the responses to question 
no. 9 are the following:
59
 
 Use of human embryo for research and innovation in cases of serious disorder; 
 ―Development of therapeutics‖ by ―Academic/NPO/Government‖; 
 Employing redundant embryos that are anyway destined for destruction; 
 Research targeted to find cure or drug development but not through commercial channels; 
 Conduct stem cell research by using ―cord blood‖. 
 
The Interpretation of the Major Key Themes derived from responses to question no. 9 can be found in 
ch. 5. 
Moreover, the experts were asked (question no. 11) if they ―consider that the benefits of hESC 
(human Embryonic Stem Cell) research is more important than the risks and costs associated to it‖.  
The Major Key Themes derived from the responses to question no. 11 focused many scientific issues 
related to the hESC research:
60
 
 Future therapeutic benefits;  
 Potential application in personalized medicine and rare diseases; 
 Not noticing any risk in research; 
 Conducting economic and viability studies; 
 Non specialized and pluripotent nature of hESC; 
 Reducing time and costs of other life science researchers; 
 Strict and harmonized regulation; 
 Increase of life expectancy; 
 Benefit human life, health and the overall society; 
 Cord blood is substitute of hESC; 
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 Does not support any kind of stem cell research that involves destroying or putting the human 
embryo at risk; 
 hESC as an applied research employing human embryo without having solid and convincing 
basic science research data; 
 Benefits of hESC are contingent upon costs, affordability, time; 
 Each scientific cases vary considerably; 
 ―Context‖ and circumstances of each case. 
The Interpretation of the Major Key Themes derived from responses to question no. 11 can be found 
in ch. 5. 
3.2 HUMAN STEM CELL RESEARCH: LEGAL LANDSCAPE 
This sub-chapter explores the legal purview of the hSCR in the countries revisited for the 
monograph. The comparative discussion is presented in the following tabular form: 
Table 3.1 Legal purview of the hSCR in the countries studied 
 Research allowed Research not allowed Observation 
EU policies & 
European Community 
Legal Landscape 
Research targeted to 
cure any defect the 
embryo might have, i.e., 
research beneficial to 
the embryo itself is 
allowed (for the purpose 
of patentability) by the 
case of Oliver Brüstle v. 
Greenpeace e.V., 2011, 
decided by the CJEU.
61
 
Human ESC research 
by causing the 
destruction of the 
embryo is prohibited 
(for the purpose of 
patentability) by 
Brüstle case (2011).
62
  
Article 18 (2) of the 
Oviedo Convention 
1997 prohibits creation 
of human embryo for 
research purposes.
63
   
Not all European 
countries have signed 
and ratified the 
Oviedo Convention. 
Patent is territorial. 
Cultural diversity and 
diverse position on 
ethical issues of the 
European States is 
acknowledged time 
and again in the 
European forum and 
that justifies the 
diverse goals 
countries attempt to 
achieve from science 
and innovation.  
Germany The German Stem Cell 
Act of 2002
64
 created a 
German Embryo 
Protection Act, 1990 
Germany is one of 
those European 
                                                 
61
 C-34/10, Judgment of the Court (Grand Chamber) 18 Oct. 2011, also available at 
http://curia.europa.eu/juris/liste.jsf?language=en&num=C-34/10  (last visited July 25, 2014). 
62
 Id.  
63
 Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of 
Biology and Medicine: Convention on Human Rights and Biomedicine art. 18(2), Apr. 4, 1997, available at 
http://conventions.coe.int/Treaty/en/Treaties/Html/164.htm (last visited Feb. 12, 2015) [hereinafter Oviedo Convention]. 
64
 Stammzellgesetz [Stem Cell Act], June 28, 2002 (unofficial translation), secs. 4, 5, 6, (Ger.), available at 
http://www.hinxtongroup.org/docs/Germany1.html (last visited Feb. 13, 2015). 
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window of opportunity 
for doing ESC research 
under strict conditions 
and continued the 
opportunity with the 
imported embryonic 
stem cell lines 
―harvested‖ before May 
1, 2007 ; the ―cut-off‖ 
date being changed by 
the amendment of 2008 
(from January 1, 2002 
(in the original version) 
to May 1, 2007 (in the 
amended version)) 
(Herrmann, Woopen 
and Brüstle 2008). The 
Central Ethics  
Committee for Stem 
Cell Research (Zentrale 
Ethik-Kommission für 
Stammzellenforschung, 
ZES) is entrusted with 
the evaluation of the 
rationale for importation 
and use of the 
embryonic stem cell 
lines in Germany and 
submits its report to the 
German federal public 
health institute RKI 
which is the licensing 
authority and also 
maintains the register of 
the imported stem cell 
lines (Robert Koch 
Institute: Office of the 
Central Ethics 
Committee for Stem 
Cell Research 2014; 
(effective from 1991) 
prevents the creation 
(fertilization (fusion of  
of sperm and egg cell)) 
of embryo in vitro for 
research and 
experiment (in general; 
reproductive purpose 
remain valid 
exercise);
65
 Section 2 
of German Embryo 
Protection Act, 1990 
makes ―[i]mproper use 
[according to the text] 
of human embryos‖ a 
punishable act.
66
 
 
countries where ―a 
restrictive but 
carefully positioned‖ 
policy is prevalent for 
the stem cell 
research.  
 
 
                                                 
65
 Section 1(2) of the Embryo Protection Act 1990 states that, ―anyone will be punished who 
1. brings about artificially the penetration of a human egg cell by a human sperm cell, or  
2. transfers a human sperm cell into a human egg cell artificially, 
without intending to bring about a pregnancy in the woman from whom the egg cell originated.‖ Gesetz zum 
Schutz von Embryonen [The Embryo Protection Act], Dec. 13, 1990, Federal Law Gazette (Part I, No. 69, Dec. 
19, 1990, Bonn,) at 2746, sec. 2 (Ger.), available at http://www.hinxtongroup.org/docs/Germany2.html (last 
visited Feb. 13, 2015). 
 
66
 Section 2(2) of the Embryo Protection Act 1990 states that, ―anyone will be punished who causes a human embryo to 
develop further outside the body for any purpose other than the bringing about of a pregnancy.‖ Id. 
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The Robert Koch 
Institute: Tasks and 
Aims 2014). 
Italy Research on embryo is 
allowed only if it is 
conducted for protecting 
the health of the embryo 
itself.
67
 
Following 
researches/activities 
are not allowed: 
 creation of 
embryo for 
research and 
experiment;
68
  
 ―interventions 
cloning 
through nuclear 
transfer‖;69 and 
 ―embryo 
splitting‖.70 
  
An environment 
exists in Italy that 
may consider 
destruction of embryo 
affecting the human 
dignity and so it is 
against the 
constitutional spirit.
71
 
Article 13 of the 
Rules on Medically 
Assisted Procreation 
2004,  maintains 
strict restrictions on 
human embryo 
related research.
72
  
Lithuania Relating to human 
embryo, ―only clinical 
observations (non-
interventional trials)‖ 
are allowed,
73
 which is 
not meant to allow 
hESC research.  
Research using 
embryo targeting 
therapeutic application 
is not possible.
74
 
Creation of embryo for 
biomedical research is 
not allowed.
75
 The 
prohibitive boundary 
on the human cloning 
seems to be very 
expansive.
76
 Import 
and export of 
embryonic stem cells 
and  embryonic stem 
cell lines  are 
prohibited.
77
 
 
Embryo cloning 
through SCNT would 
attract the wide 
prohibition. 
 
                                                 
67
 Norme in materia di procreazione medicalmente assistita [Rules on Medically Assisted Procreation], Legge 19 
febbraio 2004, n. 40, in G.U. 24 febbraio 2004, n. 45, art.13(2) (It.). 
68
 Id. art. 13(3)(a) (It.). 
69
 Id. art. 13(3)(c) (It.). 
70
 Id. 
71
 Art. 32 Costituzione [Constitution] (It.). 
72
  Supra note 67, art. 13 (It.).  
73
 Law on Ethics of Biomedical Research, Lietuvos Respublikos Seimas [The Seimas of the Republic of Lithuania], 11 
May 2000 [As amended upto 15 Nov. 2007 – No X-1325], VIII-1679, art. 3(2) (Lith.).  
74
 Id. 
75
 Id. 
76
 Id. art. 3(4). 
77
 Id. art. 3(3).  
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Spain Until the expiry of the 
14
th
 day (after in vitro 
fertilization), the 
fertilized cells are 
termed as ―pre-embryo‖ 
in Spain and they can be 
used for research and 
experiment, if donated 
(created originally for 
the reproductive 
purpose but no longer 
required; can not be 
created solely for the 
experiments).
78
  
 
Article 33 of the Law 
14/2007 of July 3 on 
Biomedical Research 
prohibits creation of 
embryo solely for the 
purpose of research 
and experiment.
79
 
Despite the Article 33 
of the Law 14/2007 
of July 3, 2007 on 
Biomedical Research 
prohibited the  
creation of embryo 
solely for experiment, 
Article 15 of the Law 
14/2006 of  May 26, 
2006  allowed the use 
of those fertilized 
cells that are 
redundant or donated 
from the IVF process 
for research purposes. 
Spain maintains 
difference in using 
the terminology for 
human embryo. 
According to the 
Spanish legal texts, 
until 15
th
 day (after 
fertilization) of the 
embryonic 
development, the 
developing cells are 
called ―pre-embryo,‖ 
whereas legal texts of 
other countries like 
Lithuania address 
them as embryo.   
U.K. Creation of human 
embryo in vitro, use of 
embryo for research (for 
specific purposes) is 
allowed until the expiry 
of the 14
th
 day after the 
fertilization by the  
Human Fertilisation and 
Embryology Act 1990, 
Human Fertilisation and 
Embryology Act, 2008, 
Certain researches 
using human embryo 
or creation of embryo 
in vitro shall require 
license or 
authorization from the 
Human Fertilization 
and Embryology 
Authority (HFEA), 
according to the 
Human Fertilization 
  
 
                                                 
78
 Ley 14/2006, de 26 de mayo, sobre técnicas de reproducción humana asistida [Law 14/2006, of 26 May, on Assisted 
Human Reproduction Techniques] (B.O.E. 2006, 9292), art. 15 (Spain), available at 
http://www.boe.es/boe/dias/2006/05/27/pdfs/A19947-19956.pdf (last visited Feb. 13, 2015); Ley 14/2007, de 3 de julio, 
de Investigación biomedical [Law 14/2007, of 3 July, on Biomedical Research] (B.O.E. 2007, 12945), art. 32, 33 (Spain), 
available at http://www.boe.es/boe/dias/2007/07/04/pdfs/A28826-28848.pdf (last visited Feb. 24, 2015); 
79
 Ley 14/2007, de 3 de julio, de Investigación biomedical [Law 14/2007, of 3 July, on Biomedical Research] (B.O.E. 
2007, 12945), art. 33 (Spain), available at http://www.boe.es/boe/dias/2007/07/04/pdfs/A28826-28848.pdf (last visited 
Feb. 24, 2015). 
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and Human Fertilisation 
and Embryology 
(Research Purposes) 
Regulations 2001. 
80
 
 
and Embryology Act 
1990.
81
 After the 
formation of primitive 
streak, the research 
involving human 
embryo is not 
allowed.
82
 
 
US Federal Policy Stem cell research 
funding is available for 
the hESC research. The 
previously existing 
barriers were removed 
in 2009 by the President 
Barak Obama through 
an executive order.
83
 
 
Research resulting to 
human-animal chimera 
is not eligible for NIH 
funding. (NIH Stem 
Cell Information: 
National Institutes of 
Health Guidelines on 
Human Stem Cell 
Research 2014). 
The stem cell 
research funding for 
hESC research will 
be available for the 
applicants who will 
use the human 
embryo created for 
the IVF purpose and 
donated by the 
owner, no longer 
being required (NIH 
Stem Cell 
Information: National 
Institutes of Health 
Guidelines on Human 
Stem Cell Research 
2014).  
The  U.S. Food and 
Drug Administration 
(FDA) exercises 
certain authority over 
the biological 
products (including 
stem cell based 
products) under the 
Federal Regulations, 
i.e., 
―21CFR1271.10‖84 
                                                 
80
 Human Fertilisation and Embryology Act, (1990) sec. 3(3)(a) (U.K.), available at 
http://www.legislation.gov.uk/ukpga/1990/37/section/3 (last visited Feb. 24, 2015); Human Fertilisation and Embryology 
Act, (2008) sec. 3(5)(4) (U.K.), available at http://www.legislation.gov.uk/ukpga/2008/22/section/3 (last visited Feb. 24, 
2015); Human Fertilisation and Embryology (Research Purposes) Regulations, 2001, art. 2(2), available at 
http://www.legislation.gov.uk/uksi/2001/188/pdfs/uksi_20010188_en.pdf (last visited Feb. 24, 2015). 
81
 Human Fertilisation and Embryology Act, (1990) sched. 2 (U.K.), available at 
http://www.legislation.gov.uk/ukpga/1990/37/schedule/2 (last visited Feb. 24, 2015); 
82
 Human Fertilisation and Embryology Act, (1990) sec. 3(3)(a) (U.K.), available at 
http://www.legislation.gov.uk/ukpga/1990/37/section/3 (last visited Feb. 24, 2015). 
83
 Exec. Order 13505, 74 Fed. Reg. 10667, 10667 (Mar. 11, 2009). 
84
 21 C.F.R. §1271.10 (2014).  
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and 
21CFR1271.15‖85 
(Knoepfler 2013, 
161--62). 
California California Constitution 
Article 35, Section 5 
allows research with: 
 Adult stem cells; 
 Cord blood stem 
cells; 
 Pluripotent stem 
cells (derivation 
of pluripotent 
stem cells from 
the IVF 
redundant 
embryos and 
SCNT is 
allowed). 
86
 
Human reproductive 
cloning is prohibited.
87
 
The derivation of 
pluripotent stem cells 
is explicitly legal. 
Massachusetts 
Chapter 27 of the Act of 
2005 on ―Enhancing 
Regenerative Medicine‖ 
allows all researches 
related to stem cells, 
namely, adult stem 
cells, cord blood stem 
cells,    SCNT, and  
―derivation and use of 
human embryonic stem 
cells‖.88 
 
Section 8, Chapter 27 
of the Act of 2005 on 
―Enhancing 
Regenerative 
Medicine‖ prohibits 
reproductive cloning 
of human.
89
  
The law on stem cell 
research in 
Massachusetts is very 
liberal.  
 
New Jersey Following activities are 
allowed in the New 
Jersey: 
 Adult stem cell 
research;
90
  
 [D]erivation and 
use‖ of hESC;91 
and 
Section 3 of the  New 
Jersey Senate Bill No. 
1909 of 2002  
prohibited ―human 
cloning‖.93 
The laws and policies 
on stem cell research 
in New Jersey is 
liberal. 
                                                 
85
 21 C.F.R. §1271.15 (2014).  
86
 CAL. CONS. CODE art. 35 § 5. 
87
 CAL. HEALTH & SAFETY CODE § 24185(a). 
88
 2005 Mass. Act § 1(c). 
89
 2005 Mass. Act § 8. 
90
 N.J. Senate Bill 1909 § 2(a) (2002). 
91
 Id.  
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 Somatic Cell 
Nuclear 
Transfer.
92
 
  
South Dakota It appears that South 
Dakota favors Adult 
Stem Cell research 
(Dakota Voice 2014).  
 
Following medical 
research that has 
relevance for the 
hSCR are prohibited 
according to the 
Codified Law of the 
South Dakota: 
 Research that 
would cause 
destruction of 
human 
embryo;
94
 
 Commercial 
transaction 
(sale or 
transfer) of 
embryos for 
non-therapeutic 
research;
95
 and 
 Human 
cloning.
96
  
 
South Dakota is one 
of the most 
conservative States in 
hSCR. The definition 
of ―non-therapeutic 
research‖ in the 
South Dakota 
Codified Laws § 34-
14-19 (2013), makes 
it clear that 
therapeutic research 
on the embryo in 
question for its own 
benefit is possible, 
but any type of 
research that destroys 
or risks this embryo 
as a means to develop 
downstream 
therapeutic 
application for the 
general population is 
prohibited.
97
 
Texas Several research centers 
are dedicated to the 
adult stem cell research, 
which includes The 
Texas A&M Health 
Science Center College 
of Medicine Institute for 
Regenerative Medicine 
(IRM) (Health Science 
Center: Background 
2014) and Texas heart 
Institute (Texas Heart 
Institute: Stem Cell 
Center 2014). 
 Despite Texas 
received third largest 
amount of NIH 
funding for stem cell 
research after 
California and 
Massachusetts in 
2009, the State does 
not have any policy 
regulating the Human 
Stem Cell Research 
(Matthews and 
Rowland 2011, 19).  
However, under the 
                                                                                                                                                                    
93
 Id. § 3. 
92
 Id.  
94
 S.D. CODIFIED LAWS § 34-14-16 (2013), available at http://law.justia.com/codes/south-dakota/2013/title-34/chapter-
14/section-34-14-16/ (last visited Dec. 09, 2014).  
95
 Id. § 34-14-17.   
96 Id. § 34-14-27. 
97
 Id. § 34-14-19. 
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The Texas Medical 
Board‘s ―Practice 
Guidelines for the Use 
of Investigational 
Agents‖ effective from 
July 8, 2012 allows the 
―experimental use of 
adult stem cells‖ in 
patients (Arnold 2012, 
1776).
98
 
new rules on ―Use of 
Investigational 
Agents,‖ adopted by 
the State Medical 
Board, physicians are 
allowed to apply 
experimental 
therapies and 
medication, subject to 
respecting certain 
safety standards.
99
 
The physician is 
playing two roles 
under this guidelines 
simultaneously, i.e., 
―physician-
investigators and 
treating 
physicians.‖100 This 
is a short-cut that 
takes the clinical trial 
from the researcher to 
the physician directly 
and apparently at the 
expense borne by the 
patients (Arnold 
2012, 1776).   
 
3.3 BIOETHICAL CONCERNS IN hSCR 
Bioethics as a knowledge discipline combines both theory and practice. It attempts to capture 
scientific evolution, finds justification in philosophic foundations and reviews the incidents as 
bioethical discussion from the societal perceptions. Offering encouragement and putting restraint to 
science, both can be beneficent stand for the bioethics, depending on circumstances. Different 
thinkers viewed bioethics from different point of views. Jonathan D. Moreno saw bioethics as a 
naturalism (Moreno, 2003, 4) and John Dewey saw it from the lens of pragmatism (McGee, 2003, 
18). Bethany J. Spielman thinks: ―The strands of bioethics are drawn from a variety of sources, 
methods, theories, and fields, combined in ways that are alternately multidisciplinary, 
interdisciplinary, and nondisciplinary‖ (2007, 4). H. Tristram Engelhardt explained that in 
contemporary bioethics for regenerative medicine there persists disagreement and conflicts between 
the religious bioethics and secular bioethics (2009, 17--18).  
Bioethics is, therefore, as diverse as the human understanding of core ethical behavior. It is most 
likely that the justification for hESC research can be found in the secular bioethics; rest of the other 
streams may find it discomforting. The non-compulsory nature of bioethics distinguishes it from 
legally binding norms. Laws reflective of bioethical principles are emerging in the developed world. 
                                                 
98
 22 TEX. ADMIN. CODE §198.3 (a) (2012); 37 Tex. Reg. 4929 (July 8, 2012). 
99
 22 TEX. ADMIN. CODE §198.3 (2012); 37 Tex. Reg. 4929 (July 8, 2012).   
100
 22 TEX. ADMIN. CODE §198.3 (a) (2012); 37 Tex. Reg. 4929 (July 8, 2012).  
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Bioethical principles are enshrined in the international legal instruments both in the form of soft law 
and hard law. Several guidelines, non-binding declarations and legal instruments are developed by 
the non-government organizations, international organizations and inter-governmental 
organizations.
101
 They have contributed to the development of bioethics, gradually towards its 
formalization.  
Following interests are channeled into bioethics: 
 
Fig. 3.10 Bioethics‘ Concerns 
There is room to develop a legal instrument for ethical hSCR. It will be difficult to achieve a binding 
treaty on the subject, as the countries‘ have different opinions on the purview of the research. The 
existing bioethics‘ instruments address the issue either remotely or along with other issues. However, 
the progress taken place in last two decades towards the ethical biomedical research can be invoked 
for the hSC research as well. 
To develop an efficacious legal framework, the marriage between bioethics and human rights laws 
can be imagined. Richard E. Ashcroft outlined several advantages of merger between bioethics and 
human rights norms (2010, 4--9) and stated that, ―advantage of linking human rights and bioethics is 
that the international human rights normative framework interdigitates quite naturally with domestic 
and international legal systems‖ (2010, 6). The typical tools that have been developed in the domain 
of human rights can be used to address the enforcement inadequacies for breach of biomedical 
research ethics. Countries may also exercise the criminal law and law of tort to regulate biomedical 
research. The specific laws dedicated to specific area of research may impose penal and tortious 
obligations. But to redress large scale prolonged breach of ethical norms requiring enforcement of 
justice between and among several countries may require more than bilateral or transnational treaties. 
                                                 
101
 Such as United Nations (UN), United Nations Educational, Scientific and Cultural Organization (UNESCO), World 
Health Organization (WHO), Council of Europe (CoE), World Medical Association (WMA), Council for International 
Organizations of Medical Sciences (CIOMS), International Society for Stem Cell Research (ISSCR), and etc. 
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54 
 
Albeit very title, some of the legal instruments demonstrate the already acknowledged 
interconnectivity between human rights and bioethics.
102
 However, bioethical spirits (relevant for 
public health) can be useful to address the health care inequalities.  
I believe that, probably it is high time that bioethics for hSCR reshape itself by taking into 
consideration: 
 the context of the application (taking into account the needs and circumstances);  
 the plurality and diversity of the ethical perceptions; 
 the need of certain degree of fluidity to adjust with the ethical conundrum in evolutionary life 
science. 
Arif Jamil (2013a, 41) observed: ―It is needless to mention that we are living in an age where our 
society is more pluralistic than ever[…]. How do we live in harmony with our differences alive? 
Importance of ethical principles seem to vary according to the context of the individual. […] [T]he 
number of context increases with the diversity of the individual or groups having differing opinions.‖ 
 
3.3.1 BIOETHICS, INNOVATION AND LAW 
In the past, bioethics was more of a merger of ethics and philosophy. As the time goes by, the 
necessity of transforming the bioethical principles into law is increasing. But it remains a question if 
the bioethical developments are able to cope with the race of evolutionary developmental biology 
(Evo-Devo). Between innovation and ―legal and ethical response,‖ which one occurs first? The legal 
and ethical responses are, many a time, subsequent to the innovation. In a race between science, 
ethics and law, it is the science (innovation) that is ahead in the race, and so, after one race is over, 
the ethical attention is paid, and thereafter, the need of a legislation is realized. Therefore, bioethics 
is a subsequent response to the innovation. However, the legal framework can pre-determine the 
boundary of permissible experiments. In such case, the innovation will never cross the limit 
foreseeable by law. It is very hard for the legislators to anticipate how idea/experiment (in science) 
may mould into innovation in future. The effort to foresee ―an innovation‖ and formulate a legal 
framework compatible to core ethics for that innovation, always will not work, due to the fact that 
scientific experimentations are capable of demonstrating more creativity than our predictions. In 
Evo-Devo, we cannot really foresee what is going to be the lab test result of a scientist tomorrow. 
Therefore, setting a general boundary of norms keeping the core ethics enshrined as a reasonable 
preemptive action may fall short in a specific situation.  
The effort to put general human ethics into binding bioethical legal framework most often fails the 
test of consensus. The signature and ratification of 1997 Oviedo Convention by a small number of 
countries‘ is an attestation of the fact that universal consensus on a legally binding form will be very 
unlikely. Despite there are universally recognized ethical principles, there will be little consensus 
when it comes to acknowledge the same ideas into a legally binding treaty. 
3.3.2 BIOETHICS AND BIOPOLICY  
When bioethics is translated into the biopolicy, it takes a whole new shape and creates different 
effect. The actors and policy framers utilize their influence during the transformation of theoretical 
bioethics into law, and hence, defining the purview of the legitimate research plays important role 
(Wolpe and McGee 2003, 181--82).  What is permissible research and what should be excluded, is 
                                                 
102
 As for example, the Convention on Human Rights and Biomedicine 1997 and the Universal Declaration on Bioethics 
and Human Rights, 2005. 
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always not the ethical concern, rather could be a matter of policy approach. Motives, goals and 
visions of the actors may play more dominant role in shaping the biopolicy. When those laws and 
policies are tested in litigations, Courts may play the role of moral arbiter. Despite ―bioethics‖ may 
be expected to balance science, ethics and law, there is no such expectation from ―biopolicy.‖  
3.3.3 ETHICAL hSCR: INFORMED CONSENT, CLINICAL TRIAL, HUMAN SUBJECT 
PROTECTION AND RESPONDENTS’ EXPERIENCE OF CONVENTIONAL 
MEDICATION FAILURE  
WMA Declaration of Helsinki as updated by 64th General Assembly of October 2013 provides 
guidelines about the gravity of the responsibility of the physician.
103
 Article 9 makes it the duty of 
the physician to protect the human subject taking part in biomedical research.
104
 Informed consent is 
will not be an estoppel for the research subject for invoking the claim of responsibility of the 
physician; and the burden of proving will lie on the physician that the he has taken best recourses to 
protect the subject by virtue of this Article 9.
105
 This Declaration instructs the physician to abide by 
the laws of his own country in one hand and international norms, on the other hand.
106
 The 
international norms on biomedical research and on bioethical issues are mostly nonbinding. A very 
few binding legal texts, such as Oviedo Convention 1997 has been ratified by a small number of 
countries. If the international norms and principles on the safety standard are nonbinding, it will lack 
substantial enforcement possibilities. If the State has poor enactments on this or absence of specific 
policy, then the countries with very low standard of rule of law could be potential breeding ground 
for human subject abuse in biomedical research. According to Article 37, the physician can apply 
―unproven intervention‖ subject to ―informed consent from the patient‖ if he believes that there 
exists no known cure for the disease.
107
 Most of the stem cell based inventions, are at present in the 
process of invention and unproven to a certain extent about their immediate and long-term 
consequences. Therefore, the Declaration of Helsinki does not attempt to create an overly ambitions 
protection regime. Article 30 favors the continuation biomedical research when the subject is not in a 
state of giving consent.
108
 Article 25 to 32 detailed how the informed consent should be obtained.
109
 
Despite Article 26 mentions that the consent is to be obtained after the subject has understood about 
the ―information‖,110 it is hard to be convinced that all biomedical research participants will 
understand perfectly the intricate biomedical research protocol and terminologies. Therefore, how 
much understanding is required from the participant and how much information should be provided 
about the research itself to constitute and satisfy ―a fully informed consent‖ can never be 
satisfactorily answered.
111
  
                                                 
103
 WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, June 1964, 
available at http://www.wma.net/en/30publications/10policies/b3/ (last visited March 12, 2015) [hereinafter Declaration 
of Helsinki]. 
104
 Id. 
105
 Id. 
106
 Id. 
107
 Declaration of Helsinki art. 37. 
108
 Declaration of Helsinki art. 30. 
109
 Declaration of Helsinki. 
110
 Declaration of Helsinki art. 26. 
111
 HeLa cells, a uniquely surviving cell lines were developed/propagated from the cervix of a cancer patient Henrietta 
Lacks by Dr. George Otto Gey at Johns Hopkins University (Wikipedia: Henrietta Lacks 2014). The removal of her cells, 
propagation of the cell lines, biomedical research on them, subsequent application and commercialization were done 
without her consent and permission (Wikipedia: Henrietta Lacks 2014). She died shortly after the diagnosis but her cell 
lines continued to be propagated and used for various biomedical research and treatments (Wikipedia: Henrietta Lacks 
2014). The biomedical research ethics and codes of ethical practices were not developed during the Henrietta‘s time 
(1951). The norms of ―informed consent‖ was not well practiced, but the ―The Nuremberg Code‖ was already in 
existence which had the first point stating that ―[t]he voluntary consent of the human subject is absolutely essential.‖ 
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Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines annexed 
to the Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest 
Attainable Standard of Physical and Mental Health provided the following instructions in guidelines 
21 and 22: “A company‘s clinical trials should observe the highest ethical and human rights 
standards, including non-discrimination, equality and the requirements of informed consent.‖112 
Article 7 of International Covenant on Civil and Political Rights, 1966 provided: ―No one shall be 
subjected to torture or to cruel, inhuman or degrading treatment or punishment. In particular, no one 
shall be subjected without his free consent to medical or scientific experimentation.‖113 Article 
3(2)(a) of the Charter of Fundamental Rights of the European Union stated:
 ―In the fields of 
medicine and biology, the following must be respected in particular: […] the free and informed 
consent of the person concerned, according to the procedures laid down by law‖. 114 Article 1 of the 
Oviedo Convention on Human Rights and Biomedicine, 1997 mentioned: ―Parties to this Convention 
shall protect the dignity and identity of all human beings and guarantee everyone, without 
discrimination, respect for their integrity and other rights and fundamental freedoms with regard to 
the application of biology and medicine.‖115 In the clinical trial, the participants, i.e., patients and 
healthy volunteers should not be deprived of these rights which are essentially meant to protect their 
privacy, dignity, and right to withdrawal from the study in the signatory States. 
The 10 points of research ethics in doing medical experiments on human subject known as the 
Nuremberg Code
116
 has been influential in the formulation of laws relating to biomedical research 
ethics in the USA, although the code itself has not been directly given into effect. Neil C. Manson 
and Onora O‘Neill (2007, 4) commented: ― Informed consent requirements have been extended from 
research to clinical ethics, and standards for seeking and giving informed consent have been made 
more explicit and more demanding.‖  
In the United States, the National Research Act of July 12, 1974
117
 created the National Commission 
for the Protection of Human Subjects of Biomedical and Behavioral Research which navigated to the 
preparation of the Belmont Report, 1979
118
 (U.S. Department of Health & Human Services: The 
Belmont Report 2014). Part B of the Report mentioned ―the principles of respect of persons, 
beneficence and justice‖ as main principles to be followed in research involving human subject.119 
The Report recognized the autonomy of the individual who is capable of making choice and 
mentioned the need to protect those who are ―immature and incapacitated‖.120 The Report 
emphasized not to cause harm to the subject (as an ―obligation‖), maximization of benefit and 
                                                                                                                                                                    
(The Nuremberg Code [1947] 1996). But the Nuremberg Code was not given effect into law (The Nuremberg Code 
[1947] 1996). 
Moore v. Regents of the University of California, 51 Cal. 3d 120, 271 Cal. Rptr. 146, 793 P.2d 479, cert. denied 499 U.S. 
936 (1991) decided that as the research subject, the patient is entitled to a ―full informed consent‖ which would include 
information on further economic potentials of the samples extracted from him, but that claim would not extend to a 
proprietary and property right over the inventions from his cells. 
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reduction of risks and harm.
121
 The Report thereby set forward the following requirements: (a) 
standard and fully informed voluntary consent obtained in proper fashion; (b) evaluation of potential 
risks and benefit ratio; and (c) justice and fairness in human subject selection for research.
122
 The 
Belmont Report is a good beginning in the American practice of ethical biomedical research on 
human (as the research subject) and initiated the Federal Regulations‘ enactment on the 
subject/discipline. Section 46.117(a) of the Code of Federal Regulations mentioned ―the use of a 
written consent form approved by the IRB
123and signed by the subject or the subject‘s legally 
authorized representative‖ as the documentation formality of informed consent.124 Section 1554 of 
the Patient Protection and Affordable Care Act, 2010 (USA) made the following assurance: 
―Notwithstanding any other provision of this Act, the Secretary of 
Health and Human Services shall not promulgate any regulation that—
[….] 
(5) violates the principles of informed consent and the ethical standards 
of health care professionals‖.125 
In the United States, within the system of the Office of Food and Drug Administration (FDA) an 
―Office of Good Clinical Practice‖ is entrusted with certain responsibilities for human subject 
protection in clinical trial (About FDA 2014). 
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 45 CFR § 46.117 (2009), available at http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html#46.117. 
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 Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148, sec. 1554 (42 U.S.C. 18114) (2010), 
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Fig. 3.11 Phase-wise Clinical Trial in the USA (Illustration from Knoepfler 2013, 174). The drawing 
shows the time required in each phase, number of the research participants and the goal of each 
phase of the trial (Illustration from Knoepfler 2013, 174) 
The World Health Organization offers ―International Clinical Trials Registry Platform‖ that 
publishes information on clinical trials in a website accessible by all and it offers an opportunity to 
build an environment of transparency in research involving human subject (World Health 
Organization: International Clinical Trials Registry Platform (ICTRP) 2014). ClinicalTrials.gov is a 
database that publishes clinical studies conducted worldwide (190 countries at the time of writing) 
and in 50 US States (ClinicalTrials.gov Background 2015). Article 40 of the Regulation (EU) No 
536/2014 of the European Parliament and of the Council of 16 April 2014 on Clinical Trials on 
Medicinal Products for Human Use, and Repealing Directive 2001/20/EC requires the reporting of 
all adverse drug reactions (ADRs) to investigational medicinal products through an electronic 
database ―EudraVigilance‖ maintained by the European Medicines Agency (EMA) in the European 
Economic Area (EEA).
126
 
Therefore, the clinical trial on human need to ensure the following formalities for ethical hSCR: 
 Voluntary informed consent by the research participant capable of understanding the 
procedure and the consequences; 
 Right to withdraw from the research; 
 Upright position for the human rights and beneficence; 
 Well documented procedure, open to the Ethics Committee; 
 Accountability to compensate in case of error in conducting the research; 
 Post trial care, if there is any likelihood of necessity.  
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With the globalization of biomedical research, poor and developing countries could be lucrative 
target for clinical trial where informed consent‘s protocol might not be respected. Aurora Plomer 
wrote: ―An audit of external sponsoring of research in developing countries carried out by the US 
Food and Drug Administration (FDA) in 2001 showed a steep increase in the number of foreign 
researchers carrying out research in the decade 1990–2000‖ (2005, 3). The highest increase was 
experienced in ―Latin America and Eastern European countries‖ (Plomer 2005, 3). The 
neighborhood of industrialized and developed countries seems to be the attractive choices for 
biomedical research and experimentation. However, the victims of many research abuses identified 
and condemned in the past were chosen from the disadvantaged communities.
127
 Marcia Angell 
(1997, 849) commented: ―The fact remains that many studies are done in the Third World that 
simply could not be done in the countries sponsoring the work. Clinical trials have become a big 
business, with many of the same imperatives.‖  
The international norm on this subject is still weak for protecting the research participants. In the 
matters of stem cell based therapy, there is a drive and competition to reach the market faster and 
ahead of the competitors. As several laboratories in different parts of the world are doing same or 
similar researches at the same time, the first one gets the patent, in jurisdictions where it is 
patentable. Therefore, there can be instances where the requirements of the safe biomedical research 
are not respected. 
However, question no. 4 intended to see if the respondents had encountered any situation of 
conventional medication failure in their life. One might assume that people who had experience of 
conventional medication failure will have greater tendency of approving the stem cell based therapy 
as the alternative treatment. In response to the question no. 4 asking if they ―have experience of 
dealing with a situation when conventional medication or treatment could not help‖, the comments of 
the respondents highlighted the limitation of the medical science. Following are the Major Key 
Themes derived from responses to question no. 4:
128
  
 Admission of the inadequacy of medical treatment; 
 Effectiveness of a particular medical treatment can be subjective, due to variability in the 
biological systems in individuals; 
 Medical professionals always encounter the non-efficiency of medical treatment; 
 Alternative approaches of treatment may exist; 
 Existence of limitation in the conventional approach of treatment taken in the biological 
science; 
 ―Metaphysical science‖ may offer some solutions where ―biological science‖ is ineffective. 
 
The Interpretation of the Major Key Themes derived from responses to question no. 4 can be found in 
ch. 5.  
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3.4 ACCESS TO THERAPY: COMPULSORY LICENSING, RIGHT TO 
“HEALTH/HEALTH CARE” AND HEALTH CARE POLICY 
The patent has implications for the price of the invented goods. After the expiry of the patent, the 
generic enters the market and the drug price goes down, as the competitors start selling the copy 
version. The typically used approaches by some of the countries for reducing the cost of the 
medicine has been issuing the ―compulsory licenses to the local manufacturer,‖ allowing ―parallel 
import,‖ and preventing ―evergreening of patent‖. There is very limited leeway to avoid the spirit of 
the TRIPS Agreement (Chandra 2010, 401), once the country has signed it. The TRIPS spirit is to 
ensure an effective mechanism for the enforcement of the IPR.  The text of the TRIPS does not make 
reference to the words ―compulsory license.‖ It makes reference to the words ―licensing contract‖ to 
mention the rights of the patent owner.
129
 The provisions that would allow the State to make an 
exception to breach an existing patent are Article 30 and 31, which strongly articulated them as 
―limited exception‖ and ―other use without authorization‖;130 clearly not meant to be read as a 
compulsory licensing tool for a country to exercise for the price reduction purpose.
131
 Article 31 
makes reference to many requirements, e.g., effort has been made to get authorization, ―national 
emergency‖, using for limited duration, ―public non-commercial use‖, etc. 132 Some conditions may 
be relaxed under Article 31(k) for redressing ―anti-competitive‖ effect.133 But it is not an excuse to 
loosen the requirement of the TRIPS. However, the Doha Declaration 2001 created an atmosphere 
for compulsory licensing while acknowledging the right of the States to ensure the ―access to 
medicine‖ and right to ―protect public health‖.134 According to paragraph 5(b) of the Doha 
Declaration, ―[e]ach member has the right to grant compulsory licences and the freedom to 
determine the grounds upon which such licences are granted‖.135 Paragraph 5(c) mentioned that 
interpretation as to determination of circumstances of ―national emergency or other circumstances of 
extreme urgency‖ shall depend on the member State, while citing ―HIV/AIDS, tuberculosis, malaria 
and other epidemic‖ as examples of emergency and extreme urgency.136 In 2006 and 2007, Thailand 
issued compulsory licences using the TRIPS flexibility combining with the Doha Declaration 2001 
for two AIDS drugs (Efavirenz and Kaletra) and another cardiac drug (Plavix), and in consequence 
of those actions, the ―Special 301 Report‖ of the office of the United States Trade Representative 
enlisted Thailand in the ―Priority Watch List‖ for disrespecting and weakening patent protection and 
enforcement and lack of transparency in the application of the compulsory licensing measure 
(USTR's 2007 Special 301 Report, 27;  Macleod 2010, 406--07). 
 
Bringing the stem cell based therapy under compulsory licensing route of TRIPS and Doha 
Declaration will be difficult. Because the therapeutic application of hSCI will mostly address the 
degenerative condition of the body, it will not fit into the perceptions of ―pandemic‖ allowing the 
country to justify the prevalence of urgent needs. Countries are supposed to implement the TRIPS in 
clear terms of the Agreement. Therefore, compulsory licensing incidents have witnessed objections 
from the patent owners and the parallel import faces legal obstructions. The rejection of new patent 
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for the insubstantial contribution over an existing patent, to block the evergreening of patent through 
the national legislation, are limited to ―few countries‘ instances.‖ 
 
Question no. 12 asked the experts: ―Do you think legal obligation for issuing ‗licenses on easy terms‘ 
or ‗compulsory licenses‘ and ‗technology transfer‘ can bring benefit to the patients by ensuring 
availability of medication/treatment at a reduced cost and may also serve as incentive for the IPR 
right owner of human stem cell based inventions/innovations at the same time?‖.  Major Key Themes 
derived from their responses to that question show their diverse thoughts on complex issues of 
incentive for innovation and fostering access to the therapy:
137
 
 
 Context of the country; 
 
 ―Political campaigns‖; 
 
 ―Corruption‖; 
 
 Excuse to blame the patent for contributing to high costs; 
 
 Does not support mandating or imposing legal obligations on patent holder; 
 
 hSCI / life science inventions should not be IPR protected; 
 
 ―Flawed‖ systems in place. 
 
The Interpretation of the Major Key Themes derived from responses to question no. 12 can be found 
in ch. 5. The experts/respondents emphasized on different issues, e.g., country context, national 
policy, etc.  
 
The TRIPS Agreement 1994
138
 and the TRIPS Plus regime for the IP protection of the 
pharmaceutical products will contribute to the higher price of the medicines, as believed by many 
commentators, while shrinking the opportunity of the competition and compulsory licensing 
(Novogrodsky 2010, 345-346). It often happens that legislations intending to make room for higher 
and cheaper access to pharmaceutical products get challenged at Court by the Drug companies, e.g., 
Pharmaceutical Manufacturers’ Association and 41 Others v. President of South Africa and 9 Others 
(2001) in which the Medicines Act
139
 intended to reduce the prices of the medicine through certain 
typical approaches like compulsory licensing, parallel import was challenged (Novogrodsky 2010, 
349). The Act had triggered the objections from 38 pharmaceutical companies (Elliot et al. 2006, 
72). In a tug of war between human rights instruments
140
and the TRIPS Agreement (enforcing patent 
rights and IPR (in general protecting inventor‘s/patentee‘s interest)), the TRIPS will have 
advantageous position. Katharine G. Young commented that, ―[t]rade rights have stronger 
enforcement machinery than human rights‖ (2010, 361). The TRIPS is a legal obligation for the 
countries to abide by. It is an enforceable legal instrument/tool, maintaining and providing the means 
of implementation, whereas the human rights‘ framework comprises mostly of non-bonding soft-law 
instruments.  
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Identification of health as ―right‖ for the citizens is a recent development. As development taking 
place in the discipline of human rights and health care, national constitution became one of the major 
mandates for ensuring the right to health for the subjects.  
Time and again, the right based approach in access to medicine has taken the forefront of the 
discussion on health care. Merger of ―access to medicine and/or health care‖ with the notions of 
human rights recognized in the national context through constitution may make way for higher 
access to medicine and health care in many countries. This idea may also allow higher access to the 
stem cell based therapies. Developing new international and national tools are always a challenging 
task. Recognition of right to health can be found in many international legal instruments. To name a 
few, there are provisions acknowledging and respecting right to health and access to medicine in: 
 WHO Constitution 1946;141  
 Universal Declaration of Human Rights 1948;142  
 International Covenant on Economic, Social and Cultural Rights (ICESCR) 1966;143 
 Declaration of Alma-Ata International Conference on Primary Health Care 1978144 
(Hogerzeil 2006, 371--373), etc.   
Invoking and integrating them for ensuring access to stem cell therapy under the broader umbrella of 
health care would be faster means of capturing the involved agenda in the discussion. However, 
integrating health care with the human rights and viewing from the right based approach is a 
relatively new approach and its implications are not much known in the European context. 
(Herrmann and Toebes, 2011, 420). Right to health can be found to be existing in many legal 
instruments, but giving recognition to health care as right is a difficult stand for the reason that the 
implementation of such right would require the ability of the State. Hence, for some countries it will 
be difficult to implement. UN Committee on Economic, Social, and Cultural Rights provided an 
interpretation of the Article 12 of the International Covenant on Economic, Social, and Cultural 
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Rights and it acknowledged in that interpretation that, ―[t]he right to health is subject to progressive 
realisation and resource availability.‖ (Quoted in Backman et al., 2008, 2049). 
Right to ―health‖ and right to ―health care‖ may be understood as synonymous expressions but can 
also be given different meanings, if the realization of the obligation is pursued. Right to ―health‖ can 
be recognized, but to guarantee the right to ―health care‖ while ensuring the ―access‖ to health care, 
more capabilities and willingness are required. When right to health could be indirectly linked to 
right to life putting the State under obligation to ensure the rights of the individual (Young 2010, 
358--59), right to health care (if understood differently from the right to health) would be more 
linked to economic, social and cultural rights getting lesser chance/means of judicial enforcement. 
However, establishing a direct link between ―right to health,‖ ―right to health care‖ and ―right to life‖ 
would require the enforcement tools, economic capability and legal development nationally and 
internationally. Therefore, to make sure that stem cell based therapy reaches to the people at 
reasonable expenses, a lot will depend on: 
 the IPR owner;145  
 the State granting the IP right; 
 the type and ability of the health care systems prevalent in that particular State; and 
 legal recognition and enforcement tools of right to ―health and/or health care.‖  
Article 168(1) (ex Article 152 TEC) of the Treaty on the Functioning of the European Union stated: 
―A high level of human health protection shall be ensured in the definition and implementation of all 
Union policies and activities.‖146 This implies the commitment of providing high standard of health 
care, but does not define the set limits. However, Article 35 of the Charter of Fundamental Rights of 
the European Union asserted that, everyone is entitled to the right to access to preventative health 
care and ―medical treatment‖ depending on the state‘s policies.147 This is a bridge between ―right to 
health‖ and ―right to access the health care‖ within the European countries. 
In the national context, constitutional ―recognition and enforcement‖ of right to ―health and/or health 
care‖ may help ensuring/fostering the access to stem cell based therapy. Hans V. Hogerzeil and Zafar 
Mirza found that more than 30 countries did not ratify the ICESCR and right to health is not 
recognized in more than 60 countries‘ constitution (2011, 1) and they had the opinion that 
―inequality‖ and ―discrimination‖ are the future challenges for accessing the ―essential medicine‖ 
(2011, 8). There exist huge gaps between affordability of the countries and hence, ability of the 
States to provide health services varies. Some commentators recommended that pharmaceutical 
companies need to be brought under responsibility to serve human rights (Hogerzeil and Mirza 2011, 
8). Preamble to the Human Rights Guidelines for Pharmaceutical Companies in relation to Access to 
Medicines provided that, ―[p]harmaceutical companies, including innovator, generic and 
biotechnology companies, have human rights responsibilities in relation to access to medicines.‖ 148 
The report of Paul Hunt
149
 on the ―Right of Everyone to the Enjoyment of the Highest Attainable 
Standard of Physical and Mental Health‖ included following two very significant recommendations 
in paragraphs 81 and 82 of the report: 
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Several provisions in the TRIPS Agreement, such as article 31 
(compulsory licensing), have significant potential for the protection of 
the public interest in areas bearing upon the right to health. The Special 
Rapporteur encourages WTO member States to place these provisions 
in national legislation as a way of safeguarding aspects of the right to 
health. […]. The Special Rapporteur recommends that States be 
cautious about enacting ―TRIPS plus‖ legislation without first 
understanding the impact of such legislation on the protection of 
human rights, including the right to health. Equally, wealthy countries 
should not pressure a developing country to implement ―TRIPS plus‖ 
legislation, unless reliable evidence confirms that such legislation will 
enhance enjoyment of the right to health in the developing country.
 150
 
(World Health Organization: Reports by the UN Special Rapporteur on 
the Right of Everyone to the Enjoyment of the Highest Attainable 
Standard of Physical and Mental Health, with Relevance to Access to 
Essential Medicines: Intellectual Property and Access to Medicines 
2004) 
 
One of the purposes behind supporting the rise of private sector is that it will encourage competition 
and eventually enhance the quality of service. As the competition can be wiped out by exclusive 
commercialization through strong IPR and by holding dominant position in the market, there is no 
question of enhancing quality of service by competition within the term of protection. Hence, the 
public sector will remain a desired channel of providing the health care services. However, in most 
cases the patients have the choice to prefer the public or private service provider. 
Lostao et al. (2014, 19--25) studied the situation of access and service availed by the people in UK 
and Spain from public and private health care, and found that despite almost everybody have access 
to public health care, some inclination towards private sector exists, and it exists amongst those who 
are economically in stronger position. However, their (Lostao et al. 2014) findings also mentioned 
that ―supplementary insurance‖ that exist alongside the public health care facilities, is mainly to 
provide those services that are not included in the public service, in the form of higher and more 
satisfactory services like without wasting time in waiting, dental care, etc. (Lostao et al. 2014, 23--
24). Stem cell based therapy can be: 
 made available through social insurance or tax based national health system or social security 
system; and/or 
 available, in addition to public health care services, through an additional supplementary 
insurance, and  
 also available through private health insurance and private clinics.  
It must be remembered that offering the services simultaneously, may enhance efficiency. But 
exclusion of the chances of availability from public channels will affect the financially weaker 
section of the society. Those who do not have employer provided insurance, can not purchase good 
private insurance package for themselves or do not have substantial means of paying the charges in 
private hospitals will not be able to avail the advantages of the therapies, in absence of the 
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Government intervention. Therefore, the service delivery through public channels is important not 
only for ensuring wider access but also to engage the public bodies to innovate means of making the 
therapies affordable. 
Question no. 5
151
 explored if the respondents will choose the stem cell based therapy for their dear 
ones and how they would like to access it. Major Key Themes derived from the responses to question 
no. 5 brought many issues to the fore that link to their choice to accept the therapy and means of 
accessing the same:
152
  
 ―Not worried about cost‖; 
 ―Decision to accept‖ the stem cell therapy and the ―source‖ that would meet the expenses of 
the therapy are separate issues; 
 Proof of the efficacy of the treatment; 
 State regulation; 
 Financed through any source; 
 Expects that the costs of the treatment are reasonable; 
 Meeting the expense will depend on the particular health care system in a country. 
 
The Interpretation of the Major Key Themes derived from responses to Question No. 5 can be found 
in Ch. 5.  
 
3.4.1 ACCOMPLISHMENTS MADE IN THE COUNTRY CONTEXT  
Both the public and private service providers exist in the countries revisited. The social insurance 
and private insurance also exist at the same time. Consumers of the health care services are free to 
exercise their choice with respect to receiving their health care service channel. Certain countries 
have been able to provide adequate service coverage to the citizens through the public channel and 
public funding and some have not. There are plenty of reasons to believe that the quality of care may 
vary depending on the affordability of a patient in some countries. It is often true that the private 
services cost a lot more for the patients.  
Despite right to health as can be found in the constitution of some countries, e.g., Italy, Spain and 
Lithuania, it can not be found as a right guaranteed by the constitution in some others, e.g., UK, USA 
and Germany. Few countries recognize the access to health care as the right of the citizen and 
prescribes means to avail it, while making it the duty of the State, e.g. Italy and Lithuania.  
 
Germany 
Health Insurance Act 1883 is the foundation of the tradition of social insurance in Germany (German 
Social Insurance: History 2014). The compulsory Statutory Health Insurance (SHI) gives coverage to 
                                                 
151
 Question No. 5 asked: ―Having a choice and at a critical stage of grave illness would you choose stem cell therapy for 
your family member, if it promises a cure (suppose already available as treatment)?‖. 
152
 Supra note 18. 
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the 90% of the Germans and the people covered are those whose gross income does not exceed 
52,200 euros per year (German Social Insurance: Health Insurance 2014; German Health Insurance: 
Employees 2014). People exceeding that limit may take SHI or opt for private insurance (Worz and 
Busse 2005, S133) and for both the type of insurances the fund is raised from the employer-
employee contributions (German Health insurance: Employees 2014). The additional services that 
are not covered under SHI, private insurance coverage can be purchased (German Health Insurance: 
Employees 2014). The SHI Modernization Act 2004 and Health Care Reform Act 2007 were 
promulgated to bring some improvements in the quality of health care services (Sauerland 2009, 79--
98).  
 
Italy 
The national health service of Italy was established in the reform of 1978, called Servizio Sanitario 
Nazionale (SSN), is run on tax-payers‘ money (France, Taroni and Donatini 2005, S187). 97% 
expenses of public health care met by the general taxes and 15% population having private health 
insurance are attestation of quite a good picture of health care (France, Taroni and Donatini 2005, 
S187). The last ranking of the world health systems conducted by WHO was in 2000, and Italy was 
second best health system after France according to that ranking (Geographic.org 2014). Art. 32 of 
the Italian Constitution acknowledge health as fundamental right and guarantee the access to health 
care by the poor/needy individual.
153
  
M. Braggion, S. Campostrini and G. Bertin studied data covering the years 2007-2010 from the  
PASSI,
154
 Italian surveillance system for the progress in medical health, and observed that diversity 
exists in the health care services amongst the twenty-one (21) Italian regions within the country, all 
of whom enjoying substantial freedom in making policies for themselves within their region (2013, 
3). Braggion, Campostrini, and Bertin (2013, 8) reported that, ―social determinants can produce 
(different) inequalities inside different welfare systems.‖   
George France, Francesco Taroni and Andrea Donatini commented after studying Italy‘s health-care: 
―Italians are living longer and with fewer functional limitations, but they consistently report low 
levels of satisfaction with SSN performance. At the same time they express strong support for a 
universalist, egalitarian and publicly funded health-care system.‖ (2005, S200). 
 
Lithuania 
Article 53 of the Constitution of Lithuania guarantees the access to health care and the State 
undertakes the responsibility of taking care of the health of the subject.
155
 The Statutory Health 
Insurance covers the basic health care expenses for the Lithuanians and the fund for that insurance is 
raised from general taxes and contribution both (European Association of Hospital Managers: The 
Lithuanian Health System 2014). The Law on Health System regulates the National Health System 
of Lithuania (NHSL) and according to Article 11(1) of that law, ―individual health care‖, ―public 
health care‖, ―pharmaceutical activities‖ are included as concerns of the executive bodies of 
NHSL.
156
 Lithuania depends on both ―state budget and health insurance funds‖ for the health care 
                                                 
153
 Art. 32 Costituzione [Constitution] (It.). 
154
 Progressi delle Aziende Sanitarie per la Salute in Italia 
155
 Constitution of the Republic of Lithuania, Oct. 25, 1992, available at 
http://www.wipo.int/wipolex/en/text.jsp?file_id=188280.  
156
 Law of the Republic of Lithuania Amending the Law on the Health System, Lietuvos Respublikos Seimas [The 
Seimas of the Republic of Lithuania], Dec. 1, 1998, No.VIII-946 (Lith.). 
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financing (Merkevicius and Bernotienė 2010, 110). Both the legal system of Germany and Lithuania 
made the ―obligatory health insurance‖ as compulsory for all (Merkevicius and Bernotienė  2010, 
113). 
 
Spain 
Sections 43 and 50 of the Spanish Constitution, 1978 recognize right to health, and makes the public 
bodies responsible to create means to provide access to the health care.
157
 Spanish residents, who are 
employed, students or self-employed can apply for Tarjata Sanitaria Individual - TSI, a health card 
from the Department of Social Security and that will cover most of the expanses of the health care 
(ExpatFocus: Spain). The additional or the remaining costs of the treatment has to be self-financed or 
come through private insurance (ExpatFocus: Spain). Only emergency treatment for the holders of 
TSI social security card or European Health Insurance Cards (EHIC) will be considered for free 
service in the public hospitals  (ExpatFocus: Spain).  
The present Spanish health care situation after the recession is not in perfect condition. Reduction in 
health care budget will delimit many services. The Economist reported that around ―873,000 non-
registered immigrants‖ will be excluded from non-emergency health care and the report referred the 
denial of emergency service to a severely ill tuberculosis patient who died afterwards (The 
Economist, December 16, 2013). The impact of increased co-payment is excluding pensioners from 
availing the full course treatment (Quigley et al. 2013, 1977).  
 
United Kingdom 
The United Kingdom has ―tax based national health system‖ (Lostao et al. 2014, 19). UK‘s health 
care providing structures are mostly financed through sources of public money (Propper 2000, 855), 
and hence, public structures play wider role. The Department of Health, UK, conducts a programme 
―Human Rights in Healthcare‖ which is an affort to highlight health care as basic to perceive several 
other core human rights (Human Rights in Healthcare 2013). Several UK public bodies, e.g., the 
Department of Health, British Institute of Human Rights (BIHR), are working together to intertwine 
human rights and health care (Human Rights in Healthcare 2013). It is mentioned as the duty of the 
Secretary of State to protect public health under Section 11 of newly framed Health and Social Care 
Act 2012.
158
 The NHS Constitution 2013 outlines one of the seven key principles that guide NHS, 
which reads as follows: ―Access to NHS services is based on clinical need, not an individual‘s ability 
to pay‖ (The NHS Constitution 2013). Goddard and Smith identified various factors that determine if 
the NHS service would be opted by an individual (2001, 1153). Amongst other reasons/factors that 
influence the decision of a patient were quality of the service and treatment by the NHS structure, 
relevant expenses of obtaining the treatment, affordability and opportunity available to the individual 
from other alternative choices, e.g. insurance, private sources and ―community care‖ (Goddard and 
Smith 2001, 1153). However, as both public and private health care coexist in the national context of 
UK, comparatively rich people are the ones who avail the facilities of private health care services, as 
found in the study by Carol Propper (2000, 873). 
                                                 
157
 Spanish Constitution [Constitución Española], Dec. 29, 1978 (Spain), available at 
http://www.wipo.int/wipolex/en/text.jsp?file_id=185360 (last visited Feb. 13, 2015). 
158
 Health and Social Care Act, (2012), available at 
http://www.legislation.gov.uk/ukpga/2012/7/pdfs/ukpga_20120007_en.pdf. 
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An individual can complaint to the office of health Ombudsman, if dissatisfied with the services of 
the NHS or public body providing the health service (Parliamentary and Health Service of 
Ombudsman 2013). The Care Quality Commission (CQC) in UK looks after the service quality of 
the health care service providers (Care Quality Commission 2013). The two leading cases, i.e., R. v. 
North and East Devon HA Ex p. Coughlan (1999)
159
 and Grogan v. Bexley NHS Care Trust & Ors 
(2006)
160
 have extended the responsibility of the NHS and other care providers through its channel to 
give more specific meaning of the primary health needs.  
In the case of Coombs v. North Dorset NHS PCT (2013)
161
 the Court found that it is possible for the 
patient to make additional payment for the expenses that are not the statutory responsibility of the 
NHS (subject to being recommended by the clinician), and there is no bar to make such additional 
payment in the law and policy.   
 
USA 
The Government subsidized insurance for public sector employees, employer provided insurance, 
privately purchased insurance and privately afforded health care obtained from strong, big and 
influential private sector are in totality the landscape of American health care. Health care services 
despite being highly expensive in the USA, the quality of the services and impacts on the human 
health is not that great, comparing the other nations who are in similar economic conditions (Kalis 
and Hlafcsakf 2012, 257--58).  In this big picture, there is trouble for the uninsured and there is 
diversity from State to State. The Federal legislations face opposition from the States, from time to 
time, despite the growing authorities of Federal Laws. In the case of National Federation of 
Independent Business, et al. v. Sebelius, Secretary of Health and Human Services, et al. (2012),
162
 
twenty-six (26) States opposed the Affordable Care Act 2010, a Federal legislation intending to 
cover more people under the insurance coverage at a lesser expense.  
The Affordable Care Act (ACA), 2010 provided a provision on ―Access to Therapies,‖163 but it did 
not empower an individual in accessing a therapy, rather prescribed which impediments to access to 
therapy will not be placed in-between the patient and access to the therapy.  
Despite ACA is seen by some commentators as a move towards realization of promise of right to 
health under ICESCR (Battaglia 2012, 155--95), a lot more needed to be done to see health care as a 
―right‖ in America. Nicholas A. Battaglia stressed on the necessity of reduction of disparity in the 
opportunities of health care facilities and the cost of the health care (2012, 170--72,173). It will take 
some time to see the benefits of the Act, as it is in the progress of creating it effect (Gorin 2011, 83).  
It is apparent that the impact of ACA is unclear now. The United States‘ Supreme Court found the 
Act in most part valid, as it was challenged by, amongst others, 26 States.
164
 However, the 
Republicans are firmly against this law (The New York Times, June 28, 2012).  
Health care services and facilities are not same in all States of the USA. The State of California 
created a marketplace called Covered California (Covered California 2014), to help individual to get 
insurance, as part of its effort to implement Patient Protection and Affordable Care Act (ACA). 
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 [2001] Q.B, 213; [2000] 2 W.L.R. 622 CA (Civ Div). 
160
 [2006] EWHC 44 (Admin). 
161
 EWCA Civ 471, (2013) MHLO 35. 
162
 567 U.S. ___ (2012), 132 S.Ct 2566. 
163
 Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148, sec. 1554 (42 U.S.C. 18114) (2010), 
available at http://housedocs.house.gov/energycommerce/ppacacon.pdf. 
164
 National Federation of Independent Business, et al. v. Sebelius, Secretary of Health and Human Services, et al. 567 
U.S. ___ (2012), 132 S.Ct 2566. 
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California is the first State to start the implementation of the ACA (Covered California 2014), The 
10 categories of services provided by the insurance coverage are called ―essential health benefits‖ 
(Covered California: What does Health Insurance Cover? 2013), and they do not include 
regenerative medicine or does not make direct reference to the stem cell based therapies. Like 
California, Massachusetts have ―state-based marketplace‖ and implementing the ACA through 
Medicaid expansion from 2014; New Jersey, South Dakota and Texas have ―Federally-facilitated 
Marketplace‖ but New Jersey is implementing the ACA from 2014, whereas Texas is not (Kaiser 
Family Foundation: State Health Facts 2014).  
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CHAPTER 4 
ANALYSIS OF IPR ISSUES 
 
4.1 EVOLVING IPR: WIDENING THE PURVIEW OF PATENT   
The patent system since its inception evolved with time. The inclusion of innovations as ―patentable 
invention‖ continued to happen as we proceeded towards the technologically brighter destiny. Many 
a times the inclusion as ―patentable invention‖ of new creation or technological contribution was 
driven by monetary and strategic purpose, rather than just appreciating and offering the intellectual 
property protection for the contribution in science. Paul Stark, the Chairman of the National 
Committee on Plant Patents, also a nursery owner, was the prime figure behind the enactment of 
Plant Patent Act, 1930 of the USA (Kelves 2002, 4--5).
1
 Paul Stark also made contribution in 
drafting the patent law‘s bill for that purpose (Kelves 2002, 5). Therefore, it is the ―lobbying group‖ 
that played a pivotal role for the inclusion of new varieties of plants as patentable invention (Kelves 
2002, 4--5).
2
 Therefore, apart from guaranteeing and recognizing the rights of the inventor and/or 
assignee, the patent law has also offered a security for the return of the investment, historically by 
widening its purview. It is a tool expected to serve the purpose of ―incentive for innovation/ 
invention‖ through the return of the investment.  
4.1.1 LIVING THINGS CAN BE PATENTED 
In Diamond v. Chakrabarty (1980) the United States Supreme Court held that ―live, human-made 
micro-organism is patentable subject matter under §101‖.3 It is the very first case that begun the era 
of patenting living things in the forms of microorganism. The patent claim of Chakrabarty included 
the process of producing a bacteria and the bacteria itself.
4
 Justice Brennan expressed in dissenting 
opinion that ―it [The Congress] may choose to craft a statute specifically designed for such living 
things.‖5  
The inclusion of the living things (microorganisms) as patentable subject matter was not what the 
law on patent specifically envisioned; rather the broadness of the provision on ―patent scope‖ offered 
                                                          
1
 The current version of the 35 U.S. Code § 161 provides the provision of patents for the plants and it states that, 
―[w]hoever invents or discovers and asexually reproduces any distinct and new variety of plant, including cultivated 
sports, mutants, hybrids, and newly found seedlings, other than a tuber propagated plant or a plant found in an 
uncultivated state, may obtain a patent therefor, subject to the conditions and requirements of this title.‖ 35 U.S.C. § 161 
(2010). 
2
 In the USA, the Plant Variety Protection (PVP) Act enacted in 1970 for the protection of the rights of owners of the 
sexually reproduced new varieties of plants, was subsequent to the similar enactments emerged in the European continent 
for the protection of the rights of the plant breeders (Strachan, 1992). 
 
Internationally, for the protection of the rights of the breeders of the new varieties of plants, the International Union for 
the Protection of New Varieties of Plants (UPOV) emerged under the mandate of the International Convention for the 
Protection of New Varieties of Plants (UPOV Convention) 1961 (the present version in force is the revised 1991 UPOV 
Convention). 
3
 447 U. S. 308-318 (1980), also available at http://supreme.justia.com/cases/federal/us/447/303/case.html#308  (last 
visited August 26, 2014). 
4
 Diamond v. Chakrabarty 447 U. S. 306 (1980), also available at 
http://supreme.justia.com/cases/federal/us/447/303/case.html#308 (last visited  August 26, 2014). 
5
 Id. at 318. 
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the opportunity to patent them.
6
 After the Chakrabarty case,
7
 living things (microorganisms) 
continued to be patented throughout the USA and beyond. The scope of the patent extended over the 
years from mechanical and chemical inventions to plant protection and other ―life forms inventions.‖ 
The ―life science inventions‖ were also in different times rejected on ethical grounds from patenting 
in different countries. But a separate uniform international protection framework mandated by a 
specific legal instrument did not develop to offer the intellectual property protection to those 
inventions. 
4.2 WHAT IS PATENTABLE: LEGAL FRAMEWORK 
The patents granted for hSCI can be both for product (e.g., stem cells) and process (e.g., methods of 
isolation) claims (Overwalle, 2004, 50--51). The legal texts on patenting reveal what are the 
patentable subject matters and the conditions of patentability. The legal framework for the patent 
system is multilayered. There are: 
 The international legal framework comprising of international conventions, international 
agreements and multilateral treaties,
8
 e.g., the Paris Convention for the Protection of Industrial 
Property (1883), the Patent Cooperation Treaty (PCT) (1970), the Strasbourg Agreement 
Concerning the International Patent Classification (1971),  the Budapest Treaty on the 
International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure 
(1977), the Patent Law Treaty (PLT) 2000, the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (1994);  
 The regional legal frameworks created by the multilateral and intergovernmental treaties e.g., 
European Patent Convention (1973) creating the European Patent organization (EPO) for 38 
Countries
9
 and the Agreement on a Unified Patent Court (2013) for creating an 
intergovernmental organization (Patent Court) for EU countries;
10
  
 The regional and supranational legal frameworks, e.g., the European Union Laws which 
includes the Treaty on the Functioning of the European Union (TFEU) or  EC Treaty (1958), 
European Patent Convention (1973), Directive on the Enforcement of Intellectual Property 
Rights (2004),  Regulation (EU) No 1257/2012 of the European Parliament and of the Council of 
17 December 2012 Implementing Enhanced Cooperation in the Area of the Creation of Unitary 
Patent Protection, Biotech Directive (Directive 98/44/EC), etc.; and 
 National Patent Laws. 
Table 4.1 International and European community level legal framework for ―patentable invention‖ 
and ―exclusion‖ from patenting 
 PATENTABLE EXCLUSION COMMENTS 
TRIPS AGREEMENT Article 27(1) of the 
TRIPS Agreement 1994 
states that: ―patents shall 
be available for any 
inventions, whether 
products or processes, in 
all fields of technology, 
Article 27(2) of the 
TRIPS Agreement 1994 
states: ―Members may 
exclude from 
patentability inventions, 
the prevention within 
their territory of the 
Patent is available 
for ―products and 
processes‖ and 
the requirements 
are typical, i.e., 
novelty, inventive 
step and industrial 
                                                          
6
 The inclusion of new subject matter as patentable inventions is also a policy and strategic concern, if viewed from the 
background of plant patent, where the lobbyist, business groups and stakeholders were the force behind the enactment of 
Plant Patent Act, 1930 (Kelves 2002, 4--5). 
7
 447 U.S. 303 (1980). 
8
 The number of contracting States are different for each of these legal instruments. 
9
 All of them are not EU members. 
10
 All the EU members are not signatory yet.   
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provided that they are 
new, involve an 
inventive step and are 
capable of industrial 
application.‖11 
commercial exploitation 
of which is necessary to 
protect ordre public or 
morality, […], provided 
that such exclusion is 
not made merely 
because the exploitation 
is prohibited by their 
law.‖12 
application. 
Countries have 
discretion in 
exercising the   
right to exclude 
inventions from 
patenting on the 
grounds of public 
policy and 
morality.  
EUROPEAN PATENT 
CONVENTION (EPC) 
Article 52(1) of the 
European Patent 
Convention, 1973  states: 
―European patents shall 
be granted for any 
inventions, in all fields of 
technology, provided that 
they are new, involve an 
inventive step and are 
susceptible of industrial 
application.‖13 
According to Article 
53(a) of the European 
Patent Convention, 
1973,  patents are not 
available for the 
―inventions the 
commercial exploitation 
of which would be 
contrary to ―ordre 
public‖ or morality; 
such exploitation shall 
not be deemed to be so 
contrary merely because 
it is prohibited by law or 
regulation in some or all 
of the Contracting 
States‖.14 
There is no 
substantial 
difference in the 
draft with the 
TRIPS 
Agreement, but 
the exclusion on 
―"ordre public" or 
morality‖ has 
been interpreted 
and exercised for 
European Patent 
(EP) to a greater 
extent than it is 
done in other 
patent systems.  
BIOETCH 
DIRECTIVE 
Article 3(1) of the  
Biotech Directive states: 
―For the purposes of this 
Directive, inventions 
which are new, which 
involve an inventive step 
and which are susceptible 
of industrial application 
shall be patentable even 
if they concern a product 
consisting of or 
containing biological 
material or a process by 
means of which 
biological material is 
Article 6(1) of the  
Biotech Directive states: 
―Inventions shall be 
considered unpatentable 
where their commercial 
exploitation would be 
contrary to ordre public 
or morality; however, 
exploitation shall not be 
deemed to be so 
contrary merely because 
it is prohibited by law or 
regulation.‖16 
Article 6(2)(c) excluded 
patenting inventions that 
What constitutes 
the ―use of human 
embryos‖ for the 
purpose of this 
Directive? 
Destruction of 
embryo only?  
The provision of 
the Biotech 
Directive on 
exclusion from 
patenting was 
interpreted to 
exclude 
inventions that 
                                                          
11
 Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Marrakesh Agreement 
Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197 (1994) [hereinafter TRIPS 
Agreement]. 
12
 TRIPS Agreement art. 27(2). 
13
 European Patent Convention, Oct. 5, 1973 (15th Edition, October 2013), available at 
http://documents.epo.org/projects/babylon/eponet.nsf/0/00E0CD7FD461C0D5C1257C060050C376/$File/EPC_15th_edi
tion_2013.pdf (last visited Feb. 03, 2015). 
14
 Id. 
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produced, processed or 
used.‖15 
―uses […] human 
embryos for industrial 
or commercial 
purposes.‖17 
encompasses the 
destruction of 
human embryos.
18
 
In a more recent 
decision of CJEU 
(2014), hpSC is 
declared 
patentable.
19
 If the 
parthenote does 
not have the 
capacity to 
develop to full 
term, it is not 
human embryo. 
20
 
 
4.2.1 LEGAL FRAMEWORK FOR PATENTING hSCI: GERMANY, ITALY, LITHUANIA, 
SPAIN AND UK  
The following table shows the legal framework at the national level in Europe for human stem cell 
research and patenting (Jamil 2013a, 34--35):
21
 The reason for choosing these countries is that their 
laws and policies on hSCR and patenting of hSCI are diverse.  
Table 4.2 The national level legal framework in Europe (from the study context: Germany, Italy, 
Lithuania, Spain and United Kingdom) for the hSCR and patenting (Illustration from Jamil 2013a, 
34--35) 
Country Type of the 
policy 
atmosphere 
prevalant 
Laws and policies in force relating to patenting and 
human stem cell research 
Italy Restrictive 
Policies Prevalent 
1. Constitution of the Italian Republic. Entry into force on 1 
January 1948 
2. Patent Law (Royal Decree No. 1127 of June 29, 1939, as 
last amended by Legislative Decree No. 198 of March 19, 
                                                                                                                                                                                                   
16
 Biotech Directive art 6(1), 1998 O.J. (L 213) 0013 – 0021, 18. 
15
 Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the Legal Protection of 
Biotechnological Inventions art 3(1), 1998 O.J. (L 213) 0013 – 0021, 18) [hereinafter Biotech Directive]. 
17
 Biotech Directive art 6(2)(c), 1998 O.J. (L 213) 0013 – 0021, 18. 
18
 See ch. 4.2.3 EXCLUSION FROM PATENTABLE INVENTIONS: COUNTRY EXAMPLES. 
19
 Case C‑364/13, International Stem Cell Corporation v. Comptroller General of Patents, Designs and Trade Marks, 
Judgment of the Court (Grand Chamber) 18 Dec. 2014, also available at 
http://curia.europa.eu/juris/document/document.jsf;jsessionid=9ea7d0f130de9c4121923b8f43769c42c1706a04f989.e34K
axiLc3eQc40LaxqMbN4ObheSe0?text=&docid=160936&pageIndex=0&doclang=EN&mode=lst&dir=&occ=first&part
=1&cid=88991#Footnote* (last visited Dec. 22, 2014). 
20
 The CJEU held: ―Article 6(2)(c) of Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 
on the legal protection of biotechnological inventions must be interpreted as meaning that an unfertilised human ovum 
whose division and further development have been stimulated by parthenogenesis does not constitute a ‗human embryo‘, 
within the meaning of that provision, if, in the light of current scientific knowledge, it does not, in itself, have the 
inherent capacity of developing into a human being, this being a matter for the national court to determine.‖ Id. paragraph 
39. 
21
 The content of this table appeared in the article of Arif Jamil published in the ―"Social technologies'13 conference 
proceedings", ISBN 978-9955-19-586-3 (online)‖ (Jamil 2013a, 34--35).  
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1996) 
3. Law No. 78 of 22 February 2006 Enacting the EU 
Directive 98/44/EC in Italy  
4. Law No. 40, Regulation of Medically Assisted 
Reproduction (2004) 
 
Lithuania Restrictive 
Policies Prevalent 
1. Law on Patents, 18 January 1994, No. I-372 (As amended 
upto 10 May 2007) 
2. Law on Ethics of Biomedical Research 2000, as amended 
upto 2007 
3. Oviedo Convention on Human Rights and Biomedicine 
(2002) 
 
 
 
 
Germany Restrictive but 
carefully 
positioned 
policies prevalent 
1. Patent Law (enacted on 5 May, 1936, as amended upto 31 
July, 2009) 
2. Embryo Protection Act (1990) 
3. Stem Cell Act 2002 and amendment of 2008 (Law on 
Protection of Embryos in Connection with Importation 
and use of Human Embryonic Stem Cells) 
4. Act of Quality and Security of Human Tissue and Cells 
(2007) 
5. Medicinal Products Act, 2009 
Spain Not so restrictive 
but carefully 
positioned 
policies prevalent 
1. Law on Patents, No. 11/1986 (enacted 20 March, 1986, 
entry into force 26 June, 1986) 
2. Law on Assisted Human Reproduction Procedures. Law 
No. 14/2006 of 26 May 2006 
3. Law on Biomedical Research, Law No. 14/2007, of 3 July 
4. Oviedo Convention on Human Rights and Biomedicine 
(Entry into force in Spain from 2000) 
5. Additional Protocol to the Convention for the Protection 
of Human Rights and Dignity of the Human Being with 
regard to the Application of Biology and Medicine, on the 
Prohibition of Cloning Human Beings (Entry into force in 
Spain 2001) 
United 
Kingdom 
Not restrictive at 
all, rather liberal 
policies prevalent 
 
1. The Patents Act 1977, Enacted 29 July, 1977 
2. Human Fertilisation and Embryology Act (1990), as 
amended by the Human Fertilisation and Embryology Act 
2008 
3. Human Reproductive Cloning Act (2001) 
4. Human Fertilisation and Embryology Act 2008 
 
 
4.2.2 IN THE USA 
Which inventions are patentable and who may obtain a patent is described in 35 U.S. Code § 101 in 
the following language: ―Whoever invents or discovers any new and useful process, machine, 
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manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a 
patent therefor, subject to the conditions and requirements of this title.‖22 According to the 35 U.S. 
Code, ―[t]he term ―invention‖ means invention or discovery‖23 and ―[t]he term ―process‖ means 
process, art or method, and includes a new use of a known process, machine, manufacture, 
composition of matter, or material.‖24 What was patentable invention according to the Patent Law of 
1793 is that, ―any new and useful art, machine, manufacture, or composition of matter, or any new or 
useful improvement thereof.‖ (Quoted in Kevles 2002, 1). The difference with the previous original 
version and the present version is that, now the word ―process‖ is substituted for the word ―art.‖ 
Therefore, for the purpose of patenting in the United States, the literal meaning of the text suggest 
that patentable inventions also include the ―discovery‖ and ―process.‖  
A good number of laws relevant for the patent, hSCR and hSCI are in force in the USA. Appendix 1 
―THE LEGAL FRAMEWORK‖ of this monograph provides a list of the Federal legislations and the 
State laws existing in the USA. 
4.2.3 EXCLUSION FROM PATENTABLE INVENTIONS: COUNTRY EXAMPLES 
According to Article 6 of the Biotech Directive, inventions that use the human embryo for ―industrial 
or commercial purposes‖ are excluded from patentability, as their commercial exploitations would be 
contrary to ―ordre public or morality‖.25 According to the Article 53(a) of the European Patent 
Convention, if the ―commercial exploitation‖ of the invention is ―contrary to "ordre public" or 
morality‖, it is excluded from patenting.26 Oliver Brüstle  v. Greenpeace e.V.27 is an application of 
the above provisions towards the widening of the exclusion from patenting. Paragraph 53(3) of the 
Judgment of the Court (Grand Chamber) excluded inventions in the following words: ―Article 
6(2)(c) of Directive 98/44 excludes an invention from patentability where the technical teaching 
which is the subject-matter of the patent application requires the prior destruction of human embryos 
or their use as base material, whatever the stage at which that takes place and even if the description 
of the technical teaching claimed does not refer to the use of human embryos.‖28[Italics added]. 
Paragraph 53(2) of the Judgment of the Court (Grand Chamber) stated the extent of the exclusion in 
the following words: ―The exclusion from patentability concerning the use of human embryos for 
industrial or commercial purposes set out in Article 6(2)(c) of Directive 98/44 also covers the use of 
human embryos for purposes of scientific research, only use for therapeutic or diagnostic purposes 
which is applied to the human embryo and is useful to it being patentable.‖29[Italics added]. 
Therefore, the research that destroys human embryos will not be able to get a patent (European 
Patent) if it results to an invention. The only invention that remains patentable is the one that uses the 
human embryo for the therapeutic purposes and is useful to the embryo itself. 
                                                          
22
 35 U.S.C § 101 (2011). 
23
 35 U.S.C. 100(a) (2011). 
24
 35 U.S.C. § 100(b) (2011). 
25
 Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the Legal Protection of 
Biotechnological Inventions, 1998 O.J. (L 213) 0013 - 0021. 
 
It is worth mentioning that therapeutic application of ―any invention that has been patented,‖ will be subject to 
commercial exploitation automatically. Therefore, if ―therapeutic application‖ is the only purpose the invention is 
expected to serve, and if ―commercial exploitation‖ has to be separated from it, the invention can not be patented. 
Because patent is a tool for commercial exploitation per se.   
26
 European Patent Convention, Oct. 5, 1973, 13 I.L.M. 268, available at http://www.epo.org/law-practice/legal-
texts/html/epc/2013/e/ar53.html (last visited Dec. 09, 2014).  
27
 C-34/10, Judgment of the Court (Grand Chamber) 18 Oct. 2011, available at 
http://curia.europa.eu/juris/liste.jsf?language=en&num=C-34/10 (last visited July 25, 2014). 
28
 Oliver Brüstle  v. Greenpeace e.V,  supra note 27. 
29
 Id. 
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Table 4.3 Exclusion from ―patentable inventions‖ 
Country Exclusion from Patentability Comments 
Germany Following are excluded from 
patenting: 
 Human cloning; 30 and 
 Inventions that use 
―human embryos for 
industrial or commercial 
purposes.‖31 
What constitutes ―use of human 
embryos‖ for the purpose of this 
Act? Destruction of embryo? 
Extraction of blastomere cell 
from the pre-implantation stage 
embryo? 
Italy Art. 13 provides that the 
―[i]nventions the working of 
which would be contrary to public 
order or morality may not form 
the subject matter of a patent‖.32 
No direct reference of hSCI are 
found in the excluded inventions. 
Lithuania Following are excluded from 
patenting: 
 Human cloning;33 
 Inventions that use 
―human embryos for 
industrial or commercial 
purposes‖;34 
 ―inventions the 
commercial exploitation 
of which would be 
contrary to public 
interests, principles of 
morality and humanity.‖35 
What constitutes ―use of human 
embryos‖ for the purpose of this 
Act? Destruction of embryo? 
Extraction of blastomere cell 
from the pre-implantation stage 
embryo? 
Inclusion of the ideas of 
―principles of morality and 
humanity,‖36 in the patent law is 
a new approach that 
acknowledge the link between 
patent and humanitarian needs.  
 
Spain Likely to be excluded: 
 ―inventions whose 
publication or working 
There is no strong exclusion 
provision observed in the patent 
law.    
                                                          
30
 Patent Act (as amended by the Law of July 31, 2009) Section 2(2)(1), available at 
http://www.wipo.int/wipolex/en/text.jsp?file_id=238776 (last visited Jan. 28, 2015). 
31
 Id. sec. 2(2)(3).  
32
 Patent Law (Royal Decree No. 1127 of June 29, 1939, as last amended by Legislative Decree No. 198 of March 19, 
1996), available at http://www.wipo.int/wipolex/en/text.jsp?file_id=128268 (last visited Jan. 28, 2015). 
33
 Law on Patents of 18 January 1994, No. I-372 (As last amended on 10 May 2007 – by Law No. X-1119) Article 2(1), 
available at http://www.wipo.int/wipolex/en/text.jsp?file_id=188691 (last visited Jan. 28, 2015).  
34
 Id. art. 2(3). 
35
 Id. art. 2(3). 
36
 Id. art. 2(3).  
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would be contrary to 
public order or morality.‖37 
U.K. A general exclusion states: ―A 
patent shall not be granted for an 
invention the commercial 
exploitation of which would be 
contrary to public policy or 
morality.‖38 
There is no strong exclusion 
provision observed in the patent 
law.    
U.S.A.  There is no exclusion on ―ordre 
public and/or morality‖ in the US 
patent law. There is no exclusion 
from patenting for the ―use and 
destruction‖ of the human 
embryo.  
 
4.2.3.1 THE EXTENT OF UNIVERSAL EXCLUSION FROM PATENTING hESC BASED 
INVENTION 
Patenting hESC based inventions attract most of the ethical controversies. Is hESC based invention 
universally excluded from patenting? The answer is ―no.‖  Is it possible to patent all kinds of stem 
cell based inventions in those countries that do not exercise wider exclusion from patentability? The 
answer is ―yes.‖ 
It is necessary to see how the international depositary institution for the purpose of deposit of 
microorganisms for patent protection under the Budapest Treaty, 1977 perceives the ethical 
requirements. Although they are not the patent granting authority, they preserve the specimen of the 
patented invention. Despite patent protection on hESC based invention has legal constraint in 
Europe, it does not have the international constraint. The National Institute for Biological Standards 
and Control (NIBSC) of UK is the International Depositary Authority under the Article 6(2) of the 
Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes 
of Patent Procedure, 1977 (World Intellectual Property Organization: Budapest Notification No. 227 
2014). Since 2002, the NIBSC is hosting the UK Stem Cell Bank which is the repository for all kinds 
of stem cell lines including hESC (World Intellectual Property Organization: Budapest Notification 
No. 227 2014). UK Stem Cell Bank will accept the deposit of the stem cell lines and shall also 
provide stem cell lines ―both for basic research and for the development of clinical applications‖ 
(World Intellectual Property Organization: Budapest Notification No. 227 2014). 
The National Institute for Biological Standards and Control (NIBSC) of UK shall accept as 
depository for the purpose of patent protection all ―[h]uman cell lines (including embryonic and 
somatic stem cell lines)‖ (National Institute for Biological Standards and Control (NIBSC): NIBSC 
Guide to the Deposit of Cultures for Patent Purposes 2014). The NIBSC Guide to the Deposit of 
Cultures for Patent Purposes clearly mentioned that ―NIBSC reserves the right to refuse deposits 
which in its opinion represent unacceptable hazards, significant technical or other difficulties, or 
where ethical considerations are inconsistent with those applied in the UK.‖ (National Institute for 
Biological Standards and Control (NIBSC): NIBSC Guide to the Deposit of Cultures for patent 
                                                          
37
 Law No. 11/1986 of March 20, 1986 on Patents Section 5(1)(a), available at 
http://www.wipo.int/wipolex/en/text.jsp?file_id=126574 (last visited Jan. 28, 2015). 
38
 The Patents Act 1977 (Chapter 37, as amended by the Tribunals, Courts and Enforcement Act 2007) Section 1(3), 
available at http://www.wipo.int/wipolex/en/text.jsp?file_id=330537 (last visited Jan. 28, 2015). 
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Purposes 2014). Hence, the ethical standards for deposit of stem cell lines for the purpose of patent 
protection under the Budapest Treaty, 1977 is the standard that is prevalent in the UK. It appears that 
the emphasis for this purpose in the UK‘s policy is that ―the cell line(s) has been ethically sourced 
with fully informed and free donor consent‖ (National Institute for Biological Standards and Control 
(NIBSC): Patent Depositary Service 2014). It is a universally acknowledged requirement that 
informed consent was obtained from the donors. Therefore, the ethical standard is the liberal, general 
and universal standard. Hence, there is no ethical barrier causing universal exclusion from patenting 
hESC based invention. There is no universal or international patent either.  
However, there can be a long discussion if the inclusion of stem cells for the deposit under the 
Budapest Treaty 1977 is an ideal thing, while associating/treating them with/as ―microorganism.‖ I 
asked Tania S. Bonny, Researcher of Public Health at the University of Florida, USA, about the 
differences of microorganisms and stem cells and the suitability of deposit of human stem cells under 
the Budapest Treaty, 1977 for the purpose of patent protection. In her opinion:  
Microorganisms and stem cells are not the same things in the strict 
sense but they both can be considered as ―living forms.‖ Stem cells in 
nature are not discreet entities rather they are part of larger living form, 
e.g. animal, human. Microorganisms can live freely in soil, air, water 
or remain associated with other non-living or living forms. But usually 
they are not essential for viability of a larger living form. Microbes are 
usually dispensable whereas stem cells are indispensable for higher 
multicellular organisms. For example, a mammal or human body 
cannot develop or remain viable without the stem cells that give rise to 
different cell types of the body. The Budapest Treaty, 1977 does not 
define the term ―microorganism.‖ It seems that the Treaty identifies 
microorganism from the context of ―genetic stability‖ and ―issue of 
reproducibility.‖ The Treaty seems to consider bacteria, virus, fungi 
and all types of cell lines (which include stem cells) etc. collectively as 
―microorganisms.‖ The justification can be that they are all living 
forms and possess DNA/RNA as their genetic material. They are all, 
therefore, susceptible to small and large scale genetic mutations and 
once mutated they might or might not possess the desired features 
anymore. Some mutations occur by chance and may impart a quality in 
the organism accidentally. Spontaneous (chance) mutations by various 
known and unknown mechanisms are frequently observed in natural 
and laboratory settings. Yet some mutations are introduced by the 
scientists deliberately to impart a desirable characteristic. Thus 
scientists need to confirm the genetic stability of the life form on which 
the invention is based upon. Invention borne out of a ―chance 
mutation‖ which cannot be reproduced is not patentable. (Tania S. 
Bonny, in email with the researcher, July 24, 2014) 
 
Therefore, the deposit is an action which satisfies the adequacy of the disclosure for the purpose of 
the patent protection. While the ―written description‖ might not always be the perfect description of 
the invention, a deposit may strengthen the IP protection.   
4.3 PATENTABILITY REQUIREMENT FOR THE hSCI 
The standard requirements for patentability are:  
 Novelty (Newness); 
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 Inventive step (Non-obviousness);39 and 
 Industrial application (Utility). 
Does a hSCI satisfy these requirements? What are the uncertainties, ambiguities and possibilities 
surrounding the hSCI when they are tested for each of these requirements?  
4.3.1 NOVELTY IN hSCI 
If the ―invention makes a technical contribution to the state of the art‖ (MacQueen et al. [2008] 2010, 
512--13), it is a patentable invention and may satisfy the requirement of novelty. Many of the 
methods of derivation of hSCs are new/novel, e.g., the reprogramming of iPSC by the direct 
introduction of transcription factors by Takahashi et al. (2007), modified SCNT protocol by 
Tachibana et al. (2013), etc. Article 5(2) of the Biotech Directive 1998 states that, ―[a]n element 
isolated from the human body or otherwise produced by means of a technical process, including the 
sequence or partial sequence of a gene, may constitute a patentable invention, even if the structure of 
that element is identical to that of a natural element.‖40 The clause saying ―element isolated from the 
human body or otherwise produced by means of a technical process‖41 can be applied in case of 
derivation of hESC, SCNT (NT-ESC) and iPSC technologies in different ways. Use of caffeine, the 
protein phosphatase inhibitor by the team of Mitalipov (Tachibana et al. 2013, 1231) demonstrates 
the application of ―technical process‖42 and an evidence of a modified protocol for embryo cloning 
by SCNT. The direct reprogramming of somatic cells into iPSC by transcription factors (Takahashi 
et al. 2007) can also be expressed in other words as produced ―by means of a technical process‖.43 
                                                          
39
 The term ―inventive step‖ is commonly used in Europe and the term ―non-obviousness‖ is used in the USA for the 
same expression.  
40
 Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the Legal Protection of 
Biotechnological Inventions, 1998 O.J. (L 213), 0013 – 0021. 
41
 Id. art. 5(2). 
42
 Id.  
43
 Id.  
 
Patents on iPSC technology is increasing day by day, ever since it started and some of the patents at the pioneering stages 
are:  
 EP 1970446, date of publication August 3, 2011 having Shinya Yamanaka as the inventor and Kyoto 
University, Kyoto, Japan as the assignee for the ―[n]uclear reprogramming factor‖. European Patent Office, 
Espacenet Patent search, available at 
http://worldwide.espacenet.com/publicationDetails/originalDocument?CC=EP&NR=1970446B1&KC=B1&loc
ale=en_EP&date=&FT=D (last visited Nov. 5, 2014); 
 United States Patent No. 8,048,999, issued on November 1, 2011 having Shinya Yamanaka, Kazutoshi 
Takahashi and Keisuke Okita as the inventors and the Kyoto University, Japan as the assignee for the ―[n]uclear 
reprogramming factor‖. United States Patent and Trademark Office, USPTO Patent Full-Text and Image 
Database, available at http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-
bool.html&r=12&f=G&l=50&co1=AND&d=PTXT&s1=8,048,999&OS=8,048,999&RS=8,048,999 (last 
visited Nov. 5, 2014); 
 United States Patent No. 8,058,065, issued on November 15, 2011, having  Shinya Yamanaka and Kazutoshi 
Takahashi as the inventors and Kyoto University, Japan as the assignee for the methods of generating iPSC by 
the nuclear reprogramming factor ―Oct3/4, Klf4, c-Myc and Sox2‖. United States Patent and Trademark Office, 
USPTO Patent Full-Text and Image Database, available at http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-
bool.html&r=8&f=G&l=50&co1=AND&d=PTXT&s1=8,058,065&OS=8,058,065&RS=8,058,065 (last visited 
Nov. 5, 2014);  
 United States Patent No. 8,129,187, issued on March 6, 2012, having Shinya Yamanaka, Kazutoshi Takahashi 
and Keisuke Okita as the inventors and the Kyoto University, Japan as the assignee for the ―[s]omatic cell 
reprogramming by retroviral vectors‖. United States Patent and Trademark Office, USPTO Patent Full-Text and 
Image Database, available at http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-
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The hESC based inventions may also encompass the ―isolation‖ and ―technical process‖.44 Huan Zhu 
(2011, 225) wrote: ―hESCs isolated from embryos and cultured in specific media are novel because 
after being cultured in an artificial environment, the molecular structure, characteristics and even 
chromosomal structure may be changed and differ from the cells of the embryos from which they 
were derived.‖ However, ―newness‖ and ―novelty‖ have different meaning for the purpose of 
satisfying the requirement of patentability in the United States. Therefore, ―invention in ordinary 
sense‖ and ―patentable inventions‖ are two different things. The requirement for patentability in the 
35 U.S. Code § 102
45
 indicates that the invention has to be not only ―new‖ but also ―novel‖, meaning 
that it is not defeated by any disclosure or prior art (Palombi 2009, 222).  
However, Article 5(1) of the Biotech Directive 1998 states that, ―[t]he human body, at the various 
stages of its formation and development, and the simple discovery of one of its elements, including 
the sequence or partial sequence of a gene, cannot constitute patentable inventions.‖46 The exclusion 
of hESC inventions (encompassing the destruction of human embryo) from patenting in Europe is 
based on the interpretation of Article 6(2)(c) of the Biotech Directive. The CJEU in the case of 
Oliver Brüstle v. Greenpeace e.V., 2011
47
 found the commercial exploitation of inventions 
encompassing the destruction of the human embryo as against the spirit of the ―ordre public or 
morality‖.48 In the United States, the scenario is different from the European supra national legal 
framework. In the US, patenting enjoys wider freedom and hESC related inventions can be patented.  
4.3.2 INVENTIVE STEP/NON-OBVIOUSNESS 
Substantial effort, research and study through trial and error is required for making the claim that the 
reprogrammed cells will function towards the desired application. Non-obviousness to a person 
skilled in art can be established and the human contribution for the ―inventive step‖ may justify an IP 
protection.
49
 The non-obviousness requirement is laid down in 35 U.S. Code § 103 as following: 
 A patent for a claimed invention may not be obtained, notwithstanding 
that the claimed invention is not identically disclosed as set forth in 
section 102, if the differences between the claimed invention and the 
prior art are such that the claimed invention as a whole would have 
been obvious before the effective filing date of the claimed invention 
to a person having ordinary skill in the art to which the claimed 
invention pertains.
50
  
                                                                                                                                                                                                   
bool.html&r=2&f=G&l=50&co1=AND&d=PTXT&s1=%22US+8129187%22&OS=%22US+8129187%22&R
S=%22US+8129187%22 (last visited Nov. 5, 2014). 
 
44
 Supra note 40, art. 5(2). 
45
 35 U.S. Code § 102 (a) states that, ―[a] person shall be entitled to a patent unless— 
(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise 
available to the public before the effective filing date of the claimed invention‖. 35 U.S.C. § 102 (2013). 
46
 Supra note 40. 
47
 C-34/10, Judgment of the Court (Grand Chamber) 18 Oct. 2011, also available at 
http://curia.europa.eu/juris/liste.jsf?language=en&num=C-34/10 (last visited July 25, 2014). 
48
 Article 6(1) states that, ―[i]nventions shall be considered unpatentable where their commercial exploitation would be 
contrary to ordre public or morality‖; and Article 6(2) states that, ―[o]n the basis of paragraph 1, the following, in 
particular, shall be considered unpatentable: 
(a) processes for cloning human beings; 
(b) processes for modifying the germ line genetic identity of human beings; 
(c) uses of human embryos for industrial or commercial purposes‖. Supra note 40. 
49
 See ch. 3.1.2.4 ARE THEY SUBSTITUTE OF EACH OTHER OR DIFFERENT FROM EACH OTHER? 
50
 35 U.S.C. § 103 (2013). 
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The non-obviousness requirement was applied in the case of Graham v. John Deere Co. (1966) by 
the U.S. Supreme Court.
51
 However, if it (the non-obviousness requirement) is strictly applied for the 
protection of hSCI, some of the subsequent inventions and second medical applications will not 
qualify for the patent protection, as they might be insubstantial invention.  
However, it cannot be decisively said that novelty and non-obviousness/inventive step apparent in an 
invention will be adequate to support the patent survive the legal battles. A patent may fail to survive 
entirely or partially in the post grant proceedings at the patent office or later at Court. The intricate 
parts of the claims may not contain enough invention/innovation to justify the novelty and non-
obviousness in a given case. After the first isolation and derivation of ES cells in non-human primate 
by the scientist James Thomson in 1995 of Wisconsin Alumni Research Foundation (WARF), the 
WARF became the assignee of many US patents on non-human primate and human ES cell 
derivation process and derived cells in the succeeding years. The relevant WARF patents are 
following:  
 The United States Patent No. 5,843,780, issued on December 1, 1998 for ―[p]rimate 
embryonic stem cells;‖52  
 The United States Patent No. 6,200,806, issued on March 13, 2001 for ―[p]rimate embryonic 
stem cells;‖ 53 
 The United States Patent No. 7,029,913, issued on April 18, 2006 for ―[p]rimate embryonic 
stem cells;‖54 and 
 The United States Patent No. 7,442,548, issued on October 28, 2008 for ―[c]ulturing human 
embryonic stem cells in medium containing pipecholic acid and gamma amino butyric 
acid.‖55 
Although the US Patent No. 5,843,780 and the US Patent No. 6,200,806 survived till date, the US 
Patent No. 7,029,913, issued on April 18, 2006 has been tangled with oppositions. However, WARF 
patents generated much debates, arguments and protests. They have faced oppositions from the 
public interest groups. Nevertheless, they survived as patent keeping the question ―if human 
embryonic stem cells should be patented to allow exclusive right at all‖ alive. Easy access to these 
inventions/innovations are very important for the other researchers to be able to develop ―biological 
drug products‖.56 In 2013, the WARF‘s US Patent No. 7,029,913 was challenged in the United States 
Court of Appeal for the Federal Circuit by the Consumer Watchdog, a nonprofit organization, in the 
                                                          
51
 Graham v. John Deere Co. of Kan. City, 383 U.S. 1 (1966).   
52
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=5,843,780.PN.&OS=PN/5,843,780&RS=PN/5,843,780  (last visited Nov. 20, 2014). 
53
 The very patent also claimed to have disclosed the ―know-how‖ for the derivation of human ES cells. United States 
Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=6,200,806.PN.&OS=PN/6,200,806&RS=PN/6,200,806  (last visited Nov. 20, 2014). 
54
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=7,029,913.PN.&OS=PN/7,029,913&RS=PN/7,029,913 (last visited Nov. 20, 2014). 
55
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=7442548.PN.&OS=PN/7442548&RS=PN/7442548 (last visited Dec.10, 2014). 
56
 FDA‘s ―Compliance Program Guidance Manual Chapter – 45 Biological Drug Products‖ mentions stem cells and cell 
therapies as ―biological drug products‖ (U.S. Food and Drug Administration: Compliance Program Guidance Manual 
(CPGM) 2014). 
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case of Consumer Watchdog v. Wisconsin Alumni Research Foundation (2013) claiming that the 
inventions are not eligible for patenting, but the appeal was dismissed on June 4, 2014.
 57
 Although 
the Appellant Consumer Watchdog claimed that the inventions lack novelty and inventive steps, they 
also indicated that patenting those inventions by WARF resulted to burden on the taxpayers’ 
money.
58
 But the rejection of Appeal did not highlight any of those (patentability criteria and 
implications of patenting) issues; rather the absence of locus standi of the Appellant as an ―aggrieved 
person‖ was shown as the justification for the rejection of Appeal by the US Court of Appeal for the 
Federal Circuit.
59
 Therefore, those inventions have not yet failed the test of the novelty and inventive 
step requirement and their justification of patenting being inventions from public funded research
60
 
shall remain as a ―debate‖ to be resolved probably by a Supreme Court‘s (US) ruling in future.  
Feldman and Furth made the following discussion on the application of non-obviousness standard in 
the field of iPSC inventions in the USA:  
In the years leading up to 2007, the Federal Circuit had been applying 
the so-called TSM test
61
 for determining obviousness. According to the 
test, an invention would not be ruled patentable as a combination of 
information available in the prior art unless that art contained a specific 
teaching, suggestion, or motivation to combine the prior art. In the 
2007 case of KSR Int’l Co. v. Teleflex Inc., the U.S. Supreme Court 
rejected the Federal Circuit‘s application of the TSM test in a case 
concerning automobile gas pedals. The Supreme Court ruled that the 
test had been applied too rigidly. The Court also held that the Federal 
Circuit also erred in concluding that application of the TSM test was 
mandatory. (2010, 31; footnote added, footnote omitted) 
It seems that the U.S. Supreme Court has a softer approach in determining the non-obviousness 
standard. On the other hand, the EPO or CJEU on patentability issues had been apparently more 
strict in the recent past. It is more likely that technical intervention involved in reprogramming of the 
iPSC‘s early inventions may survive the non-obviousness standard in some patent offices very well. 
But the downstream inventions in iPSC making small variations in iPSC generation methods and 
application might not encompass substantial ―inventive step.‖ Therefore, it is necessary that the 
claim language of each invention is very precise to its inventive aspect. An overly broad claim may 
block the subsequent inventions to get a patent.  
 
                                                          
57
 Case 13-1377, Fed. Cir. 2013. 
58
 Consumer Watchdog v. Wisconsin Alumni Research Foundation, supra note 57. 
59
 Id. (June 4, 2014). 
60
 The inventions of the US Patent No. 7,029,913, which was challenged by the Consumer Watchdog, was the result of 
the research sponsored by the US Federal Government (US Patent No. 7,029,913, issued on April 18, 2006). United 
States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=7,029,913.PN.&OS=PN/7,029,913&RS=PN/7,029,913 (last visited Nov. 20, 2014). 
61
 Teaching-Suggestion-Motivation Test. 
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Fig. 4.1 Novelty and Inventive Step (Non-obviousness) in hESC (A) (Illustration from Wikipedia: 
Inner cell mass 2014), SCNT (Embryo Cloning) (B) and iPSC (C) (Figure 1, Mummery and Roelen 
2013, 174) 
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reprogramming. 
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of Tachibana et 
al. (2013)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The successful 
reprogramming by the 
introduction of the 
transcription factors 
(Oct3/4, Sox2, c-Myc, 
and Klf4 genes) is both 
novel and non-obvious.  
 
C. iPSC of 
Takahashi and 
Yamanaka 
(2006); Takahashi 
et al. (2007)  
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4.3.3 INDUSTRIAL APPLICATION 
Takahashi et al. (2007) published ―Induction of Pluripotent Stem Cells from Adult Human 
Fibroblasts by Defined Factors‖ in 2007. The clinical trial in human for this iPSC invention started in 
2014. At the Institute for Biomedical Research and Innovation, Kobe, Japan, a 70 years old woman 
as the participant of this clinical trial received the first graft of iPSCs on September 12, 2014  (Stem 
Cells Portal: AMD Patient Receives First Induced Pluripotent Stem Cell Graft 2014). The industrial 
and commercial application of this technology will be in the market after the safety and efficacy is 
proven by this clinical trial. The observation period of this study is 3 years. (Stem Cells Portal: 
World‘s First Induced Pluripotent Stem Cells Clinical Study on Humans Launches in Japan, 2014). 
The patent shall last 20 years from the invention was first proclaimed in mouse in 2006 Takahashi  (
and Yamanaka 2006) and in human in 2007 (Takahashi et al. 2007). The year in which ―human‖ 
received the transplant for the first time is 2014 (clinical trial). The industrial and commercial 
application may begin after the safety and efficacy of the transplant is proved. The study has 
estimated observation period of 3 years. Therefore, the technology will have very short time for 
commercial exploitation after it enters the clinic for-profit basis. Mathews, Deegan, and Bubela 
(2013, 508) wrote: ―Therapies may take between 10 and 15 years to reach the clinic—a timespan that 
will likely be even longer for cell-based interventions— while patent terms extend for 20 years plus 
marginal extensions to account for regulatory approval processes and necessary clinical studies.‖ 
 
Many of the ES cell derivation patents by the WARF will be useful for the other stem cell and 
biomedical researches. As product to arrive in the clinic, many of the hESC based inventions will 
have to wait long time. While the process patents already in existence for the ES cell isolation and 
derivation, those inventions remain useful for the downstream researchers. But those patents will 
make them (the downstream researchers) to take a license for their commercial exploitation, if they 
(the downstream researchers) are successful in making any disease specific inventions. Therefore, 
the meaning of ―industrial application‖ of the patents on the primary (first generation) hSCI is yet not 
the strict application as cure for a condition or disease; rather many of them are inventions having 
utility for further research targeted to product development. However, it is worth reiterating that the 
derivation of embryonic stem cell is possible through various methods.  
Steven D Schwartz et al. (2012, 713) mentioned in their publication on the trial of ESC
62
 for the 
macular degeneration:
63
 ―It has been 13 years since the discovery of human embryonic stem cells 
(hESCs). Our report provides the first description of hESC-derived cells transplanted into human 
patients.‖ 
                                                          
62
 Advanced Cell Technology (substituted corporate name Ocata Therapeutics, Inc.), who has funded this study, patented 
(e.g., United States Patent No. 8,742,200, issued on June 3, 2014) derivation of ES cells from the blastomere cell of the 
pre-implantation stage embryo (ES cells from biopsied embryo).  
63
 Macular degeneration is a major cause of blindness. 
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Fig. 4.2 ―Images of the hESC-RPE transplantation site in the patient with Stargardt‘s macular 
dystrophy‖ (Figure 4, Schwartz et al. 2012, 718) 
 
In all cases, patent succeeds the claimed invention, but precedes the clinical trial. The time lost in 
clinical trial, is lost from the term of protection of the patent.  
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Fig. 4.3 Term of protection continues towards its end, beginning from the date of patent filing 
 
The apprehension of  losing time also can push the companies to hurry up to reach to the market. The 
diverse industrial applications may not all fit the ideal interpretation of ―industrial application‖ of the 
patentable inventions.  
The patented technique of production of retinal pigment epithelium (RPE) cells from human 
embryonic stem cells by Advanced Cell Technology (Ocata Therapeutics, Inc.) was given orphan 
drug status for the RPE cells in 2010 (American Macular Degeneration Foundation: Stargardt 
Disease 2014).
64
 There are two implications of this ―orphan drug status‖, i.e., (a) availing the benefits 
of the tax reductions; and (b) in the phase III clinical trial, FDA may recognize that the number of 
1000 participants may not be available/possible due to the lower number of population affected by 
the disease (American Macular Degeneration Foundation: What is Orphan Drug Status? 2014).  
The age related Macular Degeneration is currently ―affecting more than 10 million Americans‖ and a 
major cause of vision loss in the population over the age of 55 (American Macular Degeneration 
Foundation: What is Macular Degeneration? 2014). With the growing number of aging population in 
the industrialized world, the number of population affected by the Age-related Macular Degeneration 
(AMD) will dramatically increase. The Archives of Ophthalmology of National Eye Institute (NEI), 
USA documented in the Vol. 122, dated April 2004, that the prevalence of Advanced AMD is 
witnessed in a total of 1,749,000 (1.5%) persons and Intermediate AMD in 7,311,000 (6.1%) persons 
(among the age group of 40 and above) (National Eye Institute (NEI): Statistics and Data, Prevalence 
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 Their initial study report on safety and efficacy by Schwartz et al. (2014, 2--3) admitted a low sample size of the 18 
patients as the participants.  
 
Invention 
Claimed:  
Ready for 
Patent 
Patent Filing 
Clinical trial 
for Proving 
Safety and 
Efficacy 
Clinic/ 
Hospital 
(Commercial 
Exploitation) 
20 Years 
(TRIPS)   
Term of protection for the patent begins counting from the date of the filing and ends at 20 
years 
The time spent for the clinical trial will 
be the ―time lost‖ from the total span of 
time for the commercial exploitation 
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of Blindness Data 2014). In 10 years‘ time, from then (2004), the disease has by now affected more 
American lives. Needless to mention that it has affected population in other parts of the world too.   
Industrial application of the invention is a requirement of the patent and it is possible to fulfill this 
requirement. But how the investors are transforming their invention into the ―industrial application‖ 
has completely pulled the ―incentive for innovation‖ and ―health care‖ to the back seat and pushed 
the commercial character of the companies forward. Are the companies giving new look and 
meaning to the patent itself? Having just an ―industrial application‖ to get a patent is not enough, for 
diseases affecting lives. The patent law also need to take into account ―how the industrial 
application‖ is materialized/translated by the patentee. A new meaning of ―industrial application‖ is 
needed.  
Therefore, the hSCI will have less difficulty to fit into the patentability requirements in the present 
conditions. But a lot more concerns remain on how the patented technology will affect the health 
care receivers. Shall patent monopoly allow access to the therapy or restrict it?  Shall patent bring 
enough incentive for the inventors and assignee, if the therapy reach to the market after the 
substantial term of protection is lapsed in the last phase of clinical trial? Will patent not hinder 
downstream research? Will the health care tourism increase as a result of divergent legal framework 
having differing interpretation of ―ethical‖ issues on patentability? Therefore, these questions remain 
the challenge for the IP protection of hSCI under the umbrella of patent, rather than satisfying the 
patentability requirement for those inventions/innovations. However, the patentability has also been 
questioned in some cases.  
 
4.4 PATENT RELATED CONCERNS  
Patent is commonly referred as an incentive that encourages the invention/innovation; but it also can 
cause hindrance for the development of the new invention (Winickoff, Saha, and Graff 2009, 88). An 
exclusive right is granted in favor of the inventor and/or assignee, not only to encourage them, but 
also to exclude the ―free riders‖ who might steal the right owners‘ labor and investment. But IPR in 
which form is perfect for the hSCI?  
Question no. 6 asked the respondents if they ―think patent protection as it exists today is the best way 
to provide incentive to human stem cell based inventions/innovations‖. The Major Key Themes 
derived from the responses to question no. 6 show how they commented about the current patent 
system:
65
  
 Patent protection may not be sufficient for  biotechnology products; 
 ―Ad hoc data exclusivity rights‖; 
 Going further than this (exceeding 20 years) would affect access to therapy for the patients in 
less developed countries; 
 ―Realization and understanding‖; 
 ―Life is already in existence‖; 
 hESC research has ethical constraints; 
                                                          
65
 Some of the words/phrases used/mentioned within quotation in the major key themes and their interpretations are the 
exact words/phrases used by the respondents. Appendix V: Qualitative Analysis (Qualitative Content Analysis (QCA)). 
 
The questionnaire mentioned that, ―the identity of the participants shall be kept anonymous, unless required to prove the 
authenticity of the study.‖ Appendix II: Questionnaire. 
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 Litigations and oppositions are becoming more common; 
 ―Protecting the moral rights‖; ―not for commercialization‖; 
 Researchers are driven by ―curiosity‖ and ―altruism‖; 
 Noble purpose behind the innovation; 
 Skepticism about the appropriateness of the patent system for life sciences; 
 Possible adverse social effects; 
 Controversies around patenting second medical application of known drugs. 
The interpretation of the Major Key Themes derived from responses to question no. 6 can be found in 
ch. 5. 
The hSCR is a relatively new field and continuously evolving. While large numbers of promised 
applications are at clinical trial or simply at research stage, a lot of patents are already granted in the 
emerging technologies of stem cell researches (Winickoff, Saha, and Graff 2009, 75).  
The early patents may expire before the products are at the market or they may cause hindrance to 
the downstream researches by requiring licenses. The ―infringement litigation‖ and the ―settlement‖ 
may eat up the profits, a patent on a downstream invention might have made. Bergman and Graff 
thought that ―patent thicket‖ may ―slow and skew the overall development of new technical 
applications‖ (2007, 419). Gaetan de Rassenfosse and Bruno van Pottelsberghe de la Potterie 
conducted an empirical study on ―R&D–patent relationship‖ and found:  
A better quality of education is a factor that substantially improves 
researchers‘ productivity in a country, and hence their observed 
patenting performance. […]. S&T policies also come into play: the 
higher the share of business R&D and the more resources are allocated 
to researchers, the more productive the research efforts will be. 
Regarding the propensity to patent, the design of IP systems matters. 
Several dimensions of a patent system, including the number of 
patentable subject matters, restrictions, enforcement mechanisms, and 
especially its fees, all affect a country‘s patenting performance. 
(Rassenfosse and Potterie 2009, 788; italics added) 
 
Patent system in post TRIPS era is an economic tool. The humanitarian implication of the strong 
patent protection of inventions in health care sector is largely ignored.  The different circumstances 
and needs of the countries and their population are hardly taken into consideration.  
The respondents were asked (question no. 13): ―Do you think public opinion should be sought and be 
given importance after the invention/innovation is put to the market for commercial exploitation, in 
order to measure the impacts of the IPR protected invention/innovation on the health care receiver?‖. 
The Major Key Themes derived from responses to question no. 13:
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 Public in general are not informed enough to give valuable feedback; 
 Skeptical about the issue of consulting with the public; 
                                                          
66
 Supra note 65. 
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 ―Obvious public outcry‖; 
 Information should be made available to the consumers a priori; 
 Embryo source is central to public interest and not access, affordability, safety or efficacy of 
the therapy (in case the therapy is developed from hESC); 
 Civil society should have the legal means; 
 Pre-commercial exploitation public consultation. 
The comments showed indication that public are not really well-informed about the IP and its effect. 
The interpretation of the Major Key Themes derived from responses to question no. 13 can be found 
in ch. 5.  
The application of stem cell based therapies will range from eye care to heart diseases. Soon after the 
application arrives the clinic, they may become essential to health care. How much profit a drug 
developer may be allowed to make, by exploiting the patent, should be a legislative concern. 
Arif Jamil made a discussion on the inherent character of the ―patent‖ and explored if it is meant to 
treat the protected invention as ―property‖:  
Patent right which can give rise to monopoly was intended to 
encourage innovation by providing an incentive and was meant to 
protect the rights of the inventors (Usselman and John, 2006, p.99, 
116; Ventose, 2011, p.14). It is a tool for recovery of investment and 
generating money for future research. Inventor alone is not enough to 
commercialise an invention. Public or private funds may be needed for 
putting the invention into market. Therefore, the assignee or the 
investor is the dominant player whose interests the protection tool 
ultimately secures. Therefore, a patent makes sure that the system 
assists him to use the invention in profitable manner by excluding the 
competitors. Some of the scholars see patent as a ‗property right‘ 
(Dam, 1994, p.247). However, the purpose served by the patent and the 
profits made varies from industry to industry. […]. Bessen and Meurer 
(2008) indicate that the changes in the features of technology reduces 
demand of the earlier version, and the value of the patent deteriorates 
(Bessen and Meurer, 2008, p.100). But in the health care related 
industries, the patents are more effective than other disciplines of 
technology (Bessen and Meurer, 2008, p.106). (2013a., 28--29; Italics 
added) 
The patent system is so focused on the ―commercial exploitation‖ and ―exclusiveness‖ of the right of 
the assignee that the protected invention becomes more like a property.  
In order to confirm a stem cell based product as proven therapy, it goes through the phases of clinical 
trials. Once the acceptable levels of safety and efficacy in defined number of subject/patients is 
observed, then it is manufactured on a larger scale, i.e., on a commercial level. Based on the 
frequency of the disease in question in the general population, this level of commercialization would 
vary. Therapy to some common diseases would be produced in bulk quantities while for treating rare 
diseases, it is usually produced at a smaller scale and often customized to individual patient. 
Patent is indeed a property right owned by an individual or entity for a certain duration of time. Only 
if, from the research and innovation to the commercialization, all is conducted with public funding 
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and the services distributed through public structures, the delivery of service can be executed in non-
commercial manner. In that case, the invention will require only recognition; no exclusive rights of 
commercialization will be needed. The commercialization is an integral phenomenon of private 
investment in research, innovation. The patent is a tool that may encourage private investment in 
research and apparently shows a way to secure the return of the investment.  
The respondents were asked: ―Do you think that a new protection mechanism/framework can be / 
should be developed within the purview of intellectual property law (IPR), separate from patent, for 
the inventions/innovations that use biological materials of human origin and targeted to health 
care?‖.67 The Major Key Themes derived from responses to that question (no. 7) show that many of 
the experts are inclined to reduced commercialization of health care related inventions:
68
 
 New creation cannot be made within the realm of life science; 
 hSCI cannot be patented; 
 Health care transformed into business; 
 Stakeholders of health care should focus on how to provide affordable care and therapy to 
people; 
 Reduced commercialization;  
 Does not support any protection framework with a commercial feature; 
 Government‘s money; 
 Research targeted to health care is done for humanity; 
 
The Interpretation of the Major Key Themes derived from responses to question no. 7 can be found in 
Ch. 5. 
 
4.4.1 PROPRIETARY NATURE OF THE HUMAN STEM CELL BASED 
INVENTION/INNOVATION 
Some of the important patents on hSCI reveal that the industry is heavily influenced by the private 
and autonomous entities such as companies and universities. It is unlikely that these private entities 
will offer therapies to the patients on a ―not for profit‖ basis. In fact, they are marketing their 
inventions before the safety and efficacy of those inventions are proven from the clinical trial. The 
patents they have are the ―property‖ they own and they shall commercially exploit it as soon as the 
safety and efficacy of the methods are proven. Since they have received patent before (in some 
instances long before) the clinical trial is over, some of them may ask for new patents by showing 
some insubstantial improvement to keep the exploitation of the invention possible for a plausible 
term of protection.  
However, the assignees of some of the remarkable US Patents for/from the human stem cell industry 
in the recent past, holding the commercial interest, are:  
                                                          
67
 Question No. 7.  
 
Stem cell based inventions require the use of biological materials of human origin. 
68
 Supra note 65. 
91 
 
A. Wisconsin Alumni Research Foundation (Madison, WI, USA) holds patent for the isolation of 
primate ES cells while claiming that the same procedure will make isolation of human ES cells 
possible. 
 United States Patent No. 6,200,806 was issued on March 13, 2001 having the  Wisconsin 
Alumni Research Foundation (Madison, WI, USA)  as the assignee for "[p]rimate embryonic 
stem cells" (US Patent No. 6,200,806, issued on Mar. 13, 2001). The details of the patent is 
claiming the invention as likely methods for isolation of human embryonic stem cells. The 
isolation of ES cells in this invention was originally conducted on primates.   
 
B. Kyoto University, Japan holds iPSC (Induced Pluripotent Stem Cell) patents. 
 United States Patent No. 8,048,999 was issued on November 1, 2011 having the Kyoto 
University, Japan as the assignee for the ―[n]uclear reprogramming factor‖ (US Patent No. 
8,048,999, issued on Nov. 1, 2011);  
 United States Patent No. 8,058,065 was issued on November 15, 2011 having  Kyoto 
University, Japan as the assignee for the methods of generating iPSC by the nuclear 
reprogramming factor ―Oct3/4, Klf4, c-Myc and Sox2‖ (US Patent No. 8,058,065, issued on 
Nov. 15, 2011);  
 United States Patent No. 8,129,187 was issued on March 6, 2012 having the Kyoto 
University, Japan as the assignee for the ―[s]omatic cell reprogramming by retroviral 
vectors‖ (US Patent No. 8,129,187, issued on Mar. 6, 2012).  
 
C. International Stem Cell Corporation (a biotechnology company) based in California, USA holds 
hpSC (Human Parthenogentic Stem Cell) patent. 
 United States Patent No. 8,420,393 was issued on April 16, 2013 having International Stem 
Cell Corporation as the assignee for "[g]eneration of an autologous stem cell library from 
human oocytes parthenogenetically activated by high or low oxygen tension" (US Patent No. 
8,420,393, issued on Apr. 16, 2013).  
  
D. The New York Stem Cell Foundation, NY, USA (a non-profit organization) holds a patent on  
the derivation of pluripotent stem cells by Nuclear Transfer. 
 United States Patent No. 8,748,178 was issued on June 10, 2014 having the the New York 
Stem Cell Foundation (New York, USA) as the assignee for "[m]ethod for producing 
pluripotent stem cells" by activating the human oocyte, without removing the genome of the 
oocyte (US Patent No. 8,748,178, issued on June 10, 2014). 
 
E. Advanced Cell Technology, Inc., (Ocata Therapeutics, Inc.), a biotechnology company, based in  
Marlborough, Massachusetts, USA holds the patent on ESC derived from the Blastomere cell of 
pre-implantation stage embryo.  
 United States Patent No. 8,742,200 was issued on June 3, 2014 having the Advanced Cell 
Technology, Inc. (Marlborough, MA) as the assignee for the ―[d]erivation of embryonic 
stem cells and embryo-derived cells‖ (US Patent No. 8,742,200, issued on June 3, 2014).    
 
F. Oregon Health & Science University (OHSU), Oregon, USA, hosting the lab of Shoukhrat 
Mitalipov is likely to get US patent in near future for derivation of ESCs  by SCNT (Somatic Cell 
Nuclear Transfer) a.k.a.  NT-ESC.  
 Masahito Tachibana et al. (2013) published ―Human Embryonic Stem Cells Derived by 
Somatic Cell Nuclear Transfer‖. It is claimed to be the first ―successful‖ derivation of hESC 
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by SCNT. The most probable assignee of this invention is the Oregon Health & Science 
University (OHSU), USA. 
 
Some of the researches by the universities may be funded/covered by the Government grants but the 
Government‘s grants regulate the research ethics only. The funding institutions of the Governments 
do not usually conduct any investigation on the implications of patent protection of these inventions 
over the health care receivers. Once the research institution gets the inventions patented, it is 
essentially their intellectual property. In the light of the abovementioned patents, it appears that even 
the inventors get the recognition as the inventor only, not any share in the commercial interest. The 
recent patent landscape of the most advanced human stem cell techniques reveal that the commercial 
interests are clearly not dominated by the scientist or any ―not for profit‖ organization, rather are the 
exclusive intellectual property of the assignee institutions. However, the New York Stem Cell 
Foundation proclaims itself as a non-profit organization (The New York Stem Cell Foundation 
(NYSCF) 2014). Although an entity may proclaim itself as a non-profit organization, it is free to 
exploit the patent commercially. The WARF also proclaims as ―private, nonprofit patent and 
licensing organization for the University of Wisconsin‖ (Wisconsin Alumni Research Foundation 
(WARF) 2014), but it did have defended its ES cell patents for the commercial reasons and seeking 
―commercial partners‖ for its patents (Wisconsin Alumni Research Foundation (WARF): Drug 
Discovery: 2014). In 2006, WARF was issued another US Patent (No. 7,029,913) for isolation of 
human ES cells which received oppositions both at USPTO and the United States Court of Appeals 
for the Federal Circuit.
69
 The United States Government in its brief in the case of Consumer 
Watchdog v. Wisconsin Alumni Research Foundation, argued that the appeal should be dismissed 
and pleaded that the Appellant Consumer Watchdog neither have any concrete interest in the US 
Patent No. 7,029,913 nor aggrieved by it.
70
 Clearly representing the consumers‘ or taxpayers‘ 
interest is not enough to contest the patentability of an invention ―on the technicalities or its 
implication‖ at the US Court of Appeals for the Federal Circuit, as the appeal was eventually 
dismissed for lack of locus standi of the Consumer Watchdog as the Appellant.
71
 Despite WARF 
patents on ES cell derivation received many oppositions, they survived till date. It is worth quoting 
from the patent (US Patent No. 7,029,913) itself the following statement about the source of the 
funding behind the inventions: ―This invention was made with United States government support 
awarded by NIH NCRR Grant No. RR00167. The United States government has certain rights in 
this invention‖ (US Patent No. 7,029,913, issued on April 18, 2006; italics added).72 The report of 
the NIH to the United States Congress of 2001 regarding ―A Plan to Ensure Taxpayers' Interests are 
Protected‖ stated:  
In 1980, […] Congress enacted two laws that encourage government 
owned and government funded research laboratories to pursue 
commercialization of the results of their research. These laws are 
known as the Stevenson-Wydler Act and the Bayh-Dole Act. Their goal 
is to promote economic development, enhance U.S. competitiveness, 
and benefit the public by encouraging the commercialization of 
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 Consumer Watchdog, a nonprofit organization, challenged the patentability of the inventions in the case of Consumer 
Watchdog v. Wisconsin Alumni Research Foundation. Supra note 57. 
70
 Case 13-1377, Doc. 43, Fed. Cir. 2013 (Jan. 17, 2014). 
71
 Consumer Watchdog v. Wisconsin Alumni Research Foundation, Case 13-1377, Fed. Cir. 2013 (June 4, 2014). 
72
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=7,029,913.PN.&OS=PN/7,029,913&RS=PN/7,029,913 (last visited Nov. 20, 2014). 
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technologies that would otherwise not be developed into products due 
to lack of incentives.[…]. The Bayh-Dole Act was enacted to allow 
federal agencies to secure patent rights and convey them to 
commercial entities through licensing[…]. A key provision of the Act 
is that it provides grantees and contractors, both for-profit and not-for-
profit, the authority to retain title to government-funded inventions, 
and charges them with the responsibility to use the patent system to 
promote utilization, commercialization, and public availability of 
inventions.[…]. To accomplish the transfer of technology, NIH and 
NIH-funded recipients typically seek patent protection for inventions 
arising out of this basic research and license the rights to private 
entities to promote commercialization. Thus, private entities interested 
in practicing an invention in which they have no ownership may obtain 
rights to use and commercialize the invention by entering into a 
licensing agreement with the patent owner. A license is a contract with 
binding commitments on each party, usually involving compensation 
(i.e. royalties, milestone payments, etc.). (NIH Intellectual Property 
Policy: Protecting Taxpayers' Interests (07/2001) - NIH Response to 
the Congressional Committee Report Request for a Plan to Ensure 
Taxpayers' Interests are Protected 2014; italics added) 
This narrative of the NIH policy highlights the issues of incentive for innovation, commercialization 
and competitive advantage and patent is believed to be the tool to achieve them. But the wider access 
to the patented technology by the people, developed by the taxpayers‘ money is not anywhere at the 
forefront of the laws and policy. NIH policy summary on sharing and disseminating the biomedical 
research resources also shows that access to research by the scientific community and dissemination 
through contractual arrangement are important considerations: 
Access to research tools is a prerequisite to continuing scientific 
advancement. Ensuring broad access while preserving opportunities for 
product development requires thoughtful, strategic implementation of 
the Bayh-Dole act. The NIH urges Recipients to develop patent, 
license, and material sharing policies with this goal in mind, realizing 
both product development as well as the continuing availability of new 
research tools to the scientific community.
73
 
Although the invention of US Patent No. 7,029,913 was developed with the Federal funding, the 
patent will enable the assignee to exploit it commercially. The ultimate goal and motive of securing 
the commercial interest over the invention through the patent is to make the protected subject (the 
invention/innovation itself) a property of the assignee. However, the stakeholders express their goals 
and visions in different ways: 
 The Wisconsin Alumni Research Foundation (WARF) says: ―The Wisconsin Alumni 
Research Foundation (WARF) is seeking commercial partners interested in a purified 
preparation of pluripotent human embryonic stem cells.‖ (WARF: Through Technologies 
2014). 
  
 Center for iPS Cell Research and Application (CiRA), Kyoto University states:  ―Goals for 
2020: [...] Establish basic iPS cell technology and secure the associated intellectual property 
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 Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating 
Biomedical Research Resources: Final Notice, 64 Fed. Reg. 72090--72096 (Dec. 23, 1999). 
94 
 
rights [...].‖ (Center for iPS Cell Research and Application: Message from the Director 
2014). 
   
 International Stem Cell Corporation (ISCO) says: ―In the medium term, revenue could be 
generated from universal stem cell bank franchises […] and, longer-term, will provide the 
company with royalty from sales of each successful, hpSC-derived cellular therapeutic.‖ 
(International Stem Cell Corporation: Stem Cell Bank 2014). 
 
 The New York Stem Cell Foundation (NYSCF) claims: ―Building a bank of 2,500 stem cell 
lines […]. This revolutionary global resource will equalize access for safe and effective 
medicine for EVERYBODY including underserved populations.‖ (The New York Stem Cell 
Foundation: NYSCF Research 2014). 
 
 Advanced Cell Technology, Inc., says: ―Ocata Therapeutics, Inc. […], formerly named 
Advanced Cell Technology, is a clinical stage biotechnology company focused on the 
development and commercialization of new therapies in the field of regenerative medicine.‖ 
(Ocata Therapeutics: Company Overview 2014). 
 
 Center for Embryonic Cell and Gene Therapy, Oregon Health & Science University 
(OHSU) claims: ―Philanthropic gifts from corporations and foundations also provide critical 
money for our new research initiatives on human embryo and stem cell research.‖ (Center 
for Embryonic Cell and Gene Therapy: Support Our Lab 2014). 
 
The larger quantity
74
 of the stem cell patents under the possession of private sector may heavily 
influence the industry to achieve the commercial goals rather than serving the health care objectives. 
The assignee of several first generation inventions are corporations, universities and research 
institutes.
75
 From the cited examples, the assignees (US patent either already granted or likely to be 
granted) found are: 
 Wisconsin Alumni Research Foundation (WARF), Madison, USA; 
 Kyoto University, Japan; 
 International Stem Cell Corporation, California, USA; 
 New York Stem Cell Foundation, NY, USA; 
 Advanced Cell Technology, Inc. (Ocata Therapeutics, Inc.), Marlborough, Massachusetts, USA; 
and 
 Oregon Health & Science University (OHSU), Oregon, USA. 
 
These organizations/institutions will be able to collect royalties from licensing and make profit from 
the exploitation of the inventions, as those inventions will serve as their property.   
The respondents were asked (question no. 10): ―Who, according to your opinion, should be entitled 
to the intellectual property rights (IPR) of human stem cell based inventions/innovations?‖. The 
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 Bergman and Graff found that, ―[o]f US granted stem cell patents, 44 percent were assigned to public sector entities 
and 56 percent to private sector entities‖ (2007, 421). 
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 Even if the research institute have received the Government funding for research, it is allowed to do commercial 
exploitation through patent.  
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Major Key Themes derived (from the comments of the experts/respondents) from responses to 
question no. 10 are:
76
 
 
 Who will own the IPR shall depend on contractual arrangement as determining factor; 
 Donor of cell line should receive a compensation; 
 Scientist/inventor and patients; 
 ―Moral right‖, not an economic right; 
 Employer organization/university makes no intellectual contribution to the hSCI; 
 Entitlement determined by funding sources. 
Many of the comments had brought the humanitarian aspects of innovation to the fore. However, the 
interpretation of the Major Key Themes derived from responses to question no. 10 can be found in 
ch. 5.  
 
4.4.2 REGULATORY DATA EXCLUSIVITY, BOLAR EXEMPTION AND COMPULSORY 
LICENSE  
TRIPS Agreement does not use the term ―compulsory license‖ but there are some provisions under 
the title of ―[o]ther [u]se [w]ithout [a]uthorization of the [r]ight [h]older‖ in Article 31 that serves 
similar purpose of allowing the use (of patented invention) in limited circumstances and conditions 
being fulfilled.
77
 In order to avail the options of Article 31, the company or person seeking the 
license/approval/permission to use the patent must have tried to ―obtain authorization from the right 
holder on reasonable commercial terms and conditions‖ and was unsuccessful.78 This requirement 
may be waived for ―national emergencies‖, ―other circumstances of extreme urgency‖ or ―public 
non-commercial use‖ or use by the government or to remedy an anti-competitive practice.79 
However, Doha WTO Ministerial Declaration on the TRIPS Agreement and Public Health expressly 
use the term ―compulsory license.‖80 Article 30 of the TRIPS Agreement known as ―Bolar‖ 
provision is implemented in national laws to allow the generic drugs‘ manufacturers to use the 
patented information for availing the marketing authorization from the regulatory authority. But the 
generic cannot enter the market until the patent and the data exclusivity right has expired.  
Article 10 of the Directive 2004/27/EC states: ―A generic medicinal product authorised pursuant to 
this provision shall not be placed on the market until ten years have elapsed from the initial 
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 Supra note 65.  
77
 Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Marrakesh Agreement 
Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197 (1994) [hereinafter TRIPS 
Agreement]. 
78
 TRIPS Agreement art. 31(b). 
79
 TRIPS Agreement art. 31(b)(k). 
80
 World Trade Organization, Ministerial Declaration on the TRIPS Agreement and Public Health of 14 November 2001, 
art. 5 (b)(c), WT/MIN(01)/DEC/2, [hereinafter Doha Declaration], also available at 
http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm.  
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authorisation of the reference product.‖ 81 Apart from this 10 years, one additional year of protection 
is available for the second medical application of the already protected substance.
82
 The Bolar 
provision can be found in Article 10(6) stating that, ―[c]onducting the necessary studies and trials 
with a view to the application of paragraphs 1, 2, 3 and 4 and the consequential practical 
requirements shall not be regarded as contrary to patent rights or to supplementary protection 
certificates for medicinal products.‖83 
Anthony Tridico revisited and summarized the prevailing legal and policy landscape surrounding the 
Bolar provision, Regulatory Data Exclusivity (RDE) and generic drug manufacturing and 
commented:  
In the US, the Hatch-Waxman Act established a regulatory framework 
to encourage the marketing of generic pharmaceutical products. The 
Act also created a research exemption, indicating that ―it shall not be 
an act of infringement to make, use, offer to sell, or sell within the 
United States or import into the United States a patented invention . . . 
solely for uses reasonably related to the development and submission 
of information under a Federal law which regulates the manufacture, 
use, or sale of drugs or veterinary biological products.‖ 35 U.S.C. § 
271(e)(1) (―Bolar exemption‖). This provision overturned the Federal 
Circuit decision in Roche Products, Inc. v. Bolar Pharmaceutical Co., 
Inc., 733 F.2d 858 (1984), which held that the traditional experimental 
use exemption to patent infringement (35 U.S.C. § 271(a)) did not 
apply to pre-market testing done by a generic manufacturer and 
submitted to a regulatory agency. [….]. Notwithstanding the EU 
Directive, the exact language, scope and interpretation of Bolar 
exemptions vary across Europe. (Tridico 2014, 17--20) 
The national laws on ―Regulatory Data Exclusivity‖ protects the information of the initial 
authorization of the reference medicinal product for 10 to 11 years in Germany, Italy, Lithuania, 
Spain and UK (CMS Legal Services EEIG 2007).The Regulatory Data Exclusivity (RDE) right
84
 is 
independent of other IP rights (such as patent or trade secret). Hence, this RDE right shall be 
protected for that tenure (10-11 years) independent of the term of patent. If this RDE goes parallel 
with the patent, then patent lasts longer and RDE exhausts within the term of protection of the patent. 
But if the patented invention is delayed to enter the market as product, this RDE can extend the life 
of the IP protection of that original invention. Data Exclusivity Right (DER) exist in the US and the 
EU to offer protection in varying length. Section 355 of the US Federal Food, Drug, and Cosmetic 
Act
85
 provides provision for the protection of similar/same right. Article 39 of the TRIPS Agreement, 
which calls for protection against unfair competition,
86
 is interpreted by the US and EU to extend the 
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 Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 
2001/83/EC on the Community Code Relating to Medicinal Products for Human Use, 2004 O.J. (L 136) 34, 39. 
82
 Id. art. 10(5). 
83
 Id. art. 10(6). 
84
 Judit Rius Sanjuan explained: ―The terms "marketing exclusivity," "market exclusivity," "new drug product 
exclusivity," "Hatch-Waxman exclusivity," "sui generic protection," "data exclusivity," and "data protection" are all 
found in the U.S. and/or E.U. legal literature. Usually the term "marketing exclusivity" is more used in the U.S. 
regulatory system, and both the terms "data protection" and "data exclusivity" are more used in the E.U. system.‖ (2006, 
2n5). 
85
 21 U.S.C.§ 355 (2010). http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-
subchapV-partA-sec355.htm.  
86
 Art. 39 (3) TRIPS Agreement states: ―Members, when requiring, as a condition of approving the marketing of 
pharmaceutical […] products which utilize new chemical entities, the submission of undisclosed test or other data, the 
origination of which involves a considerable effort, shall protect such data against unfair commercial use. In addition, 
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DER in favor of the IP right owner potentially delaying the chance of the generic entering the market 
Moreover, the exercise of compulsory licensing have to take into account the ―patent and the data 
exclusivity right‖ both. Much stronger IP protection exist in the US and EU than the TRIPS required 
for the protection of pharmaceutical test data. Judit Rius Sanjuan made the following criticism of 
offering strong DER: 
The granting of exclusive rights in test data will delay the entry of 
generic products into the market, impeding the access to affordable 
medicines. [….]. The exportation of the U.S. Hatch-Waxman regime to 
other countries with very different income and needs has been strongly 
criticized by one of its proponents, Representative Henry A. Waxman. 
It is a form of double protection, since the strong patent rights are 
justified by the cost of investments in test data. According to this line 
of thinking, stronger rights in the data should be offset by weaker 
protections for the patent. […] 
Unless the exclusive rights in the data can be overridden, it can make 
compulsory licenses of patents or government use orders ineffective. 
It undermines the Bolar/ Early Working patent exception which seek to 
encourage quick access to the post patent market for generic medicines 
by exempting from patent liability certain conducts. (Sanjuan 2006, 16; 
footnote omitted) 
 
When the double protection of patent and DER are offered to the Biotech companies for the ―stem 
cell based invention‖ and the test data of ―stem cell based therapies,‖ the IP protection may 
substantially delay the generic manufacturer entering into market. Bolar exemption will not do much 
to increase the access to the therapy. Stem cell patents raises other concerns too. Granting broad 
patent in emerging techniques of biomedical science creates the fear of blocking the downstream 
research. Because the upstream inventions having no direct application for therapeutic purpose, 
might be essential for downstream research for drug development. They form the ―essential facility‖ 
for further innovation (for example, WARF patents on ES cell derivation) (McCoy 2008-2009, 86). 
The competition law and the compulsory licensing regime may not be enough tool to break the 
power of monopoly.   
The respondents were asked (question no. 8): ―How many years of protection (term of protection for 
commercial exploitation) is appropriate for human stem cell based inventions/innovations?‖. The 
following Major Key Themes derived from the responses to question no. 8 shows that a few of them 
made comments and they supported 20 years or more for the IP protection of hSCI: 
 ―Regulatory approvals‖; 
 Current protection; 
 20 or more than 20 years is appropriate; 
 
                                                                                                                                                                                                   
Members shall protect such data against disclosure, except where necessary to protect the public, or unless steps are 
taken to ensure that the data are protected against unfair commercial use.‖ TRIPS Agreement art. 39.  
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The interpretation of the Major Key Themes derived from responses to question no. 8 can be found in 
ch. 5. 
4.4.3 CONTROVERSIES, SLIM DIFFERENCES AMONG INVENTIONS, FUTURE LEGAL 
COMPLICATIONS 
The Korean scientist Woo Suk Hwang was proclaimed as ―the first to create a human embryonic 
stem cell line through cloning‖ (Ryan Davis, Law360, February 19, 2014) in 2004. Hwang et al. 
published the article ―Evidence of a Pluripotent Human Embryonic Stem Cell Line Derived from a 
Cloned Blastocyst‖ in the journal Science87 in 2004. But the journal retracted this publication and the 
subsequent Science publication
88
 of the authors in 2006 after the Seoul National University (SNU) 
declared that the publications contained fabricated data (Kennedy 2006). The scientist Woo Suk 
Hwang
89
 was issued the United States Patent No. 8,647,872 on February 11, 2014
90
 for ―[h]uman 
embryonic stem cell line prepared by nuclear transfer of a human somatic cell into an enucleated 
human oocyte.‖91 As the retracted publication and patented inventions are claimed to be either same 
or similar by some commentators,
92
 several comments and criticisms surfaced after the issuance of 
this patent. What can be possible impacts of such patents? Either the patent is meaningless (as the 
invention cannot be implemented) or it may form the part of prior art for the invention of Shoukhrat 
Mitalipov who claimed to have successfully cloned human embryo by SCNT and derived  human 
embryonic stem cells by SCNT in 2013 (Tachibana et al. 2013).
93
 From the patent perspective, the 
United States Patent No. 8,647,872 is the first of its kind, but the authenticity of the invention was 
questioned and the patent claim was also broad (Jeanne Loring, Knoepfler Lab Stem Cell Blog, Feb. 
12, 2014). Either it encompasses fake protocol or may form prior art for the invention of Tachibana 
et al (2013). Irrespective of the fact that Woo Suk Hwang‘s inventions were claimed to be fabricated, 
the US Patent and Trademark Office (USPTO) issued the patent on the same or similar claims. It 
appears that they (USPTO) do not possess the capacity or resources of ―replicating‖ the invention to 
see if the claim truly embodies/produces an invention. This is a vital weakness in the patent granting 
process for the new inventions in life sciences. As stem cell based inventions are emerging 
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 303 SCIENCE 1669, 1669-74 (2004), doi:10.1126/science.1094515. The article was retracted by Science on January 20, 
2006. 
88
 The article by Woo Suk Hwang et al. titled ―Patient-Specific Embryonic Stem Cells Derived from Human SCNT 
Blastocysts‖ was published in Science on 17 June 2005 (Vol. 308, No. 5729, pp. 1777-1783, 
doi:10.1126/science.1112286) was later (Jan. 20, 2006) retracted.  
89
 Woo-Suk Hwang is one of the inventors (US Patent No. 8,647,872, issued on February 11, 2014). 
90
 8 years after the publications/papers were retracted. 
91
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,647,872.PN.&OS=PN/8,647,872&RS=PN/8,647,872 (last visited Dec. 30, 2014). 
92
 Andrew Pollack reported: ―A committee at Seoul National University, where Dr. Hwang worked, concluded in 2006 
that evidence in his papers was faked. Science retracted both papers […]. The patent, No. 8,647,872, […], covers a 
human embryonic cell line derived through cloning and the methods for creating that line. It appears to be the cell line 
that was the subject of the first Science paper.‖ (The New York Times, Feb. 14, 2014). 
 
Ryan Davis wrote: ―Attorneys say that while it is not clear that Hwang's U.S. patent is based on exactly the same 
research that led to his problems in Korea, it appears largely similar. U.S. Patent Number 8,647,872, issued Feb. 11, 
covers an embryonic stem cell line derived through cloning and the method for creating it.‖ (Law360, February 19, 
2014). 
93
 However, Shoukhrat M. Mitalipov is one of the inventors (Shoukhrat M. Mitalipov, Don P. Wolf and James Byrne 
(inventors)) of the United States Patent No. 7,972,849 issued on July 5, 2011 for ―[p]rimate pluripotent stem cells 
produced by somatic cell nuclear transfer‖ having the Oregon Health & Science University (Portland, OR) as the 
assignee of the patent. This patent (United States Patent No. 7,972,849) is also the prior art for the publication of 
Tachibana et al. (2013) which is the publication of the Mitalipov‘s team regarding an optimized procedure of the SCNT 
technology for human embryo cloning and extracting the cells from the cloned embryo. But 2013‘s publication 
(Tachibana et al. (2013) by the team of Mitalipov) has not been issued US patent yet.  
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technology in the discipline of life science, there are more legal complications going to arise due to 
fake or bad patents. Those patents (fake or bad ones) may create hurdle to do research and get the 
patent for the credible inventions that take place subsequent to them. Filing a case/petition to declare 
the patent unenforceable (or apply for revocation/opposition/reexamination procedure) is also 
another extra burden on who might be making an invention that may apparently infringe a fake or 
bad patent. The following diagram illustrates the complications arising from the above situation:  
 
Fig. 4.4 They may have to experience reexamination / post-grant proceedings / patent litigation 
United States Patent No. 7,972,849 issued 
on July 5, 2011 having the Oregon Health & 
Science University (Portland, OR) as the 
assignee of the patent and Shoukhrat M. 
Mitalipov as one of the inventors.  
 
Retracted publications of Hwang et al.  
―Evidence of a Pluripotent Human 
Embryonic Stem Cell Line Derived from a 
Cloned Blastocyst‖ (Hwang et al. 2004) 
and 
―Patient-Specific Embryonic Stem Cells 
Derived from Human SCNT Blastocysts‖ 
(Hwang et al. 
2005). 
No US patent is granted yet for the 
publication ―Human Embryonic Stem Cells 
Derived by Somatic Cell Nuclear Transfer‖ 
(Tachibana et al. 2013) by the team of 
Mitalipov. 
 
United States Patent No. 8,647,872 issued on 
February 11, 2014 was assigned to H. Bion 
Co., Ltd., Seoul, Korea having Woo-Suk 
Hwang as one of the inventors. 
 
Prior art for Tachibana et al. 2013 
 
These publications were explicitly cited 
as references in the patent published. 
Prior art for Tachibana et al. 2013 
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Following diagram shows the yearly (in recent years) stages of development in the human stem cell 
based inventions.
94
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 For this diagram, I have chosen the SCNT and its neighboring techniques for producing pluripotent stem cells.  
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2004 & 2005 
Woo Suk Hwang  
Retracted publications of Hwang et 
al.: ―Evidence of a Pluripotent Human 
Embryonic Stem Cell Line Derived 
from a Cloned Blastocyst‖ (Hwang et 
al. 2004), and ―Patient-Specific 
Embryonic Stem Cells Derived from 
Human SCNT Blastocysts‖ (Hwang et 
al. 2005). 
2007 
Shoukhrat M. Mitalipov  
Publication of "Producing primate 
embryonic stem cells by somatic cell 
nuclear transfer" by Byrne et al. 
(2007). 
2011 July 
Shoukhrat M. Mitalipov 
United States Patent No. 7,972,849 
issued on July 5, 2011 having 
Shoukhrat M. Mitalipov as one of the 
inventors.  
 
2011 October 
Dieter Egli 
Publication of "Human oocytes 
reprogram somatic cells to a 
pluripotent state" by Noggle et al. 
(2011).    
 
 
2013 April 
Elena S. Revazova 
United States Patent No. 8,420,393, 
issued on April 16, 2013 having Elena 
S. Revazova as one of the inventors. 
 
 
 
2013 June 
Shoukhrat M. Mitalipov 
 
Publication of ―Human Embryonic 
Stem Cells Derived by Somatic Cell 
Nuclear Transfer‖  by Tachibana et al. 
(2013). 
 
2014 February 
 Woo-Suk Hwang 
United States Patent No. 8,647,872 
issued on February 11, 2014 having 
Woo-Suk Hwang as one of the 
inventors. 
 
2014 June 
Dietrich M. Egli 
United States Patent No. 8,748,178 
issued on June 10, 2014 having 
Dietrich M. Egli as one of the 
inventors.  
Fig. 4.5 The breakthrough publications, inventions and patents (U.S. Patents) in SCNT and its 
neighboring techniques from 2004 to 2014 
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In one case (Hwang et al. 2004; Hwang et al. 2005), the publications were retracted on the 
allegations of fabricated data but US patent
95
 was issued having the references of those publications. 
Noggle et al. (2011) and Tachibana et al. (2013) both derived human pluripotent stem cells but with 
an important distinction involving/surrounding the ―oocyte nucleus removal step.‖ Noggle et al. 
(2011)
96
 did not involve removal of oocyte nucleus prior to introduction of somatic cell nucleus. 
Tachibana et al. (2013),
97
 on the other hand, used an optimized SCNT procedure that involved 
caffeine treatment during spindle removal (oocyte nucleus removal) to get rid of the problem that 
Noggle et al. (2011) mentioned earlier,
98
 i.e., developmental failure at the early stage. The invention 
based on Noggle et al. (2011) was issued United States Patent No. 8,748,178 on June 10, 2014
99
 but 
no patent is yet issued on the invention of Tachibana et al. (2013).  
In 2013, the United States Patent No. 8,420,393 was issued for ―[g]eneration of an autologous stem 
cell library from human oocytes parthenogenetically activated by high or low oxygen tension‖ and 
was assigned to International Stem Cell Corporation having Elena S. Revazova, Marina V. 
Pryzhkova, Leonid N. Kuzmichev and Jeffrey D. Janus as the inventors.
100
 The 2004 research paper 
of Hwang et al. (2004) titled ―Evidence of a Pluripotent Human Embryonic Stem Cell Line Derived 
from a Cloned Blastocyst‖ published in Science (later retracted in 2006) claimed to have made the 
SCNT-ES cells but left some ambiguity. The abstract of Hwang et al. (2004, 1669; retracted in 2006) 
stated that, ―[a]lthough we cannot completely exclude the possibility that the cells had a 
parthenogenetic origin, imprinting analyses support a SCNT origin of the derived human ES cells.‖ 
Although they claimed to have DNA imprints (DNA matching analysis) data supporting that it was 
indeed made by employing SCNT, they did not completely rule out that this invention might be due 
to parthenogenesis and not SCNT. In the subsequent article published in 2005 in Science (later 
retracted in 2006) by Hwang et al., there was, however, no room for ambiguity in their language. 
They (Hwang et al. 2005) further substantiated that the invention is the result of SCNT, not 
parthenogenesis, by presenting supporting DNA imprint and histocompatibility (matching with the 
patient who donated somatic cell nucleus) data. Hwang et al. (2005, 1777; retracted in 2006) stated in 
the abstract: ―NT-hESCs were pluripotent, chromosomally normal, and matched the NT patient's 
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 United States Patent No. 8,647,872, issued on February 11, 2014 was assigned to H. Bion Co., Ltd., Seoul, Korea 
having Woo-Suk Hwang as one of the inventors. United States Patent and Trademark Office, USPTO Patent Full-Text 
and Image Database, available at http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,647,872.PN.&OS=PN/8,647,872&RS=PN/8,647,872 (last visited Nov. 7, 2014). 
96
 The process by which the team of Dieter Egli made human pluripotent stem cells is not the standard procedure of 
Somatic Cell Nuclear Transfer (SCNT), in the strict sense. They skipped one important step of SCNT. In SCNT, the 
nucleus of the egg is removed and replaced with the donor nucleus. They (Noggle et al. 2011) did not remove the egg 
nucleus but inserted donor nucleus additionally. Noggle et al. (2011, 70) reported that, ―if the oocyte genome is not 
removed and the somatic cell genome is merely added, the resultant triploid cells develop to the blastocyst stage. Stem 
cell lines derived from these blastocysts differentiate into cell types of all three germ layers[…]. This result demonstrates 
the feasibility of reprogramming human cells using oocytes […].‖  
The background of the invention of the U. S. Patent No. 8,748,178 states that, ―[t]o date, no methods are known for the 
derivation of a human embryonic stem cell line after nuclear transfer, although nuclear transfer embryos have been 
generated which have developed to the cleavage stages.‖ United States Patent No. 8,748,178, issued on June 10, 2014. 
97
 Published in June 2013. 
98
 Published in October 2011. 
99
 United States Patent No. 8,748,178 was issued on June 10, 2014, assigned to the New York Stem Cell Foundation 
(New York, NY), having Dietrich M. Egli, Scott A. Noggle and Kevin C. Eggan as the inventors. United States Patent 
and Trademark Office, USPTO Patent Full-Text and Image Database, available at http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=8,748,178.PN.&OS=PN/8,748,178&RS=PN/8,748,178 (last visited Nov. 7, 2014). 
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 U.S. Patent No. 8,420,393, issued on Apr. 16, 2013. United States Patent and Trademark Office, USPTO Patent Full-
Text and Image Database, available at http://patft.uspto.gov/netacgi/nph-
Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-
bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/8420393  (last visited Nov. 7, 2014). 
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DNA. The major histocompatibility complex identity of each NT-hESC when compared to the 
patient's own showed immunological compatibility, which is important for eventual transplantation.‖ 
The United States Patent No. 8,647,872 assigned to H. Bion Co., Ltd., Seoul, Korea having Woo-Suk 
Hwang as one of the inventors, was clearly directed towards preparation of embryonic stem cell lines 
by SCNT, not indicating the issue of parthenogenetic origin of the cells (US Patent No. 8,647,872, 
issued on February 11, 2014).  
In summary, the following important events need to be taken into account: 
 Elena S. Revazova et al. was issued the patent in 2013 for the generation of cells 
parthenogenetically activated by high or low oxygen tension; 
 Woo-Suk Hwang and others were issued the patent in 2014 on extraction of embryonic stem 
cell by SCNT, although their first paper (later retracted) made reference of parthenogenetic 
origin of the cells; 
 No one has reported to have been successful in replicating the inventions claimed by Woo-
Suk Hwang et al. (2004; 2005) and the Science retracted the papers after the Seoul National 
University (SNU) announced that the papers contained fabricated data (Kennedy 2006); 
 The U.S. Patent 8,647,872 of 2014, Woo-Suk Hwang and others are awarded, is essentially 
the invention that Tachibana et al. (2013) successfully accomplished but they (Tachibana et 
al. (2013); the team of Shoukhrat M. Mitalipov) have not yet been awarded any U.S. patent.  
 
In the recent past, there had been many incidents of reexamination and litigation against stem cell 
patents (Shyntum and Kalkreuter 2009). Many breakthrough patents are challenged or targeted at the 
patent offices or at Court, e.g., 
 WARF‘s US Patent No. 7,029,913 was challenged in Consumer Watchdog v. Wisconsin 
Alumni Research Foundation
101
 at the United States Court of Appeal for the Federal Circuit 
and was unsuccessful; 
 ―Inter Partes Review‖ petition was filed against the Kyoto University by BioGatekeeper, Inc. 
for the US Patent No. 8,058,065 (issued on November 15, 2011, assigned to Kyoto 
University) at USPTO (Official Gazette of the United States Patent and Trademark Office, 
Sept. 16, 2014). 
The complications in intellectual property protection through patent may slower the pace of the 
invention to reach the patient.  
4.5 DIVERGENT PATENT FRAMEWORK FOR hSCI 
The patent framework of hSCI is mainly divergent on the grounds of ―ordre public and morality.‖ 
The differences on the grounds of patentability requirements between Europe and the USA exists but 
they are not the main constraints on the granting and rejection of a human stem cell patent. Rather 
the interpretation of the ―exclusion from patentability‖ on ethical grounds has created a difference in 
granting or rejecting a patent application. 
4.5.1 THE PREVAILING CIRCUMSTANCES IN hSCR AND PATENT: HOW DIVERGENT 
Samantha A. Jameson (2007, 197) made a comparison of patentability of biotechnological inventions 
in the EU and USA and commented: ―For inventions dealing with humans and cells, there are 
divergent approaches as to whether and how research should be promoted or discouraged, but the 
ability to patent appears broader in the U.S., since patents may be available on embryonic stem cell 
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 Case 13-1377, Fed. Cir. 2013.  
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lines and cloning [therapeutic].‖ Daniel J. Kelves (2002, 60) commented that, ―even though 
American patent law continues to be literally amoral, anyone seeking a patent on a living organism 
in Europe will have to satisfy the requirements of Article 53(a).‖ The vison and goals of the patent 
system in Europe and the USA are different. For the human subject protection in biomedical 
research, both Europe and the USA have differently set mechanisms. The USA considers (for 
patenting hSCI) the innovation and application aspect of the research outcome more, rather than 
concentrating on the intricacies of the research process. But in Europe, the use of base material and 
their research process may lead to exclusion of the invention from patenting in many of the 
countries. However, the UK seems to have pursued significantly different goals from the European 
community‘s direction in hSCR but similar to the USA. 
Destruction of embryo (or its use in different ways for the derivation of stem cells) in hESC research 
does not bar patenting in the USA. In many States of the USA, IVF redundant embryos can be used 
for research and hESC based inventions can also be patented from the USPTO. The stem cell 
research atmosphere in the USA after the Executive Order of President Obama, 2009
102
 is described 
by Arif Jamil: 
There is an environment more conducive to HSCR and patent in the 
United Sates than in Europe at this moment. […]. There is no federal 
law that completely bans or prohibits HSCR but the Dickey- Wicker 
Amendment, 1995 had put restriction on availability of Federal 
Funding for research encompassing destruction of embryo, which is 
recently interpreted by the Court in Sherley v. Sebelius to be not an 
embargo for granting Federal Funding for stem cell research that 
―utilize already derived‖ embryonic stem cells. […] HSCR using 
donated embryos can be conducted with NIH Grants provided that they 
have been approved by the NIH according to its guidelines. (2013b, 
151, notes omitted)  
 
ClinicalTrials.gov serving as a database and registry of the U.S. National Institutes of Health 
providing information on the clinical studies conducted all over the world involving human 
subjects/participants currently (at the time of writing) shows 179,458 studies conducted in all 50 
states of the US and in 187 countries.
103
 A search using the key words ―human embryonic stem 
cell‖104 in that database of ClinicalTrials.gov shows 24 studies worldwide.105 The map showing the 
geographical location of those 24 results reveal 8 studies in the US and three 3 in Europe.
106
 The 
maps of the US and Europe showing the location
107
 of the studies are following: 
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 Executive Order 13505, Vol. 74, No. 46, Fed. Reg. 10667 (Mar. 11, 2009). 
103
 ClinicalTrials.gov, U.S. NATIONAL INSTITUTES OF HEALTH (Nov. 27, 2014, 12.51 PM CET), 
http://clinicaltrials.gov/ct2/home.  
104
 Human embryonic stem cell research attracts most of the ethical controversies. 
105
 ClinicalTrials.gov, U.S. NATIONAL INSTITUTES OF HEALTH (Nov. 26, 2014, 10.54 AM CET), 
http://clinicaltrials.gov/ct2/results?term=human+embryonic+stem+cell+&Search=Search. 
106
 But the detailed map of the Europe shows only two (2) studies; one in the UK and one in France. ClinicalTrials.gov, 
U.S. NATIONAL INSTITUTES OF HEALTH (Nov. 27, 2014, 13.17 PM CET), 
http://clinicaltrials.gov/ct2/results/map?term=human+embryonic+stem+cell.  
107
 Some studies are showing multiple locations and appear in the maps of the regions concurrently wherever they are 
being conducted. ClinicalTrials.gov, U.S. NATIONAL INSTITUTES OF HEALTH (Nov. 27, 2014, 13.24 PM CET), 
http://clinicaltrials.gov/ct2/results/map/click?map.x=199&map.y=148&term=human+embryonic+stem+cell&map=NA%
3AUS.  
105 
 
 
Fig. 4.6 Clinical trials related to ―human embryonic stem cells‖ in the USA: Among others, three (3) 
studies taking place in California (CA) and one (1) in Massachusetts (MA) (Illustration from 
ClinicalTrials.gov: On a Map 2014; arrow (CA & MA) added by Arif Jamil)
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 Map of 24 studies found by search of human embryonic stem cell. ClinicalTrials.gov, U.S. NATIONAL INSTITUTES OF 
HEALTH (Nov. 27, 2014, 13.31 PM CET), 
http://clinicaltrials.gov/ct2/results/map/click?map.x=199&map.y=148&term=human+embryonic+stem+cell&map=NA%
3AUS.  
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Fig. 4.7 Clinical trials related to ―human embryonic stem cells‖ in the Europe: Among others, one 
(1) study is taking place in the UK. (Illustration from ClinicalTrials.gov: On a Map 2014; arrow 
(UK) added by Arif Jamil)
109
 
The distribution of the studies (clinical trials) in the above geographical locations indicates that: 
 research policies on human embryonic stem cells, clinical trials and patenting may have a 
connection;  
 California and Massachusetts have liberal stem cell research policies and clinical trials are 
taking place in those States as well; 
 US provides patent on hESC based inventions and so the highest number of studies are 
taking place in the US;
110
  
 There is restriction on hESC research in many countries of Europe and the most liberal 
policies on stem cell research is prevalent in the UK. Hence, clinical trial of ESC based 
                                                          
109
 Map of 24 studies found by search of human embryonic stem cell. ClinicalTrials.gov, U.S. NATIONAL INSTITUTES OF 
HEALTH (Nov. 27, 2014, 14.06 PM CET), 
http://clinicaltrials.gov/ct2/results/map?term=human+embryonic+stem+cell&map=EU.  
110
 A number of 8 out of total 24 studies (clinical trial) are conducted in the USA. ClinicalTrials.gov, U.S. NATIONAL 
INSTITUTES OF HEALTH (Nov. 27, 2014, 14.16 PM CET),  
http://clinicaltrials.gov/ct2/results/map?term=human+embryonic+stem+cell&map.  
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invention is also taking place in the UK. The study (titled as ―Safety and Tolerability of Sub-
retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented 
Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)‖) 
recruiting participants  is sponsored by the Advanced Cell Technology, MA, USA and it is 
held at Moorefields Eye Hospital NHS Foundation Trust, London, UK.
111
 The Advanced 
Cell Technology is pioneering the application/use of hESCs derived from blastomere cell of 
the pre-implantation stage embryo. It appears that, those studies are concentrated in countries 
that are not strict towards the stem cell research and hSCI‘s patent. 
The use of egg for hSCI is not explicitly stated as contrary to the perception of ―morality,‖ when it 
comes to patenting. Therefore, the use of eggs for SCNT based inventions and parthenogenetic egg 
activation for stem cell research shall not bar the patenting in Europe or the USA. With the 
emergence of inventions/innovations, patents and applications (in degenerative conditions and 
diseases) of the SCNT and parthenogenetic stem cells, egg procurement may raise ethical concern in 
future. Until now, patent litigations have not found the use of human eggs for the stem cell research 
contrary to the notion of ―morality.‖ The justification, necessity and implications of egg donation on 
the health of the donor have not been associated with the ―ordre public and/or morality‖ by any law 
yet. The patent restrictions (in Europe) on technique that derives ES by embryo destruction, probably 
has inspired to invent multiple techniques to bypass that step (destruction of embryo).  
The CJEU in Oliver Brüstle v.Greenpeace e.V. (2011) while excluding the use of human embryo for 
the purpose of patenting from the scientific researches extended the definition of embryo to ―any 
non-fertilised human ovum whose division and further development have been stimulated by 
parthenogenesis‖.112 The Court of Justice of the European Union has taken a different stand in a 
subsequent case involving patentability of hSCs from parthenogenetically activated oocytes (eggs). 
In the case of International Stem Cell Corporation, (2014) the CJEU decided that the 
parthenogenetically activated oocytes (eggs) shall be excluded from the definition of the embryo in 
Brüstle case ―if, in the light of current scientific knowledge, it [parthenote] does not, in itself, have 
the inherent capacity of developing into a human being‖.113 Therefore, the capacity (potential) of the 
organism to develop into a human being was an ethical concern for the exclusion from patentability 
for the European Court. In the light of this decision, hpSCs are not excluded from patenting as 
European Patent. International Stem Cell Corporation, California  currently holds the US patents on 
derivation of hpSCs.
114
  
The iPSC patents are unlikely to be challenged on the ethical grounds, simply because from the 
research to the application it does not use any sensitive human biological material, e.g., egg and 
embryo. It uses only somatic cell and the reprogrammed cells shall go into application directly. 
While the ethical issues for iPSCs are different from other forms of hSCR, it will pass the test of 
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 ClinicalTrials.gov, U.S. NATIONAL INSTITUTES OF HEALTH (Nov. 27, 2014, 14.37 PM CET), 
http://clinicaltrials.gov/ct2/show/study/NCT01469832?term=human+embryonic+stem+cell&cntry1=EU%3AGB&rank=
1.  
112
 C-34/10, Judgment of the Court (Grand Chamber) 18 Oct. 2011, paragraph 53, also available at 
http://curia.europa.eu/juris/document/document.jsf?text=&docid=111402&pageIndex=0&doclang=EN&mode=lst&dir=
&occ=first&part=1&cid=90420 (last visited Dec. 22, 2014).  
113
 Case C‑364/13, International Stem Cell Corporation v. Comptroller General of Patents, Designs and Trade Marks, 
Judgment of the Court (Grand Chamber) 18 Dec. 2014, paragraph 39, also available at 
http://curia.europa.eu/juris/document/document.jsf;jsessionid=9ea7d0f130de9c4121923b8f43769c42c1706a04f989.e34K
axiLc3eQc40LaxqMbN4ObheSe0?text=&docid=160936&pageIndex=0&doclang=EN&mode=lst&dir=&occ=first&part
=1&cid=88991#Footnote* (last visited Dec. 22, 2014).  
114
 U.S. Patent No. 8,420,393, issued on Apr. 16, 2013. United States Patent and Trademark Office, USPTO Patent Full-
Text and Image Database, available at http://patft.uspto.gov/netacgi/nph-
Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-
bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/8420393  (last visited Dec. 22, 2014). 
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patenting easily, even in European countries. US Patent on ESC from the pre-implantation stage 
blastomere cell has not yet raised the ethical issue for the derivation of totipotent cells.
115
 Advanced 
Cell Technology, Inc. (Ocata Therapeutics, Inc), Marlborough, MA was assigned the United States 
Patent No. 8,742,200
116
 for the ―[d]erivation of embryonic stem cells and embryo-derived cells‖.117 
The claimed invention stated in the ―summary of the invention‖ that, ―[t]he ES cells produced from 
the blastomere may be pluripotent or by some definitions totipotent.‖118 European Patent application 
number 12197502.3 has two corresponding publications (Publication Nos. EP 2 612 906 A2 and EP 
2 612 906 A3) appearing on the database of the European Patent Register for the ―[d]erivation of 
embryonic stem cells and embryo-derived cells‖ having Advanced Cell Technology, Inc. as the 
applicants.
119
 The European Search Report of the publication number EP 2 612 906 A3 mentioned 
that several claims of this patent application (EP 12197502.3) do not comply with the requirement of 
the ―unity of invention‖.120 The search report did not make reference of derivation of the cells that 
are by some definition totipotent as a problematic situation for the claims in their (Search Division, 
European Patent Office) observation stating the lack of unity of invention.
121
 However, the patent 
examination is pending.
122
  
From the procedural perspective, following figure shows how multilayered the patent system in 
Europe is, in comparison with the same in the US:   
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 The totipotent cells, each has the total ability to form a complete organism. 
116
 Issued on June 3, 2014. 
117
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at  
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-
bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,742,200&OS=8,742,200&RS=8,742,200  (last visited Nov. 12, 
2014). 
118
 U.S. Patent Number 8,742,200 (issued June 3, 2014). United States Patent and Trademark Office, USPTO Patent 
Full-Text and Image Database, available at  http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-
bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,742,200&OS=8,742,200&RS=8,742,200  (last visited Nov. 12, 
2014). 
119
 Database last updated on Nov. 12, 2014. European Patent Office, European Patent Register, available at 
https://register.epo.org/application?number=EP12197502&tab=main  (last visited Nov. 12, 2014). 
120
 European Patent Office, European Patent Register, available at https://data.epo.org/publication-server/pdf-
document?pn=2612906&ki=A3&cc=EP (last visited Nov. 12, 2014). 
121
 Ibid. 
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 At the time of this writing. 
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Fig. 4.8 Patenting Options and Routes in Europe and the USA 
4.5.2 PATENT OFFICES (EPO, USPTO) AND FEES DIVERGENCE 
Absolute divergence exist in the patent fees (grant and renewal).
123
 Gaetan de Rassenfosse and 
Bruno van Pottelsberghe de la Potterie investigated the fee structure of 30 patent offices and found 
absolute divergences and variations when the fee is viewed and compared with ―GDP per capita‖, 
―per million inhabitants‖ and the total amount of fees (2013, 700--702). Rassenfosse and Potterie 
reported from their analysis of fees of ―30 patent offices worldwide‖: ―[S]trong variations in the 
level of fees both over time and across countries suggest that there is no consensus regarding patent 
fees. This is also reflected in the high heterogeneity in fee schedules across countries, although it 
seems that fees generally rise with patent age.‖ (Rassenfosse and Potterie 2013, 703). This is 
probably one of the reasons and justifications for differentiated pricing of patented goods. The 
assignee will not incur the same expenses for getting and maintaining the patent in all the 
jurisdictions. The patent will also not make the same profit from all the territories. Some countries 
may have smaller population but the number of consumers having the affordability of the product 
may be higher. Some countries might be large with huge population but the number of population 
possessing the affordability of that product may be low. The assignee will be keen to see how much 
profit the patent might be able to make from a market (population with affordability) after bearing 
the cost of the patent in that territory. 
The EPO and US patent office functions in different styles and have different goals. The economic 
advantages associated to patent being more important in the US, the patentable subject matter is also 
relatively wider in range at the USPTO. At the EPO, ordere public and/or morality provision of EPC 
has narrowed the range of the patentable subject matter, e.g., the process patent on derivation of 
human ES cells by the destruction of human embryo is excluded at EPO.
124
 The patentability criteria 
                                                          
123
 Patent fees may include fees (all or most of them) for filing/application, examination, grant, renewal, translation and 
validation (Rassenfosse and Potterie 2013, 715). 
124
 The Enlarged Board of Appeal at EPO declared WARF‘s US patents on ES cell derivation are not patentable as 
European patent on November 25, 2008. Case No. G 0002/06. European Patent Office, Search in the board of appeal 
decisions database, available at             http://www.epo.org/law-practice/case-law-appeals/recent/g060002ep1.html#q 
(last visited Dec. 11, 2014). 
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and the cost associated to the patent grant varies between the two offices (Mejer and Potterie 2011, 
124--25). There is a continuously existing delay in the patent granting process of both the offices. 
The approximate time will be spent from the application to the grant at the EPO can be 44 months 
and at the USPTO 35 months (Mejer and Potterie 2011, 124). The number of patent application filed 
at USPTO is also higher than the EPO (Mejer and Potterie 2011, 122--23). Mejer and Potterie 
reported that the patent application filed in 2008 at EPO was 227,000, and 450,000 at the USPTO 
(2011, 122). Deepak Hegde (2012, 149) reported that, ―patent applications at the USPTO have 
surged from 178,000 in 1991 to 509,000 in 2010.‖ The higher number of patent applications does not 
necessarily testify that inventions have surged; it may also indicate that the number of bad patents are 
increasing. And if so, there will be increase in the post-grant proceedings and patent litigations. 
Deepak Hegde reported that, ―the number of notices for lawsuits filed in selected US courts (US 
District Courts and US Courts of Appeals)‖ in the year 1993 was 1,047 and in 2009 it was 6,111 
(2012, 5, Supplementary Table 5). Michele Boldrin and David K. Levine (2013, 3) commented that, 
―in spite of the enormous increase in the number of patents and in the strength of their legal 
protection, the US economy has seen neither a dramatic acceleration in the rate of technological 
progress nor a major increase in the levels of research and development expenditure.‖ 
Patent fees varies between the patent offices. The EPO and USPTO have different fees for search, 
examination, grant and renewal (Rassenfosse and Potterie 2012, 61).  
UP will lower the patenting cost in the EU. No evidence from any empirical investigation was found 
that shows that higher fees means better quality of patents; but it is quite evident that lower fees 
means higher number of patents (Rassenfosse and Potterie 2012). Patents that are not eligible for EP 
or UP may try national patent (NP). National patents have lower value than a EP or US patent. 
Christine Greenhalgh and Mark Rogers found that, ―on average, firms that receive only UK patents 
tend to have no significant market premium. In direct contrast, patenting through the European 
Patent Office does raise market value‖ (2006, 562). Gaetan de Rassenfosse and Bruno van 
Pottelsberghe de la Potterie observed that, ―TRIADIC patents‖125 have higher quality and value 
(2009, 782--83). The patent offices around the globe evaluate the patent applications differently, 
work in different bureaucratic procedures and have different fee structures effective for markets of 
different type and size. Therefore, patent issued by different patent offices carry different meanings 
to the patent seekers. Aurora Plomer observed: ―there is mounting evidence of significant variances 
in the evaluation of prior art and interpretation of patent standards across major patent offices around 
the world.‖ (2010, 8; footnote omitted). 
4.5.3 TERRITORIALITY OF PATENT SYSTEM AND THE ENFORCEMENT ISSUES  
Article 4bis(1) of the Paris Convention for the Protection of Industrial Property, 1883 states that, 
―[p]atents applied for in the various countries of the Union by nationals of countries of the Union 
shall be independent of patents obtained for the same invention in other countries, whether members 
of the Union or not.‖126 Article 16(4) of the Convention on Jurisdiction and the Enforcement of 
Judgments in Civil and Commercial Matters, 1968 states:  
The following courts shall have exclusive jurisdiction, regardless of 
domicile: [….] in proceedings concerned with the registration or 
validity of patents, trade marks, designs, or other similar rights 
required to be deposited or registered, the courts of the Contracting 
State in which the deposit or registration has been applied for, has 
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 Patents that are filed simultaneously at US Patent and Trademark Office (USPTO), European Patent Office (EPO) and 
Japan Patent Office (JPO) (Rassenfosse and Potterie 2009, 789). 
126
 Paris Convention for the Protection of Industrial Property, Mar. 20, 1883, available at 
http://www.wipo.int/treaties/en/text.jsp?file_id=288514#P113_13775 (last visited Dec. 15, 2014). 
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taken place or is under the terms of an international convention 
deemed to have taken place; [Italics added]
127
  
 
Article 24 of the Regulation (EU) No 1215/2012 of the European Parliament and of the Council of 
12 December 2012 on Jurisdiction and the Recognition and Enforcement of Judgments in Civil and 
Commercial Matters (recast) mentioned: 
The following courts of a Member State shall have exclusive 
jurisdiction, regardless of the domicile of the parties: [….] 
 (4) in proceedings concerned with the registration or validity of 
patents, trade marks, designs, or other similar rights required to be 
deposited or registered, irrespective of whether the issue is raised by 
way of an action or as a defence, the courts of the Member State in 
which the deposit or registration has been applied for, has taken place 
or is under the terms of an instrument of the Union or an international 
convention deemed to have taken place. 
Without prejudice to the jurisdiction of the European Patent Office 
under the Convention on the Grant of European Patents, signed at 
Munich on 5 October 1973, the courts of each Member State shall 
have exclusive jurisdiction in proceedings concerned with the 
registration or validity of any European patent granted for that 
Member State; 
(5) in proceedings concerned with the enforcement of judgments, the 
courts of the Member State in which the judgment has been or is to be 
enforced.
 128
 [Italics added] 
All of these conventions recognize the territoriality of the patent system and acknowledge the right 
of the State to grant, reject and enforce a patent. Countries having the tendency of making unique 
interpretation of their ―ordre public and/or morality‖ provision in the light of their self-perception on 
―ethical issues‖ regarding the hSCR policies will continue to apply the patent law differently from 
each other for the hSCI. Article 45(1)(a) of the Regulation (EU) No 1215/2012 of the European 
Parliament and of the Council of 12 December 2012 on Jurisdiction and the Recognition and 
Enforcement of Judgments in Civil and Commercial Matters (recast) gives authority to the State to 
reject enforcement of a judgment contrary to its notion of ―ordre public‖.129 
Article 64(3) of the European Patent Convention 1973 says that, ―[a]ny infringement of a European 
patent shall be dealt with by national law.‖130 The countries that will participate in the agreement for 
the Unified Patent Court (UPC) have consented to have ―[a] Unified Patent Court for the settlement 
of disputes relating to European patents and European patents with unitary effect‖.131 The Unified 
Patent Court (UPC) will substitute the need of approaching to the national court for the participating 
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 Convention on Jurisdiction and the Enforcement of Judgments in Civil and Commercial Matters, 27 Sept. 1968, 
available at http://curia.europa.eu/common/recdoc/convention/en/c-textes/brux-idx.htm (last visited Dec. 15, 2014). 
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 2012 O.J. (L 351) 1, 11. 
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 Article 45(1)(a) states that, ―recognition of a judgment‖ can be rejected, ―if such recognition is manifestly contrary to 
public policy (ordre public) in the Member State addressed‖. Regulation (EU) No 1215/2012 of the European Parliament 
and of the Council of 12 December 2012 on Jurisdiction and the Recognition and Enforcement of Judgments in Civil and 
Commercial Matters (recast) art. 45(1)(a), 2012 O.J. (L 351) 1, 15. 
130
  Supra note 26. 
131
 Agreement on a Unified Patent Court Art. 1, Feb. 19, 2013, 2013 O.J. (C 175) 1, 2. 
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States of the Agreement. Article 1 states: ―The Unified Patent Court shall be a court common to the 
Contracting Member States and thus subject to the same obligations under Union law as any national 
court of the Contracting Member States.‖132 But the European countries not taking part in the UPC 
shall retain the authority of their national courts for the litigations on patent enforcement and 
infringement.  
The unitary patent package has also retained the national authorities over some of the issues that can 
affect the patent right of the applicant. Regarding the compulsory licensing, clause 10 of the 
preamble to the Regulation (EU) No 1257/2012 of the European Parliament and of the Council of 17 
December 2012 Implementing Enhanced Cooperation in the Area of the Creation of Unitary Patent 
Protection states: ―Compulsory licenses for European patents with unitary effect should be governed 
by the laws of the participating Member States as regards their respective territories.‖133 The 
implication of this recognition of national jurisdiction is that if there were any differing approach of 
the national laws in licensing, it would remain to be so. There is no mechanism to enforce patent 
rights internationally. Patent remains at the hands of the individual States and has to be enforced by 
their judicial systems. However, once coming into effect, the UPC will be able to enforce patent 
(validity and infringement) with unitary effect in the contracting States altogether.  
The issues of recognition and enforcement of foreign judgments is an important relevant topic for 
this discussion. Individual States follow their own laws and policies on how and to what extent 
recognize and enforce the foreign judgments. Countries pursue different approaches while 
implementing the policies and doctrines of private international laws. Principles of both public and 
private international laws can come into play when it comes to enforcement of IPR. Patent‘s validity 
and infringement is subject to interpretation by the adjudicating Court. Countries may also exercise 
restraint for the ―Act of State‖ doctrine and prefer not to interfere with decision of other States. US 
Courts may not extend jurisdiction over foreign patents. The United States Court of Appeals for the 
Federal Circuit in Voda v. Cordis Corp.
134
 decided that, ―the district court had erred in granting 
supplemental subject matter jurisdiction under 28 U.S.C. § 1367 over foreign patent infringement 
claims‖ (Herzfeld 2007). Since the judicial system of individual States will resolve the patents‘ 
validity and infringement, the repetition of proceedings shall continue to occur. This will be 
increasing the enforcement costs of the patent owner. These issues relating to ―recognition and 
enforcement‖ of ―foreign judgment‖ and ―foreign IP rights‖ will not be resolved any time soon.  
 
4.5.4 MULTILAYERED PATENT PROTECTION IN EUROPE: INCREASED 
DIVERGENCE WITHIN EUROPE  
                                                          
132
 Id. 
133
  Dec. 17, 2012, 2012 O.J. (L 361) 1.  
134
 No. 05-1238 (Fed. Cir. Feb. 1, 2007). 
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Europe has the following patent systems existing simultaneously: 
 
Fig. 4.9 Patent Systems Co-existing in Europe (at the time of the writing) 
The Preparatory Committee of the Unified Patent Court drew the following diagram in their 
brochure, ―An Enhanced European Patent System‖, showing the available routes of patenting in 
Europe after the EU patent shall come into force (The Preparatory Committee 2014): 
 
Fig. 4.10 Three Routes of Patent Protection in Europe (Illustration from the Preparatory Committee 
2014, 3) 
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The European States have differing approaches in exercising the PCT route. 
 
Fig. 4.11 Patent Route in Europe through PCT (WIPO: PCT Contracting States for which a Regional 
Patent can be Obtained via the PCT 2014) 
4.5.4.1 EUROPEAN PATENT AND UNITARY PATENT PROTECTION 
The Preparatory Committee of the Unified Patent Court in their brochure, ―An Enhanced European 
Patent System‖, stated how the European Patent shall be given effect to Unitary Patent Protection 
Via PCT: 
• Regional Patents (EP (European Patent)) 
Only;  
• No National Patent  
Italy 
Lithuania 
Via PCT: 
• National Patent and Regional Patent 
(EP (European Patent)) ; or 
•Regional Patent instead of National Patent 
Germany 
Spain 
UK 
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(The Preparatory Committee 2014) and the Steps are following:
 
Fig. 4.12 Procedural Simplification. The applicant will get patents in 25 EU Member States by one 
single application (The Preparatory Committee 2014, 4--5) 
Applicant EPO 
EPO EPO 
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The Unitary Patent (UP) protection will bring the following advantages for the patent owners: 
 
Fig. 4.13 The disadvantages EU Patent will overcome (The Preparatory Committee 2014, 5) 
The areas addressed shall bring simplification in mainly the procedural and financial aspects of 
patenting in the EU Countries. This UP did not address any of the substantive concepts of patenting. 
The countries where the patenting of hSCI are subject to strict restrictions for embryo destruction or 
on ethical grounds, can not be taken to be a part of this cluster of patents. Hence, the patent seeker 
(prospective patentee) may have to try the classical European Patent‘s route and elect the individual 
States where the patent is obtainable. Therefore, for hSCI facing exclusion on ethical grounds in 
even one of the 25 States will not be able to get the Unitary Patent Protection; because the unitary 
effect is meant to be given in the 25 states en bloc. The authority of the States over granting a 
national patent remains at the hands of the States. So, the patents not qualified to give unitary effect, 
but eligible to get patent in any of the European State shall be enforced and challenged nationally. 
Therefore, the EU patent (Unitary Patent) and UPC will not do the harmonization of human stem cell 
patent landscape, particularly in the ethically contested inventions. According to the Article 64(3) of 
the European Patent Convention 1973, the infringement of a patent granted under the European 
Patent Convention ―shall be dealt with by national law.‖135  But a Unitary Patent shall be enforced 
and challenged at the Unitary Patent Court (hereinafter referred to as UPC). It is most likely that in 
debated and controversial areas of stem cell patents, EU patent will not be available and so the UPC 
will not be the forum of litigation for infringement and validity of such patents. Therefore, ―the 
diversity in enforcement (infringement and validation) shall remain‖ in one hand, ―the option of 
choosing the route of patenting shall increase‖ on the other hand, for those inventions. The ethically 
controversial inventions from the hSCR perhaps will find the ―national patenting‖ as the better 
choice to explore.  
                                                          
135
 Supra note 26. 
Does not have to validate the patent in each States individually where the protection 
is desired (The Preparatory Committee 2014); 
Simplification in translation formalities (requires only two languages). Can 
avoid the translation requirement of the classical European Patent at the State 
level (The Preparatory Committee 2014); 
Can avoid the publication fee at the respective National Patent Office (NPO) 
(The Preparatory Committee 2014); 
 
No need to pay the renewal fee in individual States where the patent is valid; One 
renewal fee at EPO is enough (The Preparatory Committee 2014); 
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Fig. 4.14 Forum to address the validity and infringement of European and EU Patent (until the 
transitional period under the Agreement on a Unified Patent Court 2013 is over) (European Patent 
Office: Unified Patent Court 2014) 
The jurisdiction of the UPC shall extend to:136 
 
Fig. 4.15  The UPC will be competent to entertain disputes from the EP and UP and enforce the 
decision in the States ratifying the Agreement on a Unified Patent Court 2013 
However, Article 83 of the Agreement on a Unified Patent Court 2013 (hereinafter referred to as 
UPC Agreement) provides a transitional period of 7 years (with the possibility of extension to a 
further 7 years) within which the actions can be brought to the national Court of the contracting 
States of the UPC Agreement on the infringement and revocation of a European Patent.
137
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 According to Article 34 of the Agreement on a Unified Patent Court 2013, the ―[t]erritorial scope of decisions‖ of the 
UPC is stated as following: ―Decisions of the Court shall cover, in the case of a European patent, the territory of those 
Contracting Member States for which the European patent has effect.‖ Agreement on a Unified Patent Court, Feb 19, 
2013, 2013 O.J. (C 175) 1.  
137
 Article 83(1) stated that, ―[d]uring a transitional period of seven years after the date of entry into force of this 
Agreement, an action for infringement or for revocation of a European patent or an action for infringement or for 
declaration of invalidity of a supplementary protection certificate issued for a product protected by a European patent 
may still be brought before national courts or other competent national authorities.‖ Id. 
 
European Patent 
(EP) 
• National Courts of the Contracting States (38 
members + 2 Extension States) 
EU Patent 
(Unitary Patent)  
• Unified Patent Court (UPC (25 EU Member 
States)) composed of the Court of First Instance 
(Paris (Central Division), London and Munich 
(Sections)) and the Court of Appeal (Luxembourg)  
UPC 
European Patent (EP):  Enforceable in 
the States that are parties (subject to 
ratification) to the UPC Agreement 2013. 
Unitary Patent (UP): Enforceable in the 
States that will ratify the UPC Agreement 
2013. 
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An observation on the implications of the Unitary Patent package by Arif Jamil reveals how one of 
the major objectives of ―cost reduction‖ would not be a great satisfactory deal, since many serious 
issues were not addressed (which could be negotiated on this occasion):   
Harnett and Wieker (2013) aptly mentions that, ―a company may now 
secure patent protection in over 40 percent of the world market (by 
GDP) by obtaining only two patents--a US patent and a Unitary 
Patent‖ (Harnett and Wieker, 2013, p.16). The competitors for the 
patent market are identified are USA and China (European 
Commission website, 2013). The Unitary Patent hopes to lower the 
costs from 32 119 euros to 4 725 euros after the transition period, 
which is 12 years and during that time the costs shall be 6 425 
(European Commission website, 2013). Even the reduced costs remain 
much higher than the presumed competitors, where USA ends at 2 000 
euros and China 600 euros (European Commission website, 2013). 
[…]. For the market of future regenerative medicine the competitive 
advantage shall be determined by the research opportunity, not by 
patent cost. The IPR protection cost shall be borne by consumers in all 
cases. The lowering of patent cost does not bind the assignee in an 
agreement to lower the price of the patented article in itself. A 
contractual regime should have been created that would promise to 
lower the price of the treatment and medication systematically, which 
has not been done. The licensing has been left as the discretion of the 
assignee as a ―contractual license‖        [Article 8, Regulation (EU) No 
1257/2012 of the European Parliament and of the Council of 17 
December 2012 implementing enhanced cooperation in the area of the 
creation of unitary patent protection]. There is no reference made to 
enable non-commercial downstream biomedical research without 
infringing the patent. The unitary patent package as a protection tool is 
a translation of perception of protection of typical technologies. […]. 
The crisis of patents granted in ethically debated areas shall remain the 
same. (Jamil 2013a, 38) 
 
The ―Press Release‖ dated 5 May 2015 of the Court of Justice of the European Union while 
dismissing the actions/claims brought by Spain ―against the regulations implementing enhanced 
cooperation in the area of the creation of unitary patent protection‖ stated: ―unitary patent protection 
is apt to prevent divergences in terms of patent protection in the participating Member States and, 
accordingly, provides uniform protection of intellectual property rights in the territory of those 
States.‖138 If Italy and Spain are going to join in this EU patent initiative, will be clear in the coming 
days. At the time of this writing, they are not part of the new EU patent with unitary effect.  
4.5.5 LIMITATION AND PROSPECTS OF THE US PATENTS FOR hSCI  
Can a US patent be commercially exploited in all US States and also in Europe? The United States 
Patent and Trademark Office (USPTO) grants the US patent. Different States have different stem cell 
research policies. South Dakota has one of the most restrictive policies on stem cell research. Can the 
US patent be commercially exploited in a State (US State) where they do not allow the research 
                                                          
138
 CVRIA, Press Release No 49/2015 : Judgments of the Court of Justice in Cases C-146/13, C-147/13 Spain v 
Parliament and Council, available at http://curia.europa.eu/jcms/upload/docs/application/pdf/2015-05/cp150049en.pdf 
(last visited May 29, 2015). 
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itself? The WARF (Wisconsin Alumni Research Foundation) patents on ES cells can be discussed 
from the lens of the laws of South Dakota (SD). 
The WARF ES cell patents139 are the early patents on isolation and preparation of embryonic stem 
cells. Their application is limited to ―contributing‖ in further stem cell researches. The ―model 
species‖ for the first WARF patent (US Patent No. 5,843,780) on isolation of primate ES cells were 
the ―macaques and marmosets‖.140 The WARF patent of 2001 (US Patent No. 6,200,806) had its first 
claim as following: ―A purified preparation of pluripotent human embryonic stem cells which (i) will 
proliferate in an in vitro culture for over one year, (ii) maintains a karyotype in which the 
chromosomes are euploid and not altered through prolonged culture, (iii) maintains the potential to 
differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues throughout the culture, and 
(iv) is inhibited from differentiation when cultured on a fibroblast feeder layer.‖141 These inventions 
(US Patent No. 6,200,806 of 2001) also used ―macaques and marmosets‖ as the model species, but 
that very patent is the first patent claimed to have discovered the ―know-how‖ of the isolation and 
preparation of human ES cell. The claim no. 9 of the US Patent No. 6,200,806 states its invention as 
follows: 
―A method of isolating a pluripotent human embryonic stem cell line, 
comprising the steps of: (a) isolating a human blastocyst;  
(b) isolating cells from the inner cell mass of the blastocyte of (a); (c) 
plating the inner cell mass cells on embryonic fibroblasts, wherein 
inner cell mass-derived cell masses are formed; (d) dissociating the 
mass into dissociated cells; (e) replating the dissociated cells on 
embryonic feeder cells; (f) selecting colonies with compact 
morphologies and cells with high nucleus to cytoplasm ratios and 
prominent nucleoli; and (g) culturing the cells of the selected colonies 
to thereby obtain an isolated pluripotent human embryonic stem cell 
line.142 (US Patent No. 6,200,806, issued Mar. 13, 2001)  
The WARF patent of 2008 (US Patent No. 7,442,548) expressly used the term ―human‖ in the title of 
the patent which reads as ―[c]ulturing human embryonic stem cells in medium containing pipecholic 
acid and gamma amino butyric acid.‖143 Although the other two previous patents, i.e., US Patent No. 
6,200,806 (issued Mar. 13, 2001) and US Patent No. 7,029,913 (issued Apr. 18, 2006) used the word 
―primate‖ in their title, they both claimed isolation and preparation of human ES cells. Therefore, 
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 The US Patent No. 5,843,780 (issued on Dec. 01, 1998); US Patent No. 6,200,806 (issued on Mar. 13, 2001); US 
Patent No. 7,029,913 (issued on Apr. 18, 2006); and the US Patent No. 7,442,548 (issued on Oct. 28, 2008). 
140
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=5,843,780.PN.&OS=PN/5,843,780&RS=PN/5,843,780 (last visited Dec. 10, 2014). 
141
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=6,200,806.PN.&OS=PN/6,200,806&RS=PN/6,200,806 (last visited Dec. 10, 2014). 
142
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=6,200,806.PN.&OS=PN/6,200,806&RS=PN/6,200,806 (last visited Dec. 10, 2014). 
143
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=7,442,548.PN.&OS=PN/7,442,548&RS=PN/7,442,548 (last visited Dec. 10, 2014). 
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clearly the 3 patents of WARF144 will serve as primary patents on the subject (isolation and 
preparation of human ES cell) for further research. Those WARF patents may have problems in 
exploitation in South Dakota but can be freely commercially exploited in the other States e.g., 
California, Massachusetts, New Jersey, etc. 
Claim No. 9 of the US Patent 6,200,806, issued on March 13, 2001, assigned to WARF covers the 
following process:  ―A method of isolating a pluripotent human embryonic stem cell line, comprising 
the steps of: (a) isolating a human blastocyst; (b) isolating cells from the inner cell mass of the 
blastocyte [sic] of (a)‖.145 That embryo (or pre-embryo by some definition) from which the 
pluripotent cells will be derived following the technique of the WARF patent‘s (US Patent 
6,200,806) claim 9, have to be destroyed; because the isolation of the cells from the ICM of the 
blastocyst will destroy that blastocyst‘s further development as human organism. This patented 
isolation and derivation process cannot be used for stem cell research in South Dakota. §34-14-16 of 
South Dakota Codified Laws states: ―Research that destroys human embryo prohibited--Violation as 
misdemeanor. No person may knowingly conduct nontherapeutic research that destroys a human 
embryo.‖146  
The derivation process of the WARF patent would essentially destroy the embryo from which the 
stem cells will be isolated and derived, but the further research that will apply the patented technique 
may not intend or succeed to find a therapeutic application in general. Therefore, any research not 
having any direct therapeutic application by using the WARF patent will be illegal in South Dakota. 
However, the SD‘s (South Dakota Codified Laws § 34-14-19 (2013)), definition of ―non-therapeutic 
research‖ is the following: ―[T]he term, nontherapeutic research, means research that is not intended 
to help preserve the life and health of the particular embryo subjected to risk. It does not include in 
vitro fertilization and accompanying embryo transfer to a woman's body or any diagnostic test which 
may assist in the future care of a child subjected to such tests.‖147 So, they allow therapeutic research 
on the embryo in question for its own benefit. But they prohibit any type of research that destroys or 
risks this embryo as a means to invent downstream therapeutic application for the general 
population. 
Therefore, South Dakota prohibits: 
1. Any subsequent/downstream research within South Dakota (SD) that employs the process patent 
of WARF involving production of hESC by means of embryo destruction. No scientist can use the 
patented WARF methodology of embryo destruction; and 
2. No research is permitted using hESC line that was derived by embryo destruction. It does not 
matter if those cell lines were made within or outside SD. So, the hESC lines made using WARF 
process patent cannot be utilized for conducting research within the State (SD) irrespective of where 
they were made. 
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 US Patent No. 6,200,806 (issued on Mar. 13, 2001); US Patent No. 7,029,913 (issued on Apr. 18, 2006); and the US 
Patent No. 7,442,548 (issued on Oct. 28, 2008). 
145
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s
1=6,200,806.PN.&OS=PN/6,200,806&RS=PN/6,200,806 (last visited Dec. 10, 2014). 
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 S.D. CODIFIED LAWS § 34-14-16 (2013), available at http://law.justia.com/codes/south-dakota/2013/title-34/chapter-
14/section-34-14-16/ (last visited Dec. 09, 2014). However, the text does not clearly mention, if there were a therapeutic 
objective per se, the research causing destruction of the embryo would be allowed.  
147
 S.D. CODIFIED LAWS § 34-14-19 (2013), available at http://law.justia.com/codes/south-dakota/2013/title-34/chapter-
14/section-34-14-19/ (last visited Dec. 10, 2014). 
121 
 
Since there is nothing like ―State Patent,‖ there is no question of granting or rejecting any ―South 
Dakota Patent.‖ Hence, some of the early stage US patents on hSCI may not enable the assignee to 
exploit the invention commercially in all US States.   
The Enlarged Board of Appeal (EBoA) of the European Patent Office (EPO) decided on November 
25, 2008 that the WARF patent on human ES cells isolation and preparation is ―unpatentable‖ as 
―European Patent‖ under the Article 53(a)148 and Rule 28(c)149 of the European Patent Convention 
(EPC), 1973.150 The Enlarged Board of Appeal responded in G 0002/06:151 ―Rule 28(c) EPC 
(formerly Rule 23d(c) EPC) forbids the patenting of claims directed to products which- as described 
in the application — at the filing date could be prepared exclusively by a method which necessarily 
involved the destruction of the human embryos from which the said products are derived, even if the 
said method is not part of the claims.‖152 
Following statement made on behalf of the President of the European Patent Office in G 0002/06, is 
included in the published ―Decision of the Enlarged Board of Appeal‖ of 25 November 2008: 
The ratio legis of Rule 28(c) (formerly 23d(c)) EPC is the prohibition 
of misuses or the commodification of embryos. […]. The exception to 
Rule 28(c) (formerly 23d(c)) EPC stipulated in Recital 42 of the 
Directive should apply in any case where it can be established from the 
relevant invention that it serves a therapeutic or diagnostic purpose for 
the used embryo. Usefulness to the individual embryo presupposes that 
the used embryo is still in existence and is not irreversibly destroyed. 
[…]. In situations where Rule 28(c) (formerly 23d(c)) EPC is 
applicable, the legislator has predetermined a genuine European ordre 
public and morality, in substance and in time, falling under Article 
53(a) EPC, which is binding on the relevant departments of the EPO.153 
Patent encompassing the destruction of embryo is considered as serving a ―commercial purpose‖ and 
unpatentable, as it is against the principle of the ordre public and/or morality enshrined at the 
European Patent Convention (EPC) 1973 for the purpose of European Patent at EPO. Although the 
WARF patents on ES cell derivations did not mention the word ―destruction‖ in their claim 
language, EBoA rejected the patent on the issue of the destruction of the embryo for a commercial 
purpose. The ―destruction‖ was integral to the method of their producing ES cells.   
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 Article 53(a) states: ―European patents shall not be granted in respect of […] inventions the publication or exploitation 
of which would be contrary to "ordre public" or morality, provided that the exploitation shall not be deemed to be so 
contrary merely because it is prohibited by law or regulation in some or all of the Contracting States‖. Supra note 26. 
149
 Rule 28(c) of the European Patent Convention, 1973 states: ―Under Article 53(a), European patents shall not be 
granted in respect of biotechnological inventions which, in particular, concern the following: [….] uses of human 
embryos for industrial or commercial purposes‖. Supra note 26. 
150
 Case No. G 0002/06. European Patent Office, Search in the board of appeal decisions database, available at             
http://www.epo.org/law-practice/case-law-appeals/recent/g060002ep1.html#q (last visited Dec. 11, 2014). 
151
 Appellant/Applicant was Wisconsin Alumni Research Foundation (WARF).   
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 European Patent Office, Search in the board of appeal decisions database, available at             
http://www.epo.org/law-practice/case-law-appeals/recent/g060002ep1.html#q= (last visited Dec. 11, 2014). 
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 European Patent Office, Search in the board of appeal decisions database, available at             
http://www.epo.org/law-practice/case-law-appeals/recent/g060002ep1.html#q= (last visited Dec. 11, 2014). 
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4.5.6 IMPLICATIONS OF DIVERGENT PATENT FRAMEWORK 
There is no international patent. The Patent Cooperation Treaty (PCT) provides a simplified 
international patent application procedure among the contracting States.154 PCT system does not 
provide any international patent; there is nothing like that. Patent grant or rejection is the choice of 
the national office. Therefore, the divergent interpretation of the patentability will continue to exist. 
However, the divergent patent framework for the hSCI will have certain implications.  
 Mobility of Patients 
The most predictable consequence of different legal landscape of stem cell research and patenting is 
that the transplants will be available in certain countries and not in all countries. The therapies may 
not be available in all high income countries too. If it is marketed in any/some of the developing 
countries, the typical negative impacts heath care tourism creates in the access to health care, shall 
continue to occur. Affluent foreign patients can exclude the poor locals from accessing the quality 
health care (Cohen 2011-2012, 3--5). There is also a concern of protecting those health care tourists 
from malpractices, e.g., administering placebos on them, uncertainty in compensating for medical 
error (Cohen 2011-2012, 8), etc. Murdoch and Scott (2010, 17) commented that, ―[t]ransplants in 
under- or unregulated jurisdictions have not been tested in animals or in properly phased, blinded, 
and controlled clinical trials.‖ Patients may end up in such countries to receive an unproven 
treatment at their own expense to accelerate their health misery. It was reported that from 65 
countries, approximately 300,000 women155 were fitted with industrial grade silicone breast implants 
(Poly Implant Prothese (PIP)) made by a French company (BBC News Health, 10 Dec. 2013). This 
implant subsequently caused serious health concerns and many of the women received were Latin 
Americans.156 The lesson that can be learned from the PIP incident is that the foreign patients of 
developing countries receiving cutting-edge but faulty treatment from developed countries may face 
immense difficulty to access to the proper care to restore their health after they return to their home 
countries. If the technologies are available only in the country where they received the treatment, 
their home country might not be prepared for treating them, after they had received inappropriate 
treatment. It is apparent that the stem cell based therapy will not be available in those countries 
where the invention will not be IP protected. Uncertainty remains in the EU, if the patients will be 
covered by their insurance at home country for the treatments that are considered (by the home 
country) to be the product of unethical medical research, received in other member States. Therefore, 
with the chance of increasing the mobility of patients, concerns over their heath-safety and quality of 
care remains an issue.  
The fact that the affordability of patients from developed countries seeking treatment in developing 
country will be high; the locals will find it difficult to access the care in those developing countries.   
 Mobility of Scientists 
There will be a continuous flow of the scientists and researchers towards those countries (or States in 
case of the US) where the regulatory atmosphere is conducive to stem cell research. Aaron D Levine 
(2006, 866) reported that, ―data suggest the excitement generated by stem cell research and the 
disparities created by the policy patchwork governing the field may indeed be increasing scientist 
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 At the time of the writing, the number of contracting States was 148 (WIPO: The PCT now has 148 Contracting States 
2014). 
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 In some publications, the number appeared higher than this. 
156
 Santolo et al. (2014, 462) published ―a retrospective MR analysis in 64 patients‖ of the PIP implants and concluded 
that, ―[t]he results of this double center retrospective study, confirm the higher incidence (36%) of prosthesis rupture 
observed with the PIP implants, compared to other breast implants.‖ 
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mobility.‖
 
Fig. 4.16 ―Stem cell scientists received proportionally more offers for positions in California and 
other states with permissive research policies.‖ (Figure 1, Levine 2006, 866) 
 Variations in Prices of Medicinal/Drug Products 
The price of the same medicinal/drug product is ―different‖ in different countries. Kanavos et al. 
(2011, 23--24) published: ―Among the EU Member States analysed, Germany, Ireland and Sweden 
were among those with higher average prices in 2008; Spain, France and Italy had lower prices. The 
USA is an outlier, as prices of branded medicines have been consistently higher than in Europe, with 
over twice the price level of the UK in 2008.‖ 
 
Fig. 4.17 ―Price comparisons among EU Member States (and with the USA) for a basket of 150 
products; 2008 price index with UK=100‖ (Figure 6, Kanavos et al. 2011, 23) 
There may be number of factors for which the price of the medicine/drug will be higher in one 
country and lower in another. Patent protection is a contributor of higher drug price but not the 
dominant player for creating the ―variation of price.‖ The demand-supply, size of the market, 
Government‘s and insurance‘s contribution, co-pay with the insurance, Gross National Income 
(GNI) per capita, local manufacturing ability, parallel trade, Health Technology Assessment (HTA), 
health care needs and priorities of individual country, etc., may also have relation with the variation 
of prices. Kanavos et al. (2011, 32) found that, ―[t]he main factors leading to price differences 
include income levels; national (and sometimes regional) regulatory policies for pricing and value 
assessment of pharmaceuticals; approaches to regulating wholesale and retail distribution; and 
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taxation of pharmaceuticals, in particular VAT.‖ However, the varying degree of ―pre and post 
grant‖ costs (fees) of patents may have some links to the ―variation of prices,‖ but that claim will 
require more empirical investigation. As a matter fact, the price differences exist and the 
―divergence‖ in the patent framework may not be the dominant reason of ―differentiated pricing‖ or 
―price variation.‖ Kanavos et al. reported their findings regarding the price differences of 
pharmaceutical products in the EU States:  
The prices of pharmaceuticals vary across EU Member States: for a 
basket of 150 medicines, the national averages differ by up to 25%. 
For individual pharmaceuticals sold across the EU, price differences 
are even higher. For patent-protected individual pharmaceuticals, 
differences as high as 4:1 have been observed between the highest and 
lowest prices. 
Price differences appear even greater for pharmaceuticals whose 
patents have expired, as generic versions increase market competition. 
For these medicines, differences as high as 16:1 have been observed 
among Member States for individual generic pharmaceuticals. 
(Kanavos et al. 2011, 18) 
 
Kanavos et al. encountered that ―manufacturers of generics may decide not to enter smaller markets‖ 
(2011, 14).157 In order to offer the citizens cheaper medicine and materialize the benefits of generics, 
the ―local manufacturing ability‖ of a country is vital. In case of stem cell based therapies, 
―manufacturing technology transfer‖ may be an important issue.  
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 Some small European markets like Lithuania are in great need of cheaper medication, as the purchase capability, 
average income of the working class and pensions of the elderly citizens are very low. Despite patented drugs are more 
expensive in Germany compared to other EU countries (Kanavos et al. (2011, 24), the purchase capability of the 
population is also high. 
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CHAPTER 5  
QUALITATIVE DATA ANALYSIS 
 
 
5.1 QUALITATIVE DATA ANALYSIS 
Only some of the respondents made “comments/other opinions” which could be analyzed 
qualitatively.
1
 The conventional content analysis of the perceptions and views of the expert 
respondents also contributed to the formulation of the set of recommendations.  
 
Interpretation of the Major Key Themes derived from responses to question no. 1:
2
  
The respondents have emphasized the ethical controversies surrounding the hESC research. Some 
of them have viewed embryo as equal to human and “destruction” of embryo as “killing” of life. 
Both the “use” and “destruction” of human embryo for hSCR are opposed by some of the 
respondents. But some of the respondents see the hSCR as any other type of scientific research and 
finds that promising application exist. Other alternative techniques involving somatic/adult stem 
cell research is acceptable to some of the respondents.  
Many respondents are against embryonic stem cell research because they have empathy for the 
embryo. They are more into the rightness and wrongness of the action. Use of embryo as “offensive 
endeavor” for hSCR is reiterated in the responses of this question.  
 
Interpretation of the Major Key themes derived from responses to question no. 2:
3
  
Many divergent opinions surfaced. There were both recognition of the embryo as a “cellular entity” 
and conferring the embryo with some kind of “rights” that are different from that of human being. 
There is also tendency of complete denial of rights to the embryo. At the same time there is 
tendency of not drawing distinction between the embryo and human.  
It was asserted that there is no consensus at which moment the developing entity shall be termed as 
an “embryo”; a conclusive definition of embryo is believed not to exist. In the absence of “soul” as 
the vital component, the embryo is also not considered as a human. 
Embryo, human body and human life are also deemed as integral parts of each other and 
collectively they form a human being. The tendency of ascribing the embryo with “gender” 
signifies the endowment of a legal status to the embryo.  
 
                                                 
1
 The questionnaire mentioned: “The responses of the participants/respondents in this study shall be analyzed for the 
purpose of the Doctoral Study conducted by ARIF JAMIL[…]. The information provided can be used/published by the 
Research Fellow and CIRSFID, University of Bologna; otherwise shall be considered confidential and the identity of 
the participants shall be kept anonymous, unless required to prove the authenticity of the study. The 
participants/respondents hereby consent to take part in the study.” Appendix II: Questionnaire. 
 
2
 Some of the words/phrases used/mentioned within quotation in the major key themes and their interpretations are the 
exact words/phrases used by the respondents. Appendix V: Qualitative Analysis (Qualitative Content Analysis (QCA)). 
 
The questionnaire mentioned that, “the identity of the participants shall be kept anonymous, unless required to prove the 
authenticity of the study.” Appendix II: Questionnaire. 
3
 Supra note 2. 
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Non-existence of a universality of perceptions was also asserted. A different and special status of 
the embryo from the human was also acknowledged. The health, safety and well-being of human 
being were given priority, when it comes to usage of embryo in scientific research. 
 
Interpretation of the Major Key Themes derived from responses to question no. 3:
4
  
 
Respondents thought that it is acceptable to employ embryo in limited circumstances, but the 
application is unethical in general and did not support using embryo as massive therapeutic tools. 
 
The embryo/fetus is believed to be incapacitated but still possesses some rights. Balance is thought 
to be required between the conflicting interests of the entities, i.e., the “embryo” (which has the 
right to be protected) and the “society and individual” (who will gain therapeutic benefits from the 
research). 
 
Respondent supported the use of embryos in research that are redundant for clinical purposes (e.g. 
IVF) and considered the creation of in-vitro embryo exclusively for research purposes as unethical. 
In this case the rationale or reasonableness of the action was viewed from the perspective of 
proportion and reality. 
 
Respondent highlighted the scientific absence of the precise moment when the fertilized entity shall 
be termed as embryo and emphasized on the “stages of development”. 
 
Respondent also identified embryo at early stage as a “biological material of human origin” and as a 
different component from the human being or human body and thought that “there is nothing 
unethical about its use” and was inclined to use a positive connotation for the usage/practice and 
hence, preferred to use the term “use” instead of “destruction.” 
 
It was emphasized that fulfilling certain conditions like good scientific reason, informed consent 
from embryo donors and careful monitoring are critical. 
 
The respondent asserted that alternative sources are available. Cord blood is suggested as a 
substitute source of embryonic stem cells.  
 
Interpretation of the Major Key Themes derived from responses to question no. 4:
5
  
As this question was exploring the personal experience of the respondent, their professional 
experiences came to the fore. Respondent being medical professional admitted the inadequacy of 
the medical treatment. Effectiveness of a particular medical treatment can be subjective due to 
variability in the biological systems in individuals, as believed by the physician respondent. 
Respondent also asserted that medical professionals always encounter the non-efficiency of medical 
treatment.  
 
As metaphysician, the respondent believes that alternative approaches of treatment may exist. 
Limitation exists in the conventional approach of treatment taken in the biological science. 
Metaphysical science may offer some solutions where biological science is ineffective. 
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Interpretation of the Major Key Themes derived from responses to question no. 5:
6
  
 
The question tested two things: 
 
 If the respondent despite being for/against the stem cell research would accept the therapy 
for their dear ones (how objective they are); and 
 
 How they would like to access it (means of accessibility). 
 
Many of the respondents expressed that they will accept it (either they were negative or positive 
about stem cell research) and they will access it through the conventional means, e.g., free care 
from the State, insurance coverage “entirely or partially”, personal expenses. But the “State” as 
service provider was also observed as popular choice. Respondents expected that the costs should 
be reasonable, if they are to access through personal resources. 
  
Some of them were more concerned about the safety and efficacy of the treatment in scientific 
terms. They will not accept until the therapy is proven to be effective.  
 
Response to this question may have been influenced by the health care system of the respondents‟ 
country of origin and reflective of their personal experience. Higher number (70.97%) of the 
respondents come from the country of high economy group.  
 
Interpretation of the Major Key Themes derived from responses to question no. 6:
7
  
 
This question intended to see why they would support or reject patent for hSCI. The respondents 
provided many insights related to patenting aspects of hSCI.  
 
The respondent was found to be in favor of stronger IP rights and suggested “ad hoc data 
exclusivity rights” if hSCI are protected as biotech inventions. Also reminded that exceeding the 20 
years‟ term of protection would affect access to therapy for the patients in less developed countries. 
Respondent suggested simpler IPR protection framework than patent due to ethical constraint in the 
hESC research, increasing litigation and opposition.  
 
The respondent expressed skepticism about the appropriateness of the patent system for life 
sciences but he did not reject the patent system. The respondent also sees it (patent) slightly misfit 
for protecting the living organism and raises concern regarding the possible adverse social effects. 
With changes of time, “how patent is adaptable to newer inventions in life science” was raised as 
question. Respondent did not accept evergreening of patent, i.e., taking new patent for already 
known technology (for example, second medical application of known drugs). 
 
Respondent found to have supported IP protection in the form of “moral rights” only aka., right of 
recognition and integrity but rejected the commercial feature of the IPR for life science 
inventions/innovations. 
 
Respondent observed that patent has two implications: 
 
1. It is an incentive for research and development; and 
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2. It is a barrier for further research in connected fields of knowledge (limits the parallel and 
downstream research freedom). 
 
The respondent did not support the patent protection of inventions derived from living entities; 
because we are supposed to understand and gather knowledge from it. 
 
Respondent believed that most researchers are driven purely by curiosity and altruism; doctors and 
lawyers need to understand the noble purpose behind the innovation. 
 
Interpretation of the Major Key Themes derived from responses to question no. 7:
8
  
 
The respondent does not believe that a new creation can be made within the realm of life science. 
And it was also considered that IPR should be used to protect only new creations, human stem cell 
based inventions/innovations, therefore, cannot be patented because they are not new creations.  
 
Respondent had the opinion that stakeholders of health care should be more pro-people, focusing 
more on how to provide affordable care and therapy to people rather than emphasizing on gaining 
financial incentives derived from patented technology. Respondent favored reduced 
commercialization in health care sector, in general. 
 
Respondent did not support any protection framework that will have a commercial feature and 
inclined to rely on government‟s money as the source of funding for research. Respondent believed 
that research targeted to health care is done for humanity and is willing to recognize the inventor 
but will not support the commercial features of the IPR or patent. 
 
Most of the respondents making comments in response to this question had one common concern 
i.e., commercialization through IP. They emphasized that inventions having health care implications 
should be pro-people and non-commercialized. Hence the feature of any new protection framework 
should not be typical patent or traditional expressions of IP. 
 
Interpretation of the Major Key Themes derived from responses to question no. 8:
9
 
 
This question tested the respondents‟ opinion about tenure/length of IP protection for the hSCI. 
Respondents making other opinion supported 20 or more years of IP protection for the hSCI and 
cited as justifications: 
 equivalent of current patent‟s tenure; and 
 the formality of regulatory approvals.10 
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9
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 The response (comment of the respondent) indicated that the time spent in regulatory approval, if deducted from the 
term of protection, the IPR owner does not get enough time to exploit the invention commercially in the market. 
 
It is worth mentioning here that the drug developer enjoys patent right and regulatory data exclusivity right 
simultaneously. The IPR on the core content of the invention remains in force until the expiry of the last one 
(whichever ends later).  
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Interpretation of the Major Key Themes derived from responses to question no. 9:
11
 
 
Respondent will allow a very limited use of human embryo for research and innovation in cases of 
serious disorder; not for large scale commercial and industrial application (will allow limited 
therapeutic application). 
 
Respondent also supported (suggested) development of therapeutics by using human embryo, when 
they are conducted by Academic/NPO/Government. 
 
Respondent suggested employing only redundant embryos that are anyway destined for destruction, 
which indicates that she does not support in-vitro development of embryo and its deliberate 
destruction for the purpose of research and therapy. 
 
Respondent was inclined to allow the application of human embryo for research targeted to find 
cure or drug development but not through commercial channels. 
 
Respondent suggested conducting stem cell research by using the cord blood, instead of human 
embryo. The respondent believed that human embryo and cord blood are equivalent sources of any 
type of stem cells and hence there is no need to use embryo, in addition people who might object to 
application of embryo might not do so if the research involves cord blood instead of human embryo. 
He presumes that cord blood would invoke less or no ethical concern as opposed to using human 
embryo. 
 
It appears that non-commercial channel conducting the research, developing and distributing the 
therapy is the most favorite choice. They also suggested using alternative source of stem cells or 
redundant embryos for research (destined to destroy). Their comments seemed to be opposing the 
large scale commercial use of human embryo. They also suggested a limited use for therapeutic 
purposes.  
 
Interpretation of the Major Key Themes derived from responses to question no. 10:
12
 
 
Respondent asserted that the contractual arrangement is the determining factor for “who will own 
the IPR”.13  
 
The respondent thought that the donor of cell line, if not included as the owner of IPR of the 
inventions from his/her biological sample, should receive a compensation. The respondent is 
suggesting to offer a “just” compensation for commercially developing an invention from the 
samples of a research subject. 
 
Respondents supported the “moral right”, not an economic right (as the moral right is only limited 
to the recognition, not extended to the commercial exploitation). The respondent considered the 
philanthropic aspects, rather than the conventional reality of the drug development and behavior of 
the market. Scientist/Inventor, funding organization and patients were suggested to be entitled to the 
right of recognition (moral right) only. 
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 In employer and employee setting, the ownership of the patent is taken by the employer organization/university (as 
“assignee”) and the scientist is awarded the recognition for the invention (as “inventor”). It is a common practice and it 
depends on the contract between the employer and the employee. In some cases, the inventor is also seen as the 
assignee with the employer. 
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The entitlement of IP was seen as depending on the funding sources (if public funding is the source 
of research, then the entitlement should be awarded to scientist/inventor and public and eventually 
the invention should be in the public domain). 
 
Respondent is willing to award the IPR to the inventor/scientist only and thought that the employer 
organization/university makes no intellectual contribution to the hSCI and most of their expenses 
are covered by “grant”. Merely for the facilities they provide to the researchers, they should not be 
awarded with the IPR of the hSCI.
14
 
 
Interpretation of the Major Key Themes derived from responses to question no. 11:
15
 
 
At present, multiple techniques of derivation of ES cells are available to the world. Two prominent 
techniques use the embryo directly. One, derives ES cell by embryo destruction and another, 
derives from the blastomere cell of the pre-implantation stage embryo. The question explores the 
benefits vs. risks of employing the embryos.  
 
The respondent believed that the benefits of human embryonic stem cell research outweigh the risks 
and cost associated with it, as this type of research has practical application in curing many diseases 
which currently has no cure. Again they also seem promising for rare diseases where a group of 
afflicted patients can afford to pay for the research and therapy. 
 
The respondent does not notice any inherent risk of stem cell research employing human embryo. 
However, when it comes to cost, respondent emphasized on conducting economic and viability 
studies making sure that Government money (i.e., public resources) spent is well justified and 
brings out fruitful outcome. 
 
The respondent believed that the non-specialized and pluripotent nature of hESC make them an 
excellent candidate for potential therapeutic interventions on wide conditions. The benefits 
outweigh the risk and costs in hESC research as well as contemporary medical research applying 
other techniques and thus reducing time and costs of other life science researchers. 
 
The respondent considers that the benefits would be more than the risks and cost associated to it 
only if this type of research undergoes strict and harmonized regulation as to how these studies are 
conducted employing hESC. 
 
The respondent considers that this type of research is beneficial mostly because of effective 
therapeutic interventions obtained down the road which help to prolong the life of those “who are 
already living.” She indicates that the advantage may contribute to the increase of life expectancy. 
 
                                                 
14
 A big proportion of this fund secured by an inventor is mandated to flow into the research institutions he/she is 
affiliated to, which is usually termed as Indirect Cost (IDC) (also known as Facilities or administrative rates). The 
university spends this amount to provide the administrative and infrastructural support to the inventors and academics. 
For example, the current IDC rate of federally secured grant is 50% for conducting on-campus research at the 
University of Florida (UNIVERSITY of FLORIDA, Office of Research: F&A Rates (IDC) 2015). What it means is that 
50% of the grant money brought in by an academic through fierce competition goes to the University by default, he/she 
has to plan the research based on the rest 50% of fund. This mandate is a serious pressure for an inventor trying to 
secure enough funds to carry out research in a timely manner and making due progress. But when a patent is granted, it 
is often assigned to the university. The respondent did not support this current practice of ownership for the above 
mentioned reason (most likely), mostly prevalent in the US. 
15
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The respondent believed that there are inherent risks and variable amount of costs associated with 
every kind of medical research and hESC research is no exception. If risking the embryo serves to 
invent a useful therapy that can benefit human life, health and the overall society, the respondent 
thinks it is important to do so. 
 
The respondent believed that the benefits of hESC are contingent upon costs associated with 
research and affordability of the final therapy as well as the time required to bring the research 
outcome from laboratory to the clinic. 
 
Although the respondent considered the hESC research as important but had reservation to 
generalize the risks, benefits and possible consequences of every hESC research but instead 
believed that each scientific case would vary considerably on these parameters and deserves special 
scrutiny to determine the individual risk and benefit. The respondent reminded that the answer of 
this question depends on the “context” and “circumstances” of each case; there is no universal 
approach to this issue. 
 
The respondent believed that the results of basic science should be promising enough to warrant 
further applied research and considered that hESC as an applied research is employing human 
embryo without having solid and convincing basic science research data. 
 
The respondent also did not support stem cell research that involves destroying or putting the 
human embryo at risk. Respondent seems to acknowledge the dignity and rights of human embryo 
in parallel to a fully developed human being. 
 
The respondent considers stem cells derived from cord blood are equivalent in function and potency 
to that of hESC and there is absolutely no need to employ human embryo in this type of research. 
 
The respondents highlighted context, circumstances, case-by-case evaluation, regulatory control, 
sound data, therapeutic potential, economic and viability studies, alternative stem cell researches 
etc., in assessing the “benefit v. risks” of employing embryos in stem cell research. 
 
 
Interpretation of the Major Key Themes derived from responses to question no. 12:
16
 
The question intended to examine if imposing legal obligation on the IP rights of the IPR owner can 
bring a just and right balance between “ensuring availability of medication/treatment at a reduced 
cost” and “incentive for the IPR right owner of hSCI”. The examples of legal obligation cited were 
“„licenses on easy terms‟, „compulsory licenses‟ and „technology transfer‟”. The involvement of 
“public health care sector,” issuing licenses in favor of local pharmaceutical companies/hospitals, 
manufacturing and production of therapies and medications locally, were among the suggested 
options.  Very few other opinions were encountered. Respondent stressed importance on the context 
of the country. In some countries waste of resources in corruption and unnecessary programs may 
be the reasons of high drug price and the high price of drugs may have been used just as an excuse 
to blame the patent for contributing to high costs. The respondent considered that transparency and 
proper utilization of public resources are keys to realizing these goals in countries like Mexico, 
instead of issuing any forms of legal obligation but also additionally reminded that these measures 
may be beneficial for other countries with different context. 
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The respondent did not support mandating or imposing legal obligations on patent holder, rather 
believed that public authorities should be judicious on enforcing it where appropriate based on 
sophisticated and flexible conditions. 
The respondent indicated that there is need to make improvement in the IPR mechanism in order to 
facilitate access to the medication. It appears that he finds that there are some impediments caused 
by IPR in accessing the medical innovations and there are “flawed” systems in place, when it comes 
to inter-relations between the IPR and access to medications. Respondent considered that “access to 
therapies” / “products borne out of medical innovations” should not remain restricted but rather be 
made available to everyone. Respondent also asserted that hSCI / “life science inventions” are not 
new creations and should not be IPR protected in the first place. 
Interpretation of the Major Key Themes derived from responses to question no. 13:
17
 
In order to implement this idea, the public need to be well informed. It means that the public must 
have access to the information regarding the proportion of the different expenses incurred for the 
product development, e.g., R&D, IP/Patent related fees and costs, marketing costs, incentives for 
investing in future research, etc. 
Most of the other opinion were negative about seeking public opinion and the common reason 
stated is the lack of information to the public to enable them to make any solid difference through 
sensible opinion.  
Respondent indicated that, if there is any issue related to “ordre public and/or morality” (obvious 
public outcry) then public opinion can be sought, otherwise it‟s not important.   
The respondent did not support the idea of seeking public opinions to measure the post marketing 
impacts but suggested that information should be made available to the consumers a priori so that 
they can learn more about the therapy and make informed decision whether or not to purchase and 
use it.  
The respondent thought that the civil society should have the legal instruments available so that 
they can resort to adjudication against undue commercial exploitation. Respondent does not seem to 
find independent public opinion very effective as a means to giving post marketing feedback or any 
positive or negative responses. 
Respondent assumed that embryo‟s source is central to public interest and not access, affordability, 
safety or efficacy of the therapy (in case the therapy is developed from hESC), hence had the 
opinion that the common people of a particular country might not object towards an imported 
therapy if the embryo used isn‟t derived from their countrymen. 
Respondent also suggested seeking “public opinion” / “public consultation” prior to commercial 
exploitation. It remains unclear what purpose it will serve though, in terms of the key aspects of 
therapy i.e., access, affordability, long term safety and efficacy. Drug pricing rationale and policy is 
never fully disclosed to the consumer. Hence, what purpose might pre-marketing public response 
serve, if they (public) don‟t have any knowledge and decision making role in drug pricing, is not 
clear from that opinion. 
The contents of the overall summary of the Qualitative Content Analysis (QCA) can be found in ch. 
6.  
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CHAPTER 6 : SUMMARY  
 
6.1 SUMMARY OF ETHICAL AND LEGAL ANALYSIS  
The monograph is comprised of both theoretical (comparative legal and ethical analysis of the 
purview of the stem cell research and patenting in select juristictions) and empirical (qualitative 
analysis) parts. The interpretation of the Major Key Themes derived from responses to questions 
related to ethical and legal issues (question nos. 1, 2, 3, 4, 5, 11) can be found in ch. 5. The 
Major Key Themes derived from responses to questions related to ethical and legal issues appear 
in ch. 3, as and when it deems appropriate to provide more insights into the discussion. The 
overall summary of the Qualitative Content Analysis (QCA) of the questions related to ethical 
and legal issues appears in ch. 6 together with the summary drawn from the theoritical discussion 
(that took place in chaps. 2 and 3).  
Following are the summary analyses of both theoretical and empirical (qualitative) analysis on 
the ethical and legal issues in hSCR: 
I. The most advanced stem cell research techniques were investigated.1 The comprehensive 
investigation revealed various legal and ethical issues involved in these techniques. 
Overall summary of the Qualitative Content Analysis (QCA) reveal the respondents’ 
Opinions prevailing on impression/prejudice about hSCR:
2
 
• Differing opinions prevailing on impression/prejudice about hSCR. 
 
• Some are prejudiced, empathetic to embryo, destruction was referred to as 
"killing," thought hSCR politically and ethically controversial, will approve 
somatic/adult stem cell research. 
 
• Some considered hSCR as any other kind of research, and as a promising area for 
therapy. 
 
Overall summary of the Qualitative Content Analysis (QCA) reveal the respondents’ 
Opinions prevailing on benefits vs. costs and associated risks of hESC research:
3
 
 
                                                 
1
 See ch. 3.1 HUMAN STEM CELL RESEARCH: VARIOUS TYPES AND THEIR ETHICAL AND LEGAL 
ISSUES. 
2
 Some of the words/phrases used/mentioned within quotation in the major key themes and their interpretations are 
the exact words/phrases used by the respondents. Appendix V: Qualitative Analysis (Qualitative Content Analysis 
(QCA)). 
 
The questionnaire mentioned that, “the identity of the participants shall be kept anonymous, unless required to prove 
the authenticity of the study.” Appendix II: Questionnaire. 
3
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• Two contrasting ideas regarding relative benefits vs. costs and associated risks of 
hESC research: some were not supportive of employing human embryo at all, 
whereas others found it beneficial in curing disease and increasing life expectancy.  
 
•  A proper balance of conflicting interests of embryo and human beings rests upon: 
specific study context, sound basic science data to substantiate applied/clinical 
research, the costs of research relative to benefits it might bring to the society and 
ensuring strict regulatory oversight. 
 
 
II. Adult stem cells have very limited potential in application and have no significant ethical 
controversies.
4
  
 
 
III. The NT-ESC and hpSC will require healthy egg procurement5 and may create perfect 
environment for  human egg trading.
6
 NT-ESC/SCNT and hpSC will require healthy 
human eggs for the derivation of the stem cells. Apart from the ethical concern, the health 
risks of the donor women also deserve attention. The short and long-term effects of the 
procedure and artificial ovulation may cause harmful consequences to the donor’s health. 
Egg donation is not a very simple process; it involves harsh reality. It is called “donation” 
but without compensating enough, there will be dearth of donors. Eventually women in 
financial need will be exploited for the process. Loane Skene (2010, 239) wrote: “Many 
human eggs will be needed and women who may wish to be donors will no doubt be 
deterred when they are told about the risks of donation.”  
 
IV. The embryo cloning procedure described by Tachibana et al. (2013) with a modified 
SCNT protocol involves creation of a patient specific “cloned embryo” through the 
“fusion” of the “patient specific somatic cell” (serving as the nuclear donor of the 
resulting “cloned embryo”) and “enucleated egg” (donated by healthy donors).7 This 
protocol does not employ an existing/already available embryo from IVF facility; rather 
uses the “cloned embryo” propagated to the blastocyst stage in order to derive the patient 
                                                 
4
 See ch. 3.1.1 ADULT STEM CELLS AND SOMATIC CELLS. 
5
 Tachibana et al. (2013, 1236) published on NT-ESC (SCNT) derivation process: “Anonymous egg donors of ages 
23–33 were recruited [...]. Responding women were screened with respect to their reproductive, medical, and 
psychosocial health. […]. Egg donors were financially compensated for the time, effort, discomfort, and 
inconvenience associated with the donation process.”  
6
 See chaps. 3.1.2.2 REPROGRAMMING BY SOMATIC CELL NUCLEAR TRANSFER AND THE DIRECT 
INTRODUCTION OF TRANSCRIPTION FACTORS; 3.1.2.3 STEM CELLS DERIVED FROM THE PRE-
IMPLANTATION STAGE EMBRYO’S BLASTOMERE CELL, HUMAN PARTHENOGENETIC STEM CELLS, 
ETC. 
7
 The purpose of this modified SCNT protocol is therapeutic cloning (to derive patient specific NT-ESC) and not 
reproductive cloning. The blastocyst, instead of implantation into uterine wall, was cultured in vitro to isolate NT-
ESC. This isolation, therefore, essentially destroys the integrity of the blastocyst (the zona pellucida is destroyed in 
vitro by protease treatment and ICM is disintegrated during culture) (Tachibana et al. 2013, 1236--37). 
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specific NT-ESC. The NT-ESC (SCNT) derivation process destroys a “cloned embryo” 
the potential of which is presumed, not decisively established yet.
8
 
 
V. ESC derived from the blastomere of pre-implantation stage embryo raises different 
ethical concerns.
9
 If the biopsied embryo is implanted, it may compromise the health of 
the embryo and resulting child/human and the consequences of such procedure on the 
biopsied embryo is largely unknown. If the biopsied embryo is implanted, it can/may be 
viewed as a “commercial and unnecessary” intervention/action (to the embryo itself) in 
the process of normal development of an embryo. However, they may derive totipotent 
cells (in some instances), which are (likely) capable of developing into a complete 
organism. The presumed therapeutic benefit for the embryo itself (or resulting 
child/human) of preservation of autologous ES cells might be devoid of enough 
apprehension for the justification of action. 
The “EXAMPLE 5” of the United States Patent No. 8,742,200, issued on June 3, 2014 
described “Derivation of Embryonic Stem Cells without Destruction of the Embryo” as 
following: “The zona pellucida is disrupted using either Acidic Tyroides solution or 
multiple Piezo-pulses and an individual blastomere is mechanically separated from each 
denuded embryo [...]. The embryos are subsequently cryopreserved.”10 The example 
states that after the derivation they were cryopreserved. 
How cryopreservation (be it permanent or temporary) of the remaining embryo relieves 
from the ethical objection around the embryo destruction? Are we convinced that the 
dignity of the embryo is protected, if it is cryopreserved and/or “used” in research, 
instead of “destroyed” for research? The “cryopreservation of embryo” (after “biopsy” / 
“blastomere cell extraction”) is not a better substitute of “destruction of embryo,” for the 
understanding of moral philosophy. 
The extraction of totipotent blastomere cell from the pre-implantation stage embryo calls 
for ethical evaluation in embryo related research. There remains concern over the health 
of the biopsied embryo and resulting child/human, if implanted. If it is conducted 
concurrent to PGD, the objective for doing PGD
11
 and the objective of derivation of ESC 
from the extracted blastomere cell, are very different. How ethical this use of the embryo 
is, i.e., propagation of stem cells from the cells of the “to be implanted embryo” (if 
implanted later; even if done concurrent to PGD), if it is not truly useful to the embryo 
itself? The “EXAMPLE 6” of United States Patent No. 8,742,200, issued on June 3, 2014 
mentioned: “The separated blastomere undergoes cell division. One progeny cell is used 
                                                 
8
 See ch. 3.1.2.2 REPROGRAMMING BY SOMATIC CELL NUCLEAR TRANSFER AND THE DIRECT 
INTRODUCTION OF TRANSCRIPTION FACTORS. 
9
 See ch. 3.1.2.3 STEM CELLS DERIVED FROM THE PRE-IMPLANTATION STAGE EMBRYO’S 
BLASTOMERE CELL, HUMAN PARTHENOGENETIC STEM CELLS, ETC. 
10
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at  
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=5
0&s1=8,742,200.PN.&OS=PN/8,742,200&RS=PN/8,742,200 (last visited June 19, 2015). 
11
 PGD is conducted to investigate the genetic abnormality potentially harmful for the optimum development of the 
embryo. However, questions remain on “if” and “how” “safe and effective” PGD is, to ensure a healthy baby with 
normal genetic makeup.  
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for genetic testing and a different progeny cell is cultured as in Example 1 to produce a 
human ES cell.”12 
Chung et al. (2008, 133--16) stated that they used early stage (“cleavage-stage” (Chung 
et al. 2008, 115)) embryo and took out blastomere by embryo biopsy. The blastomeres 
taken out can be cultured to produce ES cells using their methodology and these cells can 
be used further for research and therapy. Chung et al. (2008, 116) mentioned: “Here we 
clearly show that hESC lines can be derived without embryo destruction and that the 
biopsy procedure did not appear to interfere with subsequent good blastocyst 
development of the parent embryo.” Chung et al. (2008, 115) also cultured the remaining 
biopsied embryo and allowed it grow to the blastocyst stage. These blastocysts were 
shown to be normal in characteristics and later cryopreserved. Unless a/the cryopreserved 
blastocyst grown from a biopsied embryo is shown to be successfully implanted and 
produce live birth (without problems (any developmental defect/abnormality) caused to 
the biopsied embryo/fetus/resulting child or human), it is not very different from “embryo 
destruction” or simply “allowing the usage of an embryo” as a “means” to propagate ES 
cells. It may be a methodological improvement but still cannot bypass the ethical  
barrier. The embryo was grown to the blastocyst stage and then cryopreserved, instead of 
destruction or implantation.
13
 They showed that they could grow the biopsied embryo to 
the blastocyst stage; the reason (justification) they claim it to be “normal.” Therefore, for 
the same reason the biopsied embryo should be able to result to live birth without 
developmental abnormality in order to claim that the biopsy does not have adverse 
impact and the embryo remained normal. But they did not proceed towards 
“implantation”, instead “cryopreserved” the biopsied embryo. 
PGD by embryo biopsy is carried out in conjunction with IVF for reproductive purpose, 
in limited circumstances. If the purpose is strictly research, not benefitting the embryo 
being biopsied, should it still be considered ethical? Unless they are expecting any long-
term need of ES cells (for the embryo biopsied) in advance, what is the purpose of 
deriving ES cells from the embryo? 
 
VI. There is a very thin line of difference between therapeutic cloning (by SCNT) and the 
reproductive cloning.
14
 If the embryo/pre-embryo (developing in-vitro) instead of 
deriving ES cells (by destroying from the blastocyst stage) is implanted and brought to 
term, it will be “human cloning.” Large prohibition exists against human reproductive 
cloning. 
 
                                                 
12
 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at  
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=5
0&s1=8,742,200.PN.&OS=PN/8,742,200&RS=PN/8,742,200 (last visited June 23, 2015). 
13
 Chung et al. (2008, 115) mentioned: “The remaining biopsied embryos were allowed to continue development and 
were frozen at the blastocyst stage.” 
14
 See ch. 3.1.2.2 REPROGRAMMING BY SOMATIC CELL NUCLEAR TRANSFER AND THE DIRECT 
INTRODUCTION OF TRANSCRIPTION FACTORS.  
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VII. Stem cell research policies are very divergent.15 Although the Federal Policy on stem cell 
research is relatively liberal, policies in different States of the USA are different from 
each other. California, Massachusetts and New Jersey follows liberal policies, whereas 
Texas and South Dakota are very restrictive. In Europe, in comparison to the USA, more 
restrictive policies are prevalent. However, at State level in Europe, significant 
differences can be observed. Italy and Lithuania have very restrictive stem cell research 
policies, whereas German policy is restrictive yet allows the research subject to certain 
conditions. Spain and UK have relatively liberal policies on hSCR in Europe.   
 
VIII. Following techniques may be said to encompass the human embryo’s use:16 
 
• Derivation of ESC from the ICM of the blastocyst (by destruction of the embryo);  
• Derivation of ESC from the extracted blastomere cell (also totipotent) of the pre-
implantation stage embryo; 
• Derivation of patient specific nuclear transfer ES cells (NT-ESCs) (by embryo 
cloning and subsequent destruction of the “cloned embryo”). 
 
None of them are ethically objectionable for the purpose of patenting in the USA. In 
Europe, the first one is rejected for EP and the fate of second one is not yet known. Are 
both the uses ethically objectionable? Which one is more objectionable? Which one may 
have further negative implications? Answer to these questions depend on ethical and 
scientific perceptions. Some countries accept those experiments as scientific endeavor 
and some find it morally disturbing. Many countries accept the stem cell research with 
IVF redundant/donated embryos.
17
   
 
 
 
Overall summary of the Qualitative Content Analysis (QCA) shows how the respondents  
commented on the definition and  rights of “embryo”:18 
 
• No conclusive definition of "Embryo" exists. Some regarded it as a cellular entity 
with no soul. Embryo, human body and human life were claimed as integral parts 
of each other.  
 
• Differing perceptions on embryo's right: from complete denial of any rights to 
conferring some rights to embryo. 
 
• A special status and rights was also acknowledged for embryo but the health, 
safety and well being of human beings given priority over that of embryo. 
 
                                                 
15
 See ch. 3.2 HUMAN STEM CELL RESEARCH: LEGAL LANDSCAPE. 
16
 See ch. 3.1.2 HUMAN PLURIPOTENT STEM CELLS. 
17
 Some of them (e.g., abandoned and redundant) are destined to be destroyed. 
18
 Supra note 2. 
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Overall summary of the Qualitative Content Analysis (QCA) also shows how the 
respondents  commented on the use (application) of human embryo:
19
 
 
• Supported research using embryo targeted to developing therapy to serious/rare 
disorders.   
 
• Opposed large scale commercial use of human embryo. 
 
• IVF redundant embryos can be used. Opposed in-vitro embryo creation with an 
intention to destroy and use the embryo in research. Alternative source of ES cells 
suggested (e.g. cord blood). 
 
• Therapy development pursued by academic/NPO/Government bodies preferred.  
 
IX. Which pluripotent hSCR (hESC, NT-ESC/SCNT, hpSC, iPSC) is free from the ethical 
debate?
20
 How do we improve the situation? All of the techniques have different degree 
of concerns either at the research process or during the clinical trial and application. 
Some of them have substantially lower degree (or no) of ethical constraints in the 
research process, e.g., iPSC. The other alternative hPSCR techniques will have concern 
around egg donation and health of the implanted embryo. Protection of women’s health is 
a concern for the NT-ESC and hpSC research. The wellbeing of the embryo biopsied is a 
real concern (if implanted after biopsy) for the technique that derives ES cells from the 
single blastomere of the pre-implantation stage embryo. Therefore, strict or liberal, 
whatever philosophical approach is taken at the policy level, there has to be a strict 
monitoring to ensure the full compliance with the policies adopted and those policies 
need to be reflective of people’s choices.   
 
X. Many arguments exist that support that human embryo should be protected.21 It is also a 
fact that many degenerative conditions and diseases do not have cure at present. 
Therefore, in ideal situation, the therapeutic application oriented all human SC research 
should continue subject to the evaluation of the ethical issues involved.
22
  
Overall summary of the Qualitative Content Analysis (QCA) reveal the respondents’ 
Opinions prevailing on inadequacy of conventional medications and alternative 
approaches:
23
 
   
                                                 
19
 Supra note 2. 
20
 See ch. 3.1.2 HUMAN PLURIPOTENT STEM CELLS. 
21
 See chaps. 3.1.2.1 EMBRYONIC STEM CELLS; 3.1.2.2 REPROGRAMMING BY SOMATIC CELL 
NUCLEAR TRANSFER AND THE DIRECT INTRODUCTION OF TRANSCRIPTION FACTORS; 3.1.2.6 
HUMAN EMBRYO FOR THE STEM CELL RESEARCH: ETHICAL AND LEGAL DILEMMA; 3.2 HUMAN 
STEM CELL RESEARCH: LEGAL LANDSCAPE.  
22
 See ch. 3.1 HUMAN STEM CELL RESEARCH: VARIOUS TYPES AND THEIR ETHICAL AND LEGAL 
ISSUES. 
23
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• Inadequacy of conventional medications often encountered by medical 
professionals. 
 
•  Efficacy of treatment highly subjective. Biological systems in person to person 
vary considerably. 
 
• Conventional approaches based on biological science have limitations. 
 
• Alternative approaches (e.g. metaphysical science) may offer some solutions.  
 
 
Therefore, human sufferings and sacrifice of embryos can be minimized by resorting to 
the best alternatives. An embryo should not be subjected to unknown risks, if it is not 
destroyed after derivation of the cell from it. The Oviedo Convention does not permit 
creation of embryo for research but the in vitro research on embryo is allowed,
24
 provided 
that the adequate protection of the embryo is ensured by the particular country. 
Therefore, the destruction and some particular manner of use of the embryo can conflict 
with the idea of “protection of the embryo” for the purpose of the Convention. Protection 
of embryo in the biomedical research is asked for, in the Oviedo Convention. 
 
Overall summary of the Qualitative Content Analysis (QCA) shows how the respondents 
commented on the destruction of human embryo:
25
 
 
• Destruction of human embryo for research was considered unethical in general. 
 
• Acceptable in limited circumstances. In-vitro creation of embryo for research 
purpose was not supported. 
 
• Not accepted as massive therapeutic tools. Suggested alternative source of ESC. 
 
• Embryo's rights (though limited) should still be respected. 
 
• Good scientific rationale, informed consent from donors and careful monitoring 
were deemed essential. 
 
 
XI. For ethical hSCR the clinical trial need to ensure certain formalities, e.g., informed 
consent, right to withdrawal, transparency and accountability (well documented 
procedure; redress by means of monetary compensation (in case of error committed by 
                                                 
24
 It actually indicates any research for the betterment of the embryo itself; NOT destroying it or extracting a 
totipotent blastomere cell for deriving the stem cells.  
25
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the researcher)), post-trial care, etc.
26
 Human Subject Protection (HSP) has to be taken 
very seriously in the process of development of human stem cell based inventions. 
Therefore, conducting the safety and efficacy study properly is very important.  
 
 
XII. All actors and stakeholders do not perceive bioethics in the same way. It is a 
conglomerate of perceptions.
27
 Bioethical principles will achieve better efficiency if they 
are fluid enough, adaptable to needs and circumstances and can be applied in the 
differing contexts.  
 
XIII. Human right to “health care” and “right” based approach may increase access to health 
care in  certain countries, which may allow access to the stem cell based therapy as 
well.
28
 It may be guaranteed in the constitutions and be enforced through the judicial 
system. The international legal instruments like TRIPS Agreement may offer more 
concession. 
The TRIPS framework ensures stronger IP protection and favors the inventor/patentee. 
The deal achieved through Doha Declaration 2001 for access to medicine is not flexible. 
Although it (Doha Declaration) helped access to essential medicines in some countries 
(for certain circumstances), a higher access to health care (e.g., for stem cell therapy) 
shall require more to be done. The compulsory licensing and authorization to local 
manufacturer is not a matter of free will of the country in need; the action has to comply 
with the criterion set by the TRIPS.  
Overall summary of the Qualitative Content Analysis (QCA) shows how the respondents 
commented on the sources of finance and cost of the therapy:
29
 
  
• Decision to accept the therapy and how it will be financed are separate    
issues. 
 
•  Acceptance contingent upon scientific proof of “treatment safety and   
efficacy.” 
 
•  Varied sources of finance: personal expenses, provided by the State,  
insurance or in combination. 
 
•  Cost expected to be reasonable, if paid out of pocket.  
 
 
XIV. The scenario of access to health care is different in different countries.30 Therefore, the 
recommendation on access to therapy may be tailored differently for different countries. 
                                                 
26
 See ch. 3.3.3 ETHICAL hSCR: INFORMED CONSENT, CLINICAL TRIAL, HUMAN SUBJECT 
PROTECTION AND RESPONDENTS’ EXPERIENCE OF CONVENTIONAL MEDICATION FAILURE.  
27
 See ch. 3.3 BIOETHICAL CONCERNS IN hSCR. 
28
 See chaps. 3.4 ACCESS TO THERAPY: COMPULSORY LICENSING, RIGHT TO “HEALTH/HEALTH 
CARE” AND HEALTH CARE POLICY.  
29
 Supra note 2. 
30
 See ch. 3.4.1 ACCOMPLISHMENTS MADE IN THE COUNTRY CONTEXT. 
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In the USA, ObamaCare was introduced as a basic care coverage for the needy, the 
future of which is unknown. The European countries have social security or public health 
system to access the health care to a good extent. If they require co-pay and if it is slim, 
the accessibility will be higher in those countries. Small countries/economies do not 
attract generic’s producer, and hence, they may enlarge their market size by merging with 
neighboring countries of similar economic/political/territorial status. A regulatory 
restructuring may be needed. It appears that the access to affordable care is limited in the 
USA. The key features of the health care facilities prevalent in the country context can be 
found in the following table: 
 
Table 6.1 Health systems (features of health care facilities) in the country context 
COUNTRY KEY FEATURES OF THE 
HEALTH SYSTEMS 
WORTH NOTICING 
GERMANY  Social Insurance 
 Compulsory Statutory 
Health Insurance 
 Private Insurance 
 
 “One third of the care providers (e.g. 
hospitals) are public; one third is not 
for profit and private, and one-third is 
for profit and private” (Simonet 2010, 
473). 
ITALY National Health Service 
(Servizio Sanitario Nazionale 
(SSN)) 
 Twenty-one (21) Italian regions 
have differing standards of 
health care services; 
 
 “[S]ocial determinants can 
produce (different) inequalities 
inside different welfare 
systems.” (Braggion, 
Campostrini, and Bertin 2013, 
8). 
 
LITHUANIA Statutory Health Insurance Disproportionate geographic 
distribution of family physician 
noticed (Buivydiene, Starkiene, and 
Smigelskas 2010, 262). 
SPAIN Health card from the 
Department of Social 
Security (Tarjata Sanitaria 
Individual (TSI)) 
 Reduction in health care 
budget; 
 Increased co-payment. 
UNITED 
KINGDOM 
 National Health 
Service (NHS)  
 Office of Health 
Ombudsman 
 Care Quality 
 “[T]ax based national health 
system” (Lostao et al. 2014, 
19); 
 Held in Coombs v. North 
Dorset NHS PCT (2013)
31
 that 
it is possible for the patient to 
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Commission (CQC) 
 
make additional payment for 
the expenses that are not the 
statutory responsibility of the 
NHS.  
USA The Affordable Care Act 
(ACA), 2010 (ObamaCare) 
In the case of National Federation of 
Independent Business, et al. v. 
Sebelius, Secretary of Health and 
Human Services, et al. (2012),
32
  
twenty-six (26) States opposed the 
Affordable Care Act 2010.  
CALIFORNIA Medi-Cal Programme  
MASSACHUSETTS  MassHealth  
 CarePlus 
 Free Care 
 
NEW JERSEY  NJ FamilyCare 
 Individual Health 
Coverage (IHC) 
 
SOUTH DAKOTA Healthcare.gov 
(Government’s marketplace)  
 
TEXAS  Rejected Medicaid 
expansion / 
ObamaCare; 
 Highest percentage of 
uninsured people 
among the American 
States. 
 
 
 
 
6.2 SUMMARY ON IPR ISSUES 
The summary on IPR issues is drawn here from the discussion that took place in ch. 4. The 
Major Key Themes derived from the responses to questions related to IPR (question nos. 6, 7, 8, 
9, 10, 12, 13) appear in ch. 4, as and when it deems appropriate to provide more insights into the 
discussion. The interpretation of the Major Key Themes derived from the responses to questions 
related to IPR can be found in Ch. 5. The overall summary of the QCA of the IPR related 
questions appear in this sub-chapter. 
Following are the summary analyses of both theoretical and empirical (qualitative) analysis on 
the IPR issues: 
                                                 
32
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I. Fate of US patent is unpredictable in Europe.33 WARF patent encompassing the 
destruction of human embryo was rejected by the Enlarged Board of Appeal (EBoA) of 
the European Patent Office (EPO) in G 0002/06
34
 as the use of human embryo was 
considered as “commercialization” objectionable on the grounds of “"ordre public" or 
morality” enshrined in the Article 53(a) of the European Patent Convention (EPC), 
1973.
35
 WARF patents on ES cells derivation survived as US patents.
36
 The recent US 
patent
37
 of the Advanced Cell Technology, Inc
38
 on the ES cell propagation from the 
totipotent and/or pluripotent blastomere cell derived from the pre-implantation stage IVF 
embryos are pending at EPO.
39
 Will it not be an “ordre public or morality” issue for the 
EPO to use totipotent cells for ES cell derivation?
40
 The CJEU’s approach on 
patentability is not very predictable. CJEU has reinterpreted the Brüstle’s (2011)41 
exclusion in the International Stem Cell Corporation case (2014)
42
 and opened the door 
for hpSC patent in Europe. The hESC patents by embryo destruction is excluded for the 
purpose of EP but hpSC patents are possible, according to the 2011 (Brüstle case) and 
2014 (International Stem Cell Corporation case) decisions of the CJEU. iPSC was 
granted EP in 2011. The fate of EP for the rest of the hSCI
43
 examined in this monograph 
is yet not known. 
 
II. The inventions are unlikely to be commercially exploited in some countries/states.44 
Patent rejection in some countries is obvious, as the interpretation of the provisions on 
“ordre public” and/or morality is differently perceived by different patent offices. In 
some countries the inventions are unlikely to be sold and IP protected, whereas they shall 
remain patented in other countries. 
 
                                                 
33
 See ch. 4.5.1 THE PREVAILING CIRCUMSTANCES IN hSCR AND PATENT: HOW DIVERGENT; 4.5.5 
LIMITATION AND PROSPECTS OF THE US PATENTS FOR hSCI.  
34
 Case No. G 0002/06. European Patent Office, Search in the board of appeal decisions database, available at             
http://www.epo.org/law-practice/case-law-appeals/recent/g060002ep1.html#q (last visited Dec. 14, 2014). 
35
 European Patent Convention, Oct. 5, 1973, 13 I.L.M. 268, available at http://www.epo.org/law-practice/legal-
texts/html/epc/1973/e/ar53.html (last visited Dec. 14, 2014). 
36
 US Patent No. 6,200,806 (issued Mar. 13, 2001); US Patent No. 7,029,913 (issued Apr. 18, 2006); and the US 
Patent No. 7,442,548 (issued Oct. 28, 2008). 
37
 US Patent No. 8,742,200 (issued June 3, 2014). United States Patent and Trademark Office, USPTO Patent Full-
Text and Image Database, available at  http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-
bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,742,200&OS=8,742,200&RS=8,742,200  (last visited 
Nov. 12, 2014). 
38
 Named as Ocata Therapeutics, Inc. since November 14, 2014. 
39
 European Patent Office, European Patent Register, available at 
https://register.epo.org/application?number=EP12197502&tab=main  (last visited Nov. 12, 2014). 
40
 The totipotent cells and an embryo have the same/similar developmental potential. 
41
 C-34/10, Judgment of the Court (Grand Chamber) 18 Oct. 2011, available at 
http://curia.europa.eu/juris/liste.jsf?language=en&num=C-34/10 (last visited July 25, 2014). 
42
 Case C‑364/13, Judgment of the Court (Grand Chamber) 18 Dec. 2014, also available at 
http://curia.europa.eu/juris/document/document.jsf;jsessionid=9ea7d0f130de9c4121923b8f43769c42c1706a04f989.
e34KaxiLc3eQc40LaxqMbN4ObheSe0?text=&docid=160936&pageIndex=0&doclang=EN&mode=lst&dir=&occ=
first&part=1&cid=88991#Footnote* (last visited Dec. 22, 2014). 
43
 NT-ESC and ESC from the blastomere cell of pre-implantation stage embryo. 
44
 See chaps. 4.5 DIVERGENT PATENT FRAMEWORK FOR hSCI; 4.5.5 LIMITATION AND PROSPECTS OF 
THE US PATENTS FOR hSCI. 
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III. Commercial exploitation of certain patented inventions (patented in the USA as US 
patent) may not be possible in all US States.
45
 The commercial exploitation of certain 
patented inventions (patented in the USA as US patent) may not be possible in all US 
States. As for example WARF patents were discussed in the chapter 4.5.5 on                    
“LIMITATION AND PROSPECTS OF THE US PATENTS FOR hSCI.” Those WARF 
patents (that derives hESC) may have problems in exploitation in the South Dakota 
(SD)
46
 but can be freely commercially exploited in the other States, e.g., California, 
Massachusetts, New Jersey, etc., where the hSCR policy is liberal. 
 
IV. Ethical issues are causing divergence.47 Divergence in patent protection of hSCI between 
the USA and Europe is mainly caused by the European interpretation of the perceptions 
of “ordre public and/or morality.” Therefore, all of the techniques detailed in chapter 3 
are perfectly patentable in the United States. Most of them have already been issued 
several US patents (or applied for it). It is worth mentioning that, some of them cannot be 
useful patent in some of the US States that are very restrictive in human stem cell 
research, e.g., South Dakota.
48
 hpSC patent is now possible in Europe. The CJEU in 2014 
affirmed that the hpSC patents of International Stem Cell Corporation are not excluded 
from the patenting in Europe and the parthenogentically activated oocyte is not a “human 
embryo” for the purpose of exclusion from patenting.49 But the restriction on derivation 
of ES cells seems to have retained its ethical constraints around the “embryo destruction” 
and “potential to live birth.” 
 
The major justification for the exclusion from patentable invention is cited as “ordre 
public” and/or “morality” in most of the legal texts revisited. Inventions 
encompassing/resulting/causing reproductive cloning and destruction of embryo are 
explicitly forbidden in many countries. Hence, they are excluded from being patented in 
those countries. 
 
 
V. Divergence in patent framework of hSCI may cause/increase the mobility of patients and 
scientists and accelerate/trigger the health care inequalities.
50
 
 
VI. Private sector dominating the industry may result to higher cost of the transplant.51 The 
most advanced techniques of human stem cell research are patented by the corporations 
and autonomous institutions. It will have implication in the “access point.” It may result 
to the higher cost of the transplant. The drug developers and downstream researchers 
developing disease specific application will have to pay royalties to these patentees, in 
                                                 
45
 See ch. 4.5.5 LIMITATION AND PROSPECTS OF THE US PATENTS FOR hSCI. 
46
 As the SD laws/policies on hSCR is very restrictive. 
47
 See ch. 4.5.1 THE PREVAILING CIRCUMSTANCES IN hSCR AND PATENT: HOW DIVERGENT. 
48
 WARF US patents on ES cell derivation techniques cannot be commercially exploited both in South Dakota (SD) 
and Europe (as European Patent).  
49
 Supra note 42. 
50
 See ch. 4.5.6 IMPLICATIONS OF DIVERGENT PATENT FRAMEWORK.  
51
 See ch. 4.4.1 PROPRIETARY NATURE OF THE HUMAN STEM CELL BASED 
INVENTION/INNOVATION. 
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addition to their own research and development effort and cost. In some cases, these 
assignees themselves are developing the drug product. Ultimately the patients will bear 
the expenses of these invisible “backyard costs” of the therapy. Since the industry is 
heavily influenced by private sector, the cost of the therapy using these patented 
inventions will be high and borne by the patients, unless they are covered by the 
mainstream health care providing channel of the particular State (through insurance or 
public hospitals).  
 
 
VII. Regulatory Data Exclusivity (RDE) might be an additional layer of protection for hSCI.52 
Many of the transplant and disease specific applications will be in the market when the 
patent will be near to end of the term of protection. The patent owners may “resort 
to”/seek the protection of clinical test data and by which the tenure of monopoly will be 
further extended. The arrival of generic product in the market shall be delayed until the 
patent and the data exclusivity right both have expired. The data exclusivity right exists 
both in the US and EU in different length. The minimum protection called in TRIPS 
(Article 39(3)) for the “undisclosed test or other data” against “unfair commercial use” 
(to prevent unfair competition)
53
 has been exercised towards extending the IP protection 
and literally creating a double protection regime, the implication of which will be 
obvious delay of arrival of the generic in the market. Therefore, the Bolar exception 
makes no significant impact in fostering access to medicine/treatment/health care. The 
opportunity to exercise the authority to allow use without authorization of the right holder 
is very limited.  
 
VIII. Patent litigation, Re-Examination and Opposition Proceedings may cause substantial 
obstacles for the inventions on its way to the clinic.
54
 Figure 4.4 shows the apparent 
reasons of the inventions encountering reexamination, post-grant proceedings and patent 
litigations. Figure 4.5 shows the breakthrough publications and issued patents (U.S. 
Patents) in SCNT and its neighboring techniques from 2004 to 2014. That sub-chapter 
also demonstrated the slim differences among the inventions. It will not be a surprise, if 
plenty of patent litigations, re-examination and opposition proceedings occur in the 
pipeline of industrial application of this emerging field of science. They may slower the 
pace of the therapy to reach the clinic. There also exists high possibility of “double 
patenting”55 and “evergreening.” 
 
IX. Patent issued/granted by different patent offices have different impacts and carries 
different weight to the patent owners.
56
 Some of the National Patents (NP) may not have 
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 See ch. 4.4.2 REGULATORY DATA EXCLUSIVITY, BOLAR EXEMPTION AND COMPULSORY 
LICENSE. 
53
 Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Marrakesh Agreement 
Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197 (1994) [hereinafter 
TRIPS Agreement]. 
54
 See ch. 4.4.3 CONTROVERSIES, SLIM DIFFERENCES AMONG INVENTIONS, FUTURE LEGAL 
COMPLICATIONS.  
55
 The chance persists as some of the inventions by the same inventors/assignees in the same direction, have very 
narrow differences. 
56
 See ch. 4.5.2 PATENT OFFICES (EPO, USPTO) AND FEES DIVERGENCE. 
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much value to the patent owner but those patents will continue to have higher value in the 
US and EU. The EU patents will be more valuable than an NP. The US patent cover 
larger single market than many other countries. Therefore, before seeking the patent, the 
applicant will calculate the “pre and post” grant costs of the patent and the return from 
the commercial exploitation of that patent in terms of profit. 
 
X. Patent grant and renewal fees are different in different patent offices.57 That may lead to 
adopting different “patent strategy” in different territory by the patent owner for the 
purpose of commercial exploitation of the invention. The patent fees (pre and post grant) 
being different at different IP offices, the cost of the patent and the return from the 
market will be a considerable factor to the patent seekers. 
 
 
XI. Territoriality of the patent system and the mode of use of compulsory licenses by some 
countries may not encourage some of the companies to commercialize their products in 
certain countries.
58
 This phenomenon cannot be avoided. More harmonization may be 
achieved among the blocks of the States, but they will be procedural uniformity, not 
achieving any uniform interpretation of patentable subject matter. The patent 
enforcement difficulties may remain largely in place.  
 
XII. The Unitary Patent shall bring only the procedural simplification for getting patents in the 
EU Countries.
59
 The prospective patentees can not try UP for inventions that are excluded 
under the current EU laws or excluded under the national laws of some EU countries. The 
patent seeker may try the classical European Patent’s route and elect the individual States 
where the patent is obtainable for that particular invention. Therefore, the patents not 
qualified for UP, but eligible for patent (NP (National Patent)) in any of the European 
States may be applied, granted, enforced and challenged nationally. Therefore, the EU 
patent (Unitary Patent) and UPC will not bring harmonization in human stem cell patent 
landscape, particularly in the ethically contested matters. 
 
 
XIII. PCT, US patent, EP, UP, NP all are offering different routes of granting the patent in 
different territories.
60
 There is no “one patent system.” From the procedural point of 
view, several patent systems co-exist. PCT and US patent exist in the USA. PCT, EP, UP 
and NP exist in the Europe. The new UP and UPC will bring procedural harmonization, 
once fully taken effect in the contracting States of the EU. But the substantive 
interpretation of patentability has not been changed by the unitary patent package. 
Therefore, the UPC will act according to the existing European laws. Therefore, the 
issues that raise questions on patentability in the Europe remain in the same situation for 
the UPC as well. There is no “international patent” and there is no international 
enforcement mechanism. Patent is a nationally granted right. Therefore, for the purpose 
of validity and enforcement of a patent right, the litigants have to proceed through the 
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 Id. 
58
 See ch. 4.5.3 TERRITORIALITY OF PATENT SYSTEM AND THE ENFORCEMENT ISSUES.  
59
 See ch. 4.5.4.1 EUROPEAN PATENT AND UNITARY PATENT PROTECTION. 
60
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national judicial system. The EP is a bunch of national patent. The PCT is a procedure to 
get multiple numbers of national patents in one click. UPC will be able to enforce patent 
right in the territories of EU that are contracting party to the agreement establishing the 
UPC. But large scale harmonization in “recognition and enforcement” of “foreign IP 
rights and foreign judgment” is not going to happen any time soon. 
  
XIV. Patent office (USPTO in this example) either do not possess the capacity and means of 
“replicating” the invention to verify the claim or simply do not do it.61 H. Bion Co., Ltd. 
(Seoul, South Korea) was assigned the United States Patent No. 8,647,872 on February 
11, 2014 having scientist Woo Suk Hwang and others as inventors for “[h]uman 
embryonic stem cell line prepared by nuclear transfer of a human somatic cell into an 
enucleated human oocyte.”62 The patent is believed to have been granted on the 
inventions the publications of which were later retracted. It indicates that patent office 
(USPTO in this case) either do not possess the capacity and means of “replicating” the 
invention to verify the claim or simply do not do it. If this is a practice/situation in all 
patent offices, then it is a vital weakness in the patent granting process. 
 
XV. Broad patent claim for the upstream inventions may block the downstream research, 
require licensing and raise the cost of the medicinal/drug products.
63
 Early hSCIs are 
going to cover broad claims undoubtedly.  
 
 
XVI. Overall summary of the Qualitative Content Analysis (QCA) shows how the respondents 
commented on the Appropriateness of patent system for life sciences 
inventions/innovations:
64
 
 
• Skepticism on the appropriateness of patent system for life sciences 
inventions/innovations. 
 
• Not supportive of evergreening of patent. 
 
•  While some supported stronger IPR if hSCI is protected as biotech inventions, 
many would like to see a simpler IPR framework due to ethical constraints, 
increasing litigations and oppositions.  
 
• More than 20-year term of protection thought to be affecting access to therapy in 
less developed countries (LDCs and Developing). The hSCI should undergo 
similar regulatory approval process as pharmaceuticals. 
                                                 
61
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 United States Patent and Trademark Office, USPTO Patent Full-Text and Image Database, available at 
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XVII. Overall summary of the Qualitative Content Analysis (QCA) shows how the respondents 
commented on the “entitlement of IPR”:65 
 
 
• Forms of entitlement of IPR: depending on funding source and contracts made. 
Researchers preferred to be acknowledged with moral rights only. Cell line 
donors deserve due compensation. 
 
• A common concern over commercialization aspect of IP.  Reduced 
commercialization suggested for hSCI targeted to health care.  
 
• Legal obligations suggested not to be mandated, should be enforced only in the 
right context. Instead, better transparency and proper utilization of public 
resources deemed more pragmatic.  
 
• A better informed public can make better decision and give useful feedback. Drug 
pricing policy and rationale should  be made more  transparent to the consumers. 
Civil society should have the legal instruments to voice against undue commercial 
exploitation. 
 
 
XVIII. The most resorted course of IP protection for hSCI at this moment is the patent. Apart 
from raising other concerns about appropriateness of the patent system for hSCI, it has 
worries for the assignees as well. The time spent in clinical trial and regulatory approval 
will be lost from the term of protection.
66
 But the regulatory data exclusivity right 
compensates that loss.
67
 However, some countries including the United States allow the 
extension of the term of protection of the patent on grounds like time lost in regulatory 
approval (Miller 2012, 10). 
 
XIX. The European Group on Ethics in Science and New Technologies to the European 
Commission in 2002 explored the alternatives to patent protection for hSCI and finally 
concluded by recommending to keep this branch of science within the patent system 
while making few suggestions regarding the patent system for it (EGE 2002, 81-82).  
As an alternative to patent,
68
 trade secret have certain difficulties. To name a few: 
 The product can be reverse-engineered in some cases or the secrets can be revealed once 
the product is in the market. 
                                                 
65
 Supra note 2. 
66
 See ch. 4.3.3 INDUSTRIAL APPLICATION. 
67
 See ch. 4.4.2 REGULATORY DATA EXCLUSIVITY, BOLAR EXEMPTION AND COMPULSORY 
LICENSE. 
68
 See generally chaps. 4.4 PATENT RELATED CONCERNS; 4.4.2 REGULATORY DATA EXCLUSIVITY, 
BOLAR EXEMPTION AND COMPULSORY LICENSE. 
149 
 
 Ex-employees may disclose information, despite confidentiality agreement.  
 Information considered secret may be published with the Court’s proceedings. Therefore, 
the IPR owner will not be interested to enforce the trade secret rights in the Court.  
 The term of protection for trade secret is not limited like other forms of IPR.  
 The law on trade secret (or on preventing unfair competition) is not so developed in many 
countries.   
Lastly, the sui generis protection will create more diversity.  
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CHAPTER 7: 
CONCLUSION AND FURTHER RESEARCH 
 
7.1 CONCLUSION 
 
Comparative analysis of ethical and legal issues in hSCR in the select jurisdictions reveal that the 
divergent interpretation of ethical issues is resulting to different legal and policy atmosphere for 
the stem cell research and patenting hSCI. Ch. 3.2 “HUMAN STEM CELL RESEARCH: 
LEGAL LANDSCAPE” showed that legal purview of hSCR policies ranges from restrictive to 
liberal. The views of the respondents are also found to be vivid, i.e., ranges from restrictive to 
liberal.
1
 Ch. 6.1 “SUMMARY OF ETHICAL AND LEGAL ANALYSIS” (I, VII, VIII, IX, X) 
reveals that there are differing degree of consent to different kinds of stem cell researches. 
Therefore, it can not be said that opting any particular approach, i.e., liberal or strict, is an ideal 
choice, since the “lack of uniform policies and differing opinions” exist in this field of science.   
  
Based on the analysis made in the chaps. 2, 3, 5 and 6, the following conclusion may be drawn to 
answer the research question
2
: 
 
 For ethical hSCR, strict monitoring will be required to ensure full compliance with the 
policies (reflective of people‟s choices) adopted. 
   
 There is need to learn how to manage plurality and diversity of choices, prioritize and 
contextualize issues, and frame policies that have fluidity and adaptability in a given 
context.
3
 It may be extremely difficult to implement.  
 
 
Ch. 3.3.3 “ETHICAL hSCR: INFORMED CONSENT, CLINICAL TRIAL, HUMAN 
SUBJECT PROTECTION AND RESPONDENTS‟ EXPERIENCE OF CONVENTIONAL 
MEDICATION FAILURE” discussed what needs to be done for ethical hSCR during the clinical 
trial and application. Based on the analysis of ethical and legal issues done by the researcher,
4
  it 
can be concluded that Clinical trial on human always shall need effective regulatory control in all 
the countries where they are conducted. There may be necessity of long term care for the 
participant/patient (by addressing the risk factors in application- tumorigenicity and immune 
rejection).
5
 
 
                                                 
1
 See ch. 5.1 QUALITATIVE DATA ANALYSIS (for the interpretation of the Major Key Themes derived from the 
responses to question (on ethical and legal issues) nos. 1, 2, 3, 4, 5, 11).  
2
 Ch. 1.3 THE RESEARCH QUESTIONS OF THE MONOGRAPH (II. What are the legal/ethical/bioethical issues 
in human Stem cell Research (hSCR) and what needs to be addressed for “ethical” hSCR?). 
3
 See chaps. 3.3 BIOETHICAL CONCERNS IN hSCR; 6.1 SUMMARY OF ETHICAL AND LEGAL ANALYSIS 
(XII). 
4
 See chaps. 3.3.3 ETHICAL hSCR: INFORMED CONSENT, CLINICAL TRIAL, HUMAN SUBJECT 
PROTECTION AND RESPONDENTS‟ EXPERIENCE OF CONVENTIONAL MEDICATION FAILURE; 6.1 
SUMMARY OF ETHICAL AND LEGAL ANALYSIS (XI). 
5
 See chaps. 3.1.2 HUMAN PLURIPOTENT STEM CELLS; 3.1.2.4 ARE THEY SUBSTITUTE OF EACH 
OTHER OR DIFFERENT FROM EACH OTHER?; 3.1.2.5 CLINICAL, ETHICAL AND LEGAL CONCERNS 
OVER THE iPSC. 
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Based on the qualitative analysis and the theoritical discussion done by the researcher,
6
 the 
following conclusion relating to the IPR issues may be made to answer the research question
7
:  
i. Certain changes in the patent system may improve the present situation;8 or 
ii. A new IP protection framework may be designed for the hSCI or IBMHO;9 or 
iii. Alternative IP protection (meaning only one should be opted; not multiple) may be 
exercised.
10
 
 
The following proposals may be considered to bring certain changes in the patent system:  
 
 In future, the technical interpretation of “industrial application” may take into account the 
“access to therapy” issues and introduce a new requirement (Accessibility Mode) for 
satisfying the “utility” / “industrial application”.11 
 
 
 It seems that the quality of patent may depend on good “search and examination”. That may 
be a costly process, but with time, the standard has to be increased. The capability/expertise 
of the patent examiners will also have to be raised.
12
   
                                                 
6
 Chaps. 5.1 QUALITATIVE DATA ANALYSIS (the interpretation of the Major Key Themes derived from the 
responses to question (on IPR issues) nos. 6, 7, 8, 9, 10, 12, 13); 4 ANALYSIS OF IPR ISSUES. 
7
 Ch. 1.3 THE RESEARCH QUESTIONS OF THE MONOGRAPH (I. What is the best way to offer IP protection 
to “human Stem Cell based Inventions/Innovations” (hSCI) / “Inventions/Innovations that use Biological Materials 
of Human Origin” (IBMHO) that would ensure incentive for invention/innovation and allow wider access to 
therapies?). 
8
 See ch. 6.2 SUMMARY ON IPR ISSUES (IV, V, VII, VIII, IX, X, XI, XIV, XV, XVI, XVII). 
9
 See ch. 6.2 SUMMARY ON IPR ISSUES (XVI; XVII). 
 
More empirical investigation shall be necessary to implement this proposal. 
 
10
 See chaps. 4.4.2 REGULATORY DATA EXCLUSIVITY, BOLAR EXEMPTION AND COMPULSORY 
LICENSE; 6.2 SUMMARY ON IPR ISSUES (VII). 
Dual protection exists in pharmaceutical inventions, i.e., patent and RDE right. Although RDE protects clinical test 
data, there may be information that are covered under an existing patent. There may be Patent, RDE and a new IP 
protection framework for the “inventions/innovations that use biological materials of human origin” / “human stem 
cell based inventions” / “regenerative medicine”. But only one should be exercised; not multiple. 
 
 If this idea will become reality or not, will depend on the will of multiple actors. 
  
11
 The commercialization channels of the invention will be scrutinized if that approach is taken seriously, while 
granting the patent. In the past, “utility or industrial application” has taken into account the feasibility of the 
invention from its technical potential and that approach has, in a way, favored the patentee only. In health care 
related inventions, a new approach in the interpretation of “industrial application” asking for the “accessibility 
mode” of the invention, may favor the patient population. The patent application may require an explanation on 
“how the researchers and general population will access/utilize the invention (to serve the „utility‟ / „industrial 
application‟ purpose).”  
 
See Chaps. 4.3 PATENTABILITY REQUIREMENT FOR THE hSCI; 4.3.3 INDUSTRIAL APPLICATION. 
12
 See chaps. 4.4.3 CONTROVERSIES, SLIM DIFFERENCES AMONG INVENTIONS, FUTURE LEGAL 
COMPLICATIONS; 6.2 SUMMARY ON IPR ISSUES (VIII; XIV). 
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 Heightening the “non-obviousness” standard will reduce the number of bad patents. Plenty of 
stem cell patents are challenged at Court over the lack of novelty and inventive steps.
13
  
 
 Generics do not recover the entry cost from small markets, and hence, small countries that 
have small markets do not get cheaper medicine even after the patent expiration.
14
 Small 
countries with similar economic circumstances can be merged with other neighboring small 
countries for the regulatory purposes and a single market can be created for those States.
15
 
Then the generic can be launched for the single market of multiple States. The wider single 
market will also reduce the frequency of parallel trade. The problem here is that the patent 
expires in different countries at different times. Exactly at which point of time the entry of 
generics will take place in that single market, have to be decided first. Therefore, this 
proposal is subject to the determination of the “term of protection” of the patent for that 
market.   
 The provisions on compulsory licensing (use without authorization) in TRIPS may be relaxed 
and wider number of circumstances can be included, under which the unauthorized use by a 
country in desperate need of the treatment/therapy can be allowed/tolerated.
16
 
 
Based on the qualitative analysis
17
 and the theoritical discussion
18
 done by the researcher, the 
following conclusion (for fostering the access to the stem cell based therapy) may be made to 
answer the research question
19
:  
 
 Differentiated pricing of pharmaceutical products already exists. We need affordable pricing 
considering the income level of the people of the respective countries where the 
invention/innovation is being commercially exploited. The IP protection needs to respect the 
affordability issues involved in accessing the medicinal products.
20
 Even co-payment with 
the insurance can be unaffordable to a higher number of patients. It is highly unlikely that the 
current patent system will offer such concessions.  
 
 
                                                 
13
 See chaps. 4.3.1 NOVELTY IN hSCI; 4.3.2 INVENTIVE STEP/NON-OBVIOUSNESS; 4.4.3 
CONTROVERSIES, SLIM DIFFERENCES AMONG INVENTIONS, FUTURE LEGAL COMPLICATIONS; 6.2 
SUMMARY ON IPR ISSUES (VIII). 
14
 See ch. 4.5.6 IMPLICATIONS OF DIVERGENT PATENT FRAMEWORK. 
15
 See ch. 6.1 SUMMARY OF ETHICAL AND LEGAL ANALYSIS (XIV). 
16
 See chaps. 3.4 ACCESS TO THERAPY: COMPULSORY LICENSING, RIGHT TO “HEALTH/HEALTH 
CARE” AND HEALTH CARE POLICY; 4.4.2 REGULATORY DATA EXCLUSIVITY, BOLAR EXEMPTION 
AND COMPULSORY LICENSE; 6.1 SUMMARY OF ETHICAL AND LEGAL ANALYSIS (XIII). 
17
 Ch. 5.1 QUALITATIVE DATA ANALYSIS. 
18
 See chaps. 3.4 ACCESS TO THERAPY: COMPULSORY LICENSING, RIGHT TO “HEALTH/HEALTH 
CARE” AND HEALTH CARE POLICY; 3.4.1 ACCOMPLISHMENTS MADE IN THE COUNTRY CONTEXT; 
4.4 PATENT RELATED CONCERNS; 6.1 SUMMARY OF ETHICAL AND LEGAL ANALYSIS (XIII; XIV).  
19
 Supra note 7. 
20
 See chaps. 3.4 ACCESS TO THERAPY: COMPULSORY LICENSING, RIGHT TO “HEALTH/HEALTH 
CARE” AND HEALTH CARE POLICY; 4.4 PATENT RELATED CONCERNS.  
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 Irrespective of the economic status of the country, efficacious health care system, pro-
patient regulatory policy, sufficiently allocated health care budget, humanitarian approach to 
IP protection of inventions having application in health care, may increase the access to the 
medicinal/drug products, if tailored for the circumstances and need of the population.
21
  
 
 The right to health care can be guaranteed domestically.22 The enforcement of such right 
will depend on the capability of the State.  
 
 Already developed legal tools of international human rights laws can be enforced to allow 
the wider access to the therapy.
23
 As an enforcement tool, human rights instruments are 
weaker than the trade agreements that protect stronger IP rights.  
 
7.2 FURTHER RESEARCH AND EXTENSION OF THIS WORK 
 
 
In future, studies can be done to reveal the correlation between “divergence in the patent 
framework” and the “stem cell tourism” / “price differences”. As an impact of divergence in the 
patent framework, the treatment may be available in some specific countries. That may increase 
the health care tourism for stem cell based therapy. Further empirical investigations may be 
needed to reveal the implications of divergent patent framework on health care tourism. 
Divergent patent framework may not be directly responsible for the variation of medicinal/drug 
product‟s prices in the different countries. The prices of on-patent products are more expensive 
and the off-patent generics are usually cheaper. But many other factors are also linked to the 
price differentiation among the countries, such as demand-supply, market size, contribution of 
the Government and the insurance, ratio of co-pay with the insurance, Gross National Income 
(GNI) per capita, local manufacturing ability, parallel trade, Health Technology Assessment 
(HTA), health care needs and priorities of individual country, regulatory policy, tax policy, etc. 
An econometric analysis may reveal the relationship between divergent patent framework and 
the price differences.  
 
 
 
 
 
                                                 
21
 See chaps. 3.4.1 ACCOMPLISHMENTS MADE IN THE COUNTRY CONTEXT; 6.1 SUMMARY OF 
ETHICAL AND LEGAL ANALYSIS (XIII; XIV). 
22
 See chaps. 3.4 ACCESS TO THERAPY: COMPULSORY LICENSING, RIGHT TO “HEALTH/HEALTH 
CARE” AND HEALTH CARE POLICY; 3.4.1 ACCOMPLISHMENTS MADE IN THE COUNTRY CONTEXT; 
6.1 SUMMARY OF ETHICAL AND LEGAL ANALYSIS (XIII).  
23
 See ch. 3.4 ACCESS TO THERAPY: COMPULSORY LICENSING, RIGHT TO “HEALTH/HEALTH CARE” 
AND HEALTH CARE POLICY. 
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Appendix I: The Legal and Policy Framework 
INTERNATIONAL LEVEL 
Paris Convention for the Protection of Industrial Property 1883 
World Health Organization Constitution 1946 
Universal Declaration of Human Rights 1948 
Convention on the Unification of Certain Points of Substantive Law on Patents for Invention 
(Strasbourg Convention) 1963 
Declaration of Helsinki 1964 
International Covenant on Economic, Social and Cultural Rights (ICESCR) 1966 
Patent Cooperation Treaty (PCT) 1970 
Strasbourg Agreement Concerning the International Patent Classification 1971   
Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the 
Purposes of Patent Procedure 1977 
WHO Declaration of Alma-Ata 1978 
Vienna Declaration and Programme of Action Adopted by the World Conference on Human Rights 
in Vienna on 25 June 1993 
Agreement on Trade-Related Aspects of Intellectual Property Rights 1994 
Convention for the Protection of Human Rights and Dignity of the Human Being with Regard to the 
Application of Biology and Medicine: Convention on Human Rights and Biomedicine 1997 
Additional Protocol to the Convention for the Protection of Human Rights and Dignity of the 
Human Being with regard to the Application of Biology and Medicine, on the Prohibition of 
Cloning Human Beings 1998 
Patent Law Treaty (PLT) 2000 
Additional Protocol to the Convention on Human Rights and Biomedicine concerning 
Transplantation of Organs and Tissues of Human Origin 2002 
Universal Declaration on Bioethics and Human Rights (UNESCO Declaration on Bioethics) 2005 
Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical 
Research, Strasbourg 2005 
United Nations Declarations on Human Cloning 2005 
Treaty of Lisbon amending the Treaty on European Union and the Treaty establishing the European 
Community 2007 
United Nations Resolution on Universal Health Coverage, 12 December 2012 
 
EUROPEAN COMMUNITY LEVEL  
Council of Europe (CoE) Convention for the Protection of Human Rights and Fundamental 
Freedoms 1950 
Convention on Jurisdiction and the Enforcement of Judgments in Civil and Commercial Matters 
1968 
European Patent Convention 1973 
Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the Legal 
Protection of Biotechnological Inventions  
Charter of Fundamental Rights of the European Union 2000 
Directive on the Enforcement of Intellectual Property Rights 2004 
Directive 2004/23/EC on Human Tissues and Cells 
Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending 
Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use 
Commission Directive 2005/28/EC of 8 April 2005 Laying Down Principles and Detailed 
Guidelines for Good Clinical Practice as Regards Investigational Medicinal Products for Human 
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Use, as well as the Requirements for Authorisation of the Manufacturing or Importation of Such 
Products 
Consolidated Version of the Treaty on the Functioning of the European Union 2012 
Regulation (EU) No 1215/2012 of the European Parliament and of the Council of 12 December 
2012 on Jurisdiction and the Recognition and Enforcement of Judgments in Civil and Commercial 
Matters 
Regulation (EU) No 1257/2012 of the European Parliament and of the Council of 17 December 
2012 Implementing Enhanced Cooperation in the Area of the Creation of Unitary Patent Protection 
The Agreement on a Unified Patent Court 2013 
Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on 
clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC  
 
COUNTRY CONTEXT 
GERMANY 
Health Insurance Act 1883 
Patent Law (enacted on 5 May, 1936, as amended upto 31 July, 2009) 
Basic Law for the Federal Republic of Germany (Grundgesetz, GG) 1949 
Hospital Financing Act 1972 
Embryo Protection Act 1990 
The SHI Modernization Act 2004  
Health Care Reform Act 2007 
Act of Quality and Security of Human Tissue and Cells 2007 
Stem Cell Act 2002 and amendment of 2008 (Law on Protection of Embryos in Connection with 
Importation and use of Human Embryonic Stem Cells) 
Medicinal Products Act 2009 
 
ITALY 
Constitution of the Italian Republic1948 
Hospital Services Reform Act 1968 
Patent Law (Royal Decree No. 1127 of June 29, 1939, as amended by Legislative Decree No. 198 
of March 19, 1996) 
Law No. 40, Regulation of Medically Assisted Reproduction 2004 
Law No. 78 of 22 February 2006 
 
LITHUANIA 
Law on Patents 1994 (As amended upto 10 May 2007) 
Law on the Health System 1998 
Law on Ethics of Biomedical Research 2000 
Oviedo Convention on Human Rights and Biomedicine 
Additional Protocol to the Convention for the Protection of Human Rights and Dignity of the 
Human Being with regard to the Application of Biology and Medicine, on the Prohibition of 
Cloning Human Beings 
Law on Pharmacy 2008 
 
SPAIN 
The Spanish Constitution 1978 
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Law on Patents 1986 
Oviedo Convention on Human Rights and Biomedicine 
Additional Protocol to the Convention for the Protection of Human Rights and Dignity of the 
Human Being with regard to the Application of Biology and Medicine, on the Prohibition of 
Cloning Human Beings 
Law on Assisted Human Reproduction Procedures 2006 
Law on Biomedical Research 2007 
 
UNITED KINGDOM 
The Patents Act 1977 
Human Fertilisation and Embryology Act 1990 (as amended by the Human Fertilisation and 
Embryology Act 2008) 
Human Rights Act 1998 
Human Reproductive Cloning Act 2001 
National Health Services Act 2006 
Health and Social Care Act 2012
1
 
 
THE USA 
The United States Constitution, Article 1, Section 8, Clause 8 
Consolidated Patent Laws 
United States Code, Title 35: Patents 
United States Code, Title 15 :The Sherman Antitrust Act 
Consolidated Patent Rules: Title 37 - Code of Federal Regulations- Patents, Trademarks, and 
Copyrights  
Manual of Patent Examining Procedure 
Leahy–Smith America Invents Act 2011 
American Inventor's Protection Act, 1999, amended by the Intellectual Property and High 
Technology Technical Amendments Act of 2002 
Patent Business Goals 2000 
NIH Grants Policy Statement, U.S. Department of Health and Human Services, National Institutes 
of Health, (Oct. 1, 2012) 
Stem Cell Therapeutic and Research Act 2005 
Stem Cell Therapeutic and Research Reauthorization Act 2010 
Human Cloning Prohibition Act 2009
2
 
Stem Cell Research Advancement Act 2009
3
 
Stem Cell Research Advancement Act 2011
4
 
Ethical Stem Cell Research Tax Credit Act 2011
5
 
Federal Food, Drug and Cosmetic Act 1938 
                                                          
1
 Royal Assent 27 March 2012; Not yet in force. 
2
 Status: Referred to the Subcommittee on Crime, Terrorism, and Homeland Security. 
3
 Status: Referred to the House Committee on Energy and Commerce. 
4
 Status: Referred to the Subcommittee on Health. 
5
 Status: Referred to the Committee on Finance. 
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Medical Practice Acts
6
 
21 CFR 314.80: Postmarketing reporting of adverse drug experiences 
Code of Federal Regulations, Title 21, Vol. 1, Revised as of April 1, 2012, Subpart B--Informed 
Consent of Human Subjects 
Code of Federal Regulations, Title 45, Part 46, Protection of Human Subjects, Subpart A, Revised 
January 15, 2009, Effective July 14, 2009 
National Research Act 1974 
42 U.S. Code Chapter 6A - PUBLIC HEALTH SERVICE  
Patient Protection and Affordable Care Act 2010 
Health Care and Education Reconciliation Act 2010 
Biologics Price Competition and Innovation Act 2009 
Drug Price Competition and Patent Term Restoration Act 1984 (Hatch-Waxman Amendments) 
US Federal Food, Drug, and Cosmetic Act, 21 U.S.C.§ 355 (2010) 
American Recovery and Reinvestment Act 2009 
American Inventors Protection Act (AIPA) 1999 
Bayh Dole Regulations, 37 CFR § 401 (2013) 
Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research, Report of the National Commission for the Protection of Human Subjects of Biomedical 
and Behavioral Research, April 18, 1979 
The Nuremberg Code 
WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects 
International Ethical Guidelines for Biomedical Research Involving Human Subjects by Council for 
International Organizations of Medical Sciences CIOMS) and World Health Organization (WHO) 
American Psychological Association (APA) Ethics Code 
Food and Drug Administration Modernization Act 1997  
Food and Drug Administration Amendments Act 2007  
 
THE USA: STATE LEVEL  
California 
CALIFORNIA CONSTITUTION, Article 35: Medical Research, Ss. 1-5 
California Health and Safety Code, Section 125292.10,  Section 24185-24187 
New Jersey 
Senate Bill No. 1909 
Massachusetts 
Chapter 27 of the Acts of 2005, Act Enhancing Regenerative Medicine in the Commonwealth. 
Texas 
Texas Medical Board’s_ Rules/ Regulations on ‘Use of Investigational Agents’ _ CHAPTER 198. 
UNLICENSED PRACTICE, 22 TAC §§198.1 - 198.3 
South Dakota 
South Dakota Codified Laws, CHAPTER 34-14: MEDICAL RESEARCH  
 
 
                                                          
6
 All States have Medical Practice Act. The Federation of State Medical Boards (FSMB) issues guidelines for the 
physicians. 
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Appendix II: Questionnaire 
The responses of the participants/respondents in this study shall be analyzed for the 
purpose of the Doctoral Study conducted by ARIF JAMIL, e-mail: 
aaajamil@yahoo.com (hereinafter referred to as Research Fellow), Erasmus Mundus 
Fellow (2012-2015) of JOINT INTERNATIONAL DOCTORAL DEGREE IN LAW, 
SCIENCE AND TECHNOLOGY (LAST-JD). http://www.last-jd.eu. The information 
provided can be used/published by the Research Fellow and CIRSFID, University of 
Bologna; otherwise shall be considered confidential and the identity of the participants 
shall be kept anonymous, unless required to prove the authenticity of the study. The 
participants/respondents hereby consent to take part in the study. 
 
 
Name (optional): 
Age Group: (A: (less than, and 25), B: (26-30), C: (31-35), D: (36-40), E: (41-45), F: (46-    
50), G: (51-55), H :( 56-60), I: (61-65), J: (more than 65)) 
Gender: 
Current City, Country: 
Profession/position: 
& Category of respondent (respondent can choose more than one category which would 
be appropriate to his/her background/profession/position): 
(a) Academic (please specify field): 
(b) Ethicist/Bioethicist 
(c) Judge 
(d) Lawyer 
(e) Patent Examiner 
(f) Patient (Medical condition can be mentioned, but optional): 
(g) Patient Advocate  
(h) Physician/Doctor 
(i) Researcher (please specify field): 
(j) Scientist (Please specify field):  
 
Note: It should be mentioned that you may respond according to your opinion, some 
answers are merely suggestions, and you may make specific remark, different from 
the suggested ones, if you think appropriate)  
 
1. Do you bear any negative impression / any prejudice about human stem cell research? 
(a) Yes 
(b) No 
If „yes‟ Why? - 
 
 
2. How do you perceive the terms „embryo‟, „human body‟ and „human life‟? 
(a) They are same things and deserve the same rights.  
(b) They are different forms of human being and deserve same rights. 
(c) They are different entity, they have different status and they have different rights.  
My answer is different from above. I think………………… 
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3. How do you see the act of destruction of human embryo for the purpose of research 
and invention/innovation? 
(a) Unethical act, because it is against God‟s will (my religion does not allow it).  
(b) Unethical act, because I consider embryo as human being or human body. 
(c) Destruction for research and scientific experiments aimed at developing means to cure 
critical diseases can be allowed, despite the ethical issues divide opinions. 
(d) Embryos are not human and if the destruction is a process that might bring medication 
for complicated and terminal diseases, I would not say that the act of destruction is 
unethical. 
(e) Embryo at early stage is a different component from human being or human body. 
They are biological material of human origin and there is nothing unethical about its 
destruction. 
My answer is different from above. I think………………… 
 
 
4. Do you have experience of dealing with a situation when conventional medication or 
treatment could not help? 
(a) Yes, for myself 
(b) Yes, not for myself but for family members 
(c) Yes, for others 
(d) No 
(e) (Please mentions here your experience in brief, if not covered by the options) 
………………………………………………………. 
 
5. Having a choice and at a critical stage of grave illness would you choose stem cell 
therapy for your family member, if it promises a cure (suppose already available as 
treatment)? 
(a) Yes, and it would be good if the State provides the expenses. 
(b) Yes, and willing to take it at personal expenses too, provided that I expect the costs 
of the treatment are reasonable. 
(c) Yes, and the insurance should cover it. 
(d) Yes (If you want to mention a reason or circumstances other than mentioned 
already, you may write here) …………….. 
(e) No. (If you want to mention a reason, you may write here) ………………. 
 
6. Do you think patent protection as it exists today is the best way to provide incentive 
to human stem cell based inventions/innovations? 
(a) Yes 
(b) No 
(c) No, because patent has embarked into too much complications and uncertainty of 
enforcement. 
(d) No, because it is inappropriate for rewarding inventions/innovations in life science. 
(e) No, because patented inventions are property of the patentee/assignee and it invokes 
exclusive commercialization. 
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(f) No, because patented human stem cell based invention/innovation is a form of 
commercialization of „life‟. 
Why/other opinion: 
 
 
 
7. Do you think that a new protection mechanism/framework can be / should be 
developed within the purview of intellectual property law (IPR), separate from patent, 
for the inventions/innovations that use biological materials of human origin and 
targeted to health care? 
(a) Yes (can be) 
(b) Yes (should be) 
(c) No 
Other opinion (please suggest)/ Why: 
 
8. How many years of protection (term of protection for commercial exploitation) is 
appropriate for human stem cell based inventions/innovations? 
(a) More than 20 years 
(b) 20 years 
(c) 15 years 
(d) 10 years 
(e) 5 years 
(f) No protection 
 
9. Which application of human embryo can be permitted according to your opinion? 
(a) Commercial and industrial application for therapeutic purposes 
(b) For research purposes 
(c) For both the above 
(d) None of the above 
Others, please mention: 
 
10. Who, according to your opinion, should be entitled to the intellectual property rights 
(IPR) of human stem cell based inventions/innovations? 
(a) Scientist/Inventor 
(b) Employer organization/University/Assignee 
(c) a and b both 
(d) State through its Department responsible for heath care; 
(e) None of the above 
(f) No one should own IPR of human stem cell based inventions/innovations. 
 
Other ( or please suggest, if your opinion is different): 
 
11. Do you consider that the benefits of hESC (human Embryonic Stem Cell) research is 
more important than the risks and costs associated to it? 
(a) Yes 
(b) No 
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Any reason? - 
 
 
12. Do you think legal obligation for issuing „licenses on easy terms‟ or „compulsory 
licenses‟ and „technology transfer‟ can bring benefit to the patients by ensuring 
availability of medication/treatment at a reduced cost and may also serve as incentive 
for the IPR right owner of human stem cell based inventions/innovations at the same 
time? 
(a) Yes 
(b) Yes, but for the cost reduction the public health care sector has to be involved. 
(c) Yes, cost reduction is possible if the licenses are issued in favor of local 
pharmaceutical companies/hospitals and therapies and medications are manufactured 
and produced locally. 
(d) I think yes but I am not so sure  
(e) No 
(f) I hold different opinion such as (or you can mention your reason here) 
______________________________________________________ 
 
13. Do you think public opinion should be sought and be given importance after the 
invention/innovation is put to the market for commercial exploitation, in order to 
measure the impacts of the IPR protected invention/innovation on the health care 
receiver? 
(a) Yes 
(b) Yes, and public opinion can be received online. 
(c) No 
(d) I have a specific opinion/suggestion about seeking public opinion. I 
think……………………………. 
 
 
 
 
Question regarding familiarity of the topic 
 
 How familiar you are with the questions asked in this questionnaire? 
(a) Very familiar.  
(b) Quite familiar but not all.  
(c) Some were familiar and some were not so familiar.  
(d) I could understand very few questions, not so familiar in general.  
(e) Not familiar at all.  
 
 
 
 
 
 
 
180 
 
  
 
 
 
General information about patent: 
Patent is granted by a State in favor of the patentee/assignee, empowering the owner 
(patentee/assignee) the right to exploit the invention commercially for the period called 
“term of protection” which is usually 20 years. Patent is granted in almost all fields of 
technologies, provided the inventions have to be new, non-obvious to the person skilled 
in the art or must have an inventive step, and shall have a commercial/industrial 
application. 
 
Patenting (both process and product) inventions/innovations in „life science‟ / 
„biomedical research field‟ / „evolutionary developmental biology‟ has existed for few 
decades. But this field of „innovation‟ has „ethical concerns‟. Countries are divided over 
the ethical issues relating to commercial application of inventions/innovations through 
patenting living objects, e.g., stem cells, genes etc.  
 
Patent is an exclusive right. The owner alone can and is supposed to exploit the invention 
in the market. The price of a patented invention has risks to be monopoly price, i.e., 
higher than competition price. A perfectly organized legal setting should have a 
competition law/anti-trust law to look after the anti-competitive effect of dominant 
producer.  
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Appendix III: The Respondents 
 Email Address (Confidential Information) 
The Questionnaire mentioned: 
“The responses of the participants/respondents in this study shall be analyzed for the purpose of 
the Doctoral Study conducted by ARIF JAMIL, e-mail: aaajamil@yahoo.com (hereinafter 
referred to as Research Fellow), Erasmus Mundus Fellow (2012-2015) of JOINT 
INTERNATIONAL DOCTORAL DEGREE IN LAW, SCIENCE AND TECHNOLOGY 
(LAST-JD). http://www.last-jd.eu. The information provided can be used/published by the 
Research Fellow and CIRSFID, University of Bologna; otherwise shall be considered 
confidential and the identity of the participants shall be kept anonymous, unless required to 
prove the authenticity of the study. The participants/respondents hereby consent to take part in 
the study.” 
 
Therefore, I do not have permission to publish their email addresses. However, the email 
addresses were submitted to the LAST-JD Board with the first draft of this “Appendix.” The list 
of the email address provided with the first draft of this file corresponds to the “Column # 1: 
Respondent Number” of the cumulative survey table.   
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Appendix IV: Questions’ Design 
 
For brevity reason, the content of this file (Appendix IV) is made available online. Please 
check the following link of the Dropbox. 
https://www.dropbox.com/s/2cfjneed9yj5wo8/back%20matter%20appendix%20iv%20qu
estions%E2%80%99%20designs%20link%20version.doc?dl=0 
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Appendix V: Qualitative Analysis (Qualitative Content Analysis (QCA)) 
 
 
ABBREVIATIONS: 
Common Key Words (CKW) 
Common Key Themes (CKT) 
Unique Key Words (UKW) 
Unique Key Themes (UKT) 
 
 
Analyst of appendix VA is Arif Jamil
1
 and analyst of appendix VB is Tania S. Bonny.
2
 The goal of 
employing two analysts from two different background is to capture the different ways of interpreting 
the answers. Therefore, in some cases: 
• there were UKT but no UKW 
• there were CKT, but no CKW 
• there were CKW, but no CKT 
• there were neither CKW, nor CKT, etc. 
 
Observations from both the analysts (developed in two separate appendices) were used to formulate 
“Common Key Themes (both analyst)” and “Unique Key Themes (one analyst)” which resulted to 
“Major Key Themes” and helped develop its interpretation. 
 
Some of the words/phrases used/mentioned within quotation in the major key themes and their 
interpretations are the exact words/phrases used by the respondents.  
 
 
1. Do you bear any negative impression / any prejudice about human stem cell research? 
 
T12: “No, even if “stem cell” is a very broad concept, I think that they represent a very promising 
therapeutic approach.” 
Common Key Words (CKW): “even if”; “broad concept”; “promising”; “therapeutic”. 
Common Key Themes (both analyst): Promising area for therapy. Application oriented approach; 
HSCR invokes differing opinions.  
Unique Key Words (UKW): “stem cell” is a very broad concept. 
Unique Key Themes (one analyst (Tania)): Stem cell is a very broad concept (encompasses different 
components and associated ambiguity). 
T20: “Yes, because to obtain those cell, we must sacrifice with embryo. But, if those research use any 
method except killing human embryo so there is no problem.” 
                                                          
1
 Ph.D. Research Fellow (2012-2015) in Bioethics and Biolaw, Erasmus Mundus Joint International Doctoral Degree in 
Law, Science and Technology (LAST-JD); LL.M. in IP. 
2
 Ph.D. Research Fellow (2013 – Onward), Dept. of Environmental & Global Health, University of Florida, USA; Lecturer, 
Dept. of Microbiology, University of Dhaka, Bangladesh; M.Sc. in Microbiology. 
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CKW: “sacrifice with embryo”, “any method except killing human embryo there is no problem”. 
Common Key Themes (both analyst): Against any stem cell research that involves destruction of 
human embryo. No objection if the research involves other methods than destruction of human embryo. 
UKW: “killing human embryo”. 
Unique Key Themes (one analyst (AJ)): She expressed the process of “destruction” of embryo as 
„killing.” 
T21: “No, I consider it as any type of scientific research.” 
CKW: “any type of scientific research”. 
Common Key Themes (both analyst): Human stem cell research is just like any other type of 
scientific research.  
T24: “Yes, to me it does not matter that-, for example, the embryos are produced in vitro – the bottom 
line is that an embryo is a living entity.” 
CKW: “embryo is a living entity”. 
Common Key Themes (both analyst): Considers embryo as a living entity and he is against using 
embryo in research.  
UKW: “Yes”.  
Unique Key Themes (one analyst (AJ)): The respondent is prejudiced about hSCR research.  
T26: “It depends on the type of stem cells used in the research. Somatic adult stem cell research as 
such generally raise no significant ethical or legal issue: I support this type of research.  
Embryonic stem cell research is highly controversial from ethical point of view: I am negative about it. 
Legal justification of such research needs some clarifications:  
1) do human embryos possess any legal subjectivity? If no, what is a cogent legal argumentation which 
identify sound conditions for the transformation from res to persona? I am afraid that there are no 
sound explanation regarding the latter question – legislators feel uncomfortable facing that question 
and instead of it they tend to employ language of competing rights/interests.    
2) is such type of research basic or applied science? If it is still a basic science issue, we already have 
several cell lines which can fully satisfy the need of biological material. In that case, it would be kind 
of “legal sacrifice” in favour of science.  From my personal conversations with the researchers 
working in that field (they foresee that practical application could be expected in 30-50 years) I come 
to the conclusion, that this type of research is still a basic science. If it is so, it would be at least 
irresponsible to conduct clinical trials with humans without proper scientific knowledge, or to induce 
women to donate eggs at the expense of their health.” 
CKW: “type of stem cells”, “embryonic stem cell research is controversial”. 
Common Key Themes (both analyst): Supports stem cell research if it uses somatic/ adult stem cell; 
He is against the hESC research for the ethical controversies.  
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UKW: “justification”, “clarification”, “legal subjectivity”, “sound condition”, “transformation from res 
to persona”, “language of competition rights/interests”, “basic or applied science” , “legal sacrifice”, 
“basic science”, “scientific knowledge”, “women to donate eggs”, “expense of their health”. 
Unique Key Themes (one analyst (AJ)): The respondent believes that no sound argumentation exist 
justifying/ illustrating the situation/ claim of the “transformation” of embryo from „object‟ to „person‟. 
He thinks that the Legislators use the “language of competing rights/interests” instead of attending the 
first mentioned situation/question. According to his opinion, the hSCR is still a basic science, therefore, 
it would be “irresponsible act” to conduct clinical trial on humans and “induce” egg donation, “without” 
having “proper scientific knowledge”.  
UKW: “highly controversial from ethical point of view”. 
Unique Key Themes (one analyst (Tania)): He/she thinks some legal justifications of performing 
ESC research require clarifications regarding: a) what status embryo holds as compared to a human b) 
why and in what type of research they are utilized (basic/applied science). The respondent considers 
usage of human embryo in basic science research as irresponsible and calls this action „legal sacrifice‟ 
in favor of science. 
T30: “Yes. I believe that specifically human embryonic stem cell research is politically and ethically 
controversial because it results in the destruction of a possible human life.” 
CKW: “human embryonic stem cell research is politically and ethically controversial”, “destruction of 
a possible human life”. 
Common Key Themes (both analyst): The respondent designates human embryo as a „possible 
human life‟ and considers that hESC research is politically and ethically controversial because it results 
in the destruction of potential human life.  
UKW: “Yes”. 
Unique Key Themes (one analyst (AJ)): The respondent is prejudiced about hSCR. 
Major Key Themes derived from responses to question 1:  
See 3.1.2.6.  
Interpretation of the Major Key Themes derived from responses to question 1:  
See Ch. 5. 
Question 2: How do you perceive the terms ‘embryo’, ‘human body’ and ‘human life’? 
T7: “an embryo does not have rights, given that it is not a human being.” 
Common Key Words (both analyst): “embryo does not have rights, given that, it is not a human 
being”. 
Unique Key Themes (one analyst (AJ)): The respondent did not recognize any right that could be 
distinct to the embryo itself.  
T9: “I think an embryo at its earliest stage has no soul. It just a mass of undifferentiated cells. The is 
nothing “human” about it at this early stage. Whereas a human body and human life includes a soul.” 
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Common Key Words (both analyst): “embryo at earliest stage has no soul”, “mass of 
undifferentiated cells”, “nothing “human” about it at this early stage”, “human body and human life 
includes a soul”. 
Common Key Themes (both analyst): Embryo at its earliest stage is a mass of undifferentiated cells.  
Unique Key Themes (one analyst (Tania)): The respondent considers presence of „soul‟ as a vital 
component of human body and human life. In the absence of „soul‟ at this early stage, there is nothing 
„human‟ about it. 
Unique Key Themes (one analyst (AJ)): The respondent recognized the embryo as a cellular entity  
and recognized some kind of rights that are different from the human being. 
T16: “I think that term “embryo” lacks definition. It is unclear from which stage of development 
fertilized egg is deemed to be an embryo.” 
Common Key Themes (both analyst):  There is no consensus at which moment the growing organism 
shall be termed as “embryo”. In her opinion, a conclusive definition of embryo does not exist. 
UKT: There is absence of preciseness, conclusiveness and consensus on the definition of embryo. 
Common Key Words (both analyst): “embryo lacks definition”, “unclear”, “stage of development”. 
Unique Key Themes (one analyst (AJ)): The respondent highlighted the absence of the consensus on 
the definition of the embryo. From her opinion, it appears that there exists an unspecified/ undefined 
period between the “fertilized egg” and the “embryos”. In her opinion, the embryo deserves a “rights 
and status” different from the human. 
UKT: There exists an unspecified/undefined period between the “fertilized egg” and the “embryos”. 
T22: “I think……human body and life are separate from embryo..” 
CKT: The respondent considered human body, human life and embryo as distinct entities. 
UKW: “separate”. 
UKT: The respondent draws a clear division between “embryo” and “human body and life”. But he 
recognizes that the embryo deserves a distinct right. 
 
T26: “I think they all form a human being. Regarding the extent of the rights there should be a realistic 
approach: in my opinion human embryo should enjoy only those rights which are in his/her interests.” 
CKW: “they all form a human being”, “human embryo should enjoy only those rights which are in 
his/her interests”. 
CKT: The respondent considers embryo, human body and human life as integral parts that collectively 
form a human being. 
UKT (Tania): The respondent considers embryo having a gender. 
UKT (AJ): The respondent shows the “gradualist” approach here. To him they are same entity having 
different rights. His later response reveals that he treats embryo as human being. 
T29: “I think it depends on case and can’t be used as a rule.” 
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CKW: “depends on case”. 
UKT (AJ): The respondent puts emphasis on the context, not on any preconceived notion. He indicates 
the prevalence of the contextually of perception and non-existence of a universality of perception. 
T30: “In my view, human embryo deserves special respect as a potential human being/possible human 
life; I would define it as the early stage of development of a human organism, however, I would not 
give to embryo completely the same moral and legal status as compared to humans, in terms of 
scientific research, abortion, etc.” 
CKW: “special respect”, “potential human”, “early stage of development”. 
CKT: The respondent acknowledged a different and special status of the embryo from the human. She 
thought that the embryo is an organism of the earliest stage of human development. 
UKT (Tania): The respondent considers human embryo as „potential human being/ possible human 
life‟ and thus it deserves „special respect‟. She gives priority to the health, safety & well being of 
human being when it comes to usage of embryo in „scientific research‟ and it‟s destruction in the case 
of „abortion‟. 
UKT (AJ): She also takes a gradualist approach. In her opinion, they (embryo, human body and human 
life) are similar entity but have different rights. 
 
Major Key Themes derived from responses to question 2:  
See 3.1.2.6. 
Interpretation of the Major Key themes derived from responses to question 2:  
See Ch. 5.  
Question 3: How do you see the act of destruction of human embryo for the purpose of research 
and invention/innovation? 
 
T4: “I think unethical but may be allowed in limited and in very serious disorder not as massive 
therapeutic tools…” 
 
CKW: “unethical”, “may be allowed in limited and in very serious disorder”. 
 
UKT (Tania): The respondent finds the application unethical in general. However, he thinks that it is 
acceptable to employ embryo in limited circumstances e.g. the case of very serious disorder and at a 
limited scale. But he does not support using embryo as massive therapeutic tools. 
 
UKT (AJ): Despite considering the embryo destruction unethical supporting the allowing embryo 
research for serious disorder or illness is not a contradictory position, rather a consequentialist/ 
utilitarian approach. He is considering the application in serious illness as more important than the 
sacrifice of ethics, but under special circumstances. To him, embryo and human being/ human body are 
the same things, deserving the same rights. 
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T6: “As always, it is a balance between protecting the rights of the incapacitated embryo/fetus, and the 
value research can bring society and other individuals (originated from fetus’s). But the individual 
rights should have priority.” 
CKW: “balance”, “rights of…embryo”, “value research can bring”, “individual right”. 
UKT (Tania): The respondent thinks that the embryo/fetus is incapacitated but still possesses some 
rights, although not to the same extent and magnitude as that of a fully developed human. He prefers a 
balance of rights and status of the embryo/fetus and the value of research that can benefit individuals 
and society. Still he/she prioritize individual rights, status and well-being over those of the 
embryo/fetus. 
UKT (AJ): The respondent recognizes that the rights of the embryo need to be protected but to him the 
contribution of the research to the society and the individual is more important. The respondent 
demonstrates a mixed response of “pragmatic” and “utilitarian” approach. He stresses that a “balance” 
is required between the conflicting interests of the entities, i.e., the “embryo” (which has the right to be 
protected) and the “society and individual” (who will gain therapeutic benefits from the research). In 
the end, he thinks that the individual should have prior right to materialize the contribution of research 
and scientific experiments. 
T12: “Destruction for research aimed at developing means to cure critical disease should be allowed 
but only on Embryos that are anyway destined for destruction. I don’t think it is ethical or correct to 
generate an in-vitro embryo in order to use it for subsequent researches.” 
CKW: “should be allowed but only on Embryos that are anyway destined for destruction”, “don‟t think 
it is ethical or correct to generate an in-vitro embryo”. 
CKT: The respondent supports only the use embryos in research that are redundant for clinical 
purposes (e.g. IVF). She considers the creation of in-vitro embryo exclusively for research purposes as 
unethical. 
UKT (Tania): She also thinks that the research should be aimed at developing cure for critical diseases. 
UKW (AJ): “Destruction for research”, “developing means to cure critical disease”. 
UKT (AJ): This comment is also a pragmatic and moderate on the ethical perspectives in the debate 
around the embryo destruction for research. However, this approach can be said to be as one that does 
not compare the embryo with human being; rather the rationale or reasonableness of the action is 
viewed from the perspective of proportion and reality. The IVF redundant embryos are destined to be 
destroyed, so the use of those embryos do not create ethical outcry in the mind of the respondent. In the 
US, the IVF redundant embryos are used for hESC research. 
T16: “I think that term “embryo” lacks definition. It is unclear from which stage of development 
fertilized egg is deemed to be an embryo.” 
CKW: “term „embryo‟ lacks definition”. 
CKT: The respondent thinks that the term „embryo‟ lacks definition.  
UKW: “unclear”, “stage of development”. 
UKT (AJ): The respondent highlighted the absence (scientific) of the precise moment when the 
fertilized entity shall be termed as embryo. She holds a pragmatic approach. She emphasized on the 
“stage of development”. 
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T18: “I suggest you to change the term "destruction" for the term "use".” 
CKW: “change the term "destruction" to "use"”. 
UKT (Tania): The word „destruction‟ has a negative connotation.  
UKT (AJ): This ideology of applying the term “use” is focused in the “application” of the embryo. 
Embryo‟s application is predominant in the mind of the respondent, and in that case, destruction of 
embryo would not create a significant ethical outcry for the process of production of the therapy. The 
“destruction” is viewed as “use”, in other words as “application”. He identifies embryo at early stage as 
a “biological material of human origin” and as a different component from the human being or human 
body.  For him, “there is nothing unethical about its use.” His suggestions for the replacement of the 
term “destruction” with the word “use” may have been intended to create a positive image of hSCR. 
T21: “This question has put me in a dilemma, my religious doesn’t allow killing embryo in general but 
GOD allows research and I think according to that I can consider the necessity of the destruction of 
embryo i.e. is the destruction of the embryo a must to study a certain disease as to decide the method of 
treatment or the drugs have to be used to save others life or for any research purposes, may be my 
religion allows that (I’m not a religious scholar but if I’m the one who will do a research on embryo, 
I’ll ask a religious man first). However, for me I don’t consider it as a non-ethical situation as I 
measure it the same as clinical tests that may involve giving a patient a toxic or carcinogenic drug that 
may lead to his death, if I’m sure of its lethal or carcinogenic effect.” 
CKW: “dilemma”, “God”, “save others life”. 
CKT: The respondent has religious convictions. 
UKW (Tania): “I‟m one who will do a research on embryo”. 
UKT (Tania): The respondent‟s scientific decision is guided by her religious views. She seems to be 
contradicting herself though. She does not find it unethical when she is not practicing it herself; she 
compares embryo destruction for research purposes to clinical trials of therapeutic drugs. But if she is 
the one employing embryo for research purposes, she is undecided and needs religious support. 
UKW (AJ): “measure”. 
UKT (AJ): There is a contradiction in perceiving the religious sense in the context of embryo 
destruction. In the end, the respondent is relying on the benefits, losses and application of the actions, 
which is a consequentialist approach. The respondent treats „embryo‟ as equal entity as „human being‟ 
but is willing to allow the destruction for finding cure to life saving treatments, because in her thoughts 
finding cure is more important than the embryo sacrifice. She is application oriented. Therefore, 
according to this approach, embryos are “human” but the destruction as an action is ethical if the future 
benefits are considered. 
T22: “There is no need for the destruction of the embryo because now people can harvest stem cells 
from cord blood-this a major misconception of the public.” 
CKW: “no need for the destruction of the embryo”, “harvest stem cells from cord blood”.  
CKT: The respondent thinks that “cord blood” will substitute the need of embryo for the stem cell 
research. The respondent thinks that alternative sources are available; hence, there is no need of use of 
human embryo for research. The respondent considers embryo destruction is not required because his 
perception is that cord blood cells can provide the same types of stem cells. 
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T30: “My answer is (c), however, with the certain conditions fulfilled like good scientific reason, 
informed consent from couples donating human embryos for research and careful research 
monitoring.” 
CKW: : “conditions”, “good scientific reason”, “informed consent”, “research monitoring”. 
CKT: The respondent supports destruction of embryo for research purpose in an attempt to developing 
cure for critical diseases but this action must pass through certain ethical barriers. She considers that 
fulfilling certain conditions like good scientific reason, informed consent from embryo donors and 
careful monitoring are critical. She is pragmatic too. 
Major Key Themes derived from responses to question 3:  
 
See Ch. 3.1.2.2.  
 
Interpretation of the Major Key Themes derived from responses to question 3:  
See Ch. 5. 
 
4. Do you have experience of dealing with a situation when conventional medication or treatment 
could not help? 
 
T6: “As a medical professionals, you always at some point in time experience non-efficient medical 
treatment – this is just part of the trade (the variance of biological systems in individuals).” 
CKT: The respondent being a medical professional has the experience of limitation of the conventional 
medication or treatment and admits the inadequacy of medical treatment at some point.  
CKW: “variance of biological systems in individuals”. 
UKW (AJ): “medical professional”. 
UKT (AJ): His reference of the differences and uniqueness of the individual‟s “biological system” 
points towards the necessity of personalized medicine/treatment. 
UKW (Tania): “non-efficient medical treatment”, “just part of the trade”. 
UKT (Tania): He considers that effectiveness of a particular medical treatment is highly subjective 
due to variability in the biological systems in individuals. 
 
T9: “Metaphysical science has a different approach where biological science fails.” 
CKW: “Metaphysical science”, “different approach”. 
CKT: Alternative approaches may exist; existence of limitation in the conventional approach of 
treatment taken in the biological science. 
UKT (AJ): The respondent refers to alternative methods of treatment and care. In his mind, 
Metaphysical Science offers some solutions to the questions that cannot be solved through the 
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biological science. His observation can be interpreted to mean that alternative approaches may exist, 
when the limitation in the conventional approach of treatment taken in the biological science is obvious.   
UKW (Tania): “biological science fails”. 
UKT (Tania): The respondent has experience dealing with medication failure in others. He thinks 
treatment based on biological science is often inadequate where metaphysical science may prove 
effective. 
 
Major Key Themes derived from responses to question 4:  
See Ch. 3.3.3.  
 
Interpretation of the Major Key Themes derived from responses to question 4:  
See Ch. 5. 
 
5. Having a choice and at a critical stage of grave illness would you choose stem cell therapy for 
your family member, if it promises a cure (suppose already available as treatment)? 
 
T4: “Yes. Not worried about cost…but better if help comes from any source.” 
CKW: “Not worried about cost”, “any source”. 
CKT: The respondent is willing to bear the cost but prefers if the expense is covered by any source. 
 
T6: “PS: I think you need to divide the decision to accept of stem cell therapy vs. the decision of 
payment system (Denmark: socialized medicine through state; US: insurance and personal expenses).” 
UKW (AJ): “decision to accept of stem cell therapy”, “decision of payment system”. 
UKT: Respondent thinks that the decision to accept the stem cell therapy and the source that would 
meet the expenses of the therapy are separate issues. 
UKT (Tania): The respondent thinks that opting for stem cell therapy and the type of payment of 
system should be independent choices. 
 
T10: “No. (The majority of stem cell treatments being marketed today have no real basis in scientific 
evidence. There is no reason to expect that they work until adequate studies have been done.)” 
CKW: “real basis in scientific evidence”, “until adequate studies”. 
UKT (Tania): The respondent considers that the majority of stem cell based therapy being marketed 
has no scientific evidence to be effective. 
UKT (AJ): His rejection is subject to proof of the efficacy of the treatment. 
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T13: “Yes and it would be good if the State provides the expenses, also considering that the State has 
to control such kind of treatment.” 
UKW (AJ): “State provides the expenses”, “State has to control such kind of treatment”. 
UKT (AJ): The respondent will opt for stem cell treatment but he expects that they are regulated by the 
State and the expenses are provided by the State too. 
 
T17: “Yes (If you want to mention a reason or circumstances other than mentioned already, you may 
write here)……………..Basically, all of the above: Yes. It would be good if the State provides the 
expenses or the insurance covers it; but if it doesn’t cover them entirely or partially, then I would be 
willing to take it at personal expenses too, provided that I expect the costs of the treatment are 
reasonable.” 
CKW: “State provides the expenses or the insurance covers it”, “willing to take it at personal expenses 
too”. 
CKT: The respondent will choose stem cell treatments at personal expenses or financed through any 
source. 
UKW (AJ): “I expect the costs of the treatment are reasonable”. 
UKT (AJ): Although willing to take the therapy at personal expense, she expects that the costs of the 
treatment are reasonable. 
 
T19: “Either a, b or c, depending of the health system in the country.” 
CKW: “State provides the expenses”, “the insurance covers it”, “willing to take it at personal expenses 
too”, “I expect the costs of the treatment are reasonable”, “depending of the health system in the 
country”. 
CKT: The respondent will choose stem cell therapy and the way the expense will be covered will 
depend on the particular health system in a country. 
T 26: “Yes if it has already shown preliminary proved effect and relevant efficacy data is published in 
peer-reviewed journals.” 
UKW (AJ): “proved effect”, “published in peer-reviewed journals”. 
UKT (AJ): The respondent is willing to take the therapy, if the safety and efficacy of the therapy is 
proven and published in “peer-reviewed journals”. He refrained from speaking about the expenses of 
the therapy. 
 
Major Key Themes derived from responses to question 5:  
See Ch. 3.4. 
Interpretation of the Major Key Themes derived from responses to question 5:  
See Ch. 5.  
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6. Do you think patent protection as it exists today is the best way to provide incentive to human 
stem cell based inventions/innovations? 
T7: “Yes. If biotech is involved in any way, patent rights alone may not be sufficient for adequate 
protection; I would propose the inclusion of ad hoc data exclusivity rights for biotech 
products/treatments.  Regarding question 8, I would say that patent protection may not be suitable, 
however, the term of protection is indeed adequate, therefore, regulatory protection running on par 
with the patent term of 20 years would be the best option, going further than 20 years may cause 
market disruptions and would complicate access to medicines and treatment for less developed markets 
or people.” 
CKW: “patent rights alone may not be sufficient for adequate protection”, “inclusion of ad hoc data 
exclusivity rights”. 
CKT: The respondent thinks that existing patent protection may not be sufficient for adequate 
protection if stem cell inventions are commercialized as biotechnology products. In that case, he 
proposes the inclusion of “ad hoc data exclusivity rights” for biotech products. He is in favor of 
stronger IP rights.  
UKW (Tania): Term of protection is adequate, market disruptions and complicate access to medicines 
and treatment, less developed markets or people. 
UKT (Tania): However, he supports the existing term of protection for 20 years; going further than 
this would affect access to therapy for the patients in less developed countries. 
T9: “To say it’s an invention or innovations or discovery in life science is totally inappropriate since 
life is already in existence. It is more appropriate to say realization and thus understanding and usage 
of the knowledge of this realization and understanding to better understand life science. Therefore how 
can any person claim patent protection on something which is already in existence.” 
CKW: “inappropriate”, “realization and understanding”, “life is already in existence”. 
CKT: The respondent does not support the patent protection of inventions derived from living entities. 
Whatever has life cannot be patented; we can only understand and gather knowledge from it. The 
respondent finds patent protection as misfit for the inventions in life science. 
T12: “No, because patent has embarked into too much complications and uncertainty of enforcement. 
Especially in the field of hESCs, there are too many morality issues (see Brüstle legal battle). 
Litigations and oppositions are more and more frequent.” 
CKW: “complications and uncertainty of enforcement”, “morality issues”, “litigations and 
oppositions”. 
CKT: The respondent considers that hESCs research has several ethical constraints. Litigations and 
oppositions are becoming more commonplace which makes it more difficult to protect these inventions. 
UKT (AJ): She is suggesting a simpler IPR protection framework than patent. 
T21: “I think incentives can be ethical only (protecting the moral rights of the inventor) but not for 
commercialization purposes.” 
CKW: “protecting the moral rights”, “not for commercialization”. 
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CKT: She supported IP protection in the form of “moral rights” only aka., right of recognition and 
integrity.  
UKT (AJ): The respondent does not support the commercial feature of the IPR for life science 
inventions/innovations. 
T22: “Yes. Patents are finite in their length of time, most researchers discover things because of 
curiosity, and that is reduced by lawyers to something that can be owned or not, irrespective of the 
value of science in general or the altruism of people wanting to make a better world.  This is something 
that lawyers and doctors seldom understand because they are motivated in the United States purely by 
profits.” 
CKW: “researchers discover things because of curiosity”. 
UKW (Tania): “irrespective of the value of science in general or the altruism”. 
UKT (Tania): The respondent seems to believe that most researchers are driven purely by curiosity 
and altruism and not by financial incentives that are gained as a result of patent rights.  
UKW (AJ): “lawyers and doctors seldom understand”. 
UKT (AJ): The respondent thinks that patent protection is ok in general (particularly it is fixed in the 
term of protection). He thinks that the stakeholders (doctors and lawyers) need to understand the noble 
purpose behind the innovation.  
T26: “I am not sure that patent protection in current shape is the best for inventions/innovations in life 
sciences – many concepts applied come from traditional fields of patent law, e.g. Chemistry inventions, 
which are little adaptable to inventions involving living organisms and thus may even have adverse 
social effect: consider recent Myriad case. If patent protects process inventions, I can’t oppose them. 
However, I feel difficult in terms of novelty or inventive step to accept patenting of new therapeutic 
indications of the same technology.” 
CKW: “little adaptable to inventions involving living organisms”, “process inventions”, “novelty or 
inventive step”, “new therapeutic indications of the same technology”. 
UKT (AJ): The respondent is skeptical about the appropriateness of the patent system for life sciences 
but he did not say “no” to patent. The respondent also see it (patent) slightly misfit for protecting the 
living organism and raises concern regarding the possible adverse social effects. He has discontent 
about the examination of “novelty and inventive step” requirements of some of the patents. With 
changes of time, how patent is adaptable to newer inventions in life science is his question. He does not 
accept evergreening of patent, i.e., taking new patent for already known technology (for example, 
second medical application of known drugs). 
UKT (Tania): The respondent is not sure if existing patent protection are appropriate and sufficient in 
the case of protecting new therapeutic products as an invention/innovation in life sciences. Traditional 
fields of patent law are hardly adaptable to inventions involving livings organisms and may create 
complicacy in enforcement. He/she, however, finds the existing framework okay in case of process 
patent. 
T30: “I am not sure, since early patenting is not only the incentive for companies to invest in research 
and development, but it also poses obstacles to collaboration and openness in research.” 
CKW: “incentive”, “obstacles”. 
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CKT: To her, patent has two implications: 1. it‟s an incentive for research and development, and 2. it‟s 
a barrier for further research in connected fields of knowledge (limits the parallel and downstream 
research freedom). 
 
Major Key Themes derived from responses to question 6:  
See Ch. 4.4. 
 
Interpretation of the Major Key Themes derived from responses to question 6:  
See Ch. 5. 
 
7. Do you think that a new protection mechanism/framework can be / should be developed within 
the purview of intellectual property law (IPR), separate from patent, for the 
inventions/innovations that use biological materials of human origin and targeted to health care? 
T9: “No, Intellectual property law should be used to protect new creations. Life science is NOT a new 
creation.” 
CKW: “Intellectual property”, “should be used to protect new creations”, “Life science is NOT a new 
creation”. 
CKT: The respondent does not believe that a new creation can be made within the realm of life science. 
As he/she considers that IPR should be used to protect only new creations, human stem cell based 
inventions/innovations cannot be patented. The respondent is against the IPR protection of the life 
science innovations. 
T10: “I think that health care in general has been transformed, excessively and to the detriment of 
patients, into a business. People working in health care should have other priorities than making 
money.” 
CKW: “health care”, “transformed”, “into a business”. 
CKT: Respondent does not support patent for many reasons. 
UKW (Tania): “should have other priorities than making money”. 
UKT (Tania): He thinks that the various stakeholders of health care should be more pro-people, 
focusing more on how to provide affordable care and therapy to people rather than emphasizing on 
gaining financial incentives derived from patented technology. 
UKT (AJ): He is in favor of reduced commercialization in health care sector, in general. The 
respondent is indifferent about a new protection framework, although thinks that patent in its current 
condition is not the best for providing incentive for hSCI. Therefore, be it a new protection framework, 
or existing patent, reduced commercialization is what the respondent expects as modification in the 
current IPR framework. 
T21: “No, I think no need to change the matter from research and development to protection which 
will be business and commercialization as this has to be done for the humanity and governments can 
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fund this. I think here we need moral rights more that economical right (I mean to be protected as in 
copyright for the ethical concerns only).” 
CKW: “humanity and governments can fund”, “moral rights”. 
CKT: She does not support any protection framework that will have a commercial feature. In her 
opinion, the source of funding for research is the government‟s money. She thinks research targeted to 
healthcare is done for humanity. She will recognize the inventor but will not support the commercial 
features of the IPR or patent. 
T22: “I am not sure.” 
CKW: “not sure”. 
CKT: The respondent is not sure if a new protection framework can be/should be developed. 
 
Major Key Themes derived from responses to question 7: 
See Ch. 4.4. 
Interpretation of the Major Key Themes derived from responses to question 7:  
See Ch. 5. 
 
8. How many years of protection (term of protection for commercial exploitation) is appropriate 
for human stem cell based inventions/innovations? 
 
T12: “20 years or more, like pharmaceuticals this kind of inventions need to go through regulatory 
approvals.” 
CKW: “regulatory approvals”. 
CKT: The respondent believes that 20 or more than 20 years is appropriate. 
UKT (AJ): She indicates that the time spent in regulatory approval, if deducted from the term of 
protection, the IPR owner does not get enough time to exploit the invention commercially in the market. 
She does not support patent for the complications around its legal and ethical issues and she supports a 
new framework, but she suggests a longer term of protection. 
UKT (Tania): The commercialization of these types of inventions/innovations should undergo similar 
type of scrutiny and obtain regulatory approvals to that of other pharmaceutical drugs. 
T19: “20 years, just because is the current protection period for patents.” 
CKW: “current protection”. 
UKT (AJ): The respondents finds the current patent system is sufficient and so she suggested 20 years 
of protection. 
Major Key Themes derived from responses to question 8: 
197 
 
See Ch. 4.4.2. 
Interpretation of the Major Key Themes derived from responses to question 8: 
See Ch. 5. 
 
9. Which application of human embryo can be permitted according to your opinion? 
T4: “Only for therapeutic purpose + research purposes.” 
CKW: “therapeutic purpose”, “research purposes”. 
CKT: He will allow a very limited use of human embryo for research and innovation in cases of 
serious disorder, not for large scale commercial and industrial application (will allow limited 
therapeutic application). 
T10: “Academic/NPO/government development of therapeutics.” 
CKW: “Academic/NPO/government”. 
CKT:  Academic/NPO/government development of therapeutics. 
UKT (Tania): The respondent supports development of therapeutics when they are conducted by 
Academic/NPO/government and not by commercial for-profit organizations. 
UKT (AJ): The respondent also supported (suggested) development of therapeutics by using human 
embryo, when they are conducted by Academic/NPO/Government. 
T12: “For both the above provided that are only used Embryos that are anyway destined for 
destruction.” 
CKW: “only used Embryos that are anyway destined for destruction”. 
CKT: The respondent supports both forms of application but only employing redundant embryos that 
are anyway destined for destruction, which indicates he/she does not support in vitro development of 
embryo and its deliberate destruction for the purpose of research and therapy.  
T18: “I suggest you to complete the answer option (b) with "For research purposes and treatments to 
third persons".” 
CKW: “For research purposes and treatments to third persons”. 
UKT (Tania): The respondent seems to advocate for application of human embryo in research and to 
derive customized therapy for specific group of ill patients requiring the therapy. 
UKT (AJ): The respondent does not support the commercial and industrial application of the human 
embryo. He is against the propertization of IPR by patent. So he is inclined to allow the application of 
human embryo for research targeted to find cure or drug development but not through commercial 
channels. 
T21: “I think that the protection to be moral only (i.e. the discoverer must have been noticed as the 
discoverer for that new drug) as an ethical incentive to him.” 
CKW: “moral only”. 
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UKT (AJ): She is neither allowing the typical applications of the human embryo and nor suggesting 
any new. She only reiterated that she will recognize the inventor‟s name but with no commercial right 
attached to it. 
T22: “Human embryos are not necessary for stem cells, cord blood can be used to generate any kind 
of stem cells- this is a reductionist 1990s approach to asking about stem cell research.  This will affect 
the way people feel about research, I think it is silly to use an embryo when you do not have to.  Many 
people who think that embryos should not be used would agree to use cord blood.” 
CKW: “cord blood”. 
CKT: The respondents believes that human embryo and cord blood are equivalent sources of any type 
of stem cells and hence there is no need to use embryo, in addition people who might object to 
application of embryo might not do so if the research involves cord blood instead of human embryo. He 
presumes that cord blood would invoke less or no ethical concern as opposed to using human embryo. 
He suggested to conduct stem cell research by using the cord blood, instead of human embryo. 
Major Key Themes derived from responses to question 9: 
See Ch. 3.1.2.6. 
 
Interpretation of the Major Key Themes derived from responses to question 9: 
See Ch. 5. 
 
10. Who, according to your opinion, should be entitled to the intellectual property rights (IPR) 
of human stem cell based inventions/innovations? 
 
T6: “(c) + Regarding stem cell inventions, I don’t see any different views when it comes down to 
ownership rights to an invention, and the related contract law (vis-à-vis an employer or contracted 
consultant).” 
CKW: “ownership rights,” “contract law”. 
UKT (AJ): Given the fact that the respondent finds the current patent system adequate to offer 
incentives for hSCI, his response to this question is a consistent reaction. He supports the present way 
of owning the IPR, particularly patent. (In employer and employee setting, the owning of the patent by 
the employer organization/ university as “assignee” and taking the recognition of invention as 
“inventor” by the scientists, is a common practice and it depends on the contract between the employer 
and the employee. In some cases, the inventor is also seen as the assignee with the employer). Given 
the fact that the “assignee” is the owner of the patent and is entitled to the right to commercial 
exploitation, the respondent asserts the contractual arrangement as determining factor, i.e., who will 
own the IPR. 
T11: “I am a bit unsure on this, but when I read a book about Henrietta Lacks, I was empathic on her 
situation and I believed that at least she should have received money for the use of her cells.” 
CKW: “Henrietta Lacks,”  “at least,” “money,” “use of her cells”. 
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CKT: She believes that a person who donates his/her stem cell for research purpose may be entitled to 
some rights or at least should be financially compensated to some extent. The respondent thinks that 
the donor of cell line, if not included as the owner of IPR of the inventions from his/her biological 
sample, should receive a compensation.  
UKT (AJ): The respondent is mentioning about a “just” compensation for commercially developing an 
invention from the samples of a research subject. 
T18: “I suggest you to complete the answer option (a) with "Scientist / Inventor and patients.” 
CKW: “Scientist/Inventor and patients”. 
CKT: The respondent supports that both scientist/inventor and patients should be entitled to the 
intellectual property rights (IPR) of human stem cell based inventions/innovations 
UKT (AJ): The respondent in his response to this questionnaire, does not support the current patent 
system for its propertization and commercialization aspect, endorses “no protection” as term of 
protection for commercial exploitation and finally endows the entitlement of the IPR to scientists, 
inventor and patients. Since he is not in favor of commercialization and propertisation, the recognition 
of the ownership in his sense seems to me a “moral right”, not an economic right (as the moral right is 
only limited to the recognition, not extended to the commercial exploitation). The respondent here 
considers the philanthropic aspects, rather than the conventional reality of the drug development and 
behavior of the market.   
T21: “The scientist is the owner of the moral right with the funding organization that funds the 
research expenses.” 
CKW: “scientist,”  “moral right,” “funding organization,” “research expenses”. 
CKT: The respondent considers the scientist as entitled to the moral right of invention along with the 
funding organization that supports the research. 
T22: “comments on option (b): Definitely not these vampires who capitalize on the work of the 
researcher and contribute zero intellectual thought-merely facilities for which they are paid by the 
grant!” 
CKW: “these,” “contribute zero,” “facilities,” “grant”. 
UKT (Tania): The respondent seems extremely frustrated on the educational/research organizations 
where scientists strive to bring in governmental or nongovernmental funds in order to support research. 
His response clearly points to the extreme competition for securing funds and associated funding crisis 
in the US research institutions. A big proportion of this fund secured by an inventor is mandated to 
flow into the research institutions he/she is affiliated to, which is usually termed as Indirect Cost 
(IDC)(also known as Facilities or administrative rates). The university spends this amount to provide 
the administrative and infrastructural support to the inventors and academics. For example the current 
IDC rate of federally secured grant is 50% for conducting on-campus research at the University of 
Florida (source: http://research.ufl.edu/faculty-and-staff/proposal-development-submission/budgeting-
information/fa-rates-idc.html). What it means is that 50% of the grant money brought in by an 
academic through fierce competition goes to the University by default, he/she has to plan the research 
based on the rest 50% of fund). This mandate is a serious pressure for an inventor trying to secure 
enough funds to carry out research in a timely manner and making due progress. But when a patent is 
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granted, it often includes both the scientist and the university as the assignee. The respondent does not 
support this current practice of ownership for the above mentioned reason, mostly prevalent in the US. 
UKT (AJ): The respondent will award the IPR to the inventor/ scientist only. Additionally he thinks 
that the employer organization/ university makes no intellectual contribution to the hSCI and most of 
their expenses are covered by “grants”. Merely for the facilities they provide to the researchers, they 
should not be awarded with the IPR of the hSCI. 
T26: “If a process invention was financed by public funds it would be reasonable to consider: a) joint 
(scientist/inventor and public) entitlement, b) the sponsor (public) of the research is free to transfer 
them to public domain” 
CKW: “financed by public funds,” “scientist/inventor and public,” “public domain”. 
UKT (AJ): The respondent see public as entitled to the IPR along with the scientist/ inventor, if the 
research is “financed by public funds.” And eventually the invention should be in the public domain as 
the financing for the research was done with public money, according to his suggestion. In his approach, 
the respondent did not consider the private funding and investment in biomedical research. His 
response to this question is subject to the funding sources (if public funding is the source of research, 
then the entitlement should be this way). 
 
Major Key Themes derived from responses to question 10: 
See Ch. 4.4.1. 
 
Interpretation of the Major Key Themes derived from responses to question 10: 
See Ch. 5. 
 
11. Do you consider that the benefits of hESC (human Embryonic Stem Cell) research is more 
important than the risks and costs associated to it? 
T2: “Yes, It can be proven beneficial in curing diseases.”  
UKW (Tania): “Proven, beneficial in curing”. 
UKT (Tania): The respondent has the conviction that human embryonic stem cell research is 
promising and can lead to developing effective cure of many diseases. 
UKW (AJ): “beneficial,” “curing diseases”.  
UKT (AJ): She puts more emphasis on future therapeutic benefits.  
T5: “Yes, because it holds promise in curing many debilitating diseases and health complications. This 
sector also opens up option of customized treatment for very rare diseases with low frequency among 
population (who are capable of paying for the research and treatment).” 
CKW: “promise,” “diseases,” “customized treatment,” “rare diseases”. 
CKT: The respondent believes that the benefits of human embryonic stem cell research outweigh the 
risks and cost associated with it, as this type of research has practical application in curing many 
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diseases which currently has no cure. Again they also seem promising for rare diseases where a group 
of afflicted patients can afford to pay for the research and therapy. The respondent favors the hESC 
research for the future therapeutic benefits and adds to this discussion its potential application in 
personalized medicine and rare diseases.  
T7: “Yes. I do not really notice any risks regarding its research, as for costs, I agree as long as 
economic and viability studies are made, if government money is being spent on the research.” 
CKW: “economic and viability studies,” “government money”. 
UKW (Tania): “not really notice any risks regarding its research ”. 
CKT: The respondent does not notice any inherent risk of stem cell research employing human embryo. 
However, when it comes to cost, he/she emphasizes on conducting economic and viability studies 
making sure that government money (i.e. public resources) spent is well justified and brings out fruitful 
outcome. 
T9: “Yes, The benefits of hESC research out weights the risk and costs associated to it many folds. 
hESC are non specialize and pluripotent thus being able to differentiate into almost any type of cells. 
This provides great potentials in medical treatments of wide conditions. Thus indirectly reducing risks 
and costs in other medical researches using different approaches. Finally reducing time and costs in 
other life science researches.” 
CKW: “potentials in medical treatments,” “reducing risks and costs in other medical researches”. 
CKT: The respondent believes that the non specialized and pluripotent nature of hESC make them an 
excellent candidate for potential therapeutic interventions on wide conditions. The benefits outweigh 
the risk and costs in hESC research as well as contemporary medical research applying other 
techniques and thus reducing time and costs of other life science researchers. 
T12: “Yes. But if controlled by and subject to a strict and harmonized regulation”. 
CKW: “strict and harmonized regulation.” 
CKT: The respondent considers that the benefits would be more than the risks and cost associated with 
it only if this type of research undergoes strict and harmonized regulation as to how these studies are 
conducted employing hESC. 
T17: “Yes. Mostly because the benefit will provide extension of those who are already living”. 
CKW: “extension,” “already living”. 
CKT: The respondent considers that this type of research is beneficial mostly because of effective 
therapeutic interventions obtained down the road which help to prolong the life of those “who are 
already living.” She indicates that the advantage may contribute the increase of life expectancy. 
T21: “As any type of scientific research I see it is so important even if I’m going to damage something 
in my research trip as to get more benefit for the society, life in future and public health.” 
CKW: “scientific research,” “benefit for the society,” “public health”. 
CKT: The respondent believes that there are inherent risks and variable amount of costs associated 
with every kind of medical research and hESC research is no exception. If risking the embryo serves to 
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invent a useful therapy that can benefit human life, health and the overall society, the respondent thinks 
it is important to do so. 
T22: “No, Again, cord blood is OK, embryonic stem cell research is not necessary at all.” 
CKW: “cord blood,” “embryonic stem cell research not necessary”. 
CKT: The respondent considers stem cells derived from cord blood are equivalent in function and 
potency to that of hESC and there is absolutely no need to employ human embryo in this type of 
research. 
T24: “No, I am not in favour of stem cell research that deals with human embryos” 
CTW: “not in favour of stem cell research that deals with human embryos”. 
CKT: The respondent does not support any kind of stem cell research that involves destroying or 
putting the human embryo at risk. He seems to acknowledge the dignity and rights of human embryo in 
parallel to a fully developed human being. 
T26: “Again, I would like to emphasize the nature of the research (basic/applied). If we do not have 
sound data from basic science, any applied research which strives for potential cures of Alzheimer’s, 
Parkinson’s and whatever other diseases is irresponsible.” 
CKW: “basic/applied” “sound data”. 
CKT: The respondent thinks that the results of basic science should be promising enough to warrant 
further applied research. He considers hESC as an applied research employing human embryo without 
having solid and convincing basic science research data. Therefore, he deems employing hESC as 
potential cures of Alzheimer‟s, Parkinson‟s and other diseases as irresponsible. 
T29: “Yes and No. It depends on price and time factor.” 
CKW: “depends on price and time”. 
UKT (Tania): The respondent believes the benefits of hESC are contingent upon costs associated with 
research and affordability of the final therapy as well as the time required to bring the research outcome 
from laboratory to the clinic. 
UKT (AJ): The respondent see this question as something the answer of which depends on the 
individual case and circumstances. He saw the risk and benefit of hESC research from the economic 
point of view. 
T30: “I consider the benefits of hESC research important, however it is hard to unequivocally 
determine the general risk-benefit ratio and the possible consequences of hESC research without 
discussing concrete scientific cases.” 
CKW: “risk-benefit ratio,” “concrete scientific cases”. 
CKT: Although the respondent considers hESC research as important but he/she has reservation to 
generalize the risks, benefits and possible consequences of every hESC research but instead believes 
each scientific cases would vary considerably on these parameters and deserves special scrutiny to 
determine the individual risk and benefit. The respondent reminds that the answer of this question 
depends on the „context‟ and circumstances of each case; there is no universal approach to this issue. 
Major Key Themes derived from responses to question 11: 
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See Ch. 3.1.2.6. 
Interpretation of the Major Key Themes derived from responses to question 11: 
See Ch. 5. 
 
12. Do you think legal obligation for issuing ‘licenses on easy terms’ or ‘compulsory licenses’ 
and ‘technology transfer’ can bring benefit to the patients by ensuring availability of medication/ 
treatment at a reduced cost and may also serve as incentive for the IPR right owner of human 
stem cell based inventions/innovations at the same time? 
T7: “No + Perhaps in another country, but as for Mexico, the huge amounts of money being spent in 
political campaigns, useless programs and corruption simply invalidate the argument that patented 
drugs or treatments are too costly for the government to step in and subsidize the costs.” 
CKW: “political campaigns,” “corruption,” “invalidate the argument”. 
UKW (AJ) : “another country”. 
CKT: The respondent raises the issue of the context of the country. He made reference of Mexico and 
raised the issues of waste of resources in corruption and unnecessary programs. He thinks that the high 
price of drugs may have been used just as an excuse to blame the patent for contributing to high costs. 
The respondents considers that issuing legal obligation in Mexico will not serve useful purpose because 
according to him public resources are wasted in various ways rather than being utilized for projects 
beneficial for the common people. He finds the cost of the drugs as not a valid argument for the 
government not being able to subsidize the costs. The respondent considers that transparency and 
proper utilization of public resources are keys to realizing these goals in Mexico instead of issuing any 
forms of legal obligation. He, however, thinks that these measures may be beneficial for other countries 
with different context. 
T9: “Scientists’ researches should not be restricted by legal obligations. Scientists are   obligated to 
Humanity. Researches are conducted to better understand life science processes and to apply their 
understanding for the betterment of Humanity.” 
CKW: “obligated to Humanity,” “understand life science processes”. 
UKT (AJ): The response can be summarized as follows:  
• hSCI/life science inventions are not new and should not be IPR protected; and therefore, 
• there should be no obligation is conducting the life science research. 
 
T10: “I think the entire system of restricting access to medical innovations based on IP rights is 
fundamentally flawed.” 
CKW: “system of restricting access,” “flawed”. 
UKT (Tania): The respondent does not support the protection of IPR for medical innovations because 
he/she considers that access to therapies/products borne out of medical innovations should not remain 
restricted but rather be made available to everyone. 
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UKT (AJ): The respondent indicates that there is need to make improvement in the IPR mechanism in 
order to facilitate access to the medication. It appears that he finds that there are some impediments 
caused by IPR in accessing the medical innovations and there are “flawed” systems in place, when it 
comes to inter-relations between the IPR and access to medications. 
T21: “I agree with the research using embryonic cell destruction as to find a drug from chemical or 
synthetic origin but I don’t agree on making drug products from embryonic cell because that means the 
embryos will be attacked for commercial purposes.” 
CKW: “drug from chemical or synthetic origin,” “commercial purposes”. 
CKT: The respondent supports use and destruction of embryo only to find a drug downstream of the 
research that will be exclusively of chemical or synthetic origin. She does not support directly utilizing 
cell components of embryo in preparing the drugs since that would encourage large scale embryo 
destruction for commercial production of therapy. 
T26: “I am not sure that there should be considered an “obligation” on patent holder – I would rather 
remain on the “faculty” of public authorities to choose compulsory license. May be in the latter case 
the list of conditions for that should be more sophisticated and flexible” 
CKW: “public authorities,” “sophisticated and flexible”. 
CKT: The respondent does not support mandating or imposing legal obligations on patent holder, 
rather he believes that public authorities should be judicious on enforcing it where appropriate based on 
sophisticated and flexible conditions.  
 
Major Key Themes derived from responses to question 12: 
See Ch. 3.4. 
 
Interpretation of the Major Key Themes derived from responses to question 12: 
See Ch. 5. 
 
13. Do you think public opinion should be sought and be given importance after the 
invention/innovation is put to the market for commercial exploitation, in order to measure the 
impacts of the IPR protected invention/innovation on the health care receiver? 
T9: “I think it is pointless for seeking public opinion when the public in general is not well informed to 
return a qualify or quantifiable opinion.” 
CKW: “not well informed”. 
CKT: The respondent considers that the public in general are not informed enough to give valuable 
feedback on the post marketing impacts of IPR protected invention/innovation. The respondent raises 
the issue of dissemination and availability of information to the public. He doubts that, as the public is 
“not well informed”, they are not likely to make solid contribution through their responses. 
UKT (Tania): He thinks that a common people cannot give constructive comment, opinion or 
suggestion irrespective of the fact that any person can be or potentially be a consumer/recipient of that 
therapy. 
T10: “I am not sure this would work particularly well...” 
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CKW: “not sure this would work”. 
CKT: He is skeptical about this issue of consulting public. He does not think that seeking public 
opinion will make any difference. The respondent is doubtful if seeking public opinion is going to be 
an effective means to measure the post marketing impacts of IPR protected invention/innovation. 
T15: “I think only if enough controversy, i.e., obvious public outcry. Otherwise it is not necessary.” 
CKW: “controversy, public outcry”. 
CKT: She indicates that, if there is any issues related to “ordre public and morality” (obvious public 
outcry) then public opinion can be sought, otherwise it‟s not important.   
T19: “No, but there should be a good information about this issue so the public can take decision after 
being properly informed.” 
CKW: “properly informed”. 
CKT: She emphasized on informing public before making their choice. But there is no need to seek 
public opinion after the product is put to market, according to her.  The respondent does not support the 
idea of seeking public opinions to measure the post marketing impacts. Rather she thinks that 
information should be made available to the consumers a priori so that they can learn more about the 
therapy and make informed decision whether or not to purchase and use it. But no emphasis is given on 
seeking feedback from a consumer who already used the therapy or response from a potential consumer 
regarding its access and affordability.  
T21: “if the drug is going to be done by the embryos of the citizen of the country so you’ve to take the 
public opinion in consideration because they are going to be one of the constituents of the drug and of 
course they have to know, but may be if the country is going to import it, you may find people not so 
angry as they aren’t going to share in making the drug by their embryos (though I’m not with any of 
the IPR systems available now can protect it in my opinion other that the right of an author of a 
published research paper).” 
UKW (AJ) : “embryos of the citizen of the country,” “constituents of the drug”. 
UKW (Tania): embryo source, imported drug, available IPR system. 
UKT (Tania): He/she also thinks that the existing IPR framework cannot protect this kind of 
invention/innovation. 
CKT: The respondent considers that the source of the embryo from which the invention/innovation is 
made is the most important or perhaps the only issue that may concern the general consumers. The 
common people of a particular country might not object towards an imported therapy if the embryo 
used isn‟t derived from their countrymen. He/she assumes embryo source is central to public interest 
and not access, affordability, safety or efficacy of the therapy (in case the therapy is developed from 
hESC).  
T26: “I think that civil society should have legal instruments to contest commercial exploitation via 
judicial procedure only.” 
CKW: “civil society,” “legal instruments,” “judicial procedure”. 
CKT: The respondent thinks that civil society should have the legal instruments available so that they 
can seek only judicial help against undue commercial exploitation. He does not seem to find 
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independent public opinion very effective as a means to giving post marketing feedback or any positive 
or negative responses. 
T29: “I think Public opinion should already be received before commercialization.” 
CKW: “before commercialization”. 
CKT: He suggests seeking public opinion prior to commercial exploitation. 
UKT (Tania): I don‟t know what purpose it will serve though, in terms of the key aspects of therapy 
i.e. access, affordability, long term safety and efficacy. Drug pricing rationale and policy is never fully 
disclosed to the consumer, so what purpose might pre-marketing public response serve if they don‟t 
have any knowledge and decision making role in drug pricing? 
Major Key Themes derived from responses to question 13: 
See Ch. 4.4.  
Interpretation of the Major Key Themes derived from responses to question 13: 
See Ch. 5. 
 
Summary of thematic analysis: 
Overall summary of 13 questions and key points in simple language are inserted in ch. 6.  
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For brevity reason, the content of this file (Appendix VA) is made available online. 
Please check the following link of the Dropbox. 
 
https://www.dropbox.com/s/oe4k4szcwhtb01h/back%20matter%20appen
dix%20ixa%20analyst%20aj%20link%20version.doc?dl=0 
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For brevity reason, the content of this file (Appendix VB) is made available online. 
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